<SEC-DOCUMENT>0001628280-25-037430.txt : 20250804
<SEC-HEADER>0001628280-25-037430.hdr.sgml : 20250804
<ACCEPTANCE-DATETIME>20250804161558
ACCESSION NUMBER:		0001628280-25-037430
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250804
DATE AS OF CHANGE:		20250804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			agilon health, inc.
		CENTRAL INDEX KEY:			0001831097
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				371915147
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40332
		FILM NUMBER:		251180472

	BUSINESS ADDRESS:	
		STREET 1:		6210 E HWY 290
		STREET 2:		SUITE 450
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78723
		BUSINESS PHONE:		562-256-3800

	MAIL ADDRESS:	
		STREET 1:		6210 E HWY 290
		STREET 2:		SUITE 450
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Agilon Health Topco, Inc.
		DATE OF NAME CHANGE:	20201103
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>agl-20250630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:13b764c6-a2b0-4a9c-9408-254f78400ab0,g:a48cf18d-4f3e-446d-9d3f-633818f822f0,d:55e39828e2d148b0a62c1216246b0676-->
<html xmlns:agl="http://agilonhealth.com/20250630" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>agl-20250630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-26">0001831097</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-27">December 31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-30">false</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-577">http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-578">http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="agl-20250630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="member"><xbrli:measure>agl:member</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="lawsuit"><xbrli:measure>agl:lawsuit</xbrli:measure></xbrli:unit><xbrli:unit id="entity"><xbrli:measure>agl:entity</xbrli:measure></xbrli:unit><xbrli:unit id="investment"><xbrli:measure>agl:investment</xbrli:measure></xbrli:unit><xbrli:unit id="partner"><xbrli:measure>agl:partner</xbrli:measure></xbrli:unit><xbrli:unit id="geography"><xbrli:measure>agl:geography</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:PlatformSupportCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:PlatformSupportCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:PlatformSupportCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:PlatformSupportCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnassertedClaimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnassertedClaimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredRevolvingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-18</xbrli:startDate><xbrli:endDate>2021-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredRevolvingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredRevolvingFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-25</xbrli:startDate><xbrli:endDate>2023-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">agl:ConsolidatedSecuritiesMatterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">agl:DerivativeMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SuretyBondMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SuretyBondMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">agl:OtherEquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">agl:OtherEquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">agl:ACOREACHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">agl:ACOREACHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831097</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i55e39828e2d148b0a62c1216246b0676_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:2.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June&#160;30, 2025</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:2.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40332</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">agilon health, inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">37-1915147</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">440 Polaris Parkway</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 550</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Westerville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Ohio</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">43082</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">(562)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">256-3800</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:35.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">AGL</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> NO </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" id="f-21">Large Accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Smaller Reporting Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging Growth Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">o</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) YES </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> NO </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">x</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At July&#160;31, 2025, there were <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">414,423,149</ix:nonFraction> shares of the registrant&#8217;s $0.01 par value common stock outstanding.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">agilon health, inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.19pt;padding-right:0.19pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_13">Financial Statements</a>:</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_16">Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_19">Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_22">Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended June 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_25">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the Three and Six Months Ended June 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_28">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_31">Notes to the Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.39pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_79">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_79">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.39pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_109">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_109">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_109">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.39pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_112">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_112">38</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.19pt;padding-right:0.19pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_115">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.39pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_118">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_118">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_118">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.39pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_121">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_121">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_124">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_124">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_124">39</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.39pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_127">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_127">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_127">39</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.39pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_130">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_130">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_130">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.39pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i55e39828e2d148b0a62c1216246b0676_133">41</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i55e39828e2d148b0a62c1216246b0676_13"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="i55e39828e2d148b0a62c1216246b0676_16"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">agilon health, inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share data) </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">171,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">188,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" format="ixt:fixed-zero" scale="3" id="f-33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">5,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">155,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">211,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">1,047,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">1,017,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">78,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">35,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">1,452,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">1,457,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-43">27,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-44">28,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-45">65,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-46">72,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-47">24,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-48">24,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">143,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">151,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-51">1,712,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-52">1,733,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical claims and related payables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-53">1,042,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-54">931,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">171,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">220,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">34,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">1,249,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">1,152,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="f-61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">34,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">54,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">76,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-65">1,303,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-66">1,263,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-67"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-68"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders' equity (deficit):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-69"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-70">0.01</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-71"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-72">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-73"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-74">414,283</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-75"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-76">412,194</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-77">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-78">4,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-79">2,083,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-80">2,053,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-81">1,679,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-82">1,586,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-83">787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-84">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-85">408,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-86">470,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity (deficit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-87">1,712,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-88">1,733,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">The condensed consolidated balance sheets include assets and liabilities of consolidated variable interest entities (&#8220;VIEs&#8221;) as agilon health, inc., together with its consolidated subsidiaries and VIEs (the &#8220;Company&#8221;), is the primary beneficiary of these VIEs. The condensed consolidated balance sheets include total assets that can only be used to settle obligations of the Company&#8217;s consolidated VIEs totaling $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-7" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="9" id="f-89">1.19</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-7" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="9" id="f-90">1.17</ix:nonFraction>&#160;billion as of June&#160;30, 2025 and December&#160;31, 2024, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-7" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="9" id="f-91">1.20</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-7" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="9" id="f-92">1.13</ix:nonFraction>&#160;billion as of June&#160;30, 2025 and December&#160;31, 2024, respectively. See Note 14 for additional details.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to the Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">agilon health, inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share data)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-93">1,392,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-94">1,479,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-95">2,921,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-96">3,080,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other operating revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-97">2,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-98">3,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-99">5,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-100">6,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-101">1,394,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-102">1,482,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-103">2,927,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-104">3,087,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-105">1,445,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-106">1,374,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-107">2,847,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-108">2,817,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-109">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-110">76,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-111">82,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-112">161,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-113">56,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-114">69,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-115">122,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-116">146,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-117">7,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-118">5,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-119">14,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-120">11,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-121">1,511,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-122">1,526,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-123">3,065,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-124">3,137,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-125">116,027</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-126">43,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-127">138,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-128">50,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-129">5,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-130">9,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-131">18,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-132">15,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-133">7,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-134">4,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-135">17,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-136">10,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-137">1,572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-138">1,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-139">3,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-140">2,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-141">104,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-142">30,245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-143">106,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-144">27,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-145">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-146">417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-147">258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-148">284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-149">104,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-150">30,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-151">106,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-152">27,415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued operations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before gain (loss) on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:fixed-zero" scale="3" id="f-153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:fixed-zero" scale="3" id="f-154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:fixed-zero" scale="3" id="f-155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="f-156">518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments on sale of assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:fixed-zero" scale="3" id="f-157">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:fixed-zero" scale="3" id="f-158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-159">14,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-160">8,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-163">14,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-164">9,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-165">104,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-166">30,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-167">92,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-168">36,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests&#8217; share in (earnings) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-170">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-172">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) attributable to common shares</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-173">104,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-174">30,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-175">92,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-176">36,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) per common share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-177"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-178">0.25</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-179"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-180">0.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-181"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-182">0.25</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-183"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-184">0.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-185"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-186">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-187"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-188">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="f-189"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-190">0.03</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-191"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="f-192">0.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-193"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-194">413,836</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-195"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-196">411,271</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-197"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-198">413,388</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-199"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-200">409,152</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to the Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">agilon health, inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-201">104,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-202">30,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-203">92,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-204">36,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized gain (loss) on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-205">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-206">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-207">822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-208">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-209">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-210">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-211">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-212">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-213">104,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-214">30,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-215">91,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-216">36,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive (income) loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="f-218">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="f-220">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total comprehensive income (loss) attributable to agilon health, inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-221">104,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-222">30,382</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-223">91,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-224">36,895</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to the Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">agilon health, inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2025: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:28.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Stockholders&#8217; Equity (Deficit)</span></td></tr><tr style="height:28pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additional <br/>Paid-In <br/>Capital </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated <br/>&#160;Deficit </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive <br/>Income (Loss) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total <br/>Stockholders&#8217; <br/>Equity <br/>(Deficit) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">April 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-225">413,023</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-226">4,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-227">2,070,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-228">1,574,865</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-229">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-230">500,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-231">104,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-232">104,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-233">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-234">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-235">24</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-236">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-237">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-238">1,733</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-239">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-240">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="f-241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Shares withheld related to net share settlement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-242">497</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-243">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-244">2,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-245">2,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-246">15,381</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-247">15,381</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-248">414,283</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-249">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-250">2,083,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-251">1,679,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-252">787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-253">408,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:14.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Stockholders&#8217; Equity (Deficit)</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additional <br/>Paid-In <br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated <br/>Deficit </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive <br/>Income (Loss) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Noncontrolling <br/>Interests </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total <br/>Stockholders&#8217; <br/>Equity<br/>(Deficit)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">April 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-254">410,843</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-255">4,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-256">2,020,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-257">1,332,890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-258">2,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-259">788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-260">688,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-261">30,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="f-262">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-263">30,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-264">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-265">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-266">42</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-267">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-268">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-269">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-270">690</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-271">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-272">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="f-273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Shares withheld related to net share settlement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-274">128</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-275">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-276">634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-277">635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-278">18,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-279">18,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-280">411,447</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-281">4,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-282">2,038,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-283">1,363,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-284">2,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-285">768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-286">675,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">agilon health, inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2025: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Stockholders&#8217; Equity (Deficit)</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additional <br/>Paid-In <br/>Capital </span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated <br/>&#160;Deficit </span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive <br/>Income (Loss) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total <br/>Stockholders&#8217; <br/>Equity <br/>(Deficit) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-287">412,194</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-288">4,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-289">2,053,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-290">1,586,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-291">88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-292">470,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-293">92,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-294">92,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-295">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-296">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-297">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-298">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-299">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-300">2,604</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-301">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-302">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="f-303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Shares withheld related to net share settlement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-304">539</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-305">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-306">2,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-307">2,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-308">32,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-309">32,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-310">414,283</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-311">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-312">2,083,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-313">1,679,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-314">787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-315">408,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2024: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Stockholders&#8217; Equity (Deficit)</span></td></tr><tr style="height:28pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additional <br/>Paid-In <br/>Capital </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated <br/>&#160;Deficit </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive <br/>Income (Loss) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Noncontrolling <br/>&#160;Interest </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total <br/>Stockholders&#8217; <br/>Equity <br/>(Deficit) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-56" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-316">406,387</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-317">4,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-318">1,986,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-319">1,326,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-320">2,298</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-321">818</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-322">661,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-323">36,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="f-324">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-325">36,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-326">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-327">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-328">1,476</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-329">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-330">2,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-331">2,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-332">1,860</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-333">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-334">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Shares withheld related to net share settlement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-336">250</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-337">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-338">1,279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-339">1,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-340">1,974</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-341">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-342">15,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-343">15,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-344">35,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-345">35,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-346">411,447</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-347">4,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-348">2,038,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-349">1,363,572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-350">2,447</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-351">768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-352">675,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to the Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">agilon health, inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-353">92,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-354">36,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net income (loss) to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-355">14,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-356">11,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-357">32,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-358">35,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss (income) from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-359">18,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-360">15,639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Distributions of earnings from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agl:DistributionsOfEarningsFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="agl:DistributionsOfEarningsFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-362">3,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments on sale of assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="f-363">14,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="f-364">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other noncash items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-365">3,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-366">837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:num-dot-decimal" scale="3" id="f-367">14,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:num-dot-decimal" scale="3" id="f-368">67,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-369">67,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-370">66,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-371">7,099</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-372">6,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-373">9,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-374">17,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investment in loans receivable and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agl:PaymentsToAcquireLoansReceivableAndOther" format="ixt:num-dot-decimal" scale="3" id="f-375">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="agl:PaymentsToAcquireLoansReceivableAndOther" format="ixt:num-dot-decimal" scale="3" id="f-376">9,742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-377">60,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-378">12,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from maturities of marketable securities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-379">125,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-380">115,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-381">47,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-382">69,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from (payments for) equity issuances, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" sign="-" name="us-gaap:ProceedsFromRepurchaseOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-383">2,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromRepurchaseOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-384">1,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-386">2,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-387">2,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-388">1,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-389">22,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-390">2,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents and restricted cash and equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-391">193,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-392">114,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents and restricted cash and equivalents, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-393">171,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-394">116,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to the Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">agilon health, inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div id="i55e39828e2d148b0a62c1216246b0676_34"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="f-395" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. Business</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agilon health, inc., together with its consolidated subsidiaries and VIEs (the &#8220;Company&#8221;), through its partnerships and platform, provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. As of June&#160;30, 2025, the Company, through its contracted physician networks, provided care to approximately <ix:nonFraction unitRef="member" contextRef="c-3" decimals="-2" name="agl:NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans" format="ixt:num-dot-decimal" scale="0" id="f-396">497,500</ix:nonFraction> Medicare Advantage members enrolled with private health plans. Additionally, the Company participates in the Centers for Medicare &amp; Medicaid Services' (&#8220;CMS&#8221;) Accountable Care Organization Realizing Equity, Access, and Community Health (&#8220;ACO REACH&#8221;) Model and Medicare Shared Savings Program (&#8220;MSSP,&#8221; and together with ACO REACH, the &#8220;CMS ACO Models&#8221;) through its equity method investments.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 14 for additional discussions related to the Company&#8217;s involvement with VIEs. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s largest shareholder is an investment fund associated with Clayton Dubilier &amp; Rice, LLC (&#8220;CD&amp;R&#8221;), a private equity firm. All funds affiliated with CD&amp;R are considered related parties.</span></div></ix:nonNumeric><div id="i55e39828e2d148b0a62c1216246b0676_37"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-397" continuedAt="f-397-1" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:24pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. Summary of Significant Accounting Policies</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-398" continuedAt="f-398-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-399" escape="true"><ix:continuation id="f-398-1">The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included.</ix:continuation></ix:nonNumeric> Operating results for the three and six months ended June&#160;30, 2025 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2025. The accompanying condensed consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December&#160;31, 2024 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-400" escape="true"><div style="margin-bottom:12pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported (&#8220;IBNR&#8221;) claims), and the valuation and related recognition of impairments of long-lived assets, including goodwill. Management&#8217;s estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.</span></div></ix:nonNumeric><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025 and December&#160;31, 2024, the Company&#8217;s gross carrying amount of property and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-401">58.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-402">52.9</ix:nonFraction> million, with accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-403">31.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-404">24.7</ix:nonFraction> million, respectively.  For the three months ended June 30, 2025 and 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-405">3.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-406">2.9</ix:nonFraction> million, respectively, in depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-407">7.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-408">5.8</ix:nonFraction> million, </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><ix:continuation id="f-397-1" continuedAt="f-397-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">respectively, in depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-409" continuedAt="f-409-1" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the income tax provision for interim periods using an estimate of the Company&#8217;s annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-409-1">On July 4, 2025, the &#8220;One Big Beautiful Bill Act&#8221; was signed into law in the U.S., which contains a broad range of tax reform provisions. The Company is evaluating the provisions of the legislation and the potential effects on its estimated annual effective tax rate, financial position, results of operations, and cash flows.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-410" continuedAt="f-410-1" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-410-1">The Company operates a Medicare-centric, capitated line of business and is organized as a single operating and reportable segment based on the manner in which the Chief Executive Officer, who is the Chief Operating Decision Maker (&#8220;CODM&#8221;), evaluates performance and makes decisions about how to allocate resources. Segment asset information, which is presented on the consolidated balance sheet, is not used by the CODM to assess performance and make decisions about how to allocate resources. The Company's segment measure of profit or loss is consolidated net income (loss). The CODM uses the segment measure of profit or loss to assess performance and make resource allocation decisions, primarily through periodic budgeting and company performance reviews. Significant expense categories included within the segment measure of profit or loss that are regularly provided to the CODM include medical services expense, other medical expense, and platform support costs. Medical services expense and other medical expense amounts are included in the consolidated statements of operations. Platform support costs were $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-411">37.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-412">41.7</ix:nonFraction> million for the three months ended June 30, 2025 and 2024, respectively. For the three months ended June 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-413">14.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-414">21.2</ix:nonFraction> million, respectively. Platform support costs were $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-415">81.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-416">87.4</ix:nonFraction> million for the six months ended June 30, 2025 and 2024, respectively. For the six months ended June 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-417">8.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-418">56.6</ix:nonFraction> million, respectively.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-419" continuedAt="f-419-1" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-09&#8221;), which amends certain disclosure requirements related to income taxes. The amendments in ASU 2023-09 require public business entities on an annual basis to: (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The amendments in ASU 2023-09 can be applied on a prospective basis or retrospective application. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on its disclosures.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2024-03&#8221;). In January 2025, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2025-01, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2025-01&#8221;). The amendments in ASU 2024-03 require public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement expense line items by breaking down certain expense line items into specified natural expense categories, including purchases of inventory, employee compensation, deprecation, intangible asset amortization, and depletion. The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The amendments in </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><ix:continuation id="f-419-1"><ix:continuation id="f-397-2"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2024-03 can be applied on a prospective basis or retrospective basis and early adoption is permitted. The amendments in ASU 2025-01 clarify the effective date of ASU 2024-03 stating that all public business entities are required to adopt the update in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. ASU 2025-01 does not change the effective date of ASU 2024-03 but was issued to provide clarity on the effective date for public business entities that do not have a calendar year-end. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 and ASU 2025-01 on its disclosures.</span></div></ix:continuation></ix:continuation><div id="i55e39828e2d148b0a62c1216246b0676_40"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="f-420" continuedAt="f-420-1" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:24pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. Revenue, Receivables, and Concentration of Credit Risk</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-421" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Services Revenue</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors (&#8220;payors&#8221;). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month (&#8220;PMPM&#8221;) fees to provide a defined range of healthcare services for Medicare Advantage health plan members (&#8220;members&#8221;) attributed to the Company&#8217;s contracted primary care physicians. In certain of the Company&#8217;s payor arrangements, it is also financially responsible for Medicare Part D pharmaceutical costs for prescriptions rendered to members. PMPM fees are determined as a percent of the premium payors receive from CMS for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are generally recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification (&#8220;ASC&#8221;) 606, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price for the Company&#8217;s capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS&#8217;s risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member&#8217;s health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company&#8217;s contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of incentive revenue will not occur once any uncertainty is resolved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ReceivablesPolicyTextBlock" id="f-422" continuedAt="f-422-1" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-422-1">Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management&#8217;s estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized.</ix:continuation> </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company contracts with various payors whereby the Company is entitled to monthly PMPM fees to provide a defined range of healthcare services for members attributed to its contracted primary care physicians. The Company generally accepts full financial risk for such members and therefore is responsible for the cost of all healthcare services required by them. Substantially all of the Company&#8217;s receivable balances are from a small number of payors. Revenue from Medicare Advantage payors constitutes substantially all of the Company&#8217;s total revenue for the three and six months ended June&#160;30, 2025 and 2024.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-423" escape="true"><ix:continuation id="f-420-1"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the Company&#8217;s revenue concentration with respect to major payors as a percentage of the Company&#8217;s total revenues: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-424">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-425">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-426">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-427">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-79" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-428">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-80" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-429">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-81" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-430">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-82" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-431">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-432">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-433">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-85" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-434">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-435">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-436">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt">Less than 10% of total revenues.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the Company&#8217;s concentration of credit risk with respect to major payors as a percentage of receivables, net:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-88" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-437">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-89" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-438">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-439">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-91" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-440">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-92" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-441">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-442">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-94" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-443">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt">Less than 10% of total receivables.</span></div></ix:continuation></ix:nonNumeric><div id="i55e39828e2d148b0a62c1216246b0676_43"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-444" continuedAt="f-444-1" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. Marketable Securities and Fair Value Measurements</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-445" continuedAt="f-445-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s marketable securities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-446">26,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-447">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-448">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-449">26,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-450">110,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-451">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-452">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-453">110,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-454">128,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-455">712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-456">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-457">129,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-458">101,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-459">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-460">213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-461">101,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-462">154,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-463">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-464">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-465">155,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-466">211,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-467">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-468">417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-469">211,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2025, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InvestmentIncomeNet" scale="6" id="f-470">3.6</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:InvestmentIncomeNet" scale="6" id="f-471">2.6</ix:nonFraction> million was related to its marketable securities investments and $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:InvestmentIncomeNet" scale="6" id="f-472">1.0</ix:nonFraction> million was related to interest on cash and cash equivalent balances. For the three months ended June 30, 2024, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-473">4.8</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-474">3.3</ix:nonFraction>&#160;million was related to its marketable securities investments and $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-475">1.5</ix:nonFraction>&#160;million was related to interest on cash and cash equivalent balances. For the six months ended June 30, 2025, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-476">7.9</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-477">5.7</ix:nonFraction>&#160;million was related to its marketable securities investments and $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-478">2.2</ix:nonFraction>&#160;million was related to interest on cash and cash equivalent balances. For the six months ended June 30, 2024, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-479">10.2</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-480">7.2</ix:nonFraction>&#160;million was related to its marketable securities investments and $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-481">3.0</ix:nonFraction>&#160;million was related to interest on cash and cash equivalent balances. </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><ix:continuation id="f-444-1" continuedAt="f-444-2"><ix:continuation id="f-445-1"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s marketable securities maturity as of June&#160;30, 2025 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-482">40,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-483">40,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="agl:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-484">62,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="agl:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-485">62,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="agl:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree" format="ixt:num-dot-decimal" scale="3" id="f-486">27,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="agl:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree" format="ixt:num-dot-decimal" scale="3" id="f-487">28,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="agl:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour" format="ixt:num-dot-decimal" scale="3" id="f-488">24,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="agl:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour" format="ixt:num-dot-decimal" scale="3" id="f-489">24,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-490">154,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-491">155,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-492" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of June&#160;30, 2025 (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="f-493">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-495">3,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-496">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-497">25,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-498">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-499">12,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-500">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-501">26,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-502">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-503">16,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-504">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of December&#160;31, 2024 (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="3" id="f-505">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-507">73,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-508">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-509">25,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-510">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-511">38,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-512">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-513">25,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-514">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-515">111,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-516">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unrealized losses from marketable securities as of June&#160;30, 2025 and December&#160;31, 2024 were caused primarily by interest rate increases. As of June&#160;30, 2025, all of the Company&#8217;s marketable securities carry an investment grade rating by nationally recognized statistical rating organizations. The Company does not intend to sell marketable securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. There was <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-517"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-518">no</ix:nonFraction></ix:nonFraction> allowance for credit losses on available-for-sale marketable securities at June&#160;30, 2025 or December&#160;31, 2024.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash and equivalents, marketable securities, receivables, other liabilities, accounts payable, certain accrued expenses, and borrowings which consist of a term loan and a revolving credit facility. The carrying values of the financial instruments classified as current in the consolidated balance sheets approximate their fair values due to their short-term maturities. The Company's cash and cash equivalents are classified within Level 1 of the fair value hierarchy. The carrying values of the term loan and revolving credit facility are a reasonable estimate of fair value because the interest rates on such borrowings approximate market rates as of the reporting date. Such borrowings are classified within Level 2 of the fair value hierarchy. During the three and six months ended June&#160;30, 2025 and 2024, there were no material transfers of financial assets or liabilities within the fair value hierarchy. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><ix:continuation id="f-444-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">unobservable inputs reflect the Company&#8217;s market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1&#8212;quoted prices for identical instruments in active markets; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2&#8212;quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3&#8212;fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-519" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-521">26,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-524">110,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-526">129,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-529">101,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-531">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-532">129,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-533">26,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-535">101,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-536">110,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i55e39828e2d148b0a62c1216246b0676_46"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherAssetsDisclosureTextBlock" id="f-538" continuedAt="f-538-1" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:12pt;padding-right:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. Other Assets</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="f-539" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s other assets (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loans to physician partners</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="agl:LoansToPhysiciansPartners" format="ixt:num-dot-decimal" scale="3" id="f-540">39,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="agl:LoansToPhysiciansPartners" format="ixt:num-dot-decimal" scale="3" id="f-541">63,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Health plan deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="agl:HealthPlanDepositsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-542">2,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="agl:HealthPlanDepositsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-543">2,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-544">77,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-545">61,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-546">8,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-547">8,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-548">14,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-549">15,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-550">143,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-551">151,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">See Note 14 for additional discussion related to the Company's equity method investments.</span></div></ix:nonNumeric><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loans to Physician Partners</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-538-1">Loans to physician partners primarily represent loans in connection with taxes payable on shares distributed to them in connection with the IPO. These loans mature between 2026 and 2031 with nominal interest compounding annually and no prepayment penalties. At June&#160;30, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LoansAndLeasesReceivableRelatedParties" scale="6" id="f-552">21.4</ix:nonFraction> million of these loans were reclassed to Prepaid expenses and other current assets, net on the condensed consolidated balance sheet as the maturities were less than 12 months. Such loans are stated at the amount expected to be collected.</ix:continuation> </span></div><div id="i55e39828e2d148b0a62c1216246b0676_49"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" id="f-553" continuedAt="f-553-1" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. Medical Claims and Related Payables</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense represents costs incurred for medical services provided to members by physicians, hospitals and other ancillary providers for which the Company is financially responsible and are paid by payors with whom the Company has contracted. Medical services expenses are recognized in the period in which services are provided and include estimates of claims that have been incurred but have either not yet been received, processed, or paid and as such, not reported.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Such estimates are developed using actuarial methods commonly used by health insurance actuaries that include a number of factors and assumptions including medical service utilization trends, changes in membership, observed medical </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><ix:continuation id="f-553-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cost trends, historical claim payment patterns and other factors. Generally, for the most recent months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average PMPM medical costs incurred in prior months for which more complete claims data are available.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each period, the Company re-examines previously established medical claims payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claims information becomes available, the Company adjusts its estimates and recognizes those changes in estimates in the period in which the change is identified. The difference between the estimated liability and the actual settlements of claims is recognized in the period the claims are settled. The Company&#8217;s medical claims payable balance represents management&#8217;s best estimate of its liability for unpaid medical costs as of June&#160;30, 2025 and 2024. The Company uses judgment to determine the appropriate assumptions for developing the required estimates.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="f-554" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of changes in medical claims and related payables (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Medical claims and related payables, beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable" format="ixt:num-dot-decimal" scale="3" id="f-555">918,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable" format="ixt:num-dot-decimal" scale="3" id="f-556">723,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Components of incurred costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-557">2,810,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-558">2,802,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-559">36,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-560">15,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="f-561">2,847,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="f-562">2,817,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="f-563">1,821,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="f-564">1,806,692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="f-565">930,606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="f-566">650,106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-567">2,751,781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-568">2,456,798</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Medical claims and related payables, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable" format="ixt:num-dot-decimal" scale="3" id="f-569">1,013,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable" format="ixt:num-dot-decimal" scale="3" id="f-570">1,084,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical claims and related payables also include $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="agl:LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable" scale="6" id="f-571">28.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="agl:LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable" scale="6" id="f-572">13.3</ix:nonFraction> million, as of June&#160;30, 2025 and December&#160;31, 2024, respectively, that is recoverable from other parties under risk sharing arrangements and is presented as prepaid expenses and other current assets, net in the condensed consolidated balance sheets.</span></div></ix:continuation><div id="i55e39828e2d148b0a62c1216246b0676_52"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="f-573" continuedAt="f-573-1" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. Other Liabilities</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherLiabilitiesTableTextBlock" id="f-574" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s other liabilities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term contingencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LossContingencyAccrualCarryingValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-575">35,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LossContingencyAccrualCarryingValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-576">49,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">L<span style="-sec-ix-hidden:f-577"><span style="-sec-ix-hidden:f-578">ease liabilities, long-term</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-579">6,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-580">6,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method liabilities &#8211; CMS ACO Models</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="agl:EquityMethodLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-581">10,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="agl:EquityMethodLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-582">12,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherSundryLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-583">3,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherSundryLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-584">8,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-585">54,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-586">76,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">See Note 14 for additional discussion related to the Company's equity method liabilities related to its CMS ACO Models investments.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-573-1">As of June&#160;30, 2025 and December&#160;31, 2024, the Company&#8217;s accruals for contingent liabilities related to unasserted claims were $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:LossContingencyAccrualCarryingValueNoncurrent" scale="6" id="f-587">35.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:LossContingencyAccrualCarryingValueNoncurrent" scale="6" id="f-588">49.0</ix:nonFraction> million, respectively.</ix:continuation>  </span></div><div id="i55e39828e2d148b0a62c1216246b0676_55"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-589" continuedAt="f-589-1" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. Debt</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;18, 2021, the Company executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021 and the Second Amendment to Credit Agreement, dated as of May 25, 2023, the &#8220;Credit Facility&#8221;). The Credit Facility includes: (i) a $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-590">100.0</ix:nonFraction>&#160;million secured term loan facility (the &#8220;Secured Term Loan </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><ix:continuation id="f-589-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility&#8221;) and (ii) a $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-591">100.0</ix:nonFraction>&#160;million senior secured revolving credit facility (the &#8220;Secured Revolving Facility&#8221;) with a capacity to issue standby letters of credit in certain circumstances up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-592">100.0</ix:nonFraction>&#160;million. Subject to specified conditions and receipt of commitments, the Secured Term Loan Facility may be expanded (or a new term loan facility, revolving credit facility or letter of credit facility added) by up to (i) $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="INF" name="agl:LineOfCreditFacilityAccordionFeatureIncreaseLimit" format="ixt:num-dot-decimal" scale="6" id="f-593">50.0</ix:nonFraction>&#160;million plus (ii) an additional amount determined in accordance with a formula tied to repayment of certain of the Company&#8217;s indebtedness. The maturity date of the Credit Facility is February&#160;18, 2026.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-594">35.0</ix:nonFraction> million outstanding under the Secured Term Loan Facility and availability under the Secured Revolving Facility was $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="f-595">19.4</ix:nonFraction> million, as the Company had outstanding letters of credit totaling $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="f-596">80.6</ix:nonFraction> million. The standby letters of credit are automatically extended without amendment for <ix:nonNumeric contextRef="c-134" name="agl:ExtendedTermOfLettersOfCredit" format="ixt-sec:durwordsen" id="f-597">one-year</ix:nonNumeric> periods, unless the Company notifies the institution in advance of the expiration date that the letter will be terminated. <ix:nonFraction unitRef="usd" contextRef="c-133" decimals="INF" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="f-598">No</ix:nonFraction> amounts have been drawn on the outstanding letters of credit as of June&#160;30, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective with the Second Amendment to Credit Agreement on May 25, 2023, the Company transitioned to the Secured Overnight Financing Rate (&#8220;SOFR&#8221;) as a benchmark interest rate used in the Credit Agreement. At the Company&#8217;s option, borrowings under the Credit Facility can be either: (i) SOFR Rate Loans, (ii) Daily Simple SOFR Rate Loans, or (iii) Base Rate Loans. Daily Simple SOFR Rate Loans and SOFR Rate Loans bear interest at a rate equal to the sum of <ix:nonFraction unitRef="number" contextRef="c-135" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-599">3.50</ix:nonFraction>% and the higher of (a) SOFR, as defined in the Credit Agreement, and (b) <ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-600">0</ix:nonFraction>%. Base Rate Loans bear interest at a rate equal to the sum of <ix:nonFraction unitRef="number" contextRef="c-137" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-601">2.50</ix:nonFraction>% and the highest of: (a) <ix:nonFraction unitRef="number" contextRef="c-138" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-602">0.50</ix:nonFraction>% in excess of the overnight federal funds rate, (b) the prime rate established by the administrative agent from time to time, (c) the one-month SOFR rate (adjusted for maximum reserves) plus <ix:nonFraction unitRef="number" contextRef="c-139" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-603">1.00</ix:nonFraction>% and (d) <ix:nonFraction unitRef="number" contextRef="c-140" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-604">0</ix:nonFraction>%. Additionally, the Company pays a commitment fee on the unfunded Secured Revolving Facility amount of <ix:nonFraction unitRef="number" contextRef="c-141" decimals="5" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="f-605">0.375</ix:nonFraction>%. The Company must also pay customary letter of credit fees. As of June&#160;30, 2025, the effective interest rate on the Secured Term Loan Facility was <ix:nonFraction unitRef="number" contextRef="c-131" decimals="5" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="f-606">8.279</ix:nonFraction>%.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility is guaranteed by certain of the Company&#8217;s subsidiaries, including those identified as VIEs, and contain customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios. Failure to meet any of these covenants could result in an event of default under the Credit Agreement. If an event of default occurs, the lenders could elect to declare all amounts outstanding under the Credit Agreement to be immediately due and payable. The Company was in compliance with all covenants under the Credit Facility.</span></div></ix:continuation><div id="i55e39828e2d148b0a62c1216246b0676_58"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-607" continuedAt="f-607-1" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;padding-right:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. Commitments and Contingencies</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to, or has a significant relationship to, legal proceedings, lawsuits, and other claims that arise in the ordinary course of the Company's business. Except as described in this Note 9, the Company is not aware of any other legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company's business, prospects, financial condition, results of operations or cash flows. The Company&#8217;s policy is to expense legal costs as they are incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February and March 2024, <ix:nonFraction unitRef="lawsuit" contextRef="c-142" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-608">three</ix:nonFraction> class action lawsuits were filed and later consolidated as one matter captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re agilon health, inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, 1:24-cv-00297 (W.D. Tex.) (the &#8220;Consolidated Securities Matter&#8221;). The Consolidated Securities Matter names the Company and certain current and former members of the Company&#8217;s executive team and Board of Directors as defendants, among others. The Consolidated Securities Matter generally asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in connection with statements made between April 2021 and February 2024 in the Company&#8217;s annual and quarterly reports, investor presentations, and earnings releases related to, among other things, the Company&#8217;s financial guidance, medical margin and Adjusted EBITDA results, growth strategy, and data management. The Consolidated Securities Matter seeks compensatory damages, judgment interest, attorney&#8217;s fees and costs, and other unspecified equitable and/or injunctive relief.&#8239;The Company and other defendants filed motions to dismiss the complaint on November 8, 2024, and the motion is now fully submitted and pending before the Court. The Company intends to vigorously oppose the complaint, but is unable to predict the outcome or estimate any ultimate individual or aggregate amount of monetary liability or financial impact due to the early stages of the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May and October 2024, <ix:nonFraction unitRef="lawsuit" contextRef="c-143" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-609">two</ix:nonFraction> putative stockholder derivative class action lawsuits were filed: (1) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Douglas v. Steven J. Sell et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, 1:24-cv-00531 (W.D. Tex.) and (2) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bingham v. Steven J. Sell et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, 1:24-cv-01181 (W.D. Tex.) (the </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><ix:continuation id="f-607-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Derivative Matters&#8221;). The Derivative Matters name the Company and certain current and former members of the Company&#8217;s executive team and Board of Directors as defendants. The Derivative Matters generally assert claims under Sections 14(a) and 10(b) of the Exchange Act, as well as common law claims including breach of fiduciary duty, among others, in connection with statements made between April 2021 and February 2024 in the Company&#8217;s annual and quarterly reports, investor presentations, and earnings releases related to, among other things, the Company&#8217;s financial guidance, medical margin and Adjusted EBITDA results, growth strategy, and data management. The </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Douglas</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit also asserts claims under Section 20(a) of the Exchange Act in connection with the same allegations and seeks contribution under Section 11(f) of the Securities Act and Section 21D of the Exchange Act. The Derivative Matters seek compensatory damages, restitution, punitive damages, attorney&#8217;s fees and costs, and other relief.&#8239;The plaintiff in the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Douglas</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> action also seeks corporate governance reforms. The Derivative Matters were consolidated in November 2024 into </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In Re agilon health, inc. Shareholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, 1:24-cv-00531-DII. The consolidated derivative matter is currently stayed, pending resolution of the motion to dismiss in the Consolidated Securities Matter. The Company intends to vigorously oppose the complaint, but is unable to predict the outcome or estimate any ultimate individual or aggregate amount of monetary liability or financial impact due to the early stage of the litigation.</span></div></ix:continuation><div id="i55e39828e2d148b0a62c1216246b0676_61"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-610" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. Common Stock</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. During the three months ended June 30, 2025, the Company issued approximately <ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="f-611">1.3</ix:nonFraction>&#160;million shares of common stock primarily in connection with vesting of stock-based awards. During the six months ended June 30, 2025, the Company issued approximately <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="f-612">2.1</ix:nonFraction>&#160;million shares of common stock primarily in connection with vesting of stock-based awards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. During the three months ended June 30, 2024, the Company issued approximately <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="f-613">0.6</ix:nonFraction>&#160;million shares of common stock primarily in connection with exercises and vesting of stock-based awards. During the six months ended June 30, 2024, the Company issued approximately <ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="f-614">3.1</ix:nonFraction>&#160;million shares of common stock primarily in connection with exercises and vesting of stock-based awards. Additionally, during the six months ended June 30, 2024, the Company issued approximately <ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="f-615">2.0</ix:nonFraction>&#160;million shares of common stock to settle liabilities related to the exchange of common stock for reduced physician partner compensation percentage in certain ACO REACH entities.</span></div></ix:nonNumeric><div id="i55e39828e2d148b0a62c1216246b0676_64"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-616" continuedAt="f-616-1" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. Net Income (Loss) Per Common Share</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share (&#8220;EPS&#8221;) is computed based upon the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed based upon the weighted average number of common shares outstanding plus the impact of common shares issuable from the assumed conversion of stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on basic net income (loss) per share are included in diluted net income (loss) per share during the periods presented.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><ix:continuation id="f-616-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-617" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-618">104,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-619">30,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-620">106,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-621">27,415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests&#8217; share in (earnings) loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-623">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-625">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to common stockholders before discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-626">104,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-627">30,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-628">106,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-629">27,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-632">14,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-633">9,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-634">104,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-635">30,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-636">92,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-637">36,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding &#8211; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-638"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-639">413,836</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-640"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-641">411,271</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-642"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-643">413,388</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-644"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-645">409,152</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) per share attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per common share from continuing operations, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-646"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-647">0.25</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-648"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-649">0.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-650"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-651">0.25</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-652"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-653">0.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per common share from discontinued operations, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-654"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-655">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-656"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-657">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-658"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="f-659">0.03</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="f-660"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-661">0.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-662" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-144" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-663">20,980</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-145" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-664">17,421</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-146" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-665">25,623</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-147" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-666">20,177</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i55e39828e2d148b0a62c1216246b0676_67"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-667" continuedAt="f-667-1" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. Goodwill and Amortizable Intangible Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of both June&#160;30, 2025 and December&#160;31, 2024, the Company&#8217;s goodwill balance was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-668"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-669">24.1</ix:nonFraction></ix:nonFraction> million. There were no events or circumstances that warranted an interim impairment test for goodwill during the six months ended June&#160;30, 2025. </span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-667-1">As of June&#160;30, 2025 and December&#160;31, 2024, the Company&#8217;s gross carrying amount of amortizable intangible assets was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="f-670">122.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="f-671">123.8</ix:nonFraction> million, respectively, with accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-672">57.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-673">51.0</ix:nonFraction> million, respectively. For the three months ended June 30, 2025 and 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-674">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-675">3.0</ix:nonFraction> million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-676">6.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-677">6.0</ix:nonFraction> million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="f-678" continuedAt="f-678-1" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. Supplemental Cash Flow Information</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="f-679" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental cash flow information (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-680">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-681">1,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-682">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-683">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use asset obtained in exchange for new operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-684">1,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-685">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Settlement of liabilities through issuance of stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-686">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-687">15,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-689" continuedAt="f-689-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-688" continuedAt="f-688-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-690">171,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-691">188,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and equivalents</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" format="ixt:fixed-zero" scale="3" id="f-692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-693">5,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-694">171,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-695">193,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><ix:continuation id="f-689-1" continuedAt="f-689-2"><ix:continuation id="f-688-1" continuedAt="f-688-2"><ix:continuation id="f-678-1" continuedAt="f-678-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></ix:continuation></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"><ix:continuation id="f-689-2"><ix:continuation id="f-688-2"><ix:continuation id="f-678-2">Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.</ix:continuation></ix:continuation></ix:continuation> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i55e39828e2d148b0a62c1216246b0676_73"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="f-696" continuedAt="f-696-1" escape="true"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14. Variable Interest Entities</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agilon health, inc.&#8217;s consolidated assets and liabilities as of June&#160;30, 2025 and December&#160;31, 2024 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to agilon health, inc.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="f-697" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agilon health, inc.&#8217;s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-698">57,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-699">78,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-701">5,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-702">1,046,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-703">1,015,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-704">31,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-705">17,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-706">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-707">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-708">43,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-709">49,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-710">5,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-711">4,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical claims and related payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-712">1,042,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-713">931,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-714">154,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-715">199,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-716">1,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-717">2,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-bearing Entities.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> At June&#160;30, 2025, the Company operates <ix:nonFraction unitRef="entity" contextRef="c-5" decimals="INF" name="agl:NumberOfWhollyOwnedRiskBearingEntities" scale="0" id="f-718">33</ix:nonFraction> wholly-owned risk-bearing entities (&#8220;RBEs&#8221;) for the purpose of entering into risk-bearing contracts with payors. Each RBE&#8217;s equity at risk is considered insufficient to </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><ix:continuation id="f-696-1" continuedAt="f-696-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">finance its activities without additional support, and, therefore, each RBE is considered a VIE. The Company consolidates the RBEs as it has determined that it is the primary beneficiary because it has: (i) the ability to control the activities that most significantly impact the RBEs&#8217; economic performance; and (ii) the obligation to absorb losses or right to receive benefits that could potentially be significant to the RBEs. Specifically, the Company has the unilateral ability and authority, through the RBE governance and management agreements, to make significant decisions about strategic and operating activities of the RBEs, including negotiating and entering into risk-bearing contracts with payors, and approving the RBEs&#8217; annual operating budgets. The Company also has the obligation to fund losses of the RBEs and the right to receive a significant percentage of any financial surplus generated by the RBEs. The assets of the RBEs primarily consist of cash and cash equivalents, receivables, net, intangible assets, net, and other assets. Its obligations primarily consist of medical claims and related payables as well as operating expenses of the RBEs (accounts payable and accrued expenses), including incentive compensation obligations to the Company&#8217;s physician partners. On February 18, 2021, the Company executed the Credit Facility, which is guaranteed by certain of the Company&#8217;s VIEs. Assets generated by the RBEs (primarily from medical services revenues) may be used, in certain limited circumstances, to settle the Company&#8217;s contractual debt obligations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company had <ix:nonFraction unitRef="investment" contextRef="c-148" decimals="INF" name="agl:NumberOfEquityMethodInvestments" scale="0" id="f-719">12</ix:nonFraction> equity method investments (liabilities), including <ix:nonFraction unitRef="entity" contextRef="c-149" decimals="INF" name="agl:NumberOfDirectContractingEntities" scale="0" id="f-720">10</ix:nonFraction> wholly-owned CMS ACO Models entities discussed below, that were deemed to be VIEs. The Company has determined that the activities that most significantly impact the performance of these VIEs consist of the allocation of resources to and other decisions related to clinical activities and provider contracting decisions. Because the Company does not have the ability to control these activities due to another party&#8217;s control of the VIEs&#8217; board of directors, the Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs. The Company provided support to assist its CMS ACO Models investments in obtaining surety bonds related to risk-bearing capital contributions to CMS. As of June&#160;30, 2025 and December&#160;31, 2024, the CMS ACO Models investments had $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-721">131.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-722">65.2</ix:nonFraction> million, respectively, of outstanding surety bonds. The Company's maximum loss exposure as a result of the Company&#8217;s involvement with the unconsolidated VIEs cannot be quantified as the Company has the obligation to provide ongoing operational support to the unconsolidated VIEs, as needed.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsTextBlock" id="f-723" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s equity method investees (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments - Other</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-724">9,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-725">9,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments - CMS ACO Models</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-726">68,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-727">52,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method liabilities - CMS ACO Models</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="agl:EquityMethodLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-728">10,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="agl:EquityMethodLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-729">12,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Other assets, net in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Other liabilities in the condensed consolidated balance sheets.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a partner in <ix:nonFraction unitRef="entity" contextRef="c-149" decimals="INF" name="agl:NumberOfDirectContractingEntities" scale="0" id="f-730">10</ix:nonFraction> wholly-owned CMS ACO Models investments in collaboration with <ix:nonFraction unitRef="partner" contextRef="c-149" decimals="INF" name="agl:NumberOfPhysicianGroupPartners" scale="0" id="f-731">13</ix:nonFraction> of its physician group partners operating in <ix:nonFraction unitRef="geography" contextRef="c-3" decimals="INF" name="agl:NumberOfGeographicalLocation" scale="0" id="f-732">12</ix:nonFraction> geographies. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" id="f-733" continuedAt="f-733-1" escape="true">The combined summarized operating results of the Company&#8217;s CMS ACO Models investments are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-733-1" continuedAt="f-733-2"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-734">434,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-735">446,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-736">848,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-737">887,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-738">401,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-739">406,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-740">753,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-741">805,713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-742">17,848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-743">22,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-744">54,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-745">47,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from operations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-746">6,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-747">11,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-748">22,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-749">20,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-750">5,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-751">9,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-752">18,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-753">15,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><ix:continuation id="f-696-2"><ix:continuation id="f-733-2"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:26.68pt">The three months ended June 30, 2025 and 2024, includes physician incentive expenses of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="agl:PhysicianCompensationExpense" scale="6" id="f-754">8.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="agl:PhysicianCompensationExpense" scale="6" id="f-755">13.7</ix:nonFraction> million, respectively. The six months ended June 30, 2025 and 2024, includes physician incentive expenses of $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="agl:PhysicianCompensationExpense" scale="6" id="f-756">36.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="agl:PhysicianCompensationExpense" scale="6" id="f-757">30.4</ix:nonFraction> million, respectively. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">The three months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-758">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-759">1.3</ix:nonFraction> million, respectively. The six months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-760">8.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-761">2.6</ix:nonFraction> million, respectively. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Income (loss) from equity method investments in the condensed consolidated statements of operations.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" id="f-762" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The combined summarized balance sheet of the Company&#8217;s CMS ACO Models investments are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-763">524,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-764">444,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-765">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-766">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-767">526,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-768">446,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current and total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-769">467,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-770">406,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i55e39828e2d148b0a62c1216246b0676_76"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-771" escape="true"><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15. Discontinued Operations</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations is a component of an entity that has either been disposed of or is deemed held-for-sale and, (i) the operations and cash flows of the component have been or will be eliminated from ongoing operations as a result of the disposal transaction, and (ii) the entity will not have any significant continuing involvement in the operations of the component after the disposal transaction. On October 31, 2023, the Company completed the disposition of MDX Hawaii, Inc. and its related operations. The Company&#8217;s decision to exit Hawaii and the Independent Practice Association line of business represents a strategic shift that will have a major effect on its operations and financial results. As such, the Company&#8217;s Hawaii operations are reflected in the condensed consolidated financial statements as discontinued operations for all periods presented. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="f-772" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results of discontinued operations are as follows (in thousands): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Expenses:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="agl:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments" format="ixt:fixed-zero" scale="3" id="f-773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="agl:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments" scale="3" id="f-774">518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:fixed-zero" scale="3" id="f-775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="f-776">518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments on sale of assets, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-777">14,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-778">8,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) from discontinued operations attributable to common shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-779">14,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-780">9,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:49.5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All references in this report to &#8220;agilon,&#8221; &#8220;the Company&#8221;, &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; mean agilon health, inc., together with its consolidated subsidiaries. Unless the context suggests otherwise, references to &#8220;agilon health, inc.&#8221; mean the parent company without its subsidiaries.</span></div><div id="i55e39828e2d148b0a62c1216246b0676_82"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Language Regarding Forward-Looking Statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Statements in this Quarterly Report on Form 10-Q (the &#8220;Report&#8221;) that are not historical factual statements are &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Some of the forward-looking statements can be identified by the use of forward-looking terms such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;shall,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;aims,&#8221; &#8220;projects,&#8221; &#8220;is optimistic,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;estimates,&#8221; &#8220;anticipates&#8221; or the negative versions of these words or other comparable terms. Forward-looking statements include, without limitation, all matters that are not historical facts. They appear in several places throughout this Report and include, without limitation, statements regarding our intentions, beliefs, assumptions or current expectations concerning, among other things, our financial position, results of operations, cash flows, prospects, and growth strategies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be outside our control. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Report, we caution you that forward-looking statements are not guarantees of future performance or outcomes and that actual performance and outcomes, including, without limitation, our actual results of operations, financial condition and liquidity, and the development of the market in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this Report. In addition, even if our results of operations, financial condition, and cash flows, and the development of the market in which we operate, are consistent with the forward-looking statements contained in this Report, those results or developments may not be indicative of results or developments in subsequent periods. You are therefore cautioned not to place undue reliance on the forward-looking statements included in this report. A number of important factors, including, without limitation, the risks and uncertainties discussed under Part I, Item 1A. &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2024, could cause actual results and outcomes to differ materially from those reflected in the forward-looking statements. Furthermore, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Report. Factors that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, without limitation: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our history of net losses and the expectation that our expenses will increase in the future;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure to identify and develop successful new geographies, physician partners and payors, or execute upon our growth initiatives;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">success in executing our operating strategies or achieving results consistent with our historical performance;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">medical expenses incurred on behalf of our members may exceed revenues we receive; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain and secure additional contracts with Medicare Advantage (&#8220;MA&#8221;) payors on favorable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to grow new physician partner relationships sufficient to recover startup costs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">availability of additional capital, on acceptable terms or at all, to support our business in the future;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant reduction in our membership;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">transition to a Total Care Model may be challenging for physician partners;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">public health crises, such as COVID-19, could adversely affect us;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inaccuracy in estimates of our members&#8217; risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of restrictive clauses or exclusivity provisions in some of our contracts with physician partners;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to hire and retain qualified personnel;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to realize the full value of our intangible assets;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">security breaches, cybersecurity attacks, loss of data and other disruptions to our information systems;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to protect the confidentiality of our know-how and other proprietary and internally developed information;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on our subsidiaries to perform and fund their operations; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our use of artificial intelligence and machine learning in our business and challenges with properly managing the development and use of these technologies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on a limited number of key payors;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the limited terms of contracts with our payors and our ability to renew them upon expiration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to navigate the changing healthcare payor market;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on our payors, physician partners and other providers to operate our business;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain accurate and complete diagnosis data;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third-party software, data, infrastructure and bandwidth;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">consolidation and competition in the healthcare industry;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of changes to, and dependence on, federal government healthcare programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">uncertain or adverse economic and macroeconomic conditions, including a downturn or decrease in government expenditures;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulation of the healthcare industry and our physician partners&#8217; ability to comply with such laws and regulations;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal and state investigations, audits and enforcement actions;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">repayment obligations arising out of payor audits;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">negative publicity regarding the managed healthcare industry generally;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our use, disclosure and processing of personally identifiable information, protected health information, and de-identified data;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure to obtain or maintain an insurance license, a certificate of authority or an equivalent authorization;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in tax laws and regulations, or changes in related judgments or assumptions;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our indebtedness and our potential to incur more debt;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our dependence on our subsidiaries for cash to fund all of our operations and expenses;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our governing documents;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve a return on investment depends on appreciation in the price of our common stock; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">lawsuits not covered by insurance and securities class action litigation;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sustainability issues; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our stock price may be volatile; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to management transitions, including the search for a permanent CEO, and our ability to effectively manage leadership changes; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to other factors discussed under Part I, Item 1A &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth in this Item 2 is intended to provide readers with an understanding of our financial condition, changes in financial condition, and results of operations and should be read in connection with the accompanying Condensed Consolidated Financial Statements and notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Report. We will discuss and provide our analysis in the following order:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Overview and Recent Developments</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Key Financial and Operating Metrics</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Key Components of Our Results of Operations</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Results of Operations</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Non-GAAP Financial Measures</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Critical Accounting Estimates</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Recent Accounting Pronouncements</span></div><div id="i55e39828e2d148b0a62c1216246b0676_85"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview and Recent Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business is transforming healthcare by empowering the primary care physicians (&#8220;PCPs&#8221;) to be the agent for change in the communities they serve. We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost, and patient experience when provided with the right infrastructure and payment model. Through our combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, we believe we are poised to revolutionize healthcare for seniors across communities throughout the United States. We believe our purpose-built model provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. Our model operates by forming risk-bearing entities (&#8220;RBEs&#8221;) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of our physician partners&#8217; attributed patients (or, global capitation arrangements). The RBEs also contract with agilon to perform certain functions and enter into long-term professional service agreements with one or more anchor physician groups pursuant to which the anchor physician groups receive a base compensation rate and share in the savings from successfully improving quality of care and reducing costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business model is differentiated by its focus on existing community-based physician groups and is built around three key elements: (1) agilon&#8217;s platform; (2) agilon&#8217;s long-term physician partnership model; and (3) agilon&#8217;s network. With our model, our goal is to remove the barriers that prevent community-based physicians from evolving to a Total Care Model, where the physician is empowered to manage health outcomes and the total healthcare needs of their attributed Medicare patients.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Second Quarter 2025 Results: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Medicare Advantage members of approximately 497,500 as of June&#160;30, 2025 decreased 3% from June&#160;30, 2024.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">CMS ACO Models (defined below) attributed beneficiaries of approximately 116,000 as of June&#160;30, 2025 decreased 12% from June&#160;30, 2024.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Total revenue of $1.4 billion decreased 6% from the second quarter of 2024. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Gross profit of negative $52 million, compared to positive $32 million in the second quarter of 2024. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Medical margin of negative $53 million, compared to positive of $106 million in the second quarter of 2024. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Net loss of $104 million, compared to $31 million in the second quarter of 2024. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Adjusted EBITDA loss of $83 million, compared to $3 million in the second quarter of 2024.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year to Date 2025 Results as of June&#160;30, 2025: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Total revenue of $2.9 billion decreased 5% from the first half of 2024. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Gross profit of negative $2 million, compared to positive $107 million in the first half of 2024. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Medical margin of $75 million, compared to $263 million in the first half of 2024. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Net loss of $92 million, compared to $37 million in the first half of 2024. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Adjusted EBITDA loss of $63 million, compared to earnings of $26 million in the first half of 2024.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Platform Membership Details </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage members decreased 3% from June&#160;30, 2024, which includes market exits during 2024, partially offset by contributions from new geographies and growth within geographies existing prior to 2024. Total members live on the agilon platform at June&#160;30, 2025 include 497,500 Medicare Advantage members and 116,000 attributed CMS ACO Models beneficiaries. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Average Medicare Advantage membership was 497,700 during the second quarter of 2025. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payor Data Pipeline </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, we implemented a payor data pipeline (the &#8220;Model&#8221;) and began onboarding certain payors onto the Mode. The Model provides enhanced visibility into member risk profiles and risk adjustment factors by integrating and interpreting the data received from our payor partners. We are continuing the process of onboarding our payors onto the Model.</span></div><div id="i55e39828e2d148b0a62c1216246b0676_88"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Key Financial and Operating Metrics</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All of our key metrics exclude historical results from our Hawaii operations (which are included as discontinued operations in our condensed consolidated financial statements). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the following key financial and operating metrics to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. We believe the following key metrics are useful in evaluating our business (dollars in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">As of and For the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">As of and For the</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MA members</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">497,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">512,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">497,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">512,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,392,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,479,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,921,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,080,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(52,427)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,705)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical margin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(53,206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">262,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Platform support costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">81,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">87,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(104,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(92,258)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(36,696)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(83,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(62,766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Medical margin and Adjusted EBITDA are non-GAAP financial measures. Gross profit (loss) is the most directly comparable financial measure calculated in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) to medical margin. Net income (loss) is the most directly comparable financial measure calculated in accordance with U.S. GAAP to Adjusted EBITDA. See &#8220;&#8212;Non-GAAP Financial Measures" below for additional information. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Advantage Members</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our MA members include all individuals enrolled in an MA plan that are attributed to the PCPs on our platform at the end of a given period.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Services Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our medical services revenue consists of capitation revenue under contracts with various payors. Under the typical capitation arrangement, we are entitled to per member per month (&#8220;PMPM&#8221;) fees to provide a defined range of healthcare </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">services for MA health plan members through our contracted physician partners and affiliated PCPs. Such fees are typically based on a defined percentage of corresponding premium that payors receive from the Centers for Medicare &amp; Medicaid Services' (&#8220;CMS&#8221;). We recognize capitation revenue over the period eligible members are entitled to receive healthcare services. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit (Loss)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit (loss) represents the amount earned from total revenues less medical services expense and other medical expenses. Total revenues include medical services revenue and other operating revenue. The Company&#8217;s costs of revenues consist of medical services expense and other medical expenses, which represents the costs that are directly related to providing the services that generate revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our gross profit (loss) (dollars in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:44.271%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,394,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,482,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,927,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,087,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,445,245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,374,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,847,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,817,902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(76,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(82,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(161,947)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(52,427)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32,175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,705)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Represents physician compensation expense related to surplus sharing and other care management expenses that help to create medical cost efficiency. Includes costs in geographies that are in implementation and are not yet generating revenue and investments to grow existing markets. For the three months ended June 30, 2025 and 2024, costs incurred in implementing geographies were $0.2 million and $0, respectively.  For the six months ended June 30, 2025 and 2024, costs incurred in implementing geographies were $(1.0) million and $0.6 million, respectively.  </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Margin</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We define medical margin as medical services revenue after medical services expense is deducted. Medical services expense represents costs incurred for medical services provided to our members. As our platform matures over time, we expect medical margin to increase in absolute dollars. However, medical margin PMPM may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to medical margin PMPM. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;&#8212;Non-GAAP Financial Measures&#8221; below for additional information regarding our use of medical margin and a reconciliation of gross profit (loss) to medical margin.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Platform Support Costs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our platform support costs, which include regionally-based support personnel and other operating costs to support our geographies, are expected to decrease over time as a percentage of revenue as our physician partners add members and our revenue grows. Our operating expenses at the enterprise level include resources and technology to support payor contracting, clinical program development, quality, data management, finance, and legal and compliance functions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents costs to support our live geographies and enterprise functions, which are included in general and administrative expenses (dollars in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Platform support costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">81,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">87,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">% of Revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) and Adjusted EBITDA</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) is the most directly comparable U.S. GAAP measure to Adjusted EBITDA. We define Adjusted EBITDA as net income (loss) adjusted to exclude: (i) income (loss) from discontinued operations, net of income taxes, (ii) interest expense, (iii) income tax expense (benefit), (iv) depreciation and amortization, (v) stock-based compensation expense, (vi) severance and related costs, and (vii) certain other items that are not considered by us in the evaluation of ongoing operating performance. We reflect our share of Adjusted EBITDA for equity method investments by applying our actual ownership percentage for the period to the applicable reconciling items on an entity-by-entity basis. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;&#8212;Non-GAAP Financial Measures&#8221; below for additional information regarding our use of Adjusted EBITDA and a reconciliation of net income (loss) to Adjusted EBITDA.</span></div><div id="i55e39828e2d148b0a62c1216246b0676_91"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Key Components of Our Results of Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Services Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our medical services revenue consists of capitation revenue under contracts with various payors. Under the typical capitation arrangement, we are entitled to PMPM fees to provide a defined range of healthcare services for MA health plan members through our contracted physician partners and affiliated PCPs. Such fees are typically based on a defined percentage of corresponding premium that payors receive from CMS. We recognize capitation revenue over the period eligible members are entitled to receive healthcare services. In certain of our payor arrangements, we are also financially responsible for Medicare Part D pharmaceutical costs for prescriptions rendered to members.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue constitutes substantially all of our total revenue for the three and six months ended June&#160;30, 2025 and 2024. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Services Expense</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In each of our geographies, a network of physicians, hospitals, and other healthcare providers provide care to our members. Medical services expense represents costs incurred for medical services provided to our members. Our medical services expense trends primarily relate to changes in per visit costs incurred by our members, along with changes in health system and provider utilization of services. Medical services expenses are recognized in the period in which services are provided and include estimates of our obligations for medical services that have been rendered by third parties but for which claims have either not yet been received, processed, or paid.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Medical Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses include: (i) partner physician compensation expense and (ii) other provider costs. Partner physician compensation expense represents obligations to our physician partners corresponding to a portion of the surplus generated in our geographies, which is a function of medical services revenues less the sum of medical services expenses, other provider costs and market operating costs, for the respective geography. Physician payment obligations are reconciled quarterly, and settlement payments are typically issued to providers on an annual basis in arrears, with interim payments issued periodically. Other provider costs include payments to support physician-patient engagement, certain other medical costs, and other care management expenses that help to create medical cost efficiency. Other provider costs include costs incurred for geographies that are in implementation and are not yet generating revenue.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of market-based support personnel and other operating costs to support our geographies, personnel and other operating costs to support our enterprise functions, and investments to support development and expansion of our physician partners. Our enterprise functions include salaries and related expenses, stock-based compensation (including shares issued under partner physician group equity agreements), operational support expenses, technology infrastructure, finance, and legal, as well as other costs associated with the continued growth of our platform. For the purposes of calculating physician partner incentive expense, we allocate a portion of our enterprise general and administrative expenses to our geographies. General and administrative expenses also include severance and accruals for unasserted claims.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses are associated with our property and equipment and acquired intangible assets. Depreciation includes expenses associated with computer equipment and software, furniture and fixtures, and leasehold improvements. Amortization primarily includes expenses associated with acquired intangible assets.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) from equity method investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from equity method investments consists primarily of income associated with our participation in the CMS the Accountable Care Organization Realizing Equity, Access, and Community Health (&#8220;ACO REACH&#8221;) Model and Shared Savings Program (&#8220;MSSP&#8221;), (collectively, &#8220;CMS ACO Models&#8221;).</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net includes interest income, which consists primarily of interest earned on our cash and cash equivalents, restricted cash and equivalents, and marketable securities, including amortization/accretion of discount/premium.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists primarily of interest expense associated with our outstanding debt, including amortization of debt discounts and issuance costs.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Benefit (Expense)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to corporate U.S. federal, state, foreign, and local income taxation. Deferred tax assets are reduced by a valuation allowance to the extent management believes it is not more likely than not to be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income. Management makes estimates and judgments about future taxable income based on assumptions that are consistent with our plans and estimates.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the &#8220;One Big Beautiful Bill Act&#8221; was signed into law in the U.S., which contains a broad range of tax reform provisions. We are evaluating the provisions of the legislation and the potential effects on our estimated annual effective tax rate, financial position, results of operations, and cash flows. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total discontinued operations primarily consist of the results of our former Hawaii operations. For certain of our divestiture transactions, we continue to be responsible for any liabilities arising from the business that were incurred prior to the closing date of such transaction, including any fines, penalties, and other sanctions, the payment of claims for medical services incurred prior to the effective date of each transaction, and other contingent liabilities that we currently believe are remote. For additional discussion, see Note 15 to the Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes key components of our results of operations (dollars in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,392,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,479,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,921,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,080,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other operating revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,394,982&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,482,758&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,927,764&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,087,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,445,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,374,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,847,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,817,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">82,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">161,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">69,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">146,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,511,009&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,526,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,065,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,137,634&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(116,027)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(43,344)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(138,137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(50,522)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,572)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,981)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(104,308)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30,245)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(106,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27,131)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(104,370)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30,662)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(106,258)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27,415)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued operations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before gain (loss) on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments on sale of assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8,763)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9,281)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(104,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30,662)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(92,258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(36,696)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests&#8217; share in (earnings) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) attributable to common shares</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(104,370)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30,682)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(92,258)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(36,746)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations as a percentage of total revenues:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other operating revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">108&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">103&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before gain (loss) on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on sales of assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests&#8217; share in (earnings) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) attributable to common shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three and Six Months Ended June&#160;30, 2025 to the Three and Six Months Ended June&#160;30, 2024</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Services Revenue</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,392,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,479,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(87,540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Medical services revenue decreased for the three months ended June&#160;30, 2025 primarily due to: (i) declines in average membership, which was attributable to the partnership exits during 2024, (ii) lower risk adjustment revenue, including unfavorable prior period development, as a result of additional risk adjustment data received from the payors and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(iii) higher costs associated with prescription drug benefits provided under the Medicare Part D program, which is a reduction to medical services revenue, related to unfavorable prior period development.  </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,921,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,080,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(158,856)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Medical services revenue decreased for the six months ended June&#160;30, 2025 primarily due to: (i) declines in average membership, which was attributable to the partnership exits during 2024, (ii) lower risk adjustment revenue, including unfavorable prior period development, as a result of additional risk adjustment data received from the payors and (iii) higher costs associated with prescription drug benefits provided under the Medicare Part D program, which is a reduction to medical services revenue, related to unfavorable prior period development.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Services Expense</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,445,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,374,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">71,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense increased for the three months ended June&#160;30, 2025 due primarily to an increase in average medical services expense per member of 7%, partially offset by a decline in average membership of 2%, which was attributable to the partnership exits during 2024. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,847,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,817,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense increased for the six months ended June&#160;30, 2025 due primarily to an increase in average medical services expense per member of 5%, partially offset by a decline in average membership of 4%, which was attributable to the partnership exits during 2024. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Medical Expenses</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(74,359)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(97)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses decreased by $74.4 million, or 97%, for the three months ended June&#160;30, 2025 compared to the same period in 2024. Partner physician incentive expense decreased by $65.2 million to $(34.9) million in 2025 compared to $30.3 million in the same period in 2024 as a result of the partnership exits during 2024 and recent losses generated in certain of our geographies, which is a function of medical services revenues less the sum of medical services expenses, other provider costs and market operating costs, for the respective geography. Other provider costs decreased by $9.3 million to $36.9 million in 2025 compared to $46.2 million in the same period in 2024, resulting from the partnership exits during 2024. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">82,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">161,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(79,590)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(49)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses decreased by $79.6 million, or 49%, for the six months ended June&#160;30, 2025 compared to the same period in 2024. Partner physician incentive expense decreased by $71.0 million to $9.1 million in 2025 compared to $80.1 million in the same period in 2024 as a result of the partnership exits during 2024 and recent losses generated in certain of our geographies, which is a function of medical services revenues less the sum of medical services expenses, other provider costs and market operating costs, for the respective geography. Other provider costs decreased by $6.9 million to $74.3 million in 2025 compared to $81.2 million in the same period in 2024, resulting from the partnership exits during 2024. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">69,612&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13,331)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses decreased $13.3 million, or 19%, for the three months ended June&#160;30, 2025 compared to the same period in 2024. Operating costs to support our live geographies and enterprise functions (platform support costs) decreased to $37.4 million in 2025, compared to $41.7 million in the same period in 2024. Investments to support geography entry decreased to $4.2 million in 2025, compared to $4.8 million in the same period in 2024 due to decreased costs associated with our geographies that are expected to become operational in subsequent calendar years and the expansion into existing geographies. In aggregate, costs incurred for severance, transaction related costs, and stock-based compensation expense decreased $8.4 million in 2025 primarily due to a reduction in severance and the cancellation of certain stock-based instruments during the second half of 2024. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122,237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">146,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(23,797)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses decreased $23.8 million, or 16%, for the six months ended June&#160;30, 2025 compared to the same period in 2024. Operating costs to support our live geographies and enterprise functions (platform support costs) decreased to $81.7 million in 2025, compared to $87.4 million in the same period in 2024. Investments to support geography entry decreased to $10.8 million in 2025, compared to $15.3 million in the same period in 2024 due to decreased costs associated with our geographies that are expected to become operational in subsequent calendar years and the expansion into existing geographies. In aggregate, costs incurred for severance, transaction related costs, and stock-based compensation expense decreased $13.5 million in 2025 primarily due to a reduction in severance and the cancellation of certain stock-based instruments during the second half of 2024. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income (loss) from equity method investments</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from equity method investments</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,412&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,955&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4,543)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(46)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from equity method investments decreased $4.5 million, or 46%, for the three months ended June&#160;30, 2025 compared to the same period in 2024 primarily from increases in operating expenses during 2025 compared to 2024 from our CMS ACO Models investments.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from equity method investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">% of total revenues</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from equity method investments increased $2.4 million, or 16%, for the six months ended June&#160;30, 2025 compared to the same period in 2024 primarily from the higher medical margin in 2025 from our CMS ACO Models investments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense), net</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net increased $3.0 million, or 63%, for the three months ended June&#160;30, 2025 compared to the same period in 2024 primarily from $4.3 million of income related to services rendered to our CMS ACO Models investments that was recognized in 2025.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net increased $6.4 million, or 60%, for the six months ended June&#160;30, 2025 compared to the same period in 2024 primarily from $8.5 million of income related to services rendered to our CMS ACO Models investments that was recognized in 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Discontinued Operations</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9,281)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total discontinued operations relates to the sale of our Hawaii operations in October 2023. Total discontinued operations for the six months ended June&#160;30, 2025 relates to the release of a contingent obligation from our Hawaii operations compared to losses from discontinued operations for the six months ended June&#160;30, 2024.</span></div><div id="i55e39828e2d148b0a62c1216246b0676_97"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to providing results that are determined in accordance with U.S. GAAP, we present medical margin and Adjusted EBITDA, which are non-GAAP financial measures.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We define medical margin as medical services revenue after medical services expense is deducted. Medical services expense represents costs incurred for medical services provided to our members. As our platform matures over time, we expect medical margin to increase in absolute dollars. However, medical margin PMPM may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to medical margin PMPM. We believe this metric provides insight into the economics of our capitation arrangements as it includes all medical services expense directly associated with our members&#8217; care.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We define Adjusted EBITDA as net income (loss) adjusted to exclude: (i) income (loss) from discontinued operations, net of income taxes, (ii) interest expense, (iii) income tax expense (benefit), (iv) depreciation and amortization, (v) stock-based compensation expense, (vi) severance and related costs, and (vii) certain other items that are not considered by us in the evaluation of ongoing operating performance. We reflect our share of Adjusted EBITDA for equity method investments by applying our actual ownership percentage for the period to the applicable reconciling items on an entity-by-entity basis. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit (loss) is the most directly comparable U.S. GAAP measure to medical margin. Net income (loss) is the most directly comparable U.S. GAAP measure to Adjusted EBITDA. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe medical margin and Adjusted EBITDA help identify underlying trends in our business and facilitate evaluation of period-to-period operating performance of our operations by eliminating items that are variable in nature and not considered by us in the evaluation of ongoing operating performance, allowing comparison of our recurring core business operating results over multiple periods. We also believe medical margin and Adjusted EBITDA provide useful information about our operating results, enhance the overall understanding of our past performance and future prospects, and allow for greater transparency with respect to key metrics we use for financial and operational decision-making. We believe medical margin and Adjusted EBITDA or similarly titled non-GAAP measures are widely used by investors, securities analysts, ratings agencies, and other parties in evaluating companies in our industry as a measure of financial performance. Other companies may calculate medical margin and Adjusted EBITDA or similarly titled non-GAAP measures differently from the way we calculate these metrics. As a result, our presentation of medical margin and Adjusted EBITDA may not be comparable to similarly titled measures of other companies, limiting their usefulness as comparative measures. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is not considered a measure of financial performance under U.S. GAAP, and the items excluded therefrom are significant components in understanding and assessing our financial performance. Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as an alternative to such U.S. GAAP measures as net income (loss), cash flows provided by or used in operating, investing, or financing activities or other financial statement data presented in our consolidated financial statements as an indicator of financial performance or liquidity. Some of these limitations are:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Adjusted EBITDA does not reflect interest expense or the requirements necessary to service interest or principal payments on debt;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Adjusted EBITDA does not reflect income tax expense (benefit) or the cash requirements to pay taxes;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Although depreciation and amortization charges are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The expenses and other items that we exclude in our calculation of Adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from similarly titled non-GAAP financial measures.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a reconciliation of gross profit (loss) to medical margin using data derived from our condensed consolidated financial statements for the periods indicated (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit (loss)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(52,427)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,705)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other operating revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3,179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">82,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">161,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical margin</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(53,206)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74,806&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">262,872&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Gross profit (loss) is defined as total revenues less medical services expense and other medical expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a reconciliation of net income (loss) to Adjusted EBITDA using data derived from our condensed consolidated financial statements for the periods indicated (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(104,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30,662)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(92,258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(36,696)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Income) loss from discontinued operations, net of income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(14,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Severance and related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">EBITDA adjustments related to equity method investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(18,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,082)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(83,333)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,830)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(62,766)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="margin-bottom:3pt;margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Includes elimination of certain administrative services provided by agilon health, inc. to equity method investments.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Includes interest income, transaction-related costs and elimination of certain administrative services provided by agilon health, inc. to equity method investments.</span></div><div style="text-align:justify;text-indent:-18pt"><span><br/></span></div><div id="i55e39828e2d148b0a62c1216246b0676_100"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operations primarily through funds generated from our capitation arrangements with payors, issuances of equity securities, and borrowings under credit agreements. We generally invest any excess cash in money market accounts, which are classified as cash equivalents, and marketable securities. Our investment strategies are designed to provide safety and preservation of capital, sufficient liquidity to meet the cash flow needs of our business operations, and attainment of a competitive return. As of June&#160;30, 2025, we had cash and cash equivalents of $171.4 million and investments in marketable securities of $155.6 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur operating losses and generate negative cash flows from operations for the foreseeable future due to the investments we intend to continue to make in expanding our business and additional general and administrative costs we expect to incur related to our operation as a public company. As a result, we may require additional capital resources in the future to execute strategic initiatives to grow our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash include payments for medical claims and other medical expenses, general and administrative expenses, costs associated with the development of new geographies and expansion of existing geographies, debt service, and capital expenditures. Final reconciliation and receipt of amounts due from payors are typically settled in arrears, following completion of the contractual program year. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on our planned operations, we believe that our existing cash and cash equivalents, investments in marketable securities, as well as available borrowing capacity under the Credit Facility (defined below), will be sufficient to meet our working capital and capital expenditure needs over at least the next 12 months, though we may require additional capital resources in the future. We have based these estimates on assumptions that may prove to be wrong and we could utilize our available capital resources sooner than we expect. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional financing in the future to fund working capital and pay our obligations. We may seek to raise any necessary additional capital through a combination of public or private equity offerings and/or debt financings. There can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us, if at all. If adequate funds are not available on acceptable terms when needed, we may be required to significantly reduce operating expenses, which may have a material adverse effect on our business, financial condition, cash flows, and results of operations. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to pay dividends to holders of our common stock is significantly limited as a practical matter by our growth plans as well as the Credit Facility insofar as we may seek to pay dividends out of funds made available to us by agilon health management, inc. (&#8220;agilon management&#8221;) or its subsidiaries because the Credit Facility restricts agilon management&#8217;s ability to pay dividends or make loans to us. The borrower on the Credit Facility is agilon management, our wholly-owned subsidiary. The Credit Facility is guaranteed by certain of our subsidiaries, including those identified as variable interest entities, and contain customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following summary discussion of our cash flows is based on the condensed consolidated statements of cash flows. The following table sets forth changes in cash flows (dollars in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(67,072)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(66,493)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">69,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(22,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided By (Used In) Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $67.1 million for the six months ended June&#160;30, 2025 compared to $66.5 million for the six months ended June&#160;30, 2024. Net cash used in operating activities remained relatively flat. Our cash flow from operations is dependent upon the number of members on our platform, the timing of settlements with payors, and the level of operating and general and administrative expenses necessary to operate and grow our business, among other factors.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided By (Used In) Investing Activities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $47.4 million for the six months ended June&#160;30, 2025 compared to $69.7 million for the six months ended June&#160;30, 2024. During the six months ended June&#160;30, 2025, we received proceeds from the maturities of marketable securities of $125.3 million and made investments of $78.0 million primarily for marketable securities, and the acquisition of intangible assets and property and equipment. During the six months ended June&#160;30, 2024, we received proceeds from the maturities of marketable securities of $115.7 million and made investments of $46.1 million primarily for marketable securities, and the acquisition of intangible assets and property and equipment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided By (Used In) Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $2.7 million for the six months ended June&#160;30, 2025, relating to equity issuances, compared to net cash used in financing activities of $1.2 million for the six months ended June&#160;30, 2024, related to repayments of debt.  </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2021, we executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021 and the Second Amendment to Credit Agreement, dated as of May 25, 2023, the &#8220;Credit Facility&#8221;). The Credit Facility includes: (i) a $100.0 million senior secured term loan (the &#8220;Secured Term Loan Facility&#8221;) and (ii) a $100.0 million senior secured revolving credit facility (the &#8220;Secured Revolving Facility&#8221;) with a capacity to issue standby letters of credit in certain circumstances up to a maximum of $100.0 million. Subject to specified conditions and receipt of commitments, the Secured Term Loan Facility may be expanded (or a new term loan facility, revolving credit facility or letter of credit facility added) by up to (i) $50.0 million plus (ii) an additional amount determined in accordance with a formula tied to repayment of certain of our indebtedness. The maturity date of the Credit Facility is February 18, 2026.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective with the Second Amendment to Credit Agreement on May 25, 2023, we transitioned to the Secured Overnight Financing Rate (&#8220;SOFR&#8221;) as a benchmark interest rate used in the Credit Agreement. At our option, borrowings under the Credit Facility can be either: (i) SOFR Rate Loans, (ii) Daily Simple SOFR Rate Loans, or (iii) Base Rate Loans. Daily Simple SOFR Rate Loans and SOFR Rate Loans bear interest at a rate equal to the sum of 3.50% and the higher of (a) SOFR, as defined in the Credit Agreement, and (b) 0%. Base Rate Loans bear interest at a rate equal to the sum of 2.50% and the highest of: (a) 0.50% in excess of the overnight federal funds rate, (b) the prime rate established by the administrative agent from time to time, (c) the one-month SOFR rate (adjusted for maximum reserves) plus 1.00% and (d) 0%. Additionally, we pay a commitment fee on the unfunded Secured Revolving Facility amount of 0.375%. We must also pay customary letter of credit fees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility contains customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion on our debt obligations, see Note 8 to the Condensed Consolidated Financial Statements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, we had 414.3&#160;million shares of common stock outstanding. See Note 10 to the Condensed Consolidated Financial Statements for additional information about our equity transactions.</span></div><div id="i55e39828e2d148b0a62c1216246b0676_103"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our historical experience, known trends and events, and various other assumptions that we believe are reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our condensed consolidated financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. A summary of our critical accounting policies is included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2024 in Part II, Item 7 &#8220;Management&#8217;s Discussion and Analysis of Financial Conditions and Results of Operations - Critical Accounting Policies&#8221; and Note 2 to the Condensed Consolidated Financial Statements. There have been no significant changes to our critical accounting policies during 2025. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the impact of new accounting standards, see Note 2 to the Condensed Consolidated Financial Statements.</span></div><div id="i55e39828e2d148b0a62c1216246b0676_109"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to various market risks, including the potential loss arising from adverse changes in interest rates. We do not use derivative financial instruments in the normal course of business or for speculative or trading purposes. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our exposures to market risk for changes in interest expense relate primarily to the Credit Facility. Indebtedness under the Credit Facility is floating rate debt and is carried at amortized cost. Therefore, fluctuations in interest rates will impact our consolidated financial statements. A rising interest rate environment will increase the amount of interest paid on this debt. A hypothetical 100 basis point change in interest rates would not have a material impact on our interest expense. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We held cash, cash equivalents, restricted cash and equivalents, and marketable securities of $327.0 million and $405.6 million as of June&#160;30, 2025 and December&#160;31, 2024, respectively, consisting of bank deposits, certificates of deposits, money market funds, U.S. Treasury notes, and corporate debt securities. Such interest-earning instruments carry a degree of interest rate risk. A hypothetical 100 basis point change in interest rates would not have a material impact on the fair value of our marketable securities. Declines in interest rates over time will reduce our investment income. The goals of our investment policy are liquidity and capital preservation. We do not enter into investments for trading or speculative purposes.</span></div><div id="i55e39828e2d148b0a62c1216246b0676_112"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Our interim Principal Executive Officers (each a &#8220;PEO&#8221; and together, the &#8220;PEOs&#8221;), one of whom also serves as our Chief Financial Officer (&#8220;CFO&#8221;), with the assistance of other members of management, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our PEOs and our CFO have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required to disclose in the reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s (&#8220;SEC&#8221;) rules and forms and (2) accumulated and communicated to our management, including our PEOs and our CFO, as appropriate to allow timely decisions regarding required disclosure. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect every misstatement. An evaluation of effectiveness is subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may decrease over time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Under applicable SEC rules (Exchange Act Rules 13a-15(d) and 15d-15(d)), management is required to evaluate any change in internal control over financial reporting that occurred during each fiscal quarter that had materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. There were no changes in our internal control over financial reporting that occurred during our most recently completed fiscal quarter ended June&#160;30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i55e39828e2d148b0a62c1216246b0676_118"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See the &#8220;Legal Proceedings&#8221; section of Note 9 to the Condensed Consolidated Financial Statements for information regarding legal proceedings, which information is incorporated by reference in this Item 1.</span></div><div id="i55e39828e2d148b0a62c1216246b0676_121"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the information set forth in this Form 10-Q, you should carefully consider the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2024. There have been no material changes to the risk factors disclosed in the Form 10-K.</span></div><div id="i55e39828e2d148b0a62c1216246b0676_124"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our agreements with our physician partner entities provide for grants of time-vested restricted stock units and performance-based restricted stock units (collectively, RSUs) to the physician partner entities. On May 19, 2025, and June 16, 2025, we issued 80,091 and 14,401 shares of our common stock upon vesting of RSUs, respectively, to our physician partners for a total of $218,807. The issuances of the common stock were exempt from registration under the Securities Act by virtue of Section 4(a)(2) of the Securities Act. These transactions did not involve any public offering, any underwriters, any underwriting discounts or commissions, or any general solicitation or advertising. The shares of common stock issued are subject to appropriate restrictive legends and the physician partner entities represented they would not transfer or distribute the common stock until all restrictions were cleared. All recipients had access, through their relationships with us or otherwise, to adequate information about us.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(c)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">None.</span></div><div id="i55e39828e2d148b0a62c1216246b0676_127"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) <ix:nonNumeric contextRef="c-15" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-781"><ix:nonNumeric contextRef="c-15" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-782">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-15" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-783"><ix:nonNumeric contextRef="c-15" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-784">terminated</ix:nonNumeric></ix:nonNumeric> any &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement&#8221; (as such terms are defined in Item 408 of Regulation S-K under the Act).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="-sec-extract:summary;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="ex10-1.htm">10.1&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex10-1.htm">Form of Employee Performance Restricted Stock Unit Agreement &#8211; Transformational Goal.&#8224;*</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="agl-20250630xexx311.htm">Certification by Benjamin Shaker, agilon&#8217;s interim Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(a).*</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="agl-20250630xexx312.htm">Certification by Jeffrey Schwaneke, agilon&#8217;s Principal Financial Officer and interim Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(a).*</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="agl-20250630xexx321.htm">Certification by Benjamin Shaker, agilon&#8217;s interim Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.**</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="agl-20250630xexx322.htm">Certification by Jeffrey Schwaneke, agilon&#8217;s Principal Financial Officer and interim Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.**</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt">Filed herewith.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">**</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26pt">Furnished herewith.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8224; &#160;&#160;&#160;&#160;Identifies each management contract or compensatory plan or arrangement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><div id="i55e39828e2d148b0a62c1216246b0676_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i55e39828e2d148b0a62c1216246b0676_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: August&#160;4, 2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agilon health, inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.19pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ JEFFREY SCHWANEKE</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.19pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Jeffrey Schwaneke</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.19pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer and Member of the Office of the Chairman</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.39pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.19pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer and Interim Principal Executive Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head><title>EX 10-1</title></head><body><div style="background-color: #E4E4E4; font-family: Arial, Sans Serif; word-wrap: break-word;"><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">1<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div id="i2dcfc617e1a34eee923147f1b6d1f260_1" style="position: absolute; top: 36pt;"></div><div style="line-height: 8pt; position: absolute; top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 503.43pt; position: absolute; text-decoration: none; white-space: pre;">Exhibit 10.1<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; text-decoration: none; white-space: pre; width: 520.65pt;">&#91;NOTE&#58; BRACKETED PARAGRAPHS REPRESENT ALTERNATE LANGUAGE FOR USE IN AWARDS TO<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 564.39pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 75.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; text-decoration: none; white-space: pre; width: 520.68pt;">CALIFORNIA EMPLOYEES AND REPLACE THE IMMEDIATE PRIOR PARAGRAPH. BRACKETED<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 564.42pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 88.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; text-decoration: none; white-space: pre; width: 379.28pt;">BLANK SPACES REPRESENT REDACTED PROPRIETARY INFORMATION&#93;<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 141.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 184.57pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre;">TRANSFORMATIONAL EMPLOYEE AWARD<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 154.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 147.86pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre;">PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 181.7pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 469.4pt;">This Transformational Employee Award Performance Restricted Stock Unit Agreement (the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 194.9pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 3.66pt;">&#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 48.3pt; position: absolute; text-decoration: underline; white-space: pre; width: 53.75pt;">Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.05pt; position: absolute; text-decoration: none; white-space: pre; width: 347.3pt;">&#8221;), by and between agilon health, inc., a Delaware corporation (the &#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 449.34999999999997pt; position: absolute; text-decoration: underline; white-space: pre; width: 47.04pt;">Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 496.39pt; position: absolute; text-decoration: none; white-space: pre; width: 53.59pt;">&#8221;), and the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 208.1pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 117.75pt;">Employee whose name<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 162.39pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 167.06pt; position: absolute; text-decoration: none; white-space: pre; width: 7.94pt;">is<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 175pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 179.67000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 14.66pt;">set<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 194.32999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 199pt; position: absolute; text-decoration: none; white-space: pre; width: 21.98pt;">forth<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 220.98000000000002pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 225.64999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 12.22pt;">on<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 237.87pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 242.54000000000002pt; position: absolute; text-decoration: underline; white-space: pre; width: 32.98pt;">Exhibit<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 275.52pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 280.19pt; position: absolute; text-decoration: underline; white-space: pre; width: 7.33pt;">A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 287.52pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 292.19pt; position: absolute; text-decoration: none; white-space: pre; width: 34.2pt;">hereto,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 326.39pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 331.06pt; position: absolute; text-decoration: none; white-space: pre; width: 7.94pt;">is<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 339pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 343.66999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 26.88pt;">being<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 370.55pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 375.21999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 37.26pt;">entered<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 412.47999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 417.15pt; position: absolute; text-decoration: none; white-space: pre; width: 17.71pt;">into<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 434.86pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 439.53pt; position: absolute; text-decoration: none; white-space: pre; width: 42.76pt;">pursuant<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 482.28999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 486.96pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 496.12pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 500.78999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 516.0600000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 520.73pt; position: absolute; text-decoration: none; white-space: pre; width: 29.32pt;">agilon<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0500000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 221.3pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 32.98pt;">health,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 77.62pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.18pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 82.8pt; position: absolute; text-decoration: none; white-space: pre; width: 17.1pt;">inc.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 99.9pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.18pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 105.08pt; position: absolute; text-decoration: none; white-space: pre; width: 384.5pt;">2021 Omnibus Equity Incentive Plan (as amended from time to time, the &#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 489.58pt; position: absolute; text-decoration: underline; white-space: pre; width: 21.99pt;">Plan<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 511.57pt; position: absolute; text-decoration: none; white-space: pre; width: 10.37pt;">&#8221;).<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 521.94pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 7.31pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 529.25pt; position: absolute; text-decoration: none; white-space: pre; width: 20.76pt;">This<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; text-decoration: none; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 234.5pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.43pt;">Agreement shall be dated as of the date it is accepted and agreed to by the Employee in accordance<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.07pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 247.7pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 86.99pt;">with Section 6(r).<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 131.63pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 7.32pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 138.95pt; position: absolute; text-decoration: none; white-space: pre; width: 54.36pt;">Capitalized<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 193.31pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 198.5pt; position: absolute; text-decoration: none; white-space: pre; width: 27.48pt;">terms<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 225.98000000000002pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 231.17000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 18.32pt;">that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 249.49pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 254.68pt; position: absolute; text-decoration: none; white-space: pre; width: 15.88pt;">are<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 270.56pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 275.75pt; position: absolute; text-decoration: none; white-space: pre; width: 23.83pt;">used<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 299.58pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 304.77pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">but<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 320.03999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 325.22999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 340.5pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 345.69pt; position: absolute; text-decoration: none; white-space: pre; width: 36.04pt;">defined<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 381.72999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 386.91999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 30.54pt;">herein<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 417.46pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 422.65pt; position: absolute; text-decoration: none; white-space: pre; width: 22.6pt;">shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 445.25pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 450.44pt; position: absolute; text-decoration: none; white-space: pre; width: 23.83pt;">have<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 474.27pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 479.46pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 494.72999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 499.91999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 50.09pt;">respective<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 260.9pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 174.67pt;">meanings given to them in the Plan.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 286.1pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 41.09pt;">Section <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 121.73pt; letter-spacing: -0.022em; position: absolute; text-decoration: none; white-space: pre; width: 8.68pt;">1.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 130.41pt; position: absolute; width: 0pt;"><font style="display: inline-block; height: 8pt; width: 23.62pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 154.03pt; position: absolute; text-decoration: underline; white-space: pre; width: 27.48pt;">Grant<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 181.51pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 4.35pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 185.86pt; position: absolute; text-decoration: underline; white-space: pre; width: 166.79pt;">of Performance Restricted Stock <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 352.65pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 24.59pt;">Units<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 377.24pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 85.24pt;">.&#160; The Company <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 462.47999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 87.53pt;">hereby evidences<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 299.3pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 371.45pt;">and confirms its grant to the Employee, effective as of the date set forth on <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 416.09pt; position: absolute; text-decoration: underline; white-space: pre; width: 42.59pt;">Exhibit A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 458.68pt; position: absolute; text-decoration: none; white-space: pre; width: 34.63pt;"> hereto<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 493.31pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.34pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 496.65pt; position: absolute; text-decoration: none; white-space: pre; width: 18.93pt;">(the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 515.58pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.34pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 518.92pt; position: absolute; text-decoration: none; white-space: pre; width: 3.66pt;">&#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 522.58pt; position: absolute; text-decoration: underline; white-space: pre; width: 27.48pt;">Grant<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0600000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 312.5pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: underline; white-space: pre; width: 23.21pt;">Date<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 67.85pt; position: absolute; text-decoration: none; white-space: pre; width: 10.37pt;">&#8221;),<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 78.22pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 81.13pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 90.28999999999999pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 93.2pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 108.47pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 111.38pt; position: absolute; text-decoration: none; white-space: pre; width: 37.26pt;">number<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 148.64pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 151.55pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 160.70999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 163.62pt; position: absolute; text-decoration: none; white-space: pre; width: 62.91pt;">Performance<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 226.52999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 229.44pt; position: absolute; text-decoration: none; white-space: pre; width: 49.47pt;">Restricted<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 278.91pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 281.82pt; position: absolute; text-decoration: none; white-space: pre; width: 27.49pt;">Stock<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 309.31pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 312.21999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 25.04pt;">Units<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 337.26pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 340.16999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 7.32pt;">(&#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 347.49pt; position: absolute; text-decoration: underline; white-space: pre; width: 36.04pt;">PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 383.53pt; position: absolute; text-decoration: none; white-space: pre; width: 7.32pt;">&#8221;)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 390.84999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 393.76pt; position: absolute; text-decoration: none; white-space: pre; width: 11.61pt;">as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 405.37pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 408.28pt; position: absolute; text-decoration: none; white-space: pre; width: 141.7pt;">shall be determined pursuant<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 325.7pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 14.66pt;">to <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 59.3pt; position: absolute; text-decoration: underline; white-space: pre; width: 44.61pt;">Exhibit A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 103.91pt; position: absolute; text-decoration: none; white-space: pre; width: 345.75pt;"> and Section 2 hereof, subject to adjustment pursuant to the Plan.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 449.65999999999997pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 7.49pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 457.15pt; position: absolute; text-decoration: none; white-space: pre; width: 92.85pt;">This Agreement is<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 338.9pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.4pt;">entered into pursuant to, and the PRSUs granted hereunder are subject to, the terms and conditions of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 352.1pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 54.14pt;">the Plan.&#160; <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 98.78pt; position: absolute; text-decoration: underline; white-space: pre; width: 43.72pt;">Exhibit A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 142.5pt; position: absolute; text-decoration: none; white-space: pre; width: 407.48pt;"> hereto, and the terms and conditions of the Plan, are incorporated by reference<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 365.3pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 33.59pt;">herein.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 78.23pt; letter-spacing: 0.363em; position: absolute; text-decoration: none; white-space: pre; width: 7.28pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 85.50999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 464.52pt;">If there is any inconsistency between any express provision of this Agreement and any express<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 378.5pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 286.41pt;">term of the Plan, the express term of the Plan shall govern.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 403.7pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 453.83pt;">In consideration of the receipt of the PRSUs, the Employee confirms his or her agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 534.47pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 6.31pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 540.78pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.94pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 416.9pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 489.71pt;">comply with the restrictive covenants to which they have agreed or is agreeing to be bound by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 534.35pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 7.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 541.52pt; position: absolute; text-decoration: none; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.07pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 430.1pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 300.12pt;">respect of the Company and the Subsidiaries as set forth in <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 344.76pt; position: absolute; text-decoration: underline; white-space: pre; width: 44.16pt;">Exhibit B<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 388.91999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 78.12pt;"> hereto&#59; it being<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 467.03999999999996pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 5.84pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 472.88pt; position: absolute; text-decoration: none; white-space: pre; width: 77.15pt;">understood that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 443.3pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.43pt;">the Employee shall be required to comply with such restrictive covenants for the periods provided<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.07pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 456.5pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.42pt;">thereby, to the extent permitted by applicable law, even if the Employee has vested in or forfeited all of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0600000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 469.7pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 57.41pt;">the PRSUs.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 494.9pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 40.41pt;">Section <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 121.05pt; letter-spacing: -0.022em; position: absolute; text-decoration: none; white-space: pre; width: 8.68pt;">2.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 129.73000000000002pt; position: absolute; width: 0pt;"><font style="display: inline-block; height: 8pt; width: 23.62pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 153.35pt; position: absolute; text-decoration: underline; white-space: pre; width: 36.05pt;">Vesting<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 189.4pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 193.07pt; position: absolute; text-decoration: underline; white-space: pre; width: 164.07pt;">of Performance Restricted Stock <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 357.14pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 24.59pt;">Units<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 381.72999999999996pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 10.3pt;">.&#160; <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 392.03pt; position: absolute; text-decoration: none; white-space: pre; width: 157.98pt;">Except as otherwise provided in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 508.1pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.35pt;">this Section 2, the PRSUs shall become earned and vested, if at all, in accordance with the terms and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 521.3pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 193.29pt;">conditions of this Agreement (including,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 237.93pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 241.37pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">but<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 256.64pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 260.08pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 275.35pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 278.79pt; position: absolute; text-decoration: none; white-space: pre; width: 31.75pt;">limited<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 310.53999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 313.97999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 12.21pt;">to,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 326.19pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 329.63pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 344.9pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 348.34pt; position: absolute; text-decoration: none; white-space: pre; width: 49.48pt;">provisions<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 397.82pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 401.26pt; position: absolute; text-decoration: none; white-space: pre; width: 36.03pt;">relating<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 437.28999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 440.72999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 449.89pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 453.33pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 468.59999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 472.03999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 39.7pt;">earning,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 511.74pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 515.1800000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 34.82pt;">vesting<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 534.5pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 62.97pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.68pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 68.65pt; position: absolute; text-decoration: none; white-space: pre; width: 43.35pt;">forfeiture<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 112pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.68pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 117.68pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 126.84pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.68pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 132.51999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 125.61pt;">PRSUs as set forth on <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 258.13pt; position: absolute; text-decoration: underline; white-space: pre; width: 44.93pt;">Exhibit A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 303.06pt; position: absolute; text-decoration: none; white-space: pre; width: 246.91pt;"> hereto) and the Plan, subject to the continued<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 547.7pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.33pt;">employment of the Employee by the Company or any Subsidiary thereof through the Vesting Date set<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 560.9pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 21.98pt;">forth<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.62pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.58pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 70.2pt; position: absolute; text-decoration: none; white-space: pre; width: 12.22pt;">on<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 82.42pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.58pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 86pt; position: absolute; text-decoration: underline; white-space: pre; width: 32.98pt;">Exhibit<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 118.98pt; letter-spacing: -0.004em; position: absolute; text-decoration: underline; white-space: pre; width: 3.58pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 122.56pt; position: absolute; text-decoration: underline; white-space: pre; width: 6.73pt;">A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 129.29000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 64.6pt;"> hereto (the &#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 193.89pt; position: absolute; text-decoration: underline; white-space: pre; width: 62.88pt;">Vesting Date<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 256.77pt; position: absolute; text-decoration: none; white-space: pre; width: 10.37pt;">&#8221;).<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 267.14pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 5.61pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 272.75pt; position: absolute; text-decoration: none; white-space: pre; width: 35.43pt;">Earned<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 308.18pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.58pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 311.76pt; position: absolute; text-decoration: none; white-space: pre; width: 36.04pt;">PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 347.8pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.58pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 351.38pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">(as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 366.65pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.58pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 370.22999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 36.04pt;">defined<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 406.27pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.58pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 409.84999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 12.22pt;">on<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 422.07pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.58pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 425.65pt; position: absolute; text-decoration: underline; white-space: pre; width: 32.98pt;">Exhibit<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 458.63pt; letter-spacing: -0.004em; position: absolute; text-decoration: underline; white-space: pre; width: 3.58pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 462.21pt; position: absolute; text-decoration: underline; white-space: pre; width: 7.33pt;">A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 469.53999999999996pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.58pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 473.12pt; position: absolute; text-decoration: none; white-space: pre; width: 34.81pt;">hereto)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 507.93pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.58pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 511.51pt; position: absolute; text-decoration: none; white-space: pre; width: 38.44pt;">shall be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.95pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 574.1pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 244.3pt;">settled as provided in Section 3 of this Agreement.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 599.3pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 13.43pt;">(a)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 116.03pt;">Effect of Termination of <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 218.26999999999998pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 60.18pt;">Employment<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 278.45pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 9.38pt;">.&#160; <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 287.83pt; position: absolute; text-decoration: none; white-space: pre; width: 26.27pt;">Upon<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 314.1pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 3.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 317.21pt; position: absolute; text-decoration: none; white-space: pre; width: 54.35pt;">termination<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 371.56pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 3.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 374.67pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 383.83pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 3.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 386.94pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 402.21000000000004pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 3.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 405.32pt; position: absolute; text-decoration: none; white-space: pre; width: 56.62pt;">Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 461.94pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 3.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 465.05pt; position: absolute; text-decoration: none; white-space: pre; width: 59.86pt;">employment<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 524.91pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 3.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 528.02pt; position: absolute; text-decoration: none; white-space: pre; width: 21.98pt;">prior<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 2.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 612.5pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.37pt;">to the Vesting Date for any reason (whether initiated by the Company or by the Employee), all PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 625.7pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 460.91pt;">shall be forfeited and canceled for no consideration effective as of the date of such termination.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 650.9pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 13.43pt;">(b)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 141.73pt;">Effect of a Change in Control<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 243.96999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 247.01999999999998pt; letter-spacing: 0.3em; position: absolute; text-decoration: none; white-space: pre; width: 6.52pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 253.54000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 296.4pt;">In the event of a Change in Control prior to the Vesting Date,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 664.1pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 67.92pt;">the treatment <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 112.56pt; letter-spacing: -0.022em; position: absolute; text-decoration: none; white-space: pre; width: 88.49pt;">of any outstanding <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 201.05pt; position: absolute; text-decoration: none; white-space: pre; width: 256.6pt;">PRSUs shall be governed by Article XIV of the Plan&#59; <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 457.65pt; position: absolute; text-decoration: underline; white-space: pre; width: 42.15pt;">provided<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 499.8pt; position: absolute; text-decoration: none; white-space: pre; width: 6.17pt;">, <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 505.96999999999997pt; position: absolute; text-decoration: underline; white-space: pre; width: 40.94pt;">however<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 546.91pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 677.3pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.34pt;">that if the Administrator reasonably determines in good faith, prior to the occurrence of the Change in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 690.5pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.43pt;">Control, that no Alternative Awards will be provided in respect of outstanding PRSUs, any outstanding<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.07pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 2.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 703.7pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 36.04pt;">PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.68pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 3.66pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 84.34pt; position: absolute; text-decoration: none; white-space: pre; width: 22.6pt;">shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 106.94pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 3.66pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 110.6pt; position: absolute; text-decoration: none; white-space: pre; width: 20.16pt;">vest<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 130.76pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 3.66pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 134.42000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">at<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 143.57999999999998pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 3.66pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 147.24pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 162.51pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 97.53pt;"> target (100%) level <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 260.04pt; position: absolute; text-decoration: none; white-space: pre; width: 289.91pt;">as of the date of the Change in Control (with no vesting of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.95pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 716.9pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.33pt;">the PRSUs in excess of such target level unless otherwise provided by the Administrator in the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 730.1pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 76.96pt;">circumstances).<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 121.6pt; position: absolute; text-decoration: none; white-space: pre; width: 6.1pt;">&#160; <font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">2<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 12.82pt;">(c)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 129.37pt;">Discretionary Acceleration<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 231.61pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 234.65999999999997pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 7.36pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 242.01999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 287.55pt;">Notwithstanding anything contained in this Agreement to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 529.5699999999999pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.23pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 534.8pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 41.94pt;">contrary,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 86.58pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 90.84pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">but<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 106.11pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 110.37pt; position: absolute; text-decoration: none; white-space: pre; width: 34.82pt;">subject<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 145.19pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 149.45pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 158.61pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 162.87pt; position: absolute; text-decoration: none; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 180.58999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 184.85000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 25.03pt;">limits<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 209.88pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 214.14pt; position: absolute; text-decoration: none; white-space: pre; width: 51.31pt;">prescribed<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 265.45pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 269.71pt; position: absolute; text-decoration: none; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 278.26pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 282.52pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 297.79pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 302.05pt; position: absolute; text-decoration: none; white-space: pre; width: 25.04pt;">Plan,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 327.09pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 331.34999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 346.62pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 350.88pt; position: absolute; text-decoration: none; white-space: pre; width: 67.18pt;">Administrator,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 418.06pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 422.32pt; position: absolute; text-decoration: none; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 430.87pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 435.13pt; position: absolute; text-decoration: none; white-space: pre; width: 10.99pt;">its<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 446.12pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 450.38pt; position: absolute; text-decoration: none; white-space: pre; width: 74.64pt;">sole discretion,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 525.02pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.26pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 529.28pt; position: absolute; text-decoration: none; white-space: pre; width: 20.77pt;">may<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0500000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 50.7pt;">accelerate<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 95.34pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 99.00999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 114.28pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 117.95pt; position: absolute; text-decoration: none; white-space: pre; width: 34.82pt;">vesting<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 152.76999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 156.44pt; position: absolute; text-decoration: none; white-space: pre; width: 19.54pt;">with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 175.98000000000002pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 179.64999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 36.04pt;">respect<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 215.69pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 219.36pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 228.51999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 232.19pt; position: absolute; text-decoration: none; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 249.91000000000003pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 253.57999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 36.04pt;">PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 289.62pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 293.29pt; position: absolute; text-decoration: none; white-space: pre; width: 28.1pt;">under<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 321.39pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 325.06pt; position: absolute; text-decoration: none; white-space: pre; width: 17.1pt;">this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 342.15999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 345.83pt; position: absolute; text-decoration: none; white-space: pre; width: 56.8pt;">Agreement,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 402.63pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 406.3pt; position: absolute; text-decoration: none; white-space: pre; width: 143.68pt;">at such times and upon such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 75.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 282.16pt;">terms and conditions as the Administrator shall determine.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 100.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 13.43pt;">(d)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 153.31pt;">No Other Accelerated Vesting<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 255.55pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 258.6pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 8.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 266.69pt; position: absolute; text-decoration: none; white-space: pre; width: 283.34pt;">The vesting and settlement provisions set forth in this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.96pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 114pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 36.65pt;">Section<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 81.28999999999999pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 87.11pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">2,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 96.27000000000001pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.14pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 111.91pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 117.73pt; position: absolute; text-decoration: none; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 126.28pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 132.15pt; position: absolute; text-decoration: none; white-space: pre; width: 36.65pt;">Section<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 168.8pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 174.62pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">3,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 183.77999999999997pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 189.64999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 199.42000000000002pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 205.24pt; position: absolute; text-decoration: none; white-space: pre; width: 46.43pt;">expressly<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 251.67000000000002pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 257.54pt; position: absolute; text-decoration: none; white-space: pre; width: 14.66pt;">set<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 272.2pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 278.02pt; position: absolute; text-decoration: none; white-space: pre; width: 21.98pt;">forth<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 300pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 305.87pt; position: absolute; text-decoration: none; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 314.41999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 320.24pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 335.51pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 341.38pt; position: absolute; text-decoration: none; white-space: pre; width: 25.04pt;">Plan,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 366.41999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 372.24pt; position: absolute; text-decoration: none; white-space: pre; width: 22.6pt;">shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 394.84pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 400.71pt; position: absolute; text-decoration: none; white-space: pre; width: 12.22pt;">be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 412.93pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 418.75pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 434.02pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 439.89pt; position: absolute; text-decoration: none; white-space: pre; width: 45.21pt;">exclusive<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 485.09999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 490.91999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 34.82pt;">vesting<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 525.74pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 531.61pt; position: absolute; text-decoration: none; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.94pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 127.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.32pt;">settlement provisions applicable to the PRSUs and shall supersede any other provisions relating to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 140.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.43pt;">vesting and settlement, unless such other such provision expressly refers to the Plan by name and this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.07pt; position: absolute; text-decoration: none; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 153.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 147.81pt;">Agreement by name and date.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 178.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 39.7pt;">Section <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 120.34pt; letter-spacing: -0.022em; position: absolute; text-decoration: none; white-space: pre; width: 8.68pt;">3.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 129.02pt; position: absolute; width: 0pt;"><font style="display: inline-block; height: 8pt; width: 23.62pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 152.64pt; position: absolute; text-decoration: underline; white-space: pre; width: 52.52pt;">Settlement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 205.16pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 2.96pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 208.12pt; position: absolute; text-decoration: underline; white-space: pre; width: 12.21pt;">of <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 220.32999999999998pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 35.59pt;">PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 255.92000000000002pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.96pt;">.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 204pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 13.43pt;">(a)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 102.41pt;">Timing of Settlement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 204.64999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 207.7pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 6.07pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 213.76999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 336.24pt;">Subject to Section 6(a), any Earned PRSUs shall be settled into an<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 217.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.42pt;">equal number of shares of Company Common Stock on a date selected by the Company that is on or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0600000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 230.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 219.75pt;">within 30 days following the Vesting Date<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 264.39pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.35pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 270.74pt; position: absolute; text-decoration: none; white-space: pre; width: 18.93pt;">(the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 289.67pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.35pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 296.02pt; position: absolute; text-decoration: none; white-space: pre; width: 3.66pt;">&#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 299.68pt; position: absolute; text-decoration: underline; white-space: pre; width: 52.52pt;">Settlement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 352.2pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 6.35pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 358.55pt; position: absolute; text-decoration: underline; white-space: pre; width: 23.21pt;">Date<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 381.76pt; position: absolute; text-decoration: none; white-space: pre; width: 10.37pt;">&#8221;)&#59;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 392.13pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.35pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 398.47999999999996pt; position: absolute; text-decoration: underline; white-space: pre; width: 42.15pt;">provided<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 440.63pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.35pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 446.97999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 21.37pt;">that,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 468.34999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.35pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 474.7pt; position: absolute; text-decoration: none; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 483.25pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.35pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 489.59999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 504.87pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.35pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 511.21999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 23.22pt;">case<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 534.44pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.35pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 540.79pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.95pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 243.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 56.81pt;">accelerated<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 101.45pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.85pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 105.3pt; position: absolute; text-decoration: none; white-space: pre; width: 444.66pt;">vesting of PRSUs pursuant to Section 2(b) or 2(c), the PRSUs that vest pursuant to such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 256.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.33pt;">acceleration shall be settled in an equal number of shares of Company Common Stock on a date<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 270pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.44pt;">selected by the Company that is within 30 days following the vesting of such PRSUs (subject to Section<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.08pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 283.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 26.25pt;">6(a)).<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 308.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 13.43pt;">(b)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 52.54pt;">Mechanics<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 154.78pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: underline; white-space: pre; width: 5.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 159.8pt; position: absolute; text-decoration: underline; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 168.95999999999998pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: underline; white-space: pre; width: 5.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 173.98pt; position: absolute; text-decoration: underline; white-space: pre; width: 52.52pt;">Settlement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 226.5pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 229.55pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 7.2pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 236.75pt; position: absolute; text-decoration: none; white-space: pre; width: 14.66pt;">On<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 251.40999999999997pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 256.43pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 271.7pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 276.71999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 52.52pt;">Settlement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 329.24pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 334.26pt; position: absolute; text-decoration: none; white-space: pre; width: 215.72pt;">Date (or other applicable date pursuant to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 321.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 55.08pt;">Section 3),<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 99.72pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.42pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 105.14pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 120.41pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.42pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 125.83pt; position: absolute; text-decoration: none; white-space: pre; width: 47.04pt;">Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 172.87pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.42pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 178.29000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 22.6pt;">shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 200.89pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.42pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 206.31pt; position: absolute; text-decoration: none; white-space: pre; width: 343.7pt;">electronically issue to the Employee one whole share of Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 334.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.35pt;">Common Stock for each PRSU that became earned and vested as of the Settlement Date (except as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 348pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.39pt;">provided in Section 6(a)), and, upon such issuance, the Employee&#8217;s rights in respect of such PRSU<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 361.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 110.97pt;">shall be extinguished.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 155.61pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 7.69pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 163.3pt; position: absolute; text-decoration: none; white-space: pre; width: 386.65pt;">If there are any fractional PRSUs that became vested on such date, such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.95pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 374.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.35pt;">fractional PRSUs shall be settled through a cash payment equal to such fractional PRSU multiplied by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 387.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.33pt;">the Fair Market Value of one share of Company Common Stock on the Settlement Date. At the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 400.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.31pt;">Company&#8217;s election, the Company may choose to settle any fractional PRSUs by rounding up to the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.95pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 414pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 261.23pt;">next whole share rather than issuing a cash payment.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 305.87pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 5.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 311.03999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 238.98pt;">No fractional shares of Company Common Stock<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 427.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 196.05pt;">shall be issued in respect of the PRSUs.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 452.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 80.64pt; position: absolute; width: 54.45pt;">Section 4.<font style="display: inline-block; height: 8pt; width: 23.14pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 158.23000000000002pt; position: absolute; text-decoration: underline; white-space: pre; width: 143.72pt;">Securities Law Compliance<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 301.95pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 305pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 10.63pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 315.63pt; position: absolute; text-decoration: none; white-space: pre; width: 234.38pt;">Notwithstanding any other provision of this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; text-decoration: none; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 465.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.39pt;">Agreement, the Employee may not sell the shares of Company Common Stock acquired upon<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 478.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 50.69pt;">settlement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 95.33pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 101.05pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 110.21pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 115.93pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 131.2pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 136.92000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 36.04pt;">PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 172.95999999999998pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 178.68pt; position: absolute; text-decoration: none; white-space: pre; width: 31.77pt;">unless<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 210.45pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 216.17000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 23.22pt;">such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 239.39pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 245.11pt; position: absolute; text-decoration: none; white-space: pre; width: 32.99pt;">shares<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 278.1pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 283.82pt; position: absolute; text-decoration: none; white-space: pre; width: 15.88pt;">are<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 299.7pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 305.41999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 48.86pt;">registered<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 354.28pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 360pt; position: absolute; text-decoration: none; white-space: pre; width: 28.1pt;">under<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 388.09999999999997pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 393.82pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 409.09pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 414.81pt; position: absolute; text-decoration: none; white-space: pre; width: 48.25pt;">Securities<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 463.06pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 468.78pt; position: absolute; text-decoration: none; white-space: pre; width: 15.88pt;">Act<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 484.65999999999997pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 490.38pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 499.53999999999996pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 505.26pt; position: absolute; text-decoration: none; white-space: pre; width: 27.49pt;">1933,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 532.75pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 5.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 538.47pt; position: absolute; text-decoration: none; white-space: pre; width: 11.61pt;">as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.08pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 492pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 45.82pt;">amended<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 90.46000000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 93.52000000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 18.93pt;">(the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 112.45pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 115.51pt; position: absolute; text-decoration: none; white-space: pre; width: 3.66pt;">&#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 119.17pt; position: absolute; text-decoration: underline; white-space: pre; width: 48.25pt;">Securities<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 167.42000000000002pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 170.48000000000002pt; position: absolute; text-decoration: underline; white-space: pre; width: 15.88pt;">Act<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 186.36pt; position: absolute; text-decoration: none; white-space: pre; width: 10.37pt;">&#8221;),<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 196.73000000000002pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 199.79000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 12.22pt;">or,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 212.01pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 215.07pt; position: absolute; text-decoration: none; white-space: pre; width: 5.49pt;">if<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 220.56pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 223.62pt; position: absolute; text-decoration: none; white-space: pre; width: 23.22pt;">such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 246.83999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 249.89999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 32.99pt;">shares<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 282.89pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 285.95pt; position: absolute; text-decoration: none; white-space: pre; width: 15.88pt;">are<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 301.83pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 304.89pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 320.15999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 323.21999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 21.38pt;">then<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 344.59999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 347.65999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 11.61pt;">so<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 359.27pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 362.33pt; position: absolute; text-decoration: none; white-space: pre; width: 51.91pt;">registered,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 414.24pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 417.3pt; position: absolute; text-decoration: none; white-space: pre; width: 23.22pt;">such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 440.52pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 443.58pt; position: absolute; text-decoration: none; white-space: pre; width: 20.16pt;">sale<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 463.74pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 466.8pt; position: absolute; text-decoration: none; white-space: pre; width: 28.71pt;">would<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 495.51pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 498.57pt; position: absolute; text-decoration: none; white-space: pre; width: 51.46pt;">be exempt<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 505.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 270.33pt;">from the registration requirements of the Securities Act.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 314.96999999999997pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 5.36pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 320.33pt; position: absolute; text-decoration: none; white-space: pre; width: 168.66pt;">The sale of such shares must also<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 488.99pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.33pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 492.32pt; position: absolute; text-decoration: none; white-space: pre; width: 34.82pt;">comply<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 527.14pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.33pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 530.47pt; position: absolute; text-decoration: none; white-space: pre; width: 19.54pt;">with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 518.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 25.04pt;">other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 69.68pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 73.35pt; position: absolute; text-decoration: none; white-space: pre; width: 49.48pt;">applicable<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 122.83pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 126.5pt; position: absolute; text-decoration: none; white-space: pre; width: 21.99pt;">laws<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 148.49pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 152.16pt; position: absolute; text-decoration: none; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 170.49pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 174.16000000000003pt; position: absolute; text-decoration: none; white-space: pre; width: 53.75pt;">regulations<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 227.91000000000003pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 231.57999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 48.26pt;">governing<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 279.84pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 283.51pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 298.78pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 302.45pt; position: absolute; text-decoration: none; white-space: pre; width: 47.04pt;">Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 349.49pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 353.15999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 44.59pt;">Common<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 397.75pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre; width: 3.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 401.41999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 148.62pt;">Stock, and the Employee may<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 531.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.31pt;">not sell the shares of Company Common Stock if the Company determines that such sale would not be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.95pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 544.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 264.45pt;">in material compliance with such laws and regulations.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 570pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 80.64pt; position: absolute; width: 52.36pt;">Section 5.<font style="display: inline-block; height: 8pt; width: 23.14pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 156.14pt; position: absolute; text-decoration: underline; white-space: pre; width: 51.91pt;">Restriction<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 208.05pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: underline; white-space: pre; width: 6.36pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 214.41000000000003pt; position: absolute; text-decoration: underline; white-space: pre; width: 12.22pt;">on<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 226.63pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: underline; white-space: pre; width: 6.36pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 232.99pt; position: absolute; text-decoration: underline; white-space: pre; width: 43.56pt;">Transfer&#59;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 276.55pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: underline; white-space: pre; width: 6.36pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 282.91pt; position: absolute; text-decoration: underline; white-space: pre; width: 92.42pt;">Non-Transferability<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 375.33pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: underline; white-space: pre; width: 6.36pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 381.69pt; position: absolute; text-decoration: underline; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 390.84999999999997pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: underline; white-space: pre; width: 6.36pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 397.21pt; position: absolute; text-decoration: underline; white-space: pre; width: 36.04pt;">PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 433.25pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 436.3pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 8.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 444.84pt; position: absolute; text-decoration: none; white-space: pre; width: 18.93pt;">The<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 463.77pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 6.36pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 470.13pt; position: absolute; text-decoration: none; white-space: pre; width: 36.04pt;">PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 506.16999999999996pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 6.36pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 512.53pt; position: absolute; text-decoration: none; white-space: pre; width: 15.88pt;">are<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 528.41pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 6.36pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 534.77pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 583.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.31pt;">assignable or transferable, in whole or in part, and they may not, directly or indirectly, be offered,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.95pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 596.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.36pt;">transferred, sold, pledged, assigned, alienated, hypothecated or otherwise disposed of or encumbered<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 609.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.3pt;">(including, but not limited to, by gift, operation of law or otherwise) other than by will or by the laws of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.94pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 622.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 425.32pt;">descent and distribution to the estate of the Employee upon the Employee&#8217;s death.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 469.96pt; letter-spacing: 0.363em; position: absolute; text-decoration: none; white-space: pre; width: 9.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 479.02pt; position: absolute; text-decoration: none; white-space: pre; width: 71.04pt;">Any purported<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0600000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 636pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 240.61pt;">transfer in violation of this Section 5 shall be void <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: italic; font-weight: normal; left: 285.25pt; position: absolute; text-decoration: none; white-space: pre; width: 37.86pt;">ab initio<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 323.11pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 661.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 39.7pt;">Section <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 120.34pt; letter-spacing: -0.022em; position: absolute; text-decoration: none; white-space: pre; width: 8.68pt;">6.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 129.02pt; position: absolute; width: 0pt;"><font style="display: inline-block; height: 8pt; width: 23.62pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 152.64pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 68.47pt;">Miscellaneous<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 221.11pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.96pt;">.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 686.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 13.43pt;">(a)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 17.11pt;">Tax<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 119.35pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 6.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 125.78999999999999pt; position: absolute; text-decoration: underline; white-space: pre; width: 57.41pt;">Withholding<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 183.2pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 186.25pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 8.57pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 194.82pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">In<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 203.98pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 210.42000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 225.69pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 232.13pt; position: absolute; text-decoration: none; white-space: pre; width: 26.88pt;">event<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 259.01pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 265.45pt; position: absolute; text-decoration: none; white-space: pre; width: 18.32pt;">that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 283.77pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 290.21pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 305.48pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 311.92pt; position: absolute; text-decoration: none; white-space: pre; width: 47.04pt;">Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 358.96000000000004pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 365.40000000000003pt; position: absolute; text-decoration: none; white-space: pre; width: 31.76pt;">settles<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 397.16pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 403.6pt; position: absolute; text-decoration: none; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 421.32pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 427.76pt; position: absolute; text-decoration: none; white-space: pre; width: 36.04pt;">PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 463.8pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 470.24pt; position: absolute; text-decoration: none; white-space: pre; width: 26.27pt;">using<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 496.51pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 6.44pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 502.95pt; position: absolute; text-decoration: none; white-space: pre; width: 47.04pt;">Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 699.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 44.59pt;">Common<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 89.23pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 94.02000000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 30.54pt;">Stock,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 124.56pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 129.35pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 144.62pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 149.41pt; position: absolute; text-decoration: none; white-space: pre; width: 47.04pt;">Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 196.45pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 201.24pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 211.01pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 215.8pt; position: absolute; text-decoration: none; white-space: pre; width: 18.33pt;">one<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 234.13pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 238.92000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 248.07999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 252.87pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 268.14pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 272.93pt; position: absolute; text-decoration: none; white-space: pre; width: 59.86pt;">Subsidiaries<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 332.78999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 337.58pt; position: absolute; text-decoration: none; white-space: pre; width: 22.6pt;">shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 360.18pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 364.96999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 34.2pt;">require<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 399.16999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 403.96pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 419.22999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 424.02pt; position: absolute; text-decoration: none; white-space: pre; width: 48.87pt;">Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 472.89pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 477.68pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 486.84pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 491.63pt; position: absolute; text-decoration: none; white-space: pre; width: 24.42pt;">remit<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 516.0500000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 520.84pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 530pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 534.79pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0600000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 712.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.44pt;">Company an amount in cash sufficient to satisfy any applicable U.S. federal, state and local and non-<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 726pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.44pt;">U.S. tax withholding obligations that may arise in connection with the vesting of the PRSUs and the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.08pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 739.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 273.48pt;">related issuance of shares of Company Common Stock.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 318.12pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 5.28pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 323.4pt; position: absolute; text-decoration: none; white-space: pre; width: 226.57pt;">Notwithstanding the preceding sentence, if the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 752.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 321.17pt;">Employee elects not to remit cash in respect of such obligations, (<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 365.81pt; position: absolute; text-decoration: underline; white-space: pre; width: 5.5pt;">x<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 371.31pt; position: absolute; text-decoration: none; white-space: pre; width: 178.68pt;">) the Company shall retain a number<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">3<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.35pt;">of shares of Company Common Stock issued in respect of the PRSUs then vesting that have an<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.33pt;">aggregate Fair Market Value as of the Settlement Date equal to the amount of such taxes required to be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.37pt;">withheld not in excess of such amount as may be necessary to avoid liability award accounting and any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 75.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 314.55pt;">remaining amount shall be remitted in cash or withheld and (<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 359.19pt; position: absolute; text-decoration: underline; white-space: pre; width: 5.5pt;">y<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 364.69pt; position: absolute; text-decoration: none; white-space: pre; width: 185.32pt;">) the number of shares of Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 88.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.29pt;">Common Stock to be issued in respect of the PRSUs shall thereupon be reduced by the number of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9300000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 102pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.36pt;">shares of Company Common Stock so retained (and the Employee shall thereupon be deemed to have<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 115.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 281.92pt;">satisfied his or her obligations under this Section 6(a)).<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 326.56pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 7.15pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 333.71pt; position: absolute; text-decoration: none; white-space: pre; width: 216.29pt;">The method of withholding set forth in the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 128.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.31pt;">immediately preceding sentence shall not be available if withholding in this manner would violate any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.95pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 141.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.35pt;">financing instrument of the Company or any of the Subsidiaries. For country-specific tax withholding and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 154.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 172.81pt;">treatment, please refer to Exhibit D.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 180pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 13.43pt;">(b)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 104.32pt;">Dividend Equivalents<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 206.56pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 209.61pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 6.74pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 216.35pt; position: absolute; text-decoration: none; white-space: pre; width: 333.73pt;">If the Company pays any ordinary dividend in cash on a share of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 193.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.33pt;">Company Common Stock following the Grant Date and prior to the Date with respect to any PRSUs,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 206.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 416.32pt;">there shall be credited to the account of the Employee in respect of each outstanding<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 460.96pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.2pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 464.15999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 30.54pt;">PRSU<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 494.7pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.2pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 497.9pt; position: absolute; text-decoration: none; white-space: pre; width: 12.22pt;">an<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 510.12pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.2pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 513.32pt; position: absolute; text-decoration: none; white-space: pre; width: 36.65pt;">amount<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 219.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 26.88pt;">equal<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 71.52pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.93pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 74.45pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 83.61pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.93pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 86.53999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 101.81pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.93pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 104.74000000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 36.65pt;">amount<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 141.39pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.93pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 144.32pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 153.48000000000002pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.93pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 156.41pt; position: absolute; text-decoration: none; white-space: pre; width: 23.22pt;">such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 179.63pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.93pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 182.56pt; position: absolute; text-decoration: none; white-space: pre; width: 43.98pt;">dividend.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 226.54000000000002pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 5.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 231.60000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 18.93pt;">The<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 250.52999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.93pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 253.45999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 36.65pt;">amount<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 290.11pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.93pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 293.04pt; position: absolute; text-decoration: none; white-space: pre; width: 11.61pt;">so<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 304.65pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.93pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 307.58pt; position: absolute; text-decoration: none; white-space: pre; width: 39.09pt;">credited<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 346.66999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.93pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 349.59999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 200.41pt;">shall be deferred (without interest, unless<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 232.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.32pt;">the Administrator determines otherwise) until the applicable Settlement Date of the PRSUs and then<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 246pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.4pt;">paid in cash proportionate to the amount of the PRSUs, if any, that have been earned or vested, but to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 259.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.33pt;">the extent any PRSUs are canceled a proportionate amount of such accumulated amounts shall be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 272.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 42.74pt;">forfeited.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 297.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 12.82pt;">(c)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 192.91pt;">Authorization to Share Personal Data<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 295.15pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 298.2pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 7.92pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 306.12pt; position: absolute; text-decoration: none; white-space: pre; width: 243.88pt;">The Employee authorizes the Company or any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 310.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 35.83pt;">Affiliate<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.47pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 83.64pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 92.8pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 95.97pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 111.24pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 114.41pt; position: absolute; text-decoration: none; white-space: pre; width: 47.04pt;">Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 161.45pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 164.62pt; position: absolute; text-decoration: none; white-space: pre; width: 18.32pt;">that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 182.94pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 186.11pt; position: absolute; text-decoration: none; white-space: pre; width: 17.72pt;">has<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 203.82999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 207pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 216.76999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 219.94pt; position: absolute; text-decoration: none; white-space: pre; width: 36.03pt;">lawfully<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 255.97000000000003pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 259.14pt; position: absolute; text-decoration: none; white-space: pre; width: 35.43pt;">obtains<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 294.57pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 297.74pt; position: absolute; text-decoration: none; white-space: pre; width: 42.15pt;">personal<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 339.89pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 343.06pt; position: absolute; text-decoration: none; white-space: pre; width: 21.38pt;">data<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 364.44pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 367.61pt; position: absolute; text-decoration: none; white-space: pre; width: 36.03pt;">relating<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 403.64pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 406.81pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 415.96999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 419.14pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 434.40999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 437.58pt; position: absolute; text-decoration: none; white-space: pre; width: 48.87pt;">Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 486.45pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.17pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 489.62pt; position: absolute; text-decoration: none; white-space: pre; width: 60.37pt;">to divulge or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 324pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.36pt;">transfer such personal data to the Company or to a third party, in each case in any jurisdiction, if and to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 337.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 491.64pt;">the extent reasonably appropriate in connection with this Agreement or the administration of the Plan.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 362.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 13.43pt;">(d)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 229.04pt;">No Rights as Stockholder&#59; No Voting Rights<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 331.28pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 334.33pt; letter-spacing: 0.363em; position: absolute; text-decoration: none; white-space: pre; width: 9.89pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 344.21999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 205.82pt;">Except as provided in Section 6(b), the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 375.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.32pt;">Employee shall have no rights as a stockholder of the Company with respect to any shares of Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 388.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 44.59pt;">Common<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 89.23pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 94.24000000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 27.49pt;">Stock<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 121.73pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 126.74pt; position: absolute; text-decoration: none; white-space: pre; width: 39.1pt;">covered<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 165.84pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 170.85pt; position: absolute; text-decoration: none; white-space: pre; width: 11.61pt;">by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 182.45999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 187.47000000000003pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 202.74pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 207.75pt; position: absolute; text-decoration: none; white-space: pre; width: 36.04pt;">PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 243.79000000000002pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 248.8pt; position: absolute; text-decoration: none; white-space: pre; width: 21.98pt;">prior<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 270.78pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 275.79pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 284.95pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 289.96pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 305.22999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 310.24pt; position: absolute; text-decoration: none; white-space: pre; width: 43.38pt;">issuance<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 353.62pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 358.63pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 367.78999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 372.8pt; position: absolute; text-decoration: none; white-space: pre; width: 23.22pt;">such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 396.02pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 401.03pt; position: absolute; text-decoration: none; white-space: pre; width: 32.99pt;">shares<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 434.02pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 439.03pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 448.19pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 453.2pt; position: absolute; text-decoration: none; white-space: pre; width: 96.78pt;">Company Common<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 402pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 30.54pt;">Stock.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 427.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 13.43pt;">(e)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 14.05pt;">No<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 116.28999999999999pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 3.3pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 119.59pt; position: absolute; text-decoration: underline; white-space: pre; width: 25.65pt;">Right<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 145.24pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 3.3pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 148.54pt; position: absolute; text-decoration: underline; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 157.7pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 3.3pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 161pt; position: absolute; text-decoration: underline; white-space: pre; width: 36.46pt;">Awards<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 197.45999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 200.51pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 5.43pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 205.94pt; position: absolute; text-decoration: none; white-space: pre; width: 18.93pt;">The<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 224.87pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.3pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 228.17000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 48.87pt;">Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 277.04pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.3pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 280.34pt; position: absolute; text-decoration: none; white-space: pre; width: 69.65pt;">acknowledges<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 349.99pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.3pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 353.29pt; position: absolute; text-decoration: none; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 371.62pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.3pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 374.92pt; position: absolute; text-decoration: none; white-space: pre; width: 33.6pt;">agrees<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 408.52pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.3pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 411.82pt; position: absolute; text-decoration: none; white-space: pre; width: 18.32pt;">that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 430.14pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.3pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 433.44pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 448.71000000000004pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.3pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 452.01pt; position: absolute; text-decoration: none; white-space: pre; width: 25.04pt;">grant<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 477.05pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.3pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 480.35pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 489.51pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.3pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 492.81pt; position: absolute; text-decoration: none; white-space: pre; width: 57.2pt;">any PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 440.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 446.2pt;">(i) is being made on an exceptional basis and is not intended to be renewed or repeated, (<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 490.84pt; position: absolute; text-decoration: underline; white-space: pre; width: 4.88pt;">ii<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 495.71999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 54.24pt;">) is entirely<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 453.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 315.44pt;">voluntary on the part of the Company and the Subsidiaries and (<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 360.08pt; position: absolute; text-decoration: underline; white-space: pre; width: 7.32pt;">iii<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 367.4pt; position: absolute; text-decoration: none; white-space: pre; width: 125.43pt;">) should not be construed<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 492.83pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 496.09999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 11.61pt;">as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 507.71pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 510.97999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 39.09pt;">creating<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.07pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 466.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 62.36pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 67.41pt; position: absolute; text-decoration: none; white-space: pre; width: 47.03pt;">obligation<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 114.44pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 119.49pt; position: absolute; text-decoration: none; white-space: pre; width: 12.22pt;">on<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 131.70999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 136.76pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 152.03pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 157.07999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 18.93pt;">part<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 176.01pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 181.06pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 190.22000000000003pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 195.26999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 210.54000000000002pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 215.58999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 47.04pt;">Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 262.63pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 267.68pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 277.45pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 282.5pt; position: absolute; text-decoration: none; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 300.22pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 305.27pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 314.43pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 319.47999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 334.75pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 339.8pt; position: absolute; text-decoration: none; white-space: pre; width: 59.86pt;">Subsidiaries<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 399.65999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 404.71pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 413.87pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 418.91999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 131.12pt;">offer any PRSUs or other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; text-decoration: none; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 480pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 100.57pt;">Awards in the future.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 505.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 10.37pt;">(f)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 14.05pt;">No<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 116.28999999999999pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 5.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 122pt; position: absolute; text-decoration: underline; white-space: pre; width: 25.65pt;">Right<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 147.64999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 5.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 153.35999999999999pt; position: absolute; text-decoration: underline; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 162.51999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 5.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 168.23pt; position: absolute; text-decoration: underline; white-space: pre; width: 50.09pt;">Continued<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 218.32pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 5.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 224.03pt; position: absolute; text-decoration: underline; white-space: pre; width: 61.08pt;">Employment<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 285.11pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 288.15999999999997pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 7.84pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 296pt; position: absolute; text-decoration: none; white-space: pre; width: 37.87pt;">Nothing<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 333.87pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 339.58pt; position: absolute; text-decoration: none; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 348.13pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 353.84pt; position: absolute; text-decoration: none; white-space: pre; width: 17.1pt;">this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 370.94pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 376.65000000000003pt; position: absolute; text-decoration: none; white-space: pre; width: 53.75pt;">Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 430.40000000000003pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 79.04pt;"> or its exhibits <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 509.44pt; position: absolute; text-decoration: none; white-space: pre; width: 22.6pt;">shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 532.04pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 537.75pt; position: absolute; text-decoration: none; white-space: pre; width: 12.22pt;">be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 518.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 39.71pt;">deemed<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 84.35pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.84pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 90.19pt; position: absolute; text-decoration: none; white-space: pre; width: 459.74pt;">to confer on the Employee any right to continue in the employ of the Company or any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9300000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 531.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.39pt;">Subsidiary, or to interfere with or limit in any way the right of the Company or any Subsidiary to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 544.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 194.82pt;">terminate such employment at any time.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 570pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 13.43pt;">(g)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 82.46pt;">Nature of Award<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 184.7pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 187.75pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 6.97pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 194.72pt; position: absolute; text-decoration: none; white-space: pre; width: 355.3pt;">This award of PRSUs and any delivery or payment in respect thereof<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 583.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 419.81pt;">constitutes a special incentive payment to the Employee and shall not be considered<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 464.45pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.69pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 468.14pt; position: absolute; text-decoration: none; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 476.69pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.69pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 480.38pt; position: absolute; text-decoration: none; white-space: pre; width: 50.7pt;">computing<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 531.08pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.69pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 534.77pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 596.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 36.65pt;">amount<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 81.28999999999999pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 86.58pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 95.74000000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 101.03pt; position: absolute; text-decoration: none; white-space: pre; width: 29.32pt;">salary<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 130.35pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 135.64pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 145.41pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 150.7pt; position: absolute; text-decoration: none; white-space: pre; width: 68.42pt;">compensation<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 219.12pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 224.41000000000003pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 233.57pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 238.86pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 254.13pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 259.42pt; position: absolute; text-decoration: none; white-space: pre; width: 48.87pt;">Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 308.28999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 313.58pt; position: absolute; text-decoration: none; white-space: pre; width: 12.82pt;">for<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 326.4pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 331.69pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 346.96pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 352.25pt; position: absolute; text-decoration: none; white-space: pre; width: 39.71pt;">purpose<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 391.96pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 397.25pt; position: absolute; text-decoration: none; white-space: pre; width: 72pt;">of determining<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 469.25pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 474.53999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 492.26pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 497.55pt; position: absolute; text-decoration: none; white-space: pre; width: 52.51pt;">retirement,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0600000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 609.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 30.54pt;">death,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 75.18pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 78.27000000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 88.03999999999999pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 91.13pt; position: absolute; text-decoration: none; white-space: pre; width: 25.04pt;">other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 116.17pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 119.26pt; position: absolute; text-decoration: none; white-space: pre; width: 38.48pt;">benefits<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 157.74pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 160.82999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 28.1pt;">under<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 188.93pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 192.01999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 3.66pt;">(<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 195.68pt; position: absolute; text-decoration: underline; white-space: pre; width: 5.5pt;">x<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 201.18pt; position: absolute; text-decoration: none; white-space: pre; width: 3.66pt;">)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 204.83999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 207.93pt; position: absolute; text-decoration: none; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 225.64999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 228.74pt; position: absolute; text-decoration: none; white-space: pre; width: 52.51pt;">retirement,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 281.25pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 284.34pt; position: absolute; text-decoration: none; white-space: pre; width: 32.99pt;">bonus,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 317.33pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 320.41999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 14.04pt;">life<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 334.46pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 337.55pt; position: absolute; text-decoration: none; white-space: pre; width: 212.4pt;">insurance or other employee benefit plan of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.95pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 622.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 89.38pt;">the Company, or (<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 134.01999999999998pt; position: absolute; text-decoration: underline; white-space: pre; width: 5.5pt;">y<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 139.51999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 410.43pt;">) any agreement between the Company and the Employee, except as such plan or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.95pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 636pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 219.88pt;">agreement shall otherwise expressly provide.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 661.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 13.43pt;">(h)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 64.73pt;">Interpretation<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 166.97pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 170.01999999999998pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 8.31pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 178.32999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 371.66pt;">The Administrator shall have full power and discretion to construe and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 674.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 472.38pt;">interpret the Plan (and any rules and regulations issued thereunder) and this Award (including <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 517.02pt; position: absolute; text-decoration: underline; white-space: pre; width: 32.98pt;">Exhibit<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; text-decoration: underline; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 687.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: underline; white-space: pre; width: 7.33pt;">A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 51.97pt; position: absolute; text-decoration: none; white-space: pre; width: 6.71pt;">).<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 58.68pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 8.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 67.22pt; position: absolute; text-decoration: none; white-space: pre; width: 482.76pt;">Any determination or interpretation by the Administrator under or pursuant to the Plan, this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; text-decoration: none; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 700.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 104.79pt;">Agreement (including<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 149.43pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 153.3pt; position: absolute; text-decoration: underline; white-space: pre; width: 32.98pt;">Exhibit<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 186.27999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 190.14999999999998pt; position: absolute; text-decoration: underline; white-space: pre; width: 7.33pt;">A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 197.48000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 3.66pt;">)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 201.14pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 205.01pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 214.77999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 218.64999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 17.1pt;">this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 235.75pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 239.62pt; position: absolute; text-decoration: none; white-space: pre; width: 30.96pt;">Award<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 270.58pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 274.45pt; position: absolute; text-decoration: none; white-space: pre; width: 22.6pt;">shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 297.05pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 300.91999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 12.22pt;">be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 313.14pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 317.01pt; position: absolute; text-decoration: none; white-space: pre; width: 20.15pt;">final<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 337.15999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 341.03pt; position: absolute; text-decoration: none; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 359.36pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 363.22999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 35.43pt;">binding<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 398.65999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 402.53pt; position: absolute; text-decoration: none; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 420.86pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 424.72999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 51.32pt;">conclusive<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 476.05pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 479.91999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 12.22pt;">on<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 492.14pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 496.01pt; position: absolute; text-decoration: none; white-space: pre; width: 10.99pt;">all<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 507pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.87pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 510.87pt; position: absolute; text-decoration: none; white-space: pre; width: 39.1pt;">persons<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 714pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 41.95pt;">affected <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 86.59pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 35.21pt;">hereby.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 739.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 9.76pt;">(i)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 47.01pt;">Forfeiture<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 149.25pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 5.64pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 154.89pt; position: absolute; text-decoration: underline; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 164.05pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 5.64pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 169.69pt; position: absolute; text-decoration: underline; white-space: pre; width: 36.46pt;">Awards<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 206.14999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 209.2pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 7.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 216.92000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 18.93pt;">The<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 235.85000000000002pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.64pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 241.49pt; position: absolute; text-decoration: none; white-space: pre; width: 36.04pt;">PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 277.53pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.64pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 283.17pt; position: absolute; text-decoration: none; white-space: pre; width: 37.26pt;">granted<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 320.43pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.64pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 326.07pt; position: absolute; text-decoration: none; white-space: pre; width: 50.09pt;">hereunder<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 376.16pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.64pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 381.8pt; position: absolute; text-decoration: none; white-space: pre; width: 21.99pt;">(and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 403.79pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.64pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 409.43pt; position: absolute; text-decoration: none; white-space: pre; width: 26.27pt;">gains<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 435.7pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.64pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 441.34000000000003pt; position: absolute; text-decoration: none; white-space: pre; width: 34.21pt;">earned<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 475.55pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.64pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 481.19pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 490.96000000000004pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 5.64pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 496.6pt; position: absolute; text-decoration: none; white-space: pre; width: 53.38pt;">accrued in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 752.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.37pt;">connection therewith) shall be subject to such generally applicable policies as to forfeiture and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">4<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.38pt;">recoupment (including, without limitation, upon the occurrence of material financial or accounting errors,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 471.36pt;">financial or other misconduct or Competitive Activity) as may be adopted by the Administrator<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 516pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 520.45pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 530.22pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 534.67pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.94pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 29.32pt;">Board<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 73.96000000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 77.46000000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 21.98pt;">from<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 99.44pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.94pt; position: absolute; text-decoration: none; white-space: pre; width: 20.76pt;">time<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 123.7pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 127.2pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 136.36pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 139.86pt; position: absolute; text-decoration: none; white-space: pre; width: 20.76pt;">time<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 160.62pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 164.12pt; position: absolute; text-decoration: none; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 182.45pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 185.95pt; position: absolute; text-decoration: none; white-space: pre; width: 71.47pt;">communicated<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 257.42pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 260.92pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 270.08pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 273.58pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 288.85pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 292.35pt; position: absolute; text-decoration: none; white-space: pre; width: 48.87pt;">Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 341.21999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 344.71999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 354.49pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 357.99pt; position: absolute; text-decoration: none; white-space: pre; width: 11.61pt;">as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 369.59999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 373.09999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 40.31pt;">required<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 413.40999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 416.90999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 133.09pt;">by Applicable Law, and are<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 75.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 392.07pt;">otherwise subject to forfeiture or disgorgement of profits as provided by the Plan.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 100.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 9.76pt;">(j)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 149.32pt;">Consent to Electronic Delivery<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 251.56pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 254.61pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 6.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 260.63pt; position: absolute; text-decoration: none; white-space: pre; width: 289.41pt;">By entering into this Agreement and accepting the PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 2.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 114pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 50.1pt;">evidenced<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 94.74000000000001pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.57pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 100.31pt; position: absolute; text-decoration: none; white-space: pre; width: 35.84pt;">hereby,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 136.15pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.57pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 141.72pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 156.99pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.57pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 162.56pt; position: absolute; text-decoration: none; white-space: pre; width: 48.87pt;">Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 211.43pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.57pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 217pt; position: absolute; text-decoration: none; white-space: pre; width: 33.6pt;">hereby<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 250.60000000000002pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.57pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 256.17pt; position: absolute; text-decoration: none; white-space: pre; width: 43.99pt;">consents<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 300.16pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.57pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 305.72999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 314.89pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.57pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 320.46pt; position: absolute; text-decoration: none; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 335.72999999999996pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.57pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 341.3pt; position: absolute; text-decoration: none; white-space: pre; width: 37.87pt;">delivery<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 379.16999999999996pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.57pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 384.74pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 393.9pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.57pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 399.46999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 54.35pt;">information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 453.82pt; letter-spacing: -0.018000000000000002em; position: absolute; text-decoration: none; white-space: pre; width: 5.57pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 459.39pt; position: absolute; text-decoration: none; white-space: pre; width: 90.65pt;">(including, without<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 127.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.41pt;">limitation, information required to be delivered to the Employee pursuant to applicable securities laws)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0500000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 140.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.33pt;">regarding the Company and the Subsidiaries, the Plan, this Agreement and the PRSUs via Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 153.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 171.41pt;">website or other electronic delivery.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 178.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 12.82pt;">(k)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 115.52pt;">Binding Effect&#59; Benefits<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 217.76pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 220.81pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 6.1pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 226.91pt; position: absolute; text-decoration: none; white-space: pre; width: 323.14pt;">This Agreement shall be binding upon and inure to the benefit of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 192pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 368.29pt;">the parties to this Agreement and their respective successors and assigns.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 412.93pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 5.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 418.64pt; position: absolute; text-decoration: none; white-space: pre; width: 70.96pt;">Nothing in this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 489.59999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 3.58pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 493.18pt; position: absolute; text-decoration: none; white-space: pre; width: 56.8pt;">Agreement,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 205.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 38.49pt;">express<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 83.13pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 87.25pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 97.02000000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 101.14pt; position: absolute; text-decoration: none; white-space: pre; width: 37.86pt;">implied,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 139pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 143.12pt; position: absolute; text-decoration: none; white-space: pre; width: 7.94pt;">is<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 151.06pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 155.18pt; position: absolute; text-decoration: none; white-space: pre; width: 42.15pt;">intended<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 197.32999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 201.45pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 211.22000000000003pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 215.33999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 22.6pt;">shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 237.94pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 242.06pt; position: absolute; text-decoration: none; white-space: pre; width: 12.22pt;">be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 254.27999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 258.4pt; position: absolute; text-decoration: none; white-space: pre; width: 48.26pt;">construed<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 306.65999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 310.78pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 319.94pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 324.06pt; position: absolute; text-decoration: none; white-space: pre; width: 20.16pt;">give<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 344.21999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 348.34pt; position: absolute; text-decoration: none; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 366.06pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 370.18pt; position: absolute; text-decoration: none; white-space: pre; width: 33.6pt;">person<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 403.78pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 407.9pt; position: absolute; text-decoration: none; white-space: pre; width: 25.04pt;">other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 432.94pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.12pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 437.06pt; position: absolute; text-decoration: none; white-space: pre; width: 112.93pt;">than the parties to this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; text-decoration: none; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 218.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 505.34pt;">Agreement or their respective successors or assigns any legal or equitable right, remedy or claim under<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 231.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre; width: 316.98pt;">or in respect of any agreement or any provision contained herein.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 256.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 9.76pt;">(l)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 39.9pt;">Waiver&#59; <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 142.14pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 58.44pt;">Amendment<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 200.57999999999998pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.96pt;">.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 282pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 116.64000000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 9.76pt;">(i)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 138.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 33.2pt;">Waiver<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 171.44pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 174.49pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 6.72pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 181.21pt; position: absolute; text-decoration: none; white-space: pre; width: 368.87pt;">Any party hereto or beneficiary hereof may by written notice to the other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 295.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 40.47pt;">parties (<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 121.11pt; position: absolute; text-decoration: underline; white-space: pre; width: 7.33pt;">A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 128.44pt; position: absolute; text-decoration: none; white-space: pre; width: 421.64pt;">) extend the time for the performance of any of the obligations or other actions of the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.08pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 308.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 197.98pt;">other parties under this Agreement, (<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 278.62pt; position: absolute; text-decoration: underline; white-space: pre; width: 7.33pt;">B<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 285.95pt; position: absolute; text-decoration: none; white-space: pre; width: 264.13pt;">) waive compliance with any of the conditions or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.08pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 321.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 312.99pt;">covenants of the other parties contained in this Agreement and (<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 393.63pt; position: absolute; text-decoration: underline; white-space: pre; width: 7.94pt;">C<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 401.57pt; position: absolute; text-decoration: none; white-space: pre; width: 148.39pt;">) waive or modify performance<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 334.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 469.43pt;">of any of the obligations of the other parties under this Agreement. Except as provided in the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.07pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 348pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 469.43pt;">preceding sentence, no action taken pursuant to this Agreement, including, without limitation,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.07pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 361.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 469.38pt;">any investigation by or on behalf of any party or beneficiary, shall be deemed to constitute a<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 374.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 469.35pt;">waiver by the party or beneficiary taking such action of compliance with any representations,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 387.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 283.48pt;">warranties, covenants, or agreements contained herein.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 364.12pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 7.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 371.62pt; position: absolute; text-decoration: none; white-space: pre; width: 178.43pt;">The waiver by any party hereto or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0500000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 400.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 469.35pt;">beneficiary hereof of a breach of any provision of this Agreement shall not operate or be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 414pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 469.36pt;">construed as a waiver of any preceding or succeeding breach and no failure by a party or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 427.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 469.41pt;">beneficiary to exercise any right or privilege hereunder shall be deemed a waiver of such party&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0500000000001pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 440.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 227.31pt;">or beneficiary&#8217;s rights or privileges hereunder<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 307.95pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 312.51pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 322.28pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 326.84pt; position: absolute; text-decoration: none; white-space: pre; width: 22.6pt;">shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 349.44pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 354pt; position: absolute; text-decoration: none; white-space: pre; width: 12.22pt;">be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 366.21999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 370.78pt; position: absolute; text-decoration: none; white-space: pre; width: 39.71pt;">deemed<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 410.49pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 415.05pt; position: absolute; text-decoration: none; white-space: pre; width: 6.11pt;">a<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 421.15999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 425.71999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 31.76pt;">waiver<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 457.47999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 462.03999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 471.2pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 475.76pt; position: absolute; text-decoration: none; white-space: pre; width: 23.22pt;">such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 498.97999999999996pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 503.53999999999996pt; position: absolute; text-decoration: none; white-space: pre; width: 32.18pt;">party&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 535.72pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 4.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 540.28pt; position: absolute; text-decoration: none; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0500000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 453.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; text-decoration: none; white-space: pre; width: 60.89pt;">beneficiary&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 141.53pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 144.44pt; position: absolute; text-decoration: none; white-space: pre; width: 26.87pt;">rights<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 171.31pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 174.22pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 183.38pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 186.29000000000002pt; position: absolute; text-decoration: none; white-space: pre; width: 40.93pt;">exercise<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 227.22000000000003pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: none; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 230.13pt; position: absolute; text-decoration: none; white-space: pre; width: 259.58pt;">the same at any subsequent time or times hereunder.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 478.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 117.54pt; position: absolute; width: 12.2pt;">(ii)<font style="display: inline-block; height: 8pt; width: 23.8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 153.54000000000002pt; position: absolute; text-decoration: underline; white-space: pre; width: 59.25pt;">Amendment<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 212.79000000000002pt; position: absolute; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 215.84pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 222.03pt; position: absolute; white-space: pre; width: 328.02pt;">This Agreement may not be amended, modified, or supplemented<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 492pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; white-space: pre; width: 28.5pt;">orally,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 109.14pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 112.05pt; position: absolute; white-space: pre; width: 15.27pt;">but<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 127.32pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 130.23000000000002pt; position: absolute; white-space: pre; width: 20.16pt;">only<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 150.39pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 153.3pt; position: absolute; white-space: pre; width: 11.61pt;">by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 164.91pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 167.82pt; position: absolute; white-space: pre; width: 6.11pt;">a<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 173.93pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 176.84pt; position: absolute; white-space: pre; width: 32.36pt;">written<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 209.2pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 212.11pt; position: absolute; white-space: pre; width: 51.3pt;">instrument<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 263.41pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 266.32pt; position: absolute; white-space: pre; width: 44.6pt;">executed<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 310.92pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 313.83pt; position: absolute; white-space: pre; width: 11.61pt;">by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 325.44pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 328.35pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 343.62pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 346.53pt; position: absolute; white-space: pre; width: 48.87pt;">Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 395.4pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 398.31pt; position: absolute; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 416.64pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 419.55pt; position: absolute; white-space: pre; width: 18.32pt;">the <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 437.87pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 48.56pt;">Company.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 517.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 81.09pt; position: absolute; width: 16.48pt;">(m)<font style="display: inline-block; height: 8pt; width: 15.37pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 112.94pt; position: absolute; text-decoration: underline; white-space: pre; width: 60.27pt;">Assignability<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 173.21pt; position: absolute; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 176.26pt; letter-spacing: 0.3em; position: absolute; white-space: pre; width: 7.32pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 183.57999999999998pt; position: absolute; white-space: pre; width: 298.61pt;">Neither this Agreement nor any right, remedy, obligation, or <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 482.19000000000005pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 67.83pt;">liability arising<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 2.96pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 530.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 50.09pt;">hereunder<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 96.08000000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 99.84pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 109.61pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 113.37pt; position: absolute; white-space: pre; width: 11.61pt;">by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 124.97999999999999pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 128.74pt; position: absolute; white-space: pre; width: 33.6pt;">reason<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 162.34pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 166.1pt; position: absolute; white-space: pre; width: 31.15pt;">hereof<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 197.25pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 201.01000000000002pt; position: absolute; white-space: pre; width: 22.6pt;">shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 223.61pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 227.37pt; position: absolute; white-space: pre; width: 12.22pt;">be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 239.59pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 243.35000000000002pt; position: absolute; white-space: pre; width: 52.54pt;">assignable<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 295.89pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 299.65pt; position: absolute; white-space: pre; width: 11.61pt;">by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 311.26pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 315.02pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 330.29pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 334.05pt; position: absolute; white-space: pre; width: 47.04pt;">Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 381.09000000000003pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 384.85pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 394.62pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 398.38pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 413.65000000000003pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 417.41pt; position: absolute; white-space: pre; width: 132.63pt;">Employee without the prior<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 543.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 162.24pt;">written consent of the other party.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 568.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 81.09pt; position: absolute; width: 13.43pt;">(n)<font style="display: inline-block; height: 8pt; width: 19.27pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 113.79pt; position: absolute; text-decoration: underline; white-space: pre; width: 75.7pt;">Applicable Law<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 189.49pt; position: absolute; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 192.54000000000002pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.43pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 199.97pt; position: absolute; white-space: pre; width: 350.04pt;">This Agreement shall be governed in all respects, including, but not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 582pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.54pt; position: absolute; white-space: pre; width: 31.75pt;">limited<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 77.28999999999999pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.83pt; position: absolute; white-space: pre; width: 12.21pt;">to,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 93.03999999999999pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 96.58pt; position: absolute; white-space: pre; width: 11.61pt;">as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 108.19pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 111.72999999999999pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 120.88999999999999pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 124.43pt; position: absolute; white-space: pre; width: 35.83pt;">validity,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 160.26pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 163.8pt; position: absolute; white-space: pre; width: 67.17pt;">interpretation,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 230.97pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 234.51pt; position: absolute; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 252.84pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 256.38pt; position: absolute; white-space: pre; width: 29.73pt;">effect,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 286.11pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 289.65000000000003pt; position: absolute; white-space: pre; width: 11.61pt;">by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 301.26pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 304.8pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 320.07pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 323.61pt; position: absolute; white-space: pre; width: 36.03pt;">internal<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 359.64000000000004pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 363.18pt; position: absolute; white-space: pre; width: 21.99pt;">laws<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 385.17pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 388.71000000000004pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 397.87pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 401.41pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 416.68pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 420.22pt; position: absolute; white-space: pre; width: 25.65pt;">State<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 445.87pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 449.41pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 458.57pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 462.11pt; position: absolute; white-space: pre; width: 87.86pt;">Delaware, without<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 595.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.54pt; position: absolute; white-space: pre; width: 46.42pt;">reference<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 91.96000000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 94.87pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 104.03pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 106.94pt; position: absolute; white-space: pre; width: 46.42pt;">principles<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 153.35999999999999pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 156.27pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 165.43pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 168.34pt; position: absolute; white-space: pre; width: 34.2pt;">conflict<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 202.54pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 205.45pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 214.60999999999999pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 217.51999999999998pt; position: absolute; white-space: pre; width: 16.49pt;">law<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 234.01pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 236.92pt; position: absolute; white-space: pre; width: 18.32pt;">that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 255.23999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 258.15000000000003pt; position: absolute; white-space: pre; width: 28.71pt;">would<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 286.86pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 289.77pt; position: absolute; white-space: pre; width: 34.2pt;">require<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 323.97pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 326.88pt; position: absolute; white-space: pre; width: 52.53pt;">application<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 379.41pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 382.32pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 391.48pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 394.39000000000004pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 409.66pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 412.57pt; position: absolute; white-space: pre; width: 16.49pt;">law<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 429.06pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 431.97pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 441.13pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 444.04pt; position: absolute; white-space: pre; width: 40.31pt;">another <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 484.35pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 53.79pt;">jurisdiction.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 620.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 81.09pt; position: absolute; width: 13.43pt;">(o)<font style="display: inline-block; height: 8pt; width: 19.27pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 113.79pt; position: absolute; text-decoration: underline; white-space: pre; width: 104.45pt;">Waiver of Jury Trial<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 218.24pt; position: absolute; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 221.29pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.64pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 229.93pt; position: absolute; white-space: pre; width: 320.05pt;">Each party hereby waives, to the fullest extent permitted by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 633.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 49.48pt;">applicable<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 93.22pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 97.16pt; position: absolute; white-space: pre; width: 18.94pt;">law,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 116.1pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 120.03999999999999pt; position: absolute; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 137.76pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 141.7pt; position: absolute; white-space: pre; width: 21.37pt;">right<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 163.07pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 167.01pt; position: absolute; white-space: pre; width: 15.27pt;">he,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 182.28pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 186.22pt; position: absolute; white-space: pre; width: 20.77pt;">she,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 206.99pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 210.93pt; position: absolute; white-space: pre; width: 23.01pt;">they,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 233.94pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 237.88pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 247.65pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 251.59pt; position: absolute; white-space: pre; width: 5.49pt;">it<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 257.08pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 261.02pt; position: absolute; white-space: pre; width: 20.77pt;">may<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 281.79pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 285.73pt; position: absolute; white-space: pre; width: 23.83pt;">have<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 309.56pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 313.5pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 322.66pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 326.6pt; position: absolute; white-space: pre; width: 6.11pt;">a<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 332.71000000000004pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 336.65000000000003pt; position: absolute; white-space: pre; width: 17.7pt;">trial<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 354.35pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 358.29pt; position: absolute; white-space: pre; width: 11.61pt;">by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 369.90000000000003pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 373.84000000000003pt; position: absolute; white-space: pre; width: 17.71pt;">jury<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 391.55pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 395.49pt; position: absolute; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 404.04pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 407.98pt; position: absolute; white-space: pre; width: 36.04pt;">respect<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 444.02pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 447.96000000000004pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 457.12pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 461.06pt; position: absolute; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 478.78000000000003pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 482.72pt; position: absolute; white-space: pre; width: 20.15pt;">suit,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 502.87pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 3.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 506.81pt; position: absolute; white-space: pre; width: 43.12pt;">action or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.93pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 646.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 395.07pt;">proceeding arising out of this Agreement or any transaction contemplated hereby.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.81pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 443.86pt; position: absolute; white-space: pre; width: 65.36pt;">Each party (i)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 509.22pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.92pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 512.14pt; position: absolute; white-space: pre; width: 37.86pt;">certifies<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 660pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 18.32pt;">that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 62.06pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 65.08pt; position: absolute; white-space: pre; width: 12.22pt;">no<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 77.30000000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.32pt; position: absolute; white-space: pre; width: 72.68pt;">representative,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 153pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 156.02pt; position: absolute; white-space: pre; width: 27.49pt;">agent<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 183.51000000000002pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 186.53pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 196.3pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 199.32000000000002pt; position: absolute; white-space: pre; width: 39.7pt;">attorney<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 239.02pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 242.04000000000002pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 251.20000000000002pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 254.22pt; position: absolute; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 271.94pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 274.96pt; position: absolute; white-space: pre; width: 25.04pt;">other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 300pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 303.02pt; position: absolute; white-space: pre; width: 24.43pt;">party<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 327.45pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 330.47pt; position: absolute; white-space: pre; width: 17.72pt;">has<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 348.19pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 351.21000000000004pt; position: absolute; white-space: pre; width: 61.69pt;">represented,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 412.90000000000003pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.02pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 415.92pt; position: absolute; white-space: pre; width: 134.08pt;">expressly or otherwise, that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 673.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 497.74pt;">such other party would not, in the event of litigation, seek to enforce the foregoing waiver and (<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 541.48pt; position: absolute; text-decoration: underline; white-space: pre; width: 4.88pt;">ii<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 546.36pt; position: absolute; white-space: pre; width: 3.66pt;">)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 686.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">acknowledges that he, she, they or it and the other party hereto have been induced to enter into the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 699.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 448.06pt;">Agreement by, among other things, the mutual waivers and certifications in this Section 6(o).<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 724.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 81.09pt; position: absolute; width: 13.43pt;">(p)<font style="display: inline-block; height: 8pt; width: 18.62pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 113.14pt; position: absolute; text-decoration: underline; white-space: pre; width: 104.1pt;">Limitations of Actions<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 217.24pt; position: absolute; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 220.29pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.48pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 225.77pt; position: absolute; white-space: pre; width: 324.23pt;">No lawsuit relating to this Agreement may be filed before a written<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 738pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 25.65pt;">claim<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 69.39pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 73.58pt; position: absolute; white-space: pre; width: 7.94pt;">is<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 81.52000000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 85.71000000000001pt; position: absolute; white-space: pre; width: 20.15pt;">filed<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 105.86pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 110.05000000000001pt; position: absolute; white-space: pre; width: 19.54pt;">with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 129.59pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 133.78pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 149.05pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 153.24pt; position: absolute; white-space: pre; width: 64.73pt;">Administrator<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 217.97pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 222.16pt; position: absolute; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 240.49pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 244.68pt; position: absolute; white-space: pre; width: 7.94pt;">is<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 252.62pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 256.81pt; position: absolute; white-space: pre; width: 32.99pt;">denied<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 289.8pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 293.99pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 303.76pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 307.95pt; position: absolute; white-space: pre; width: 39.71pt;">deemed<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 347.66pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 351.85pt; position: absolute; white-space: pre; width: 32.99pt;">denied<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 384.84000000000003pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 389.03000000000003pt; position: absolute; white-space: pre; width: 11.61pt;">as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 400.64pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 404.83pt; position: absolute; white-space: pre; width: 42.15pt;">provided<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 446.98pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 451.17pt; position: absolute; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 459.72pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 463.91pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 479.18pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 483.37pt; position: absolute; white-space: pre; width: 66.7pt;">Plan and any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 751.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 400.02pt;">lawsuit must be filed within one year of such denial or deemed denial or be forever<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 443.76pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 448.8pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 34.18pt;">barred.<font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">5<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 81.54pt; position: absolute; width: 13.43pt;">(q)<font style="display: inline-block; height: 8pt; width: 18.82pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 113.79pt; position: absolute; text-decoration: underline; white-space: pre; width: 36.65pt;">Section<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 150.44pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 5.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 156.23000000000002pt; position: absolute; text-decoration: underline; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 174.56pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 5.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 180.35000000000002pt; position: absolute; text-decoration: underline; white-space: pre; width: 27.48pt;">Other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 207.83pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 5.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 213.62pt; position: absolute; text-decoration: underline; white-space: pre; width: 49.48pt;">Headings,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 263.1pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 5.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 268.89pt; position: absolute; text-decoration: underline; white-space: pre; width: 14.66pt;">etc<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 283.55pt; position: absolute; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 286.6pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.92pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 294.52pt; position: absolute; white-space: pre; width: 18.93pt;">The<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 313.45pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 319.24pt; position: absolute; white-space: pre; width: 34.82pt;">section<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 354.06pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 359.85pt; position: absolute; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 378.18pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 383.97pt; position: absolute; white-space: pre; width: 25.04pt;">other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 409.01000000000005pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 414.8pt; position: absolute; white-space: pre; width: 44.6pt;">headings<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 459.40000000000003pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 465.19pt; position: absolute; white-space: pre; width: 47.65pt;">contained<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 512.84pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 518.63pt; position: absolute; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 527.18pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 532.97pt; position: absolute; white-space: pre; width: 17.1pt;">this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.54pt; position: absolute; white-space: pre; width: 504.44pt;">Agreement are for reference purposes only and shall not affect the meaning or interpretation of this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.54pt; position: absolute; white-space: pre; width: 56.8pt;">Agreement.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 87.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 81.09pt; position: absolute; width: 10.98pt;">(r)<font style="display: inline-block; height: 8pt; width: 20.12pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 112.19pt; position: absolute; text-decoration: underline; white-space: pre; width: 191.11pt;">Acceptance of PRSUs and Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 303.3pt; position: absolute; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 306.35pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.24pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 312.59000000000003pt; position: absolute; white-space: pre; width: 237.44pt;">The Employee has indicated his or her consent<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 100.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 504.02pt;">and acknowledgement of the terms of this Agreement pursuant to the instructions provided to the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 114pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 233.15pt;">Employee by or on behalf of the Company.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 279.14pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 10.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 289.85pt; position: absolute; white-space: pre; width: 260.22pt;">The Employee acknowledges receipt of the Plan,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 127.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 503.97pt;">represents to the Company that they have read and understood this Agreement and the Plan, and, as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 140.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 504.06pt;">an express condition to the grant of the PRSUs under this Agreement, agrees to be bound by the terms<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 153.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 178.15pt;">of both this Agreement and the Plan.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 224.14000000000001pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 231.25pt; position: absolute; white-space: pre; width: 318.81pt;">The Employee and the Company each agrees and acknowledges<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 166.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 503.95pt;">that the use of electronic media (including, without limitation, a clickthrough button or checkbox on a<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 180pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 504.06pt;">website of the Company or a third-party administrator) to indicate the Employee&#8217;s confirmation,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 193.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 503.96pt;">consent, signature, agreement and delivery of this Agreement and the PRSUs is legally valid and has<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 206.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 269.95pt;">the same legal force and effect as if the Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 315.94pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.85pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 321.79pt; position: absolute; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 340.12pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.85pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 345.97pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 361.24pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.85pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 367.09000000000003pt; position: absolute; white-space: pre; width: 47.04pt;">Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 414.13pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.85pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 419.98pt; position: absolute; white-space: pre; width: 32.38pt;">signed<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 452.36pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.85pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 458.21000000000004pt; position: absolute; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 476.54pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.85pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 482.39pt; position: absolute; white-space: pre; width: 44.6pt;">executed<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 526.99pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 5.85pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 532.84pt; position: absolute; white-space: pre; width: 17.1pt;">this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 219.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 53.75pt;">Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 99.74000000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.2pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 103.94pt; position: absolute; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 112.49000000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.2pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 116.69pt; position: absolute; white-space: pre; width: 28.1pt;">paper<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 144.79pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.2pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 148.99pt; position: absolute; white-space: pre; width: 401.07pt;">form. The Company may, in its sole discretion, decide to deliver any documents<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 232.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 504.09pt;">related to current or future participation in the Plan by electronic means. The Employee hereby<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 246pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 504.02pt;">consents to receive such documents by electronic delivery and agrees to participate in the Plan through<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 259.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 504.05pt;">an online or electronic delivery system established and maintained by the Company or a third party<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 272.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 504.03pt;">designated by the Company. If the Employee does not complete the online or acceptance process, the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 285.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 503.98pt;">Employee will be deemed to have accepted the PRSUs and have agreed to the terms provided in the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 298.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 248.07pt;">Plan and this Agreement prior to the first vest date.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 294.06pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.19pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 299.25pt; position: absolute; white-space: pre; width: 18.93pt;">The<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 318.18pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 321.24pt; position: absolute; white-space: pre; width: 26.88pt;">same<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 348.12pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 351.18pt; position: absolute; white-space: pre; width: 17.72pt;">use<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 368.90000000000003pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.06pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 371.96000000000004pt; position: absolute; white-space: pre; width: 178.02pt;">of electronic means may be used for<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 312pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 45.99pt; position: absolute; white-space: pre; width: 218.04pt;">any amendment or waiver of this Agreement.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 337.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 79.74pt; position: absolute; width: 12.82pt;">(s)<font style="display: inline-block; height: 8pt; width: 23.18pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 115.74pt; position: absolute; text-decoration: underline; white-space: pre; width: 38.48pt;">Exhibits<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 154.22pt; position: absolute; white-space: pre; width: 395.82pt;">. Notwithstanding any provisions in this Agreement, the Agreement shall be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 350.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">subject to any special terms and conditions set forth in the Exhibits to this Agreement. Moreover, if<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 363.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">Employee relocates to a country outside the United States, then special terms and conditions for such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 376.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.19pt;">country, whether set forth in the Exhibits or otherwise, may apply to the Employee, to the extent the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.93pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 390pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">Company determines that the application of such terms and conditions is necessary or advisable for<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 403.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">legal or administrative reasons. The Exhibits constitute part of this Agreement. In accepting this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 416.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">Agreement, Employee acknowledges receipt of, understands and agrees to the additional terms and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 429.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 238.2pt;">conditions included in the Exhibits, as applicable.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 454.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 79.74pt; position: absolute; width: 10.37pt;">(t)<font style="display: inline-block; height: 8pt; width: 22.08pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 112.19pt; position: absolute; text-decoration: underline; white-space: pre; width: 87.91pt;">Entire Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 200.1pt; position: absolute; white-space: pre; width: 197.36pt;">.&#160; This Agreement, together with the <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 397.46000000000004pt; position: absolute; text-decoration: underline; white-space: pre; width: 38.48pt;">Exhibits<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 435.94pt; position: absolute; white-space: pre; width: 114.03pt;"> hereto and the Plan,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 468pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">constitutes the entire terms of the Employee&#8217;s PRSUs subject to this Award and participation in the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 481.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">Company&#8217;s 2025 transformational long-term incentive award program and supersedes all prior<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 494.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">agreements, promises, understandings, arrangements, communications, representations, and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 507.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">warranties, whether oral or written, by any person, officer, employee or representative of the Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 520.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">(including, without limitation, previous communications regarding and summaries of the Company&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 534pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 285.81pt;">2025 transformational long-term incentive award program).<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 591.51pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: italic; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 36.24pt; position: absolute;">&#160;  __________________________ <font style="display: inline-block; height: 8.73pt; width: 29.26pt;"></font></font><font style="left: 252.24pt; position: absolute;"><font style="display: inline-block; height: 8.73pt; width: 36pt;"></font></font><font style="left: 288.24pt; position: absolute;"><font style="display: inline-block; height: 8.73pt; width: 36pt;"></font></font><font style="left: 324.24pt; position: absolute;">________________________<font style="display: inline-block; height: 8.73pt;"></font></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 610.51pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 36.24pt; position: absolute;">&#160;  Employee Signature<font style="display: inline-block; height: 8.73pt; width: 26.02pt;"></font></font><font style="left: 180.24pt; position: absolute;"><font style="display: inline-block; height: 8.73pt; width: 36pt;"></font></font><font style="left: 216.24pt; position: absolute;"><font style="display: inline-block; height: 8.73pt; width: 36pt;"></font></font><font style="left: 252.24pt; position: absolute;"><font style="display: inline-block; height: 8.73pt; width: 36pt;"></font></font><font style="left: 288.24pt; position: absolute;"><font style="display: inline-block; height: 8.73pt; width: 36pt;"></font></font><font style="left: 324.24pt; position: absolute;">Date<font style="display: inline-block; height: 8.73pt;"></font></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">1<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div id="i2dcfc617e1a34eee923147f1b6d1f260_4" style="position: absolute; top: 36pt;"></div><div style="line-height: 8pt; position: absolute; top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 270.19pt; position: absolute; text-decoration: none; white-space: pre;">EXHIBIT A <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 52.35pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 289.73pt; position: absolute; text-decoration: none; white-space: pre;">TO<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 65.55pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 183.17pt; position: absolute; text-decoration: none; white-space: pre;">TRANSFORMATIONAL EMPLOYEE AWARD<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 78.75pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 145.92pt; position: absolute; text-decoration: none; white-space: pre;">PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 105.55pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre;">Employee&#58;<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 130.75pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre;">Grant <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 75.17pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre;">Date&#58;<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 155.95pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre;">Target<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 75.18pt; letter-spacing: -0.059000000000000004em; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 77.59pt; position: absolute; text-decoration: none; white-space: pre;">Amount<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 115.46pt; letter-spacing: -0.059000000000000004em; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 117.87pt; position: absolute; text-decoration: none; white-space: pre;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 127.03pt; letter-spacing: -0.059000000000000004em; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 129.44pt; position: absolute; text-decoration: none; white-space: pre;">PRSUs <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 168.53pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre;">granted<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 169.15pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; text-decoration: none; white-space: pre;">hereby<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 78.24000000000001pt; letter-spacing: -0.004em; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 81.25pt; position: absolute; text-decoration: none; white-space: pre;">(the &#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 106.89pt; position: absolute; text-decoration: underline; white-space: pre;">Target <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 140.48000000000002pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: underline; white-space: pre;">Amount<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 177.81pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre;">&#8221;)&#58;<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 194.35pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.239999999999995pt; position: absolute; white-space: pre; width: 9.16pt;">1.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 180.96pt;">Performance Restricted Stock Units<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 247.2pt; position: absolute; white-space: pre; width: 302.78pt;">. The total number of PRSUs subject to this Award will be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 207.55pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 54.97pt;">determined<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 94.21000000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 97.97pt; position: absolute; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 106.52000000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 110.28pt; position: absolute; white-space: pre; width: 6.11pt;">a<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 116.39000000000001pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 120.15pt; position: absolute; white-space: pre; width: 28.1pt;">range<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 148.25pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 152.01pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 161.17000000000002pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 164.93pt; position: absolute; white-space: pre; width: 27.58pt;">&#91;&#160;  &#93;%<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 192.51000000000002pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 196.27pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 205.43pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 209.19pt; position: absolute; white-space: pre; width: 27.58pt;">&#91;&#160;  &#93;%<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 236.77pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 240.53pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 249.69pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 253.45000000000002pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 268.71999999999997pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 272.48pt; position: absolute; white-space: pre; width: 30.54pt;">Target<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 303.02pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 306.78000000000003pt; position: absolute; white-space: pre; width: 119.2pt;">Amount set forth above,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 425.98pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 429.74pt; position: absolute; white-space: pre; width: 34.82pt;">subject<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 464.56pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 468.32pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 477.48pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 481.24pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 496.51pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 500.27pt; position: absolute; white-space: pre; width: 27.48pt;">terms<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 527.75pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 531.51pt; position: absolute; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.84pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 220.75pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 126.43pt;">conditions set forth below.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 245.95pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 79.74pt; position: absolute; width: 13.43pt;">(a)<font style="display: inline-block; height: 8pt; width: 20.02pt;"></font></font><font style="left: 113.19pt; position: absolute; width: 18.93pt;">The<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 132.12pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.08pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 135.2pt; position: absolute; white-space: pre; width: 29.93pt;">extent<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 165.13pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.08pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 168.20999999999998pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 177.37pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.08pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 180.45pt; position: absolute; white-space: pre; width: 28.1pt;">which<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 208.55pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.08pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 211.63pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 226.89999999999998pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.08pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 229.98000000000002pt; position: absolute; white-space: pre; width: 30.96pt;">Award<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 260.94pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 3.08pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 264.02pt; position: absolute; white-space: pre; width: 7.94pt;">is<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 271.96pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 278.02pt;"> eligible to vest based on performance shall be determined<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 259.15pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 510.84pt;">by multiplying the Target Amount by the applicable vesting percentage, with the applicable vesting<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 272.35pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 400.89pt;">percentage determined in accordance with the chart below based on the Company&#8217;s <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 440.13pt; position: absolute; white-space: pre; width: 18.3pt;">&#91;&#160;  &#93;&#58;<font style="display: inline-block; height: 8pt;"></font></font></div><div style="position: absolute; top: 297.55pt; width: 594.72pt;"><div style="font-size: 0pt; left: 42.59pt; position: absolute; top: 0pt; width: 510.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 76.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 89.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 89.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 89.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 89.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 77.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 27pt;"><td style="background-color: #bfbfbf; border-bottom: 2pt solid #000000; border-left: 2pt solid #000000; border-right: 2pt solid #000000; border-top: 2pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="6"><div style="left: 0pt; position: absolute; top: 0pt; width: 510.75pt;"><div><div style="line-height: 8pt; position: absolute; top: 2.63pt; width: 510.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 212.63pt; position: absolute; white-space: pre;">&#91;&#160;  &#93; <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 230.93pt; position: absolute; white-space: pre;">Performance<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr><tr style="height: 52.5pt;"><td style="border-bottom: 2pt solid #000000; border-left: 2pt solid #000000; border-right: 2pt solid #000000; border-top: 2pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 27pt; width: 76.5pt;"><div><div style="line-height: 8pt; position: absolute; top: 2.63pt; width: 76.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 5.4pt; position: absolute; white-space: pre;">If the <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 15.83pt; width: 76.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 5.4pt; position: absolute; white-space: pre;">Company&#8217;s <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 29.03pt; width: 76.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 5.4pt; position: absolute; white-space: pre;">&#91;&#160;  &#93; is&#58;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="border-bottom: 2pt solid #000000; border-left: 2pt solid #000000; border-right: 2pt solid #000000; border-top: 2pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 76.5pt; position: absolute; top: 27pt; width: 89.25pt;"><div><div style="line-height: 8pt; position: absolute; top: 21.66pt; width: 89.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 11.65pt; position: absolute; white-space: pre;">Less than &#91;&#160;  &#93;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="border-bottom: 2pt solid #000000; border-left: 2pt solid #000000; border-right: 2pt solid #000000; border-top: 2pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 165.75pt; position: absolute; top: 27pt; width: 89.25pt;"><div><div style="line-height: 8pt; position: absolute; top: 21.66pt; width: 89.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 37pt; position: absolute; white-space: pre;">&#91;&#160;  &#93;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="border-bottom: 2pt solid #000000; border-left: 2pt solid #000000; border-right: 2pt solid #000000; border-top: 2pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 255pt; position: absolute; top: 27pt; width: 89.25pt;"><div><div style="line-height: 8pt; position: absolute; top: 21.66pt; width: 89.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 35.47pt; position: absolute; white-space: pre;"> &#91;&#160;  &#93;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="border-bottom: 2pt solid #000000; border-left: 2pt solid #000000; border-right: 2pt solid #000000; border-top: 2pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 344.25pt; position: absolute; top: 27pt; width: 89.25pt;"><div><div style="line-height: 8pt; position: absolute; top: 21.66pt; width: 89.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 37pt; position: absolute; white-space: pre;">&#91;&#160;  &#93;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="border-bottom: 2pt solid #000000; border-left: 2pt solid #000000; border-right: 2pt solid #000000; border-top: 2pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 433.5pt; position: absolute; top: 27pt; width: 77.25pt;"><div><div style="line-height: 8pt; position: absolute; top: 21.66pt; width: 77.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 10.54pt; position: absolute; white-space: pre;">&#91;&#160;  &#93; or more<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr><tr style="height: 80.25pt;"><td style="border-bottom: 2pt solid #000000; border-left: 2pt solid #000000; border-right: 2pt solid #000000; border-top: 2pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 79.5pt; width: 76.5pt;"><div><div style="line-height: 8pt; position: absolute; top: 2.63pt; width: 76.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 5.4pt; position: absolute; white-space: pre;">Then the <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 15.83pt; width: 76.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 5.4pt; position: absolute; white-space: pre;">applicable <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 29.03pt; width: 76.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 5.4pt; position: absolute; white-space: pre;">vesting <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 42.23pt; width: 76.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 5.4pt; position: absolute; white-space: pre;">percentage <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 55.43pt; width: 76.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 5.4pt; position: absolute; white-space: pre;">is&#58;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="border-bottom: 2pt solid #000000; border-left: 2pt solid #000000; border-right: 2pt solid #000000; border-top: 2pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 76.5pt; position: absolute; top: 79.5pt; width: 89.25pt;"><div><div style="line-height: 8pt; position: absolute; top: 35.53pt; width: 89.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 32.11pt; position: absolute; white-space: pre;">&#91;&#160;  &#93;%<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="border-bottom: 2pt solid #000000; border-left: 2pt solid #000000; border-right: 2pt solid #000000; border-top: 2pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 165.75pt; position: absolute; top: 79.5pt; width: 89.25pt;"><div><div style="line-height: 8pt; position: absolute; top: 19.33pt; width: 89.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 32.11pt; position: absolute; white-space: pre;">&#91;&#160;  &#93;%<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 38.53pt; width: 89.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 18.36pt; position: absolute; white-space: pre;">(Threshold <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 51.73pt; width: 89.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 16.93pt; position: absolute; white-space: pre;">and Target)<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="border-bottom: 2pt solid #000000; border-left: 2pt solid #000000; border-right: 2pt solid #000000; border-top: 2pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 255pt; position: absolute; top: 79.5pt; width: 89.25pt;"><div><div style="line-height: 8pt; position: absolute; top: 35.53pt; width: 89.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 32.11pt; position: absolute; white-space: pre;">&#91;&#160;  &#93;%<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="border-bottom: 2pt solid #000000; border-left: 2pt solid #000000; border-right: 2pt solid #000000; border-top: 2pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 344.25pt; position: absolute; top: 79.5pt; width: 89.25pt;"><div><div style="line-height: 8pt; position: absolute; top: 35.53pt; width: 89.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 32.11pt; position: absolute; white-space: pre;">&#91;&#160;  &#93;%<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="border-bottom: 2pt solid #000000; border-left: 2pt solid #000000; border-right: 2pt solid #000000; border-top: 2pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 433.5pt; position: absolute; top: 79.5pt; width: 77.25pt;"><div><div style="line-height: 8pt; position: absolute; top: 25.93pt; width: 77.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 26.11pt; position: absolute; white-space: pre;">&#91;&#160;  &#93;%<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 45.13pt; width: 77.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 11.14pt; position: absolute; white-space: pre;">(Maximum)<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 475.9pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; white-space: pre; width: 469.41pt;">If the Company&#8217;s &#91;&#160;  &#93; is greater than &#91;&#160;  &#93; and less than &#91;&#160;  &#93;, and between two performance levels<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0500000000001pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 489.1pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.73pt;">in the table above, the applicable vesting percentage will be determined on a straight-line basis for<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 502.3pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.75pt;">performance between those two levels.&#160; For the avoidance of doubt, in no event shall the applicable<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 515.5pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.7pt;">vesting percentage exceed &#91;&#160;  &#93;%, and the applicable vesting percentage shall be &#91;&#160;  &#93;% if the Company&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 528.7pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 94.62pt;">&#91;&#160;  &#93; is less than &#91;&#160;  &#93;.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 553.9pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; white-space: pre; width: 256.89pt;">For these purposes, &#8220;&#91;&#160;  &#93;&#8221; means the Company&#8217;s &#91;&#160;  &#93;.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 579.1pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; white-space: pre; width: 469.37pt;">The Administrator shall equitably and proportionately adjust the &#91;&#160;  &#93; performance levels set forth<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 592.3pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.61pt;">in the chart above (or the level of &#91;&#160;  &#93; obtained, as the case may be) to the extent, if any, it determines<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.85pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 605.5pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.81pt;">appropriate to preserve the intended incentives and mitigate the impact of any merger, acquisition, or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 618.7pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 321.23pt;">disposition, or any change in the methodology for determining &#91;&#160;  &#93;.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 643.9pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 84.24pt; position: absolute; width: 13.43pt;">(b)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 120.24pt; position: absolute; width: 429.73pt;">The number of PRSUs determined to be eligible to vest based on performance pursuant<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 657.1pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 96.38pt;">to Section 1 of this <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 135.62pt; position: absolute; text-decoration: underline; white-space: pre; width: 42.75pt;">Exhibit A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 178.37pt; position: absolute; white-space: pre; width: 371.54pt;"> shall vest on &#91;&#160;  &#93; (the &#8220;Vesting Date&#8221;) if both of the following conditions are<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.91pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 670.3pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.79pt;">satisfied&#58; (i) there has not been a termination of the Employee&#8217;s employment prior to the Vesting Date<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 683.5pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.74pt;">(regardless of the reason for such termination, whether initiated by the Company or by the Employee)&#59;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 696.7pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.82pt;">and&#160; (ii) the Employee has maintained a performance rating of &#8220;Meets Expectations&#8221; or better from the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 709.9pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.82pt;">Company for both the 2025 and 2026 performance rating years to be eligible for the full value granted. If<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 723.1pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.7pt;">employees do not meet the minimum performance thresholds in subsection (ii), a deduction of up to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 736.3pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.8pt;">&#91;&#160;  &#93;% will be applied to the final equity award. If all such vesting conditions are satisfied, the number of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">2<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.7pt;">PRSUs determined to be eligible to vest based on performance pursuant to Section 1 of this Exhibit A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 62.9pt;">shall be the &#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.14pt; position: absolute; text-decoration: underline; white-space: pre; width: 74.52pt;">Earned PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 176.66pt; position: absolute; white-space: pre; width: 6.71pt;">&#8221;.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 74.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 84.24pt; position: absolute; width: 12.82pt;">(c)<font style="display: inline-block; height: 8pt; width: 23.18pt;"></font></font><font style="left: 120.24pt; position: absolute; width: 18.94pt;">Any<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 139.18pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 143.26999999999998pt; position: absolute; white-space: pre; width: 36.04pt;">PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 179.31pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 183.39999999999998pt; position: absolute; white-space: pre; width: 18.32pt;">that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 201.72pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 205.81pt; position: absolute; white-space: pre; width: 15.88pt;">are<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 221.69pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.09pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 225.77999999999997pt; position: absolute; white-space: pre; width: 15.27pt;">not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 241.05pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 308.92pt;"> eligible to vest based on performance pursuant to Section 1 of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 87.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 22.12pt;">this <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 61.36pt; letter-spacing: -0.013000000000000001em; position: absolute; text-decoration: underline; white-space: pre; width: 43.57pt;">Exhibit A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 104.93pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 313.62pt;"> at the conclusion of the applicable performance period shall <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 418.55pt; position: absolute; white-space: pre; width: 131.39pt;">be forfeited and canceled<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 100.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.83pt;">effective as of such time.&#160; If the Employee receives below a &#8220;Meets Expectations&#8221; rating for either 2025<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 114pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.69pt;">or 2026, there will be a prorated amount deducted from the award.&#160; The Employee shall have no right<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.93pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 127.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.79pt;">with respect to any PRSUs that are canceled pursuant to this Section 1(c) or pursuant to Section 2(a) of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 140.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.81pt;">the Agreement.&#160; No portion of the PRSUs shall be considered earned unless all of the vesting conditions<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 153.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 148.99pt;">set forth in Section 2(b) of this <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 188.23000000000002pt; position: absolute; text-decoration: underline; white-space: pre; width: 42.16pt;">Exhibit A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 230.39000000000001pt; position: absolute; white-space: pre; width: 65.34pt;"> are satisfied.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 295.73pt; position: absolute; white-space: pre; width: 6.1pt;">&#160; <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 178.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.239999999999995pt; position: absolute; white-space: pre; width: 9.16pt;">2.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 129.7pt;">Administrator Certification<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 195.94pt; position: absolute; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 198.99pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 10.95pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 209.94pt; position: absolute; white-space: pre; width: 340.06pt;">After the end of 2026 but not later than the Vesting Date, the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.91pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 192pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.83pt;">Administrator shall certify in writing the extent to which the PRSUs are eligible to vest based on<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 205.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 222.1pt;">performance pursuant to Section 1(a) of this <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 261.34pt; position: absolute; text-decoration: underline; white-space: pre; width: 43.43pt;">Exhibit A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 304.77pt; position: absolute; white-space: pre; width: 245.23pt;">.&#160; The Administrator has the sole right to construe<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 218.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 86.74pt;">and interpret this <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 125.97999999999999pt; position: absolute; text-decoration: underline; white-space: pre; width: 43.38pt;">Exhibit A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 169.36pt; position: absolute; white-space: pre; width: 380.6pt;">, and to make any and all determinations required with respect to the PRSUs<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 231.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 510.71pt;">(including, without limitation, the extent to which the PRSUs are eligible to vest based on performance<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 244.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 160.71pt;">pursuant to Section 1(a) of this <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 199.95000000000002pt; position: absolute; text-decoration: underline; white-space: pre; width: 44.1pt;">Exhibit A<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 244.05pt; position: absolute; white-space: pre; width: 305.97pt;">, the level of &#91;&#160;  &#93; obtained, and the Employee&#8217;s performance<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 258pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 39.24pt; position: absolute; white-space: pre; width: 309.03pt;">rating for each of the 2025 and 2026 performance rating years).<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 283.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 287.89pt; position: absolute; white-space: pre;">* * *<font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">1<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div id="i2dcfc617e1a34eee923147f1b6d1f260_7" style="position: absolute; top: 36pt;"></div><div style="line-height: 8pt; position: absolute; top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 270.19pt; position: absolute; white-space: pre;">EXHIBIT B<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 289.73pt; position: absolute; text-decoration: none; white-space: pre;">TO<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 75.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 183.17pt; position: absolute; text-decoration: none; white-space: pre;">TRANSFORMATIONAL EMPLOYEE AWARD<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 88.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 145.92pt; position: absolute; white-space: pre;">PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 115.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 156.01pt; position: absolute; white-space: pre;">CERTAIN CONTRACTUAL AND LEGAL OBLIGATIONS<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 142pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; white-space: pre; width: 469.31pt;">As a condition of Employee&#8217;s continued employment with agilon health, inc. or any of its<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.95pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 155.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; white-space: pre; width: 253.16pt;">subsidiaries or affiliates (collectively referred to as &#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 297.8pt; position: absolute; text-decoration: underline; white-space: pre; width: 65.96pt;">the Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 363.76pt; position: absolute; white-space: pre; width: 186.21pt;">&#8221;) and in exchange for the opportunity<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 168.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; white-space: pre; width: 438.42pt;">to participate in the in the Company&#8217;s Omnibus Equity Incentive Plan pursuant to the <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 483.06pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 52.94pt;">Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 536pt; position: absolute; white-space: pre; width: 14.05pt;"> to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0500000000001pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 181.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; white-space: pre; width: 308.43pt;">which this Exhibit B is attached, Employee hereby agrees as fol<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #1a1a1a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 353.07pt; position: absolute; text-decoration: none; white-space: pre; width: 25.04pt;">lows&#58;<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 206.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 9.16pt;">1.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 90.81pt;">Company Property<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 193.05pt; position: absolute; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 232pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 80.64pt; position: absolute; width: 13.43pt;">(a)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 116.64pt; position: absolute; width: 433.44pt;">Employee acknowledges and agrees that all Trade Secrets and Confidential Information<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.08pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 245.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">(as defined below) developed, created or maintained by Employee, alone or with others, while<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 258.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">Employee is employed by the Company, shall remain at all times the sole property of the Company,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 271.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">regardless of where such Trade Secrets and Confidential Information may be stored or maintained by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 284.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">Employee, including, without limitation, on any personal electronic or mobile device owned by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 298pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">Employee. Employee further acknowledges and agrees that all contact information of and all<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 311.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">communications (including emails, text messages, and other private electronic messages) with the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 324.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">Company&#8217;s Customers, prospective Customers, referral sources, and vendors that Employee may come<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 337.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">to possess during Employee&#8217;s employment with the Company shall remain the sole property of the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 350.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">Company even if Employee stores such information on Employee&#8217;s personal cell phone or electronic<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 364pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">device, and Employee shall not take and fail to return such information after termination of Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 377.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">employment with the Company for any reason. Employee will be in breach of this Paragraph if<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 390.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">Employee retains any such information on his&#47;her personal cell phone, personal electronic device or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 403.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 409.03pt;">personal email account after Employee&#8217;s employment with the Company has ended.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 428.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 80.64pt; position: absolute; width: 13.43pt;">(b)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 116.64pt; position: absolute; width: 433.38pt;">Employee further agrees and acknowledges that the Company has a property interest<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 442pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">and right in protecting its Confidential Information that is separate and distinct from its property interest<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 455.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.2pt;">in Trade Secrets, and that such property interest in Confidential Information shall provide the basis for<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 468.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">any and all remedies the Company shall have under the common law in the event of Employee&#8217;s breach<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 481.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">or attempted breach of Employee&#8217;s obligations under this Exhibit B with respect to Confidential<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 494.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">Information regardless of whether such information constitutes a trade secret under applicable law. The<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 508pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">Company&#8217;s separate property interest in its Confidential Information is based on this Exhibit B and other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 521.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 71.47pt;">applicable law.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 115.21000000000001pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 546.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 80.64pt; position: absolute; width: 16.48pt;">&#91;(b)<font style="display: inline-block; height: 8pt; width: 19.52pt;"></font></font><font style="left: 116.64pt; position: absolute; width: 433.38pt;">Employee further agrees and acknowledges that the Company has a property interest<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 559.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">and right in protecting its Confidential Information that is separate and distinct from its property interest<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 572.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.2pt;">in Trade Secrets, and that such property interest in Confidential Information shall provide the basis for<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 586pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">any and all remedies the Company shall have under the common law and California&#8217;s unfair competition<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 599.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">statute in the event of Employee&#8217;s breach or attempted breach of Employee&#8217;s obligations under this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 612.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">Exhibit B with respect to Confidential Information regardless of whether such information constitutes a<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 625.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">trade secret under applicable law. The Company&#8217;s separate property interest in its Confidential<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 638.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">Information is based on this Exhibit B, California Labor Code section 2860, and other applicable law.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 652pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">Employee hereby knowingly and voluntarily waives Employee&#8217;s right to plead, allege, argue, claim or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 665.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.16pt;">raise as a defense in any legal proceeding that any claim by the Company arising out of or based on<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 678.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">Employee&#8217;s breach or attempted breach of Employee&#8217;s obligations under this Exhibit B with respect to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 691.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">Confidential Information not constituting a trade secret under the law is preempted by the California<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 704.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 134.37pt;">Uniform Trade Secrets Act.&#93;<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 730pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 9.16pt;">2.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 254.88pt;">Safeguarding of Company&#8217;s Property &#38; Information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 357.12pt; position: absolute; white-space: pre; width: 192.9pt;">.&#160; Employee is strictly prohibited, at all<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 743.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">times during Employee&#8217;s employment with the Company except with prior written approval of the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 756.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">Company&#8217;s President, from forwarding from Employee&#8217;s Company email account to Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">2<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">personal email account(s) any emails or documents containing any Company Trade Secrets and&#47;or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">Confidential Information, as well as from copying, transferring or uploading to Employee&#8217;s personal<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">Cloud-based or online storage accounts such as a personal Dropbox or Google Docs account any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 75.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">documents containing any Company Trade Secrets and&#47;or Confidential Information. Employee is also<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 88.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">strictly prohibited, at all times during Employee&#8217;s employment with the Company except with the express<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 102pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.18pt;">or implicit authorization of the Company, and then only for the sole benefit of the Company during the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.92pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 115.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">term of employment, from removing from the premises of the Company any physical item or document,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 128.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">or any written, electronic or recorded copy of any physical item or document, containing or embodying<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 141.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">any Company Trade Secrets and&#47;or Confidential Information, including without limitations the same in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 154.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">electronic or digital form. Employee shall not leave any of the Company&#8217;s Trade Secrets and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 168pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">Confidential Information unattended in any area, whether on or off the Company&#8217;s premises, where<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 181.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">leaving such information unattended creates a risk that the information may be accessed or acquired by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 194.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">any individual who is not authorized to view or access the Company&#8217;s Trade Secrets and Confidential<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 207.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">Information. Employee will exercise due diligence and reasonable care when handling, maintaining,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 220.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">transferring, disposing or storing any Trade Secrets and&#47;or Confidential Information so as to not risk<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 234pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">unauthorized use or disclosure of the information or violate any federal or state privacy laws. Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 247.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">agrees to fully and completely comply with any and all security and privacy policies and directives of the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 260.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">Company. Employee will immediately give notice to the Company of any unauthorized use or disclosure<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 273.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">of Trade Secrets and&#47;or Confidential Information and will assist the Company in remedying any such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 286.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 152.7pt;">unauthorized use or disclosure.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 312pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 9.16pt;">3.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 254.52pt;">Company-Issued or Subsidized Electronic Devices<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 356.76pt; position: absolute; white-space: pre; width: 193.32pt;">. If Employee is issued any electronic<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 325.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">device by the Company such as a smart phone, iPad, laptop computer, or external hard drive, or if the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 338.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">Company is otherwise subsidizing the cost of Employee&#8217;s use of any electronic device, Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 351.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">agrees that the following shall govern Employee&#8217;s use, access, and possession of such devices&#58; (a)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 364.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">Employee has no right to privacy with respect to any data that is stored on the device&#59; (b) Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 378pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">use of the device shall be in accordance with the Employee Handbook and policies pertaining to use of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 391.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">Company equipment, computers, networks and systems&#59; (c) Employee will not use the device in any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 404.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">circumstances in which use of the device may distract Employee or others from any business task that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 417.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">requires close attention or otherwise may create an unsafe condition&#59; (d) Employee will not use the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 430.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">device in a manner that violates any applicable federal, state and local laws such as driving laws&#59; (e)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 444pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">Employee will return all such devices to the Company when requested to do so by the Company and&#47;or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 457.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">immediately upon termination of Employee&#8217;s employment with the Company for any reason&#59; (f) as soon<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 470.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">as Employee begins to consider leaving the Company or Employee realizes his&#47;her employment with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 483.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.17pt;">the Company has or will soon come to an end, Employee will not wipe or delete or cause any data to be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.91pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 496.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">wiped or deleted from any such device before returning the device to the Company&#59; (g) as soon as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 510pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">Employee&#8217;s employment with the Company terminates for any reason, or as soon as the Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 523.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">requests that Employee return the device for any reason, Employee no longer has authorization or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 536.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">consent from the Company to access the device and Employee will not access the device for any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 549.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">reason before returning it to the Company&#59; and (h) before Employee returns the device to the Company,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 562.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">whether upon request by the Company to return it or termination of Employee&#8217;s employment, if<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 576pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">Employee has stored any data on the device that Employee considers to be personal, Employee will not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 589.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">retrieve or access the device to retrieve such personal data except with the written consent of the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 602.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 345.7pt;">Company or in the presence of an authorized Company representative.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 627.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 9.16pt;">4.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 447.81pt;">Covenant Not to Use, Publish or Disclose the Company&#8217;s Trade Secrets and&#47;or Confidential<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; text-decoration: underline; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 640.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; text-decoration: underline; white-space: pre; width: 273.41pt;">Information During and After Termination of Employment<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 317.15000000000003pt; position: absolute; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 666pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 79.74pt; position: absolute; width: 13.43pt;">(a)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 115.74pt; position: absolute; width: 434.26pt;">Employee acknowledges and agrees that Employee&#8217;s employment with the Company<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 679.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">creates a relationship of confidence and trust with the Company with respect to all of the Company&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 2.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 692.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">Trade Secrets and Confidential Information (as defined below). Therefore, all of the Company&#8217;s Trade<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 705.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">Secrets and Confidential Information shall forever be maintained in confidence by Employee and used<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 718.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">by Employee only to such extent as may be necessary in the ordinary course of performing services for<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 732pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">the Company. Employee shall not at any time either during Employee&#8217;s term of employment or following<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 745.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">the termination of Employee&#8217;s employment with the Company (whether voluntary or involuntary), without<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 758.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">the prior written consent of the Company, reveal, disclose, divulge, publish, disseminate, communicate,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">3<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">use or employ for the benefit of Employee or others (including without limitation, any corporation,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">partnership, company, business, group, association, firm, trust, venture or entity other than the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">Company or any person not then employed by the Company) any Trade Secrets and&#47;or Confidential<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 75.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">Information except as provided in this Exhibit B. Notwithstanding the foregoing, this Paragraph does not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 88.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">prohibit or limit the right of Employee to discuss, debate and communicate with other employees of the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 102pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">Company regarding Employee&#8217;s workplace terms and conditions of employment, including wages, and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 115.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">does not prohibit or limit Employee&#8217;s right to disclose details about alleged incidents or claims of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 128.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">discrimination, retaliation, or harassment. This Paragraph also does not prohibit Employee&#8217;s ability to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 141.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">communicate with any government agencies regarding matters within their jurisdiction or otherwise<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 154.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">participate in any investigation or proceeding that may be conducted by any government agency,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 168pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 383.95pt;">including providing documents or other information, without notice to Company.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 193.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 79.74pt; position: absolute; width: 13.43pt;">(b)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 115.74pt; position: absolute; width: 434.32pt;">Employee&#8217;s agreement not to use Trade Secrets and&#47;or Confidential Information includes<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 206.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">an agreement that Employee will not, directly or indirectly, use the Company&#8217;s Trade Secrets and&#47;or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 219.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">Confidential Information to&#58; (i) identify existing customers of the Company for Employee&#8217;s own personal<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 232.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.17pt;">benefit or the benefit of any other firm or entity&#59; (ii) as set forth more fully in Paragraph 5 below, facilitate<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.91pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 246pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">the solicitation, for Employee&#8217;s personal benefit or the benefit of any other firm or entity, of any existing<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 259.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">or prospective customers of the Company that Employee serviced or solicited or about whom Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 272.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">otherwise gained Trade Secrets and&#47;or Confidential Information during Employee&#8217;s employment with the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 285.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">Company&#59; and&#47;or (iii) otherwise unfairly compete with the Company.&#160; Additionally, Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 298.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">agreement not to disclose or use Trade Secrets and&#47;or Confidential Information includes an agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 312pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">to exercise due diligence and reasonable care when handling, maintaining, transferring, disposing or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 325.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">storing any Trade Secrets and&#47;or Confidential Information so as to not violate any consumer federal or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 338.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.2pt;">state privacy laws.&#160; Employee also agrees to fully and completely comply with any and all security and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 351.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.2pt;">privacy policies enacted by the Company, including but not limited to all policies and directives of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 364.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 49.28pt;">Company.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 390pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 79.74pt; position: absolute; width: 12.82pt;">(c)<font style="display: inline-block; height: 8pt; width: 23.18pt;"></font></font><font style="left: 115.74pt; position: absolute; width: 434.24pt;">Notwithstanding any provisions in this Exhibit B or Company policy applicable to the<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 403.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">unauthorized use or disclosure of trade secrets, Employee is hereby notified that, pursuant to the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 416.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">Defend Trade Secrets Act as contained in 18 U.S.C. &#167; 1833, Employee cannot be held criminally or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 429.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that is made<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 442.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 456pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">attorney&#59; and (ii) solely for the purpose of reporting or investigating a suspected violation of law.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 469.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">Employee also may not be held so liable for such disclosures made in a complaint or other document<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 482.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, individuals who file a<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 495.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 508.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">secret to the attorney of the individual and use the trade secret information in the court proceeding, if the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 522pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">individual files any document containing the trade secret under seal and does not disclose the trade<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 535.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">secret, except pursuant to court order provided the Employee&#8217;s actions are consistent with 18 U.S.C. &#167;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 548.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 27.49pt;">1833.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 573.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 79.74pt; position: absolute; width: 13.43pt;">(d)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 115.74pt; position: absolute; width: 434.23pt;">Employee understands that the Company has in the past received, and in the future may<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 586.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">receive from third parties (such as Customers as defined below), confidential or proprietary information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 600pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 66.66pt;">(hereinafter &#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 110.4pt; position: absolute; text-decoration: underline; white-space: pre; width: 119.28pt;">Third Party Information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 229.68pt; position: absolute; white-space: pre; width: 320.37pt;">&#8221;) subject to a duty on the Company&#8217;s part to maintain the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 613.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.2pt;">confidentiality of such information and to use it only for certain limited purposes. During and after<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 626.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">Employee&#8217;s employment with the Company, Employee will honor all such agreements to protect Third<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 639.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">Party Information and will keep all such information received by Employee in the strictest confidence<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 652.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">and will not disclose it to anyone (other than to Company personnel who need to know such information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 666pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">in connection with their work for the Company) or use it, except in connection with Employee&#8217;s work for<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 679.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">the Company. Employee will direct any questions regarding the continuing existence of any such Third<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 692.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">Party Information to the Company prior to disclosing or using any such information. Notwithstanding the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 705.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">foregoing, this Paragraph is not intended to have the purpose or effect of concealing details about<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 718.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 344.43pt;">alleged incidents or claims of discrimination, retaliation, or harassment.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 744pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 9.16pt;">5.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 447.76pt;">Covenant Not to Solicit the Company&#8217;s Customers After Termination of Employment<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; text-decoration: underline; white-space: pre; width: 2.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 757.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; text-decoration: underline; white-space: pre; width: 407.76pt;">Through the Use of the Company&#8217;s Trade Secrets and&#47;or Confidential Information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 451.5pt; position: absolute; white-space: pre; width: 98.51pt;">.&#160; Employee agrees<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">4<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">that, for at least during the Restricted Period following the termination of Employee&#8217;s employment with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">the Company, whether voluntary or involuntary, Employee shall not, directly or indirectly, solicit or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 298.16pt;">attempt to solicit any business from any of the Company&#8217;s &#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 341.90000000000003pt; position: absolute; text-decoration: underline; white-space: pre; width: 53.14pt;">Customers<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 395.04pt; position: absolute; white-space: pre; width: 154.97pt;">&#8221;, (which are defined to include<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 75.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">but are not limited to the physician practices, physicians, health plans or payors), for the purposes of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 88.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">providing Products and Services that are competitive with those provided by the Company where such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 102pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">solicitation and&#47;or attempt at solicitation is done by Employee through the use of the Company&#8217;s Trade<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 115.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">Secrets and&#47;or Confidential Information&#59; provided, however, that the foregoing restriction shall continue<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 128.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">to apply for at least two (2) years following Employee&#8217;s separation from the Company and thereafter for<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 141.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">as long as the information used by Employee in the solicitation of the Company&#8217;s Customers qualifies as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 2.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 154.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 356.85pt;">Trade Secrets and&#47;or Confidential Information as defined in this Exhibit B.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 180pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 9.16pt;">6.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 130.91pt;">Covenant Not to Compete<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 233.14999999999998pt; position: absolute; white-space: pre; width: 26.13pt;">. The<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 259.28pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 8.33pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 267.61pt; position: absolute; white-space: pre; width: 48.87pt;">Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 316.48pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 8.33pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 324.81pt; position: absolute; white-space: pre; width: 33.6pt;">hereby<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 358.41pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 8.33pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 366.74pt; position: absolute; white-space: pre; width: 50.1pt;">covenants<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 416.84000000000003pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 8.33pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 425.17pt; position: absolute; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 443.5pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 8.33pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 451.83pt; position: absolute; white-space: pre; width: 33.6pt;">agrees<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 485.43pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 8.33pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 493.76pt; position: absolute; white-space: pre; width: 56.25pt;">that, during<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 193.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 59.010000000000005pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.73pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 64.74000000000001pt; position: absolute; white-space: pre; width: 56.62pt;">Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 121.36000000000001pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.73pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 127.09pt; position: absolute; white-space: pre; width: 59.86pt;">employment<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 186.95000000000002pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.73pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 192.68pt; position: absolute; white-space: pre; width: 19.54pt;">with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 212.22pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.73pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 217.95000000000002pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 233.22pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.73pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 238.95000000000002pt; position: absolute; white-space: pre; width: 47.04pt;">Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 285.99pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.73pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 291.71999999999997pt; position: absolute; white-space: pre; width: 21.38pt;">and,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 313.1pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.73pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 318.83pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 327.99pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.73pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 333.72pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 348.99pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.73pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 354.72pt; position: absolute; white-space: pre; width: 29.93pt;">extent<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 384.65000000000003pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.73pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 390.38pt; position: absolute; white-space: pre; width: 45.8pt;">permitted<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 436.18pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.73pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 441.91pt; position: absolute; white-space: pre; width: 64.83pt;">by applicable<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 506.74pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.73pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 512.47pt; position: absolute; white-space: pre; width: 18.94pt;">law,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 531.41pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.73pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 537.14pt; position: absolute; white-space: pre; width: 12.82pt;">for<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 206.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 59.010000000000005pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.6pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 65.61pt; position: absolute; white-space: pre; width: 43.37pt;">one-year<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 108.97999999999999pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.6pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 115.58000000000001pt; position: absolute; white-space: pre; width: 30.54pt;">period<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 146.12pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.6pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 152.72pt; position: absolute; white-space: pre; width: 42.75pt;">following<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 195.47pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.6pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 202.07000000000002pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 217.34pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.6pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 223.94pt; position: absolute; white-space: pre; width: 21.38pt;">date<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 245.32000000000002pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.6pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 251.92000000000002pt; position: absolute; white-space: pre; width: 12.22pt;">on<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 264.14pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.6pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 270.74pt; position: absolute; white-space: pre; width: 28.1pt;">which<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 298.84pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.6pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 305.44pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 320.71000000000004pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.6pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 327.31pt; position: absolute; white-space: pre; width: 121.09pt;">Employee&#8217;s employment<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 448.40000000000003pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.6pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 455pt; position: absolute; white-space: pre; width: 19.54pt;">with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 474.54pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.6pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 481.14pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 496.41pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.6pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 503.01pt; position: absolute; white-space: pre; width: 47.04pt;">Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 219.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 51.3pt;">terminates<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 95.03999999999999pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 101.15pt; position: absolute; white-space: pre; width: 12.82pt;">for<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 113.97pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 120.08000000000001pt; position: absolute; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 137.8pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 143.91pt; position: absolute; white-space: pre; width: 36.65pt;">reason,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 180.56pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 186.67000000000002pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 201.94pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 208.05pt; position: absolute; white-space: pre; width: 48.87pt;">Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 256.92pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 263.03pt; position: absolute; white-space: pre; width: 22.6pt;">shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 285.63pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 291.74pt; position: absolute; white-space: pre; width: 18.32pt;">not,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 310.06pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 316.17pt; position: absolute; white-space: pre; width: 34.81pt;">directly<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 350.98pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 8.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 359.09000000000003pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 368.86pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 374.97pt; position: absolute; white-space: pre; width: 45.6pt;">indirectly,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 420.57pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 426.68pt; position: absolute; white-space: pre; width: 11.61pt;">as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.29pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 444.40000000000003pt; position: absolute; white-space: pre; width: 12.22pt;">an<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 456.62pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 462.73pt; position: absolute; white-space: pre; width: 50.7pt;">employee,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 513.43pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.11pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 519.54pt; position: absolute; white-space: pre; width: 30.54pt;">agent,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 232.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 53.14pt;">consultant,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 96.88pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 103.44pt; position: absolute; white-space: pre; width: 37.26pt;">partner,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 140.7pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 147.26pt; position: absolute; white-space: pre; width: 20.15pt;">joint<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 167.41pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 173.97pt; position: absolute; white-space: pre; width: 39.7pt;">venture,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 213.67000000000002pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 220.23000000000002pt; position: absolute; white-space: pre; width: 32.38pt;">owner,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 252.61pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 259.17pt; position: absolute; white-space: pre; width: 32.18pt;">officer,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 291.35pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 8.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 299.91pt; position: absolute; white-space: pre; width: 39.09pt;">director,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 339pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 345.56pt; position: absolute; white-space: pre; width: 40.31pt;">member<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 385.87pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 392.43pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 401.59000000000003pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 408.15000000000003pt; position: absolute; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 425.87pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 432.43pt; position: absolute; white-space: pre; width: 25.04pt;">other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 457.47pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 464.03000000000003pt; position: absolute; white-space: pre; width: 21.36pt;">firm,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 485.39pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.56pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 491.95pt; position: absolute; white-space: pre; width: 58.02pt;">partnership,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 246pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 54.97pt;">corporation<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 98.71000000000001pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 105pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 114.77000000000001pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 121.06pt; position: absolute; white-space: pre; width: 25.04pt;">other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 146.1pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 152.39000000000001pt; position: absolute; white-space: pre; width: 26.26pt;">entity<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 178.65pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 184.94pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 194.71pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 201pt; position: absolute; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 209.55pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 215.84pt; position: absolute; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 233.56pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 239.85000000000002pt; position: absolute; white-space: pre; width: 69.66pt;">other capacity<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 309.51pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 315.8pt; position: absolute; white-space: pre; width: 28.7pt;">(other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 344.5pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 350.79pt; position: absolute; white-space: pre; width: 21.38pt;">than<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 372.17pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 378.46000000000004pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 393.73pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 400.02pt; position: absolute; white-space: pre; width: 56.62pt;">Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 456.64pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 462.93pt; position: absolute; white-space: pre; width: 50.09pt;">ownership<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 513.02pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 519.31pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 528.47pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.29pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 534.76pt; position: absolute; white-space: pre; width: 15.27pt;">not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 259.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 25.04pt;">more<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 68.78pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 78.28pt; position: absolute; white-space: pre; width: 21.38pt;">than<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 99.66pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 109.16pt; position: absolute; white-space: pre; width: 15.89pt;">2%<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 125.05000000000001pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 134.55pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 143.71pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 153.21pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 168.48pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 177.98000000000002pt; position: absolute; white-space: pre; width: 93.64pt;">outstanding equity<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 271.62pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 281.12pt; position: absolute; white-space: pre; width: 46.42pt;">securities<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 327.54pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 337.04pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 346.2pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 355.7pt; position: absolute; white-space: pre; width: 6.11pt;">a<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 361.81pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 371.31pt; position: absolute; white-space: pre; width: 71.46pt;">publicly-traded<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 442.77pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 452.27pt; position: absolute; white-space: pre; width: 51.31pt;">company),<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 503.58pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 513.0799999999999pt; position: absolute; white-space: pre; width: 12.22pt;">on<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 525.3pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.5pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 534.8pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 272.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 56.62pt;">Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 100.36pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 105.81pt; position: absolute; white-space: pre; width: 20.16pt;">own<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 125.97pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 131.42000000000002pt; position: absolute; white-space: pre; width: 29.93pt;">behalf<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 161.35pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 166.8pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 176.57000000000002pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 182.02pt; position: absolute; white-space: pre; width: 12.22pt;">on<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 194.24pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 199.69pt; position: absolute; white-space: pre; width: 42.55pt;">behalf of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 242.24pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 247.69pt; position: absolute; white-space: pre; width: 39.71pt;">another,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 287.4pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 292.85pt; position: absolute; white-space: pre; width: 12.22pt;">be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 305.07pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 310.52pt; position: absolute; white-space: pre; width: 47.65pt;">employed<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 358.17pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 363.62pt; position: absolute; white-space: pre; width: 13.85pt;">by,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 377.47pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 382.92pt; position: absolute; white-space: pre; width: 36.04pt;">provide<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 418.96000000000004pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 424.41pt; position: absolute; white-space: pre; width: 40.32pt;">services<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 464.73pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 470.18pt; position: absolute; white-space: pre; width: 12.21pt;">to,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 482.39pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 487.84000000000003pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 497.61pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 503.06pt; position: absolute; white-space: pre; width: 23.83pt;">have<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 526.89pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 532.34pt; position: absolute; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 285.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 43.38pt;">business<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 87.12pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.97pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 96.09pt; position: absolute; white-space: pre; width: 53.15pt;">connection<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 149.24pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.97pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 158.21pt; position: absolute; white-space: pre; width: 19.54pt;">with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 177.75pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.97pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 186.72pt; position: absolute; white-space: pre; width: 49.74pt;">any other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 236.46pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.97pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 245.43pt; position: absolute; white-space: pre; width: 36.65pt;">person,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 282.08pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.97pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 291.05pt; position: absolute; white-space: pre; width: 58.02pt;">corporation,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 349.07pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.97pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 358.04pt; position: absolute; white-space: pre; width: 21.36pt;">firm,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 379.40000000000003pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.97pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 388.37pt; position: absolute; white-space: pre; width: 54.97pt;">partnership<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 443.34000000000003pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.97pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 452.31pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 462.08pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.97pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 471.05pt; position: absolute; white-space: pre; width: 25.04pt;">other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 496.09000000000003pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.97pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 505.06pt; position: absolute; white-space: pre; width: 26.26pt;">entity<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 531.3199999999999pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.97pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 540.29pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 298.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 59.86pt;">organization<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 103.6pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 110.36000000000001pt; position: absolute; white-space: pre; width: 56.2pt;">whatsoever<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 166.56pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 173.32000000000002pt; position: absolute; white-space: pre; width: 18.32pt;">that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 191.64000000000001pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 8.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 200.4pt; position: absolute; white-space: pre; width: 47.65pt;">competes<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 248.05pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 254.81pt; position: absolute; white-space: pre; width: 19.54pt;">with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 274.35pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 281.11pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 296.38pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 303.14pt; position: absolute; white-space: pre; width: 43.38pt;">business<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 346.52pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 353.28000000000003pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 362.44pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 369.2pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 384.47pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 391.23pt; position: absolute; white-space: pre; width: 49.28pt;">Company,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 440.51pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 447.27pt; position: absolute; white-space: pre; width: 10.99pt;">its<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 458.26pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 465.02pt; position: absolute; white-space: pre; width: 59.86pt;">Subsidiaries<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 524.88pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 531.64pt; position: absolute; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 312pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 41.33pt;">Affiliates<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 85.07pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 94.08000000000001pt; position: absolute; white-space: pre; width: 11.61pt;">as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 105.69pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 114.69999999999999pt; position: absolute; white-space: pre; width: 82.16pt;">then conducted,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 196.86pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 205.87pt; position: absolute; white-space: pre; width: 52.53pt;">throughout<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 258.4pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 267.40999999999997pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 282.68pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 291.69pt; position: absolute; white-space: pre; width: 31.76pt;">United<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 323.45pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 332.46000000000004pt; position: absolute; white-space: pre; width: 31.15pt;">States<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 363.61pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 372.62pt; position: absolute; white-space: pre; width: 29.93pt;">where<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 402.55pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 411.56pt; position: absolute; white-space: pre; width: 17.72pt;">any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 429.28000000000003pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.29pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 447.45pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 456.46000000000004pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 471.73pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 480.74pt; position: absolute; white-space: pre; width: 49.28pt;">Company,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 530.02pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 9.01pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 539.03pt; position: absolute; white-space: pre; width: 10.99pt;">its<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 325.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 59.86pt;">Subsidiaries<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 103.6pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 111.87pt; position: absolute; white-space: pre; width: 56.78pt;">or Affiliates<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 168.65pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 176.92000000000002pt; position: absolute; white-space: pre; width: 21.38pt;">then<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 198.3pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 206.57000000000002pt; position: absolute; white-space: pre; width: 43.99pt;">conducts<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 250.56pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 258.83pt; position: absolute; white-space: pre; width: 43.38pt;">business<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 302.21000000000004pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 310.48pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 320.25pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 328.52pt; position: absolute; white-space: pre; width: 7.94pt;">is<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 336.46000000000004pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 344.73pt; position: absolute; white-space: pre; width: 36.65pt;">actively<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 381.38pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 389.65000000000003pt; position: absolute; white-space: pre; width: 41.54pt;">planning<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 431.19pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 439.46000000000004pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 448.62pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 456.89pt; position: absolute; white-space: pre; width: 38.49pt;">conduct<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 495.38pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 8.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 503.65000000000003pt; position: absolute; white-space: pre; width: 46.43pt;">business,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 338.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 46.42pt;">including,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 90.16pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 97.98pt; position: absolute; white-space: pre; width: 34.81pt;">without<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 132.79pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 140.61pt; position: absolute; white-space: pre; width: 46.4pt;">limitation,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 187.01000000000002pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 194.83pt; position: absolute; white-space: pre; width: 63.52pt;">partnerships,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 258.35pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 266.17pt; position: absolute; white-space: pre; width: 20.15pt;">joint<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 286.32pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 294.14pt; position: absolute; white-space: pre; width: 42.15pt;">ventures<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 336.29pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 344.11pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 353.88pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 361.7pt; position: absolute; white-space: pre; width: 31.75pt;">similar<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 393.45pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 401.27pt; position: absolute; white-space: pre; width: 67.8pt;">arrangements<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 469.07pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 476.89pt; position: absolute; white-space: pre; width: 19.54pt;">with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 496.43pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.82pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 504.25pt; position: absolute; white-space: pre; width: 45.82pt;">physician<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 351.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 43.98pt;">practices<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 87.72pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 93.25pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.41pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 107.94pt; position: absolute; white-space: pre; width: 39.09pt;">contract<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 147.03pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 152.56pt; position: absolute; white-space: pre; width: 19.54pt;">with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 172.10000000000002pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 177.63pt; position: absolute; white-space: pre; width: 45.2pt;">Medicare<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 222.83pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 228.36pt; position: absolute; white-space: pre; width: 52.54pt;">Advantage<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 280.9pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 286.43pt; position: absolute; white-space: pre; width: 29.93pt;">health<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 316.36pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 321.89pt; position: absolute; white-space: pre; width: 39.09pt;">insurers<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 360.98pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 366.51pt; position: absolute; white-space: pre; width: 28.1pt;">under<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 394.61pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 400.14pt; position: absolute; white-space: pre; width: 29.32pt;">global<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 429.46000000000004pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 434.99pt; position: absolute; white-space: pre; width: 17.1pt;">risk<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 452.09000000000003pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 457.62pt; position: absolute; white-space: pre; width: 44.59pt;">contracts<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 502.21000000000004pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 509.74pt; position: absolute; white-space: pre; width: 21.98pt;">(but,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 531.72pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 537.25pt; position: absolute; white-space: pre; width: 12.82pt;">for<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 364.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 59.010000000000005pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.77pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 65.78pt; position: absolute; white-space: pre; width: 50.1pt;">avoidance<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 115.88pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.77pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 122.65pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 131.81pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.77pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 138.58pt; position: absolute; white-space: pre; width: 30.54pt;">doubt,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 169.12pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.77pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 175.89000000000001pt; position: absolute; white-space: pre; width: 15.27pt;">not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 191.16pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.77pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 197.93pt; position: absolute; white-space: pre; width: 34.82pt;">owning<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 232.75pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.77pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 239.52pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 249.29000000000002pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.77pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 256.06pt; position: absolute; white-space: pre; width: 45.81pt;">operating<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 301.87pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.77pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 308.64pt; position: absolute; white-space: pre; width: 45.2pt;">Medicare<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 353.84000000000003pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.77pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 360.61pt; position: absolute; white-space: pre; width: 52.54pt;">Advantage<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 413.15000000000003pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.77pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 419.92pt; position: absolute; white-space: pre; width: 29.93pt;">health<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 449.85pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.77pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 456.62pt; position: absolute; white-space: pre; width: 40.82pt;">plans or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 497.44pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.77pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 504.21000000000004pt; position: absolute; white-space: pre; width: 45.82pt;">physician<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 378pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 43.98pt;">practices<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 87.72pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 92.76pt; position: absolute; white-space: pre; width: 62.3pt;">themselves).<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 403.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 3.05pt;">&#91;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 69.28999999999999pt; position: absolute; width: 9.16pt;">6.<font style="display: inline-block; height: 8pt; width: 23.79pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 281.42pt;">Covenant Not to Compete During Term of Employment<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 383.66pt; position: absolute; white-space: pre; width: 166.33pt;">. Employee promises that during<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 416.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">Employee&#8217;s employment with the Company, Employee shall not, directly or indirectly, either as an<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 429.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">employee, employer, consultant, agent, principal, partner, corporate officer, board member, director, or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 442.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">in any other individual or representative capacity, engage or attempt to engage in any competitive<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 456pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">activity relating to the subject matter of Employee&#8217;s employment with the Company or relating to the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 469.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 139.68pt;">Company&#8217;s line of business.&#93;<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 494.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 9.16pt;">7.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 126.51pt;">Non-Recruiting Covenant<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 228.75pt; position: absolute; white-space: pre; width: 321.29pt;">. Employee acknowledges and agrees that the Company has<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 507.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">invested substantial time and effort in assembling its present personnel, consultants, and independent<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 520.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.19pt;">contractors, and that, as a result of your employment with the Company, Employee will become privy to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.93pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 534pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">and familiar with the Company&#8217;s personnel, consultants, independent contractors, recruiting practices<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 547.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">and strategies, human capital, and talent.&#160; Therefore, to the extent permitted by applicable law,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 560.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">Employee agrees that during the Restriction Period (as defined below), whether voluntary or involuntary,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 573.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">Employee will not directly solicit or attempt to solicit, recruit or attempt to recruit, or otherwise aid or abet<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 586.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">any third party in soliciting or recruiting, or induce or attempt to induce, any person who is at the time of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 600pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">being recruited or solicited a current employee, consultant or independent contractor of the Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 613.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">with whom Employee worked or had contact or about whom Employee received or accessed any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 626.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">Confidential Information or Trade Secrets at any time during the last two (2) years of Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 639.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">employment with the Company, or induce or attempt to induce any such employee, consultant or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 652.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">independent contractor of the Company to terminate or cease employment or other relationship with the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 666pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">Company or to work for or with any business that competes with the Company.&#160; Notwithstanding the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 679.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">foregoing, nothing in this Section shall prevent Employee from receiving and considering any application<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 692.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">or proposal from any employee, consultant or independent contractor of the Company that is not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 705.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 230.07pt;">solicited by Employee or on Employee&#8217;s behalf.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 730.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 9.16pt;">8.<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #1a1a1a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 98.34pt;">Non-Disparagement<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #1a1a1a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 200.57999999999998pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #1a1a1a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 203.63pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre; width: 6.39pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 210.01999999999998pt; position: absolute; white-space: pre; width: 339.99pt;">Employee agrees that during the Restriction Period, Employee shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 744pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">not, directly or indirectly, disparage the Company or any of its subsidiaries or affiliates, any of their<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 757.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 333.69pt;">products, or any of their directors, officers, employees or sharehold<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #2d2d2d; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 377.43pt; position: absolute; text-decoration: none; white-space: pre; width: 18.32pt;">ers.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 395.75pt; position: absolute; white-space: pre; width: 154.25pt;"> Notwithstanding the foregoing,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">5<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">this Paragraph does not prohibit or limit the right of Employee to discuss, debate and communicate with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">other employees of the Company regarding Employee&#8217;s workplace terms and conditions of employment,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">including wages, and does not prohibit or limit Employee&#8217;s right to disclose details about alleged<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 75.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 305.95pt;">incidents or claims of discrimination, retaliation, or harassment.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 100.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 9.16pt;">9.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 174.06pt;">Assignment of Interest in Inventions<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 276.3pt; position: absolute; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 126pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 13.43pt;">(a)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 138.24pt; position: absolute; width: 411.75pt;">Employee agrees that any and all inventions, works of authorship, copyrightable<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 139.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">works in any medium of expression, software (including both object and source code), utility models,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 152.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">topography rights, database rights, formulas, ideas, discoveries, designs and design improvements,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 165.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">methods, processes, manufacturing techniques, trade secrets, mask works, moral rights, know-how,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 178.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">and all other intellectual property, whether or not patentable or registrable under patent, copyright or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 192pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">similar laws (including, without limitation, developments and derivative works with respect to any of the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 205.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">foregoing, and any other forms of technology), and any and all rights and benefits resulting therefrom<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 218.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 165.69pt;">(collectively referred to herein as &#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 209.43pt; position: absolute; text-decoration: underline; white-space: pre; width: 50.09pt;">Inventions<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 259.52pt; position: absolute; white-space: pre; width: 290.45pt;">&#8221;), that are made, created, developed or reduced to practice<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 231.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">by Employee solely or jointly with others during the term of Employee&#8217;s employment with the Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 244.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">and that (1) are made with the Company&#8217;s equipment, supplies, facilities, trade secrets, or time<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 258pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">(including through use of the Company&#8217;s internet or WiFi or any of its computers, networks, and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 271.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">electronic systems) or (2) relate, at the time of conception or of reduction to practice, to the business of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 284.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">the Company or the Company&#8217;s actual or demonstrably anticipated research or development, or (3)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 297.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">result from any work performed by Employee for the Company or result from the use of premises<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 310.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">owned, leased or otherwise used or acquired by the Company, shall belong to the Company and are<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 324pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">referred to as &#8220;Assigned Inventions,&#8221; and Employee agrees and promises to irrevocably and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 337.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">permanently assign and hereby irrevocably and permanently assigns any and all rights in such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 350.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 208.27pt;">Inventions to the Company or its designee.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 375.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 13.43pt;">(b)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 138.24pt; position: absolute; width: 411.74pt;">Employee will not, without the Company&#8217;s prior written approval, during or after<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 388.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">Employee&#8217;s employment with the Company, design, disclose, create or in any other way use or exploit<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 402pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">any Inventions that are identical or substantially similar to any Assigned Inventions to or for any third<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 415.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 26.67pt;">party.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 440.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 12.82pt;">(c)<font style="display: inline-block; height: 8pt; width: 23.18pt;"></font></font><font style="left: 138.24pt; position: absolute; width: 411.81pt;">Employee agrees that any Inventions made by Employee solely or jointly with<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 453.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">others, made after the date that this Exhibit B terminates, that are based on the Company&#8217;s Trade<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 466.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">Secrets, shall belong to the Company and be considered Assigned Inventions, and Employee promises<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 480pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">to assign any and all rights in such Inventions to the Company or its designee. For the purposes of this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 493.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">Exhibit B, an Invention is based on the Company&#8217;s Trade Secrets if the invention incorporates any such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 506.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">secrets in design or principal. For the purpose of this Exhibit B, an Invention is deemed to have been<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 519.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">made during the Employee&#8217;s period of employment if the Invention was conceived or actually first<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 532.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 185.05pt;">reduced to practice during that period.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 558pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 13.43pt;">(d)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 138.24pt; position: absolute; width: 411.83pt;">Employee also agrees that the Company shall have the right to keep any Assigned<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 571.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">Inventions covered by this Exhibit B as trade secrets, and Employee agrees not to disclose such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 584.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 437.73pt;">Assigned Inventions to any third parties except as specifically authorized by the Company.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 609.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 13.43pt;">(e)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 138.24pt; position: absolute; width: 411.83pt;">Employee agrees to assign and hereby does assign to the Company or its designee<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 622.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.18pt;">all rights in any other Assigned Inventions made by Employee as required to grant those rights to the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.92pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 636pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 236.97pt;">United States government or any of its agencies.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 661.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 10.37pt;">(f)<font style="display: inline-block; height: 8pt; width: 25.63pt;"></font></font><font style="left: 138.24pt; position: absolute; width: 411.83pt;">Employee acknowledges that all original works of authorship which are made by<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 674.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">Employee (solely or jointly with others) within the scope of Employee&#8217;s employment with the Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 687.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">and which are eligible for copyright protection are &#8220;works made for hire&#8221; as that term is defined in the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 700.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">United States Copyright Act (17 U.S.C., Section 101). The Company shall be the sole and exclusive<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 714pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.18pt;">owner and copyright proprietor of all rights and title in any and all materials created or submitted by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.92pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 727.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">Employee (whether alone or with any other person) during the term of Employee&#8217;s employment with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 740.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">Company.&#160; If for any reason the results of Employee&#8217;s services are determined at any time not to be a<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 753.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">&#34;Work Made for Hire&#34;, Employee hereby irrevocably transfers and assigns to Company all right, title and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">6<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">interest therein, including all copyrights, as well as all renewals and extensions thereto, including the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 359.71pt;">rights to reproduce, distribute, display and create derivative works thereof.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 74.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 106.74pt; position: absolute; width: 13.43pt;">(g)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 142.74pt; position: absolute; width: 407.25pt;">Notwithstanding any provision of this Paragraph 10 or its subparts, Employee shall<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 87.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">not be required to assign, nor shall Employee be deemed to have assigned, any of Employee&#8217;s rights in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 100.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">any inventions, that Employee develops entirely on Employee&#8217;s own time without using the Company&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 114pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">equipment, supplies, facilities, or trade secrets, except for inventions that either (1) relate, at the time<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 127.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.19pt;">that the invention is conceived or reduced to practice, to the Company&#8217;s business or to actual or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.93pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 140.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">demonstrably anticipated research or development of the Company&#59; or (2) result from any work<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 153.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 203.18pt;">performed by Employee for the Company.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 178.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 107.29pt; position: absolute; width: 16.48pt;">&#91;(g)<font style="display: inline-block; height: 8pt; width: 19.52pt;"></font></font><font style="left: 143.29000000000002pt; position: absolute; width: 406.7pt;">Notwithstanding any provision of this Paragraph 10 or its subparts, Employee shall<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 192pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.94pt; position: absolute; white-space: pre; width: 506.11pt;">not be required to assign, nor shall Employee be deemed to have assigned, any of Employee&#8217;s rights in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 205.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.94pt; position: absolute; white-space: pre; width: 506.01pt;">any inventions, as set forth in Labor Code section 2870 (reprinted in its entirety and attached hereto as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.95pt; position: absolute; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 218.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.94pt; position: absolute; text-decoration: underline; white-space: pre; width: 118.8pt;">Appendix 1 to Exhibit B<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 162.74pt; position: absolute; white-space: pre; width: 387.27pt;">), that Employee develops entirely on Employee&#8217;s own time without using the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 231.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.94pt; position: absolute; white-space: pre; width: 506.06pt;">Company&#8217;s equipment, supplies, facilities, or trade secrets, except for inventions that either (1) relate, at<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 244.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.94pt; position: absolute; white-space: pre; width: 506.14pt;">the time that the invention is conceived or reduced to practice, to the Company&#8217;s business or to actual<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 258pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.94pt; position: absolute; white-space: pre; width: 506.03pt;">or demonstrably anticipated research or development of the Company&#59; or (2) result from any work<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 271.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.94pt; position: absolute; white-space: pre; width: 206.23pt;">performed by Employee for the Company.&#93;<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 296.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 13.43pt;">(h)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 138.24pt; position: absolute; width: 411.82pt;">In order to permit the Company to claim rights to which it may be entitled, Employee<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 309.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">agrees to disclose to the Company in confidence (1) all Inventions that Employee makes, either solely<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 322.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">or jointly with others, during the term of Employee&#8217;s employment, and (2) all patent applications filed by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 336pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">Employee during, or within one (1) year after termination of Employee&#8217;s employment. Employee also<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 349.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">agrees to submit to a reasonable and confidential review process under which the Company may<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 362.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 275.45pt;">determine such issues as may arise under this Exhibit B.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 387.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 9.76pt;">(i)<font style="display: inline-block; height: 8pt; width: 26.24pt;"></font></font><font style="left: 138.24pt; position: absolute; width: 411.75pt;">Employee shall assist the Company in applying for, prosecuting, obtaining or<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 400.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">enforcing any and all patents, copyrights or other right or protection relating to any Assigned Inventions,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 414pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">designs, improvements, and discoveries deemed patentable by the Company in the United States and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 427.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">in all foreign countries, and shall execute all documents and do all things necessary to obtain letters of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 440.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">patent, to vest the Company with full and extensive titles to those patents and&#47;or copyrights, and to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 453.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.19pt;">protect the same against infringement by others, from, during and after the termination of this Exhibit B.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.93pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 466.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">In the event that assistance of the Employee is needed after the termination of this Exhibit B, Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 480pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 459.25pt;">will be paid for that assistance at the hourly rate he&#47;she earned when this Exhibit B terminated.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 505.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 9.76pt;">(j)<font style="display: inline-block; height: 8pt; width: 26.24pt;"></font></font><font style="left: 138.24pt; position: absolute; width: 411.81pt;">If the Company is unable to secure Employee&#8217;s signature on any document<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 518.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">necessary to apply for, prosecute, obtain, or enforce any patent, copyright, or other right or protection<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 531.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">relating to any Assigned Invention, whether due to Employee&#8217;s mental or physical incapacity or any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 544.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">other cause, Employee hereby irrevocably designates and appoints the Company and each of its duly<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 558pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">authorized officers and agents as Employee&#8217;s Agent and Attorney-In-Fact, to act for and in Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 571.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">behalf to execute and file any such document and to do all other lawfully permitted acts to further the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 584.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">prosecution, issuance, and enforcement of patents, copyrights, or other rights or protections, with the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 597.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 314.97pt;">same force and effect as if executed and delivered by Employee.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 622.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 12.82pt;">(k)<font style="display: inline-block; height: 8pt; width: 23.18pt;"></font></font><font style="left: 138.24pt; position: absolute; width: 411.76pt;">Employee acknowledges that there are no inventions, original works of authorship,<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 636pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">developments, improvements, and trade secrets that were made by Employee prior to becoming<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 649.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 204.37pt;">employed by the Company (collectively, &#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 248.11pt; position: absolute; text-decoration: underline; white-space: pre; width: 77.31pt;">Prior Inventions<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 325.42pt; position: absolute; white-space: pre; width: 224.55pt;">&#8221;) that belong to Employee, may relate to the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 662.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">Company&#8217;s current or reasonably anticipated business, products or research and development, and are<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 675.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">not assigned to the Company. If, during Employee&#8217;s employment with the Company, Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 688.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">incorporates into a Company product or process a Prior Invention developed by Employee prior to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 702pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">Employee becoming employed by Company that is owned by Employee or in which Employee has an<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 715.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">interest, Employee agrees that the Company is hereby granted and shall have a nonexclusive, royalty-<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 728.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">free, irrevocable, perpetual, worldwide license to make, have made, modify, use and sell such Prior<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 741.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 367.67pt;">Invention as part of or in connection with such product, process or machine.<font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">7<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre;">10.<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #1a1a1a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre;">Definitions<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #1a1a1a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 153.54pt; position: absolute; text-decoration: none; white-space: pre;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #1a1a1a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 156.59pt; letter-spacing: 0.177em; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="color: #1a1a1a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 161.57999999999998pt; position: absolute; text-decoration: none; white-space: pre;">For purposes of this Exhibit B<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #1a1a1a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 305.09pt; letter-spacing: -0.009000000000000001em; position: absolute; text-decoration: none; white-space: pre;">&#58;<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 61.2pt; width: 594.72pt;"><font style="color: #4d4d4d; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 13.43pt;">(a)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 138.24pt; position: absolute; width: 3.66pt;">&#8220;<font style="display: inline-block; height: 8pt;"></font></font></font><font style="color: #1a1a1a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 141.89999999999998pt; position: absolute; text-decoration: underline; white-space: pre; width: 51.91pt;">Restriction<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #1a1a1a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 193.81pt; letter-spacing: -0.068em; position: absolute; text-decoration: underline; white-space: pre; width: 3.53pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="color: #2f2f2f; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 197.33999999999997pt; position: absolute; text-decoration: underline; white-space: pre; width: 31.76pt;">Period<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #2f2f2f; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 229.1pt; position: absolute; text-decoration: none; white-space: pre; width: 3.66pt;">&#8221;<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #2f2f2f; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 232.76pt; letter-spacing: -0.063em; position: absolute; text-decoration: none; white-space: pre; width: 3.58pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="color: #2f2f2f; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 236.33999999999997pt; position: absolute; text-decoration: none; white-space: pre; width: 5.5pt;">s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 241.83999999999997pt; position: absolute; white-space: pre; width: 308.22pt;">hall mean the term of Employee&#8217;s employment with Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 74.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">or any of its subsidiaries or affiliates and a period of two (2) years thereafter. Company may, in its sole<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 87.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 428.09pt;">discretion, waive all or any portion of the Restriction Period by providing written notice to<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #2f2f2f; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 471.83pt; position: absolute; text-decoration: none; white-space: pre; width: 54.97pt;"> Employee.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 112.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 13.43pt;">(b)<font style="display: inline-block; height: 8pt; width: 22.57pt;"></font></font><font style="left: 138.24pt; position: absolute; width: 3.66pt;">&#8220;<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 141.89999999999998pt; position: absolute; text-decoration: underline; white-space: pre; width: 71.13pt;">Trade Secrets<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 213.03pt; position: absolute; white-space: pre; width: 336.97pt;">.&#8221;&#160; Employee acknowledges and agrees that, through Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 126pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">employment with the Company, Employee has or will be exposed to and&#47;or provided with the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 139.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 137.85pt;">Company&#8217;s Trade Secrets. &#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 181.59pt; position: absolute; text-decoration: underline; white-space: pre; width: 69.22pt;">Trade Secrets<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 250.81pt; position: absolute; white-space: pre; width: 299.22pt;">&#8221; mean information, including a formula, pattern, compilation,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 152.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">program, device, method, technique or process, that&#58; (1) derives independent economic value, actual or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 165.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">potential, from not being generally known to the public or to other persons or entities who can obtain<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 178.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">economic value from its disclosure or use and (2) is the subject of efforts that are reasonable under the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 192pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">circumstances to maintain its secrecy. The Company&#8217;s Trade Secrets include, but are not limited to, the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 205.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">following&#58; The Company&#8217;s files and records regarding Customers, prospective Customers, independent<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 218.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">contractors, subcontractors, vendors, distributors, and suppliers, such as key person contact<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 231.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">information&#59; Customer lists&#59; prospective Customer lists&#59; Customer profiles, needs, specifications,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 244.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">account history, habits, and correspondence&#59; information and documents pertaining to analyses and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 258pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">forecasts of capacity and readiness to meet Customer needs&#59; business plans and strategy&#59; information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 271.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">and documents regarding the composition of the Company&#8217;s Products and Services (including, but not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 284.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">limited to, manuals, plans, drawings, designs, blueprints, formulas, flowcharts, schematics,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 297.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">specifications, and other products containing information that may be useful to a competitor)&#59; custom<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 310.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">forms and documents created for internal use in conducting Company business&#59; software developed by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 324pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.2pt;">or for the benefit of the Company including but not limited to for its Medicare centric Total Care Model<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 337.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">platform of clinical and financial management and related data source code and programming<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 350.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">information (whether or not patentable or registered under copyright or similar statutes)&#59; all information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 363.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">contained in the Company&#8217;s databases such as CRM&#8217;s, MS Teams, MS OneDrive and shared folders on<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 376.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">Company servers or equipment&#59; the methods and systems used by the Company in soliciting,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 390pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">marketing, selling and providing its Products and Services to its Customers&#59; financial and accounting<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 403.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">information, such as budgets, cost, pricing, and billing information, estimating processes, revenues, and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 416.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">profit margins, targets, and forecasts&#59; unpublished financial statements&#59; and sales and marketing plans,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 429.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">strategies, programs, methods, and techniques. Employee acknowledges and agrees that the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 442.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">Company&#8217;s Trade Secrets are not generally known to the public or to the Company&#8217;s competitors, were<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 456pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">developed or compiled at significant expense by the Company over an extended period of time, are the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 469.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">subject of the Company&#8217;s reasonable efforts to maintain their secrecy, and that the Company derives<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 482.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 378.7pt;">significant independent economic value by keeping its Trade Secrets a secret.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 507.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 12.82pt;">(c)<font style="display: inline-block; height: 8pt; width: 22.43pt;"></font></font><font style="left: 137.49pt; position: absolute; width: 3.66pt;">&#8220;<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 141.14999999999998pt; position: absolute; text-decoration: underline; white-space: pre; width: 121.57pt;">Confidential Information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 262.71999999999997pt; position: absolute; white-space: pre; width: 287.33pt;">.&#8221; Employee acknowledges and agrees that, through<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 520.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">Employee&#8217;s employment with the Company, Employee has or will be exposed to and&#47;or provided with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 534pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 207.67pt;">the Company&#8217;s Confidential Information. &#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 251.41pt; position: absolute; text-decoration: underline; white-space: pre; width: 117.46pt;">Confidential Information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 368.87pt; position: absolute; white-space: pre; width: 181.2pt;">&#8221; means all information belonging to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 547.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">the Company, whether reduced to writing or in a form from which such information can be obtained,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 560.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">translated or derived into reasonably usable form, and whether the information is simply in Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 573.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">head, that has been provided to Employee during Employee&#8217;s employment with the Company and&#47;or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 586.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">Employee has gained access to while employed by the Company and&#47;or was developed by Employee in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 600pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">the course of Employee&#8217;s employment with the Company, that is proprietary and confidential in nature.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 2.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 613.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">The Company&#8217;s Confidential Information includes, but is not limited to, information believed by the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 626.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.19pt;">Company to be a Trade Secret that ultimately does not qualify as such under applicable state or federal<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.93pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 639.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">law but nonetheless was maintained by the Company as confidential, as well as other information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 652.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">maintained as confidential by the Company, including, but not limited to&#58; information concerning the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 666pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">nature of the Company&#8217;s business and its manner of operation&#59; the methods, strategies, programs, and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 679.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">systems used by the Company in soliciting, marketing, selling and providing its Products and Services<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 692.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">to its Customers&#59; financial and accounting information (such as cost, pricing and billing information,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 705.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">price lists, customer profiles and needs, financial policies and procedures estimating processes,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 718.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">revenues, and profit margins, targets, and forecasts)&#59; sales and marketing information, such as sales<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 732pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">strategies and programs&#59; information concerning the Company&#8217;s Customers and Prospective customers<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 745.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">(that are not otherwise publicly known including, but not limited to, Customer lists, prospective Customer<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 758.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">lists, product and service pricing information, revenues from Customer accounts, Customer purchasing<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">8<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">habits and special needs, contract terms and expiration dates, personal and private information and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">data of Customers and prospective Customers, correspondence with Customers, negotiation histories,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">billing histories, and any information about specific Customers&#8217; needs and pricing or service<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 75.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">preferences)&#59; information identifying persons who previously purchased any Products and Services from<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 88.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">the Company&#59; information concerning the Company&#8217;s independent contractors, subcontractors, vendors,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 102pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">distributors, and suppliers (including lists of all the foregoing)&#59; plans and projections for business<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 115.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">opportunities for new or developing business&#59; information regarding the Company&#8217;s Products and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 128.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">Services such as technical data design and&#47;or architectural drawings, flowcharts, plans, proposals,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 141.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">blueprints, schematics, processes, formulae, data and know-how, discoveries, developments, designs,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 154.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">improvements, inventions (whether or not patentable), experimental and research work&#59; software<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 168pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">developed by or for the benefit of the Company including but not limited to for its Medicare centric Total<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 181.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">Care Model platform of clinical and financial management and related data source code and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 194.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">programming information (whether or not patentable or registered under copyright or similar statutes)&#59;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 207.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">unpublished financial statements, budgets, projections, and licenses&#59; employee training methods and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 220.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">employee policies and procedures&#59; personnel files and employment-related records of the Company&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 234pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">current and former employees (other than you)(including, but not limited to, information related to the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 247.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">hiring, recruitment, retention, and termination of the Company&#8217;s current and former employees (other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 260.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">than you), as well as information related to their job duties, assignments, skills, performance, discipline,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 273.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">promotions, compensation, benefits, leaves of absence, and medical files) but only to the extent an<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 286.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">employee&#8217;s personnel file or employment records and information is disclosed or used without such<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 300pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.2pt;">employee&#8217;s consent or in violation of the employee&#8217;s right to privacy, as well as to the extent this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9399999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 313.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">information is disclosed to a competitor or used for the benefit of a competitor to recruit or target<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 326.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">employees with solicitation or recruiting efforts&#59; the Company&#8217;s organizational structure and internal<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 339.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">correspondence regarding personnel changes and internal reporting structures&#59; and information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 352.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">concerning the Company&#8217;s business relationships with persons, firms, corporations and other entities.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 366pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">Additionally, Confidential Information includes private information of and&#47;or about the Company&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 379.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">customers that the Company collects, compiles and maintains, including without limitation credit<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 392.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">information, social security numbers, addresses, phone numbers, and other private data, whether or not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 405.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">the Company has a legal obligation to safeguard the privacy of such information under applicable state<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 418.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 76.96pt;">and federal law.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 444pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 13.43pt;">(d)<font style="display: inline-block; height: 8pt; width: 21.82pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 137.49pt; position: absolute; text-decoration: underline; white-space: pre; width: 412.5pt;">Information Not Included Within the Definition of Trade Secrets and&#47;or Confidential<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; text-decoration: underline; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 457.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; text-decoration: underline; white-space: pre; width: 54.96pt;">Information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 98.7pt; position: absolute; white-space: pre; width: 451.27pt;">. For avoidance of doubt, the Company&#8217;s Trade Secrets and Confidential Information do not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 470.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">include any information that&#58; (1) is already in the public domain or becomes available to the public<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 483.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.29pt;">through no breach by Employee of this Exhibit B&#59; (2) was lawfully in Employee&#8217;s possession prior to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 496.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">disclosure to Employee by the Company&#59; (3) is lawfully disclosed to Employee by a third party without<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 510pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">any obligations of confidentiality attaching to such disclosure&#59; (4) is developed by Employee entirely on<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 523.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">Employee&#8217;s own time without the Company&#8217;s equipment, supplies or facilities and does not relate at the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 536.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">time of conception to the Company&#8217;s business or actual or demonstrably anticipated research or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 549.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">development of the Company&#59; or (5) relates to a claim of discrimination, retaliation or harassment.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 562.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">Notwithstanding these exclusions from the definitions of Trade Secrets and Confidential Information, if<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 576pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">Employee combines information that fits into any of the above five exceptions into the same document,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 589.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">spreadsheet, compilation or database with other information that qualifies as a Trade Secret and&#47;or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 602.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">Confidential Information, the combined document, spreadsheet, compilation or database shall be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 615.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.27pt;">protected as a Trade Secret and&#47;or Confidential Information of the Company regardless of the fact that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 628.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">some of the information contained therein may otherwise, standing alone, fit within any of the five<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 642pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 207.67pt;">exceptions stated above in this Paragraph.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 667.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; white-space: pre;"><font style="left: 102.24pt; position: absolute; width: 13.43pt;">(e)<font style="display: inline-block; height: 8pt; width: 21.82pt;"></font></font><font style="left: 137.49pt; position: absolute; width: 3.66pt;">&#8220;<font style="display: inline-block; height: 8pt;"></font></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 141.14999999999998pt; position: absolute; text-decoration: underline; white-space: pre; width: 113.75pt;">Products and Services<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 254.89999999999998pt; position: absolute; white-space: pre; width: 228.43pt;">.&#8221;&#160; For purposes of this Exhibit B, the term &#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 483.33pt; position: absolute; text-decoration: underline; white-space: pre; width: 66.65pt;">Products and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; text-decoration: underline; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 680.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; text-decoration: underline; white-space: pre; width: 42.15pt;">Services<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 85.89pt; position: absolute; white-space: pre; width: 464.11pt;">&#8221; means any and all products and services that Company provides related to its Medicare<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 693.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 461.71pt;">centric &#8220;Total Care Model&#8221; platform of clinical and financial management products and services.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 718.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 15.27pt;">11.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 47.01pt;">Forfeiture<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 149.25pt; letter-spacing: 0.181em; position: absolute; text-decoration: underline; white-space: pre; width: 5.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 154.92pt; position: absolute; text-decoration: underline; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 164.07999999999998pt; letter-spacing: 0.181em; position: absolute; text-decoration: underline; white-space: pre; width: 5.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 169.75pt; position: absolute; text-decoration: underline; white-space: pre; width: 36.46pt;">Awards<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 206.20999999999998pt; position: absolute; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 209.26pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 216.93pt; position: absolute; white-space: pre; width: 18.93pt;">The<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 235.86pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 241.52999999999997pt; position: absolute; white-space: pre; width: 37.87pt;">Options<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 279.4pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 285.07pt; position: absolute; white-space: pre; width: 37.26pt;">granted<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 322.33pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 328pt; position: absolute; white-space: pre; width: 50.09pt;">hereunder<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 378.09000000000003pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 383.76pt; position: absolute; white-space: pre; width: 51.94pt;">(and gains<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 435.7pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 441.37pt; position: absolute; white-space: pre; width: 34.21pt;">earned<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 475.58pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 481.25pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 491.02pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 496.69pt; position: absolute; white-space: pre; width: 39.1pt;">accrued<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 535.79pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.67pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 541.46pt; position: absolute; white-space: pre; width: 8.55pt;">in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 732pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 53.15pt;">connection<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 96.89pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 103.94pt; position: absolute; white-space: pre; width: 48.24pt;">therewith)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 152.18pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 159.23pt; position: absolute; white-space: pre; width: 22.6pt;">shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 181.83pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 188.88pt; position: absolute; white-space: pre; width: 12.22pt;">be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 201.10000000000002pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 208.15pt; position: absolute; white-space: pre; width: 34.82pt;">subject<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 242.97pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 250.02pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 259.18pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 266.23pt; position: absolute; white-space: pre; width: 72.87pt;">such generally<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 339.1pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 346.15000000000003pt; position: absolute; white-space: pre; width: 49.48pt;">applicable<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 395.63pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 402.68pt; position: absolute; white-space: pre; width: 36.65pt;">policies<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 439.33pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 446.38pt; position: absolute; white-space: pre; width: 11.61pt;">as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 457.99pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 465.04pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 474.2pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 481.25pt; position: absolute; white-space: pre; width: 43.35pt;">forfeiture<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 524.6pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 7.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 531.65pt; position: absolute; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 745.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 58.03pt;">recoupment<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 101.77000000000001pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 10.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 112.63pt; position: absolute; white-space: pre; width: 50.08pt;">(including,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 162.71pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 10.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 173.57000000000002pt; position: absolute; white-space: pre; width: 34.81pt;">without<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 208.38pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 12.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 221.24pt; position: absolute; white-space: pre; width: 46.4pt;">limitation,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 267.64pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 12.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 280.5pt; position: absolute; white-space: pre; width: 24.44pt;">upon<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 304.94pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 12.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 317.8pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 333.07pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 12.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 345.93pt; position: absolute; white-space: pre; width: 54.37pt;">occurrence<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 400.3pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 12.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 413.16pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 422.32pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 12.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 435.18pt; position: absolute; white-space: pre; width: 39.08pt;">material<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 474.26pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 12.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 487.12pt; position: absolute; white-space: pre; width: 40.31pt;">financial<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 527.43pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 12.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 540.29pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 758.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 53.15pt;">accounting<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 96.89pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 104.6pt; position: absolute; white-space: pre; width: 75.78pt;">errors, financial<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 180.38pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 188.09pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 197.86pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 205.57000000000002pt; position: absolute; white-space: pre; width: 25.04pt;">other<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 230.61pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 238.32000000000002pt; position: absolute; white-space: pre; width: 55.59pt;">misconduct<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 293.90999999999997pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 301.62pt; position: absolute; white-space: pre; width: 43.37pt;">including<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 344.99pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 352.7pt; position: absolute; white-space: pre; width: 6.11pt;">a<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 358.81pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 7.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 366.52pt; position: absolute; white-space: pre; width: 76.4pt;">material breach<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 442.92pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 448.63pt; position: absolute; white-space: pre; width: 9.16pt;">of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 457.79pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 463.5pt; position: absolute; text-decoration: underline; white-space: pre; width: 32.98pt;">Exhibit<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 496.48pt; letter-spacing: 0.181em; position: absolute; text-decoration: underline; white-space: pre; width: 5.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 502.19pt; position: absolute; text-decoration: underline; white-space: pre; width: 7.33pt;">B<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 509.52pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.71pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 515.23pt; position: absolute; white-space: pre; width: 34.81pt;">hereto)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">9<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 11.61pt;">as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 55.35pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.23pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 61.58pt; position: absolute; white-space: pre; width: 20.77pt;">may<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 82.35pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.23pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 88.58000000000001pt; position: absolute; white-space: pre; width: 12.22pt;">be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 100.80000000000001pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.23pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 107.03pt; position: absolute; white-space: pre; width: 39.71pt;">adopted<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 146.74pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.23pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 152.97pt; position: absolute; white-space: pre; width: 11.61pt;">by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 164.58pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.23pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 170.81pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 186.08pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 41.19pt;"> plan <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 227.27pt; position: absolute; white-space: pre; width: 63.51pt;">administrator<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 290.78pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.23pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 297.01pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 306.78000000000003pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.23pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 313.01pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 328.28000000000003pt; letter-spacing: 0.363em; position: absolute; white-space: pre; width: 8.23pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 336.51pt; position: absolute; white-space: pre; width: 29.32pt;">Board<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 365.83pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 92.8pt;"> of Company <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 458.63pt; position: absolute; white-space: pre; width: 21.98pt;">from<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 480.61pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.23pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 486.84000000000003pt; position: absolute; white-space: pre; width: 20.76pt;">time<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 507.6pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.23pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 513.8299999999999pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 522.99pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.23pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 529.22pt; position: absolute; white-space: pre; width: 20.76pt;">time<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 62.07pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.62pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 67.69pt; position: absolute; white-space: pre; width: 71.47pt;">communicated<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 139.16pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.62pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 144.78pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 153.94pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.62pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 159.56pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 174.83pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.62pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 180.45000000000002pt; position: absolute; white-space: pre; width: 48.87pt;">Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 229.32000000000002pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.62pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 234.94pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 244.71pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.62pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 250.33pt; position: absolute; white-space: pre; width: 11.61pt;">as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 261.94pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.62pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 267.56pt; position: absolute; white-space: pre; width: 40.31pt;">required<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 307.87pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.62pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 313.49pt; position: absolute; white-space: pre; width: 64.72pt;">by applicable<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 378.21000000000004pt; letter-spacing: 0.34em; position: absolute; white-space: pre; width: 7.37pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 385.58pt; position: absolute; white-space: pre; width: 18.94pt;">law,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 404.52pt; letter-spacing: 0.34em; position: absolute; white-space: pre; width: 7.37pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 411.89pt; position: absolute; white-space: pre; width: 18.33pt;">and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 430.22pt; letter-spacing: 0.34em; position: absolute; white-space: pre; width: 7.37pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 437.59000000000003pt; position: absolute; white-space: pre; width: 15.88pt;">are<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 453.47pt; letter-spacing: 0.34em; position: absolute; white-space: pre; width: 7.37pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 460.84000000000003pt; position: absolute; white-space: pre; width: 47.03pt;">otherwise<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 507.87pt; letter-spacing: 0.34em; position: absolute; white-space: pre; width: 7.37pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 515.24pt; position: absolute; white-space: pre; width: 34.82pt;">subject<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; letter-spacing: 0.34em; position: absolute; white-space: pre; width: 6.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 9.16pt;">to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 52.900000000000006pt; letter-spacing: 0.34em; position: absolute; white-space: pre; width: 6.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 59.69pt; position: absolute; white-space: pre; width: 43.35pt;">forfeiture<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 103.03999999999999pt; letter-spacing: 0.34em; position: absolute; white-space: pre; width: 6.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 109.83000000000001pt; position: absolute; white-space: pre; width: 9.77pt;">or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 119.6pt; letter-spacing: 0.34em; position: absolute; white-space: pre; width: 6.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 126.39000000000001pt; position: absolute; white-space: pre; width: 66.58pt;">disgorgement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 192.97pt; letter-spacing: 0.34em; position: absolute; white-space: pre; width: 6.79pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 199.76000000000002pt; position: absolute; white-space: pre; width: 42.13pt;">of profits<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 241.89000000000001pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 246.93pt; position: absolute; white-space: pre; width: 11.61pt;">as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 258.54pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 263.58pt; position: absolute; white-space: pre; width: 42.15pt;">provided<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 305.73pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 310.77pt; position: absolute; white-space: pre; width: 11.61pt;">by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 322.38pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 327.42pt; position: absolute; white-space: pre; width: 15.27pt;">the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 342.69pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.04pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 347.73pt; position: absolute; white-space: pre; width: 25.04pt;">Plan.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 87.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 15.27pt;">12.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 84.92pt;">Reasonableness.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 187.16pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 6.27pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 193.43pt; position: absolute; white-space: pre; width: 48.87pt;">Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 242.3pt; letter-spacing: -0.068em; position: absolute; white-space: pre; width: 3.54pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 245.83999999999997pt; position: absolute; white-space: pre; width: 304.22pt;">acknowledges that the restrictions contained in this Exhibit B<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 100.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">(i) are, individually and in the aggregate, properly required by Company and reasonable in duration,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 114pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 152.13pt;">scope, area and nature and (ii)<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 195.87pt; letter-spacing: -0.004em; position: absolute; white-space: pre; width: 3.51pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 199.38pt; position: absolute; white-space: pre; width: 350.61pt;">shall survive the termination of Employee&#8217;s employment and be binding<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 127.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 301.53pt;">by their terms at all times subsequent to the termination of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 345.27pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 4.85pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 350.12pt; position: absolute; white-space: pre; width: 56.62pt;">Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 406.74pt; letter-spacing: -0.063em; position: absolute; white-space: pre; width: 4.3pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 411.04pt; position: absolute; white-space: pre; width: 138.96pt;">employment for the periods<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; letter-spacing: -0.027em; position: absolute; white-space: pre; width: 2.76pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 140.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 80.04pt;">specified herein.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 123.78pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.07pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 128.85pt; position: absolute; white-space: pre; width: 74.55pt;">Employee shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 203.4pt; letter-spacing: -0.013000000000000001em; position: absolute; white-space: pre; width: 2.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 206.34pt; position: absolute; white-space: pre; width: 18.32pt;">not,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 224.66pt; letter-spacing: -0.045em; position: absolute; white-space: pre; width: 2.59pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 227.25pt; position: absolute; white-space: pre; width: 322.79pt;">and Employee hereby waives and releases any rights or claims to,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 153.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">contest or challenge the reasonableness, validity or enforceability of the restrictions contained in this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 166.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 202.89pt;">Exhibit B whether in court, arbitration or <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 246.63pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 105.3pt;">otherwise. Moreover, <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 351.93pt; position: absolute; white-space: pre; width: 198.07pt;">Employee acknowledges that Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 180pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 348.61pt;">has carefully read and considered the terms of this Exhibit B to the <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 392.35pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 52.94pt;">Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 445.29pt; position: absolute; white-space: pre; width: 104.64pt;"> and agrees that the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.93pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 193.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">restrictions set forth therein are fair and reasonable, are supported by valid consideration, and are<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 206.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">reasonably required to protect the legitimate business interests of Company. Employee acknowledges<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 219.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.34pt;">and agrees that the restrictions herein do not and will not interfere with or unduly limit Employee&#8217;s ability<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0799999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 232.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">to obtain suitable alternative employment following termination of employment. By employing or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 246pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">continuing to employ Employee, Company is relying on Employee&#8217;s representation in this Section that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 259.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 453.3pt;">Employee has carefully read and considered the covenants contained in this Exhibit B to the <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 497.04pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 52.94pt;">Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 272.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">and agrees they are reasonable, supported by valid consideration, and are reasonably required to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 285.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">protect the legitimate business interests of Company. Accordingly, Employee agrees that Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 298.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">shall be legally estopped from taking any position in any proceeding or forum that is inconsistent with<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 312pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 59.85pt;">this Section.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 337.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 15.27pt;">13.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 81.06pt;">Injunctive Relief.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 183.3pt; letter-spacing: 0.181em; position: absolute; white-space: pre; width: 5.49pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 188.79pt; position: absolute; white-space: pre; width: 361.19pt;">Employee acknowledges and agrees that if the Company&#8217;s Trade Secrets<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 350.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">and&#47;or Confidential Information were disclosed to a competing business or used in an unauthorized<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 363.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">manner as provided herein, such unauthorized disclosure or use would cause immediate and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 376.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">irreparable harm to the Company and would give a competing business an unfair business advantage<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 390pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">against the Company for which the Company may not have an adequate remedy at law. Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 403.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">further acknowledges that because of the nature of the Company&#8217;s business and the subject matter of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 416.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 343.32pt;">this Exhibit B, a breach or attempted breach of this Exhibit B to the <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 387.06pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 52.94pt;">Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 440pt; position: absolute; white-space: pre; width: 109.96pt;"> will cause substantial<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 429.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.28pt;">injury to the Company for which money damages alone may not provide an adequate remedy. As such,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 442.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.19pt;">Employee agrees that the Company shall be entitled to any proper injunction, including but not limited to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.93pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 456pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.32pt;">temporary, preliminary, final injunctions, temporary restraining orders, and temporary protective orders,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 469.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 217.86pt;">to enforce the terms of this Exhibit B to the <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 261.6pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 52.94pt;">Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 314.54pt; position: absolute; white-space: pre; width: 235.44pt;"> in the event of breach or threatened breach by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 482.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">Employee, in addition to any other remedies available to the Company at law or in equity. The restrictive<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 495.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">covenants contained in this Exhibit B are independent of any other obligations between the parties, and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 508.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">the existence of any other claim or cause of action against the Company is not a defense to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 522pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.25pt;">enforcement of said covenants by injunction. Employee agrees that in connection with any application<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 535.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">for injunctive relief, discovery shall be conducted on an expedited basis even without a court order<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 548.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.23pt;">permitting or granting leave to conduct expedited discovery, and neither party will require the other to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 561.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">post a bond at any stage in litigation or arbitration of such matter, and both parties hereby waive the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 574.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">right to request posting of a bond by the party requesting injunctive relief. Employee further agrees that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 588pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.18pt;">Employee shall not, in any proceeding involving it, relating to the enforcement of this Exhibit B to the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.92pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 601.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 52.94pt;">Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 96.68pt; position: absolute; white-space: pre; width: 335.93pt;">, raise the defense that the Company has an adequate remedy at law<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #2d2d2d; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 432.61pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 626.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 15.27pt;">14.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 55.99pt;">Severability<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #2d2d2d; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 158.23pt; position: absolute; text-decoration: underline; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #2d2d2d; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 161.28pt; letter-spacing: 0.336em; position: absolute; text-decoration: none; white-space: pre; width: 8.94pt;"> <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 170.22pt; position: absolute; white-space: pre; width: 379.76pt;">If any of the restrictions contained in this Exhibit B should for any reason<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 639.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.33pt;">whatsoever be declared invalid in any jurisdiction, the validity or enforceability of the remainder of this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.0699999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 652.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.18pt;">Exhibit B shall not be adversely affected thereby. If any term or provision of this Exhibit B is deemed to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.92pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 666pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.24pt;">be so broad as to be invalid or unenforceable in a particular jurisdiction, Employee and Company agree,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.98pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 679.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.26pt;">with respect to such jurisdiction, to reduce the scope, duration, area or applicability of the term or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 692.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.22pt;">provision, to delete specific words or phrases, or to replace any invalid, void or unenforceable term or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 705.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">provision with a term or provision that is valid and enforceable and that comes closest to expressing the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 718.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 315.12pt;">original intention of the invalid or unenforceable term or provision<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #181818; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 358.86pt; position: absolute; text-decoration: none; white-space: pre; width: 3.05pt;">.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 744pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 15.27pt;">15.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 75.98pt;">Attorneys&#8217; Fees<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 178.22pt; position: absolute; white-space: pre; width: 371.8pt;">. Employee and the Company agree that in any legal proceeding undertaken<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 757.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.21pt;">to enforce the terms and provisions of this Agreement, the prevailing party shall be entitled to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.9499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 291.8pt; position: absolute; text-decoration: none; white-space: pre;">10<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">reimbursement of its actual costs and expenses, including without limitation its reasonable attorneys&#8217;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 95.3pt;">fees and expenses.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 74.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre; width: 15.27pt;">16.<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #282828; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 28.7pt;">Entire<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 130.94pt; position: absolute; text-decoration: underline; white-space: pre; width: 59.29pt;"> Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 190.23pt; position: absolute; white-space: pre; width: 131.34pt;">.&#160; This Exhibit B to the <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 321.57pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 52.94pt;">Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 374.51pt; position: absolute; white-space: pre; width: 175.46pt;"> is the entire agreement between<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 87.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">Employee and Company regarding the issues contained in this Exhibit B and this Exhibit B to the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 100.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 52.94pt;">Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 96.68pt; position: absolute; white-space: pre; width: 206.41pt;"> supersedes the original Exhibit B to the <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 303.09000000000003pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre; width: 52.94pt;">Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 356.03000000000003pt; position: absolute; white-space: pre; width: 194.01pt;"> regarding these issues. This Exhibit B<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 114pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.19pt;">cannot be orally modified. Any amendment or modification to this Exhibit B must be in writing, signed by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.93pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 127.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.3pt;">Employee and a duly authorized representative of the Company. This Exhibit B consists of a series of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.04pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 140.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 506.31pt;">separate restrictive covenants, all of which shall survive and be enforceable in law and&#47;or equity after<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.05pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 153.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre; width: 254.49pt;">Employee&#8217;s termination or cessation of employment.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 178.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; white-space: pre;">17.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; text-decoration: underline; white-space: pre;">Governing<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #282828; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 152.94pt; position: absolute; text-decoration: underline; white-space: pre;"> Law <font style="display: inline-block; height: 8pt;"></font></font><font style="color: #3a3a3a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 179.2pt; position: absolute; text-decoration: underline; white-space: pre;">and <font style="display: inline-block; height: 8pt;"></font></font><font style="color: #181818; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 200.57999999999998pt; position: absolute; text-decoration: underline; white-space: pre;">Juri<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #3a3a3a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 218.29pt; position: absolute; text-decoration: underline; white-space: pre;">sdic<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #181818; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 237.83999999999997pt; position: absolute; text-decoration: underline; white-space: pre;">ti<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #3a3a3a; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 243.32999999999998pt; position: absolute; text-decoration: underline; white-space: pre;">o<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #181818; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 249.44pt; position: absolute; text-decoration: underline; white-space: pre;">n<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #5d5d5d; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 255.55pt; position: absolute; text-decoration: none; white-space: pre;">.<font style="display: inline-block; height: 8pt;"></font></font><font style="color: #5d5d5d; font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 258.6pt; letter-spacing: 0.181em; position: absolute; text-decoration: none; white-space: pre;">&#160; <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 268.68pt; position: absolute; white-space: pre;">Notwithstanding any provision to the contrary contained <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 192pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre;">in the <font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 73.66pt; letter-spacing: -0.009000000000000001em; position: absolute; white-space: pre;">Agreement<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 126.6pt; position: absolute; white-space: pre;"> or the 2021 Omnibus Equity Incentive Plan, all issues and questions concerning the <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 205.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre;">construction, validity, enforcement, and interpretation of this Exhibit B shall be governed by, and <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 218.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre;">construed in accordance with, the laws of the State of Delaware, without giving effect to the principles of <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 231.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre;">conflict of laws.&#160; Subject to any applicable arbitration agreement, the parties agree that any action or <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 244.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre;">proceeding to enforce or arising out of this Exhibit B must be commenced in the foregoing state.&#160; The <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 258pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre;">parties consent to the exclusive personal jurisdiction of the state and federal courts and arbitrators <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 271.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre;">located in the foregoing state for any dispute arising out of or relating to this Exhibit B, agree that venue <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 284.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre;">will be proper in such courts or in front of such arbitrators, and waive any objections based upon forum <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 297.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre;">non conveniens.&#160; The choice of forum set forth in this Section shall not be deemed to preclude the <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 310.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre;">enforcement of any action under this Exhibit B in any other jurisdiction.<font style="display: inline-block; height: 8pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">1<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div id="i2dcfc617e1a34eee923147f1b6d1f260_10" style="position: absolute; top: 36pt;"></div><div style="line-height: 8pt; position: absolute; top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 225pt; position: absolute; text-decoration: underline; white-space: pre;">&#91;APPENDIX 1 TO EXHIBIT B<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 184.41pt; position: absolute; white-space: pre;">THE COMPANY&#8217;S WRITTEN NOTIFICATION<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 75.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 113.87pt; position: absolute; white-space: pre;">TO CALIFORNIA-BASED EMPLOYEE OF LABOR CODE SECTION 2870<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 102.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; white-space: pre; width: 469.33pt;">In accordance with California Labor Code section 2870, you are hereby notified that this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.97pt; position: absolute; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 115.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; white-space: pre; width: 505.43pt;">Agreement does not require you to assign to the Company any Invention for which no equipment,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.07pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 128.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; white-space: pre; width: 505.32pt;">supplies, facility or trade secrets of the Company was used and that was developed entirely on your<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 142pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; white-space: pre; width: 505.38pt;">own time, and does not relate to the business of the Company or to the Company&#8217;s actual or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 155.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; white-space: pre; width: 505.37pt;">demonstrably anticipated research or development, or does not result from any work performed by you<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 168.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; white-space: pre; width: 83.47pt;">for the Company.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 193.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 80.64pt; position: absolute; white-space: pre; width: 305.35pt;">The following is the text of California Labor Code section 2870&#58;<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 218.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; white-space: pre; width: 426.18pt;">(a) Any provision in an Employment Agreement which provides that an employee shall<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 528.42pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 232pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; white-space: pre; width: 426.13pt;">assign, or offer to assign, any of his or her right to an invention to his or her employer<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 528.37pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 245.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; white-space: pre; width: 426.1pt;">shall not apply to an invention that the employee developed entirely on his or her own<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 528.34pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 258.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; white-space: pre; width: 426.16pt;">time without using the employer&#8217;s equipment, supplies, facilities, or trade secret<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 528.4pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 271.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; white-space: pre; width: 182.6pt;">information except for inventions that&#58;<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 298.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 120.24pt; position: absolute; white-space: pre; width: 408.14pt;">(1) Relate at the time of conception or reduction to practice of the invention to the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 528.38pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 311.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 120.24pt; position: absolute; white-space: pre; width: 408.2pt;">employer&#8217;s business, or actual or demonstrably anticipated research or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 528.4399999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 324.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 120.24pt; position: absolute; white-space: pre; width: 157.57pt;">development of the employer&#59; or<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 350pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 120.24pt; position: absolute; white-space: pre; width: 341.39pt;">(2) Result from any work performed by the employee for the employer.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 375.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; white-space: pre; width: 426.21pt;">(b) To the extent a provision in the employment agreement purports to require an<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 528.4499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 388.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; white-space: pre; width: 426.21pt;">employee to assign an invention otherwise excluded from being required to be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 528.4499999999999pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 401.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; white-space: pre; width: 426.22pt;">assigned under subdivision (a), the provision is against the public policy of this state<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 528.46pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 414.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 102.24pt; position: absolute; white-space: pre; width: 105.06pt;">and is unenforceable.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 490pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: italic; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 36.24pt; position: absolute;">&#160;  __________________________ <font style="display: inline-block; height: 8.73pt; width: 29.26pt;"></font></font><font style="left: 252.24pt; position: absolute;"><font style="display: inline-block; height: 8.73pt; width: 36pt;"></font></font><font style="left: 288.24pt; position: absolute;"><font style="display: inline-block; height: 8.73pt; width: 36pt;"></font></font><font style="left: 324.24pt; position: absolute;">________________________<font style="display: inline-block; height: 8.73pt;"></font></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 509pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 36.24pt; position: absolute;">&#160;  Employee Signature<font style="display: inline-block; height: 8.73pt; width: 26.02pt;"></font></font><font style="left: 180.24pt; position: absolute;"><font style="display: inline-block; height: 8.73pt; width: 36pt;"></font></font><font style="left: 216.24pt; position: absolute;"><font style="display: inline-block; height: 8.73pt; width: 36pt;"></font></font><font style="left: 252.24pt; position: absolute;"><font style="display: inline-block; height: 8.73pt; width: 36pt;"></font></font><font style="left: 288.24pt; position: absolute;"><font style="display: inline-block; height: 8.73pt; width: 36pt;"></font></font><font style="left: 324.24pt; position: absolute;">Date&#93;<font style="display: inline-block; height: 8.73pt;"></font></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">2<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="line-height: 8pt; position: absolute; top: 36pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 270.19pt; position: absolute; white-space: pre;">EXHIBIT C<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 49.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 289.73pt; position: absolute; text-decoration: none; white-space: pre;">TO <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 62.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 183.17pt; position: absolute; text-decoration: none; white-space: pre;">TRANSFORMATIONAL EMPLOYEE AWARD<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 75.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 145.92pt; position: absolute; white-space: pre;">PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; top: 102pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: bold; left: 193.25pt; position: absolute; white-space: pre;">ADDITIONAL TERMS AND CONDITIONS<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 128.8pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; white-space: pre; width: 505.38pt;">This Exhibit includes additional terms and conditions that govern PRSUs. Capitalized terms not<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 550.02pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 142pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; white-space: pre; width: 505.28pt;">explicitly defined in this Exhibit but defined in the Agreement shall have the same definitions as in the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.92pt; position: absolute; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 155.2pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; white-space: pre; width: 56.8pt;">Agreement.<font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 180.4pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; white-space: pre; width: 25.08pt;">1.&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 69.72pt; position: absolute; text-decoration: underline; white-space: pre; width: 77.58pt;">Nature of Grant<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 147.3pt; position: absolute; white-space: pre; width: 402.66pt;">. In accepting the PRSUs, the Employee understands, acknowledges and agrees<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 549.96pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 193.6pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.64pt; position: absolute; white-space: pre; width: 21.37pt;">that&#58;<font style="display: inline-block; height: 8pt;"></font></font></div><div style="position: absolute; top: 218.8pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 535.5pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 82.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 453pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 57pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 15.75pt; width: 82.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 82.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 15.27pt;">1.1<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 82.5pt; position: absolute; top: 15.75pt; width: 453pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.49pt;">the Plan is established voluntarily by the Company, it is discretionary in nature and it may<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.49pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.54pt;">be modified, amended, suspended or terminated by the Company at any time, to the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.54pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 29.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 139.85pt;">extent permitted by the Plan&#59;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 309.75pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 535.5pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 82.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 453pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 57pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 82.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 82.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 15.27pt;">1.2<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 82.5pt; position: absolute; top: 0pt; width: 453pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.58pt;">the grant of the PRSUs is exceptional, voluntary and occasional and does not create any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.58pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.6pt;">contractual or other right to receive future grants of PRSUs, or benefits in lieu of PRSUs,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.6pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 29.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 222.93pt;">even if PRSUs have been granted in the past&#59;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 384.95pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 535.5pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 82.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 453pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 44.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 82.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 82.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 15.27pt;">1.3<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 82.5pt; position: absolute; top: 0pt; width: 453pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.48pt;">all decisions with respect to future PRSUs or other grants, if any, will be at the sole<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.48pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 130.7pt;">discretion of the Company&#59;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 447.4pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 535.5pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 82.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 453pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 57pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 82.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 82.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 15.27pt;">1.4<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 82.5pt; position: absolute; top: 0pt; width: 453pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.47pt;">the PRSUs grant and the Employee&#8217;s participation in the Plan shall not create a right to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.47pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">employment or be interpreted as forming an employment or services contract with the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 29.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 50.09pt;">Company&#59;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 522.6pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 348.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 82.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 266.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 31.5pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 82.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 82.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 15.27pt;">1.5<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 82.5pt; position: absolute; top: 0pt; width: 266.25pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 266.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 251pt;">the Employee is voluntarily participating in the Plan&#59;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 572.3pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 535.5pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 82.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 453pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 44.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 82.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 82.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 15.27pt;">1.6<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 82.5pt; position: absolute; top: 0pt; width: 453pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.59pt;">the PRSUs and the Shares subject to the PRSUs, and the income from and value of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.59pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 343.25pt;">same, are not intended to replace any pension rights or compensation&#59;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 634.75pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 535.5pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 82.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 453pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 81.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 15.75pt; width: 82.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 82.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 15.27pt;">1.7<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 82.5pt; position: absolute; top: 15.75pt; width: 453pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.59pt;">the PRSUs and the Shares subject to the PRSUs, and the income from and value of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.59pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.48pt;">same, are not part of normal or expected compensation for any purpose, including for<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.48pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 29.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.53pt;">purposes of calculating any severance, resignation, termination, redundancy, dismissal,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.53pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 42.23pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.58pt;">end-of-service payments, bonuses, holiday pay, long-service awards, pension or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.58pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 55.43pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 243.65pt;">retirement or welfare benefits or similar payments&#59;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">3<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="position: absolute; top: 36pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 535.5pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 82.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 453pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 44.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 15.75pt; width: 82.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 82.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 15.27pt;">1.8<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 82.5pt; position: absolute; top: 15.75pt; width: 453pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">the future value of the underlying Shares is unknown, indeterminable and cannot be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 115.42pt;">predicted with certainty&#59;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 114.2pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 535.5pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 82.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 453pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 132.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 15.75pt; width: 82.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 82.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 15.27pt;">1.9<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 82.5pt; position: absolute; top: 15.75pt; width: 453pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.5pt;">no claim or entitlement to compensation or damages shall arise from forfeiture of the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.5pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.56pt;">PRSUs resulting from the termination of the Employee&#8217;s employment or other service<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.56pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 29.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.51pt;">relationship (for any reason whatsoever whether or not later found to be invalid or in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.51pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 42.23pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.48pt;">breach of employment laws in the jurisdiction where the Employee is employed or the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.48pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 55.43pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">terms of the Employee&#8217;s employment agreement, if any) and in consideration of the grant<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 68.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.52pt;">of the PRSUs, the Employee agrees not to institute any claim against the Company, any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.52pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 81.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.51pt;">parent or subsidiary corporation of the Company (including the Employer) as to any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.51pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 95.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.51pt;">forfeiture of the PRSUs resulting from the termination of the Employee&#8217;s employment or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.51pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 108.23pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 125.2pt;">other service relationship&#59;<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 280.9pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 535.5pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 90pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 445.5pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 81.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 15.75pt; width: 90pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 90pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 21.38pt;">1.10<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 57.379999999999995pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 90pt; position: absolute; top: 15.75pt; width: 445.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 445.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 431.06pt;">unless otherwise provided in the Plan or by the Company in its discretion, the Shares<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 431.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 445.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 431pt;">and benefits evidenced by this Agreement do not create any entitlement to have the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 431pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 29.03pt; width: 445.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 431.01pt;">Shares or any such benefits transferred to, or assumed by, another company nor to be<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 431.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 42.23pt; width: 445.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 431.01pt;">exchanged, cashed out or substituted for, in connection with any corporation transaction<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 431.01pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 55.43pt; width: 445.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 121.96pt;">affecting the Shares&#59; and<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 396.6pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 537pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 88.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 445.5pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="2"></td></tr><tr style="height: 94.5pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="2"><div style="left: 0pt; position: absolute; top: 15.75pt; width: 91.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 91.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 20.57pt;">1.11<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 56.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 91.5pt; position: absolute; top: 15.75pt; width: 445.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 445.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 431.1pt;">neither the Company, nor any parent or other subsidiary corporation of the Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 431.1pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 445.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 431.06pt;">shall be liable for any foreign exchange rate fluctuation between the Employee&#8217;s local<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 431.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 29.03pt; width: 445.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 430.99pt;">currency and the United States Dollar that may affect the value of the PRSUs or of any<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 430.99pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 42.23pt; width: 445.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 431.03pt;">amounts due to the Employee pursuant to the dividend equivalent payment (as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 431.03pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 55.43pt; width: 445.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 431.06pt;">described in Section 6(b) of the Agreement) or the subsequent sale of any Shares<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 431.06pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 68.63pt; width: 445.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 180.18pt;">acquired upon vesting of the PRSUs.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 180.18pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 512.25pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 44.63999999999999pt; position: absolute; text-decoration: none; white-space: pre; width: 9.16pt;">2.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 66.24pt; position: absolute; text-decoration: underline; white-space: pre; width: 62.3pt;">Data Privacy<font style="display: inline-block; height: 8pt;"></font></font></div><div style="position: absolute; top: 537.45pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 535.5pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 82.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 453pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 81.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 82.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 82.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 15.27pt;">2.1<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 82.5pt; position: absolute; top: 0pt; width: 453pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.56pt;">The Employee hereby explicitly and unambiguously consents to the collection, use and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.56pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.51pt;">transfer, in electronic or other form, of the Employee&#8217;s personal data as described in this<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.51pt; position: absolute; white-space: pre; width: 2.45pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 29.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.52pt;">Agreement and any other PRSU grant materials by and among, as applicable, the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.52pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 42.23pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.52pt;">Company and any parent or subsidiary corporation for the exclusive purpose of<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.52pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 55.43pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 407.78pt;">implementing, administering and managing the Employee&#8217;s participation in the Plan.<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr><tr style="height: 132pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 81.75pt; width: 82.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 82.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 15.27pt;">2.2<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 82.5pt; position: absolute; top: 81.75pt; width: 453pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.53pt;">The Employee understands that the Company may hold certain personal information<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.53pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.5pt;">about the Employee, including, but not limited to, the Employee&#8217;s name, home address<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.5pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 29.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">and telephone number, email address, date of birth, social insurance number, passport or<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 42.23pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.5pt;">other identification number, salary, nationality, job title, any Shares or directorships held in<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.5pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 55.43pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.54pt;">the Company, details of all PRSUs or any other entitlement to Shares awarded, canceled,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.54pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 68.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.54pt;">exercised, vested, unvested or outstanding in the Employee&#8217;s favor (&#8220;Data&#8221;), for the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.54pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 81.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 359.13pt;">exclusive purpose of implementing, administering and managing the Plan.<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 841.68pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 594.72pt;"><div style="left: 0pt; position: absolute; top: 768.96pt;"><div style="width: 534pt;"><div style="line-height: 7.28pt; position: absolute; top: 14.41pt; width: 594.72pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.58pt; position: absolute; text-decoration: none; white-space: pre;">4<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 534pt;"></div></div><div><div style="position: absolute; top: 36pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 535.5pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 82.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 453pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 384.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 82.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 82.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 15.27pt;">2.3<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 82.5pt; position: absolute; top: 0pt; width: 453pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">The Employee understands that Data will be transferred to Fidelity Stock Plan Services<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 176.83pt;">and any of its affiliated companies (&#8220;<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 176.83pt; position: absolute; text-decoration: underline; white-space: pre; width: 34.8pt;">Fidelity<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 211.63pt; position: absolute; white-space: pre; width: 226.88pt;">&#8221;), or such other stock plan service provider as<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.51pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 29.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">may be selected by the Company in the future, which is assisting the Company with the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 42.23pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">implementation, administration and management of the Plan. The Employee understands<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 55.43pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.49pt;">that the recipients of the Data may be located in the United States or elsewhere, and that<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.49pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 68.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">the recipients&#8217; country (e.g., the United States) may have different data privacy laws and<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 81.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.51pt;">protections than the Employee&#8217;s country. The Employee understands that he or she may<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.51pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 95.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.52pt;">request a list with the names and addresses of any potential recipients of the Data by<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.52pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 108.23pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">contacting his or her local human resources representative. The Employee authorizes the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 121.43pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">Company, Fidelity and any other possible recipients which may assist the Company<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 134.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">(presently or in the future) with implementing, administering and managing the Plan to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 147.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.59pt;">receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.59pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 161.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.53pt;">purpose of implementing, administering and managing his or her participation in the Plan.<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.53pt; position: absolute; white-space: pre; width: 2.86pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 174.23pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.59pt;">The Employee understands that Data will be held only as long as is necessary to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.59pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 187.43pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.6pt;">implement, administer and manage the Employee&#8217;s participation in the Plan. The<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.6pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 200.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">Employee understands he or she may, at any time, view Data, request additional<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 213.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.58pt;">information about the storage and processing of Data, require any necessary<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.58pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 227.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.56pt;">amendments to Data or refuse or withdraw the consents herein, in any case without cost,<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.56pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 240.23pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">by contacting in writing his or her local human resources representative. Further, the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 253.43pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">Employee understands that he or she is providing the consents herein on a purely<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 266.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.57pt;">voluntary basis. If the Employee does not consent, or if the Employee later seeks to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.57pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 279.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.51pt;">revoke his or her consent, his or her employment status or service with the Company will<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.51pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 293.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.55pt;">not be affected&#59; the only consequence of refusing or withdrawing the Employee&#8217;s consent<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.55pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 306.23pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.49pt;">is that the Company would not be able to grant PRSUs or other equity awards to the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.49pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 319.43pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.54pt;">Employee or administer or maintain such awards. Therefore, the Employee understands<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.54pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 332.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.5pt;">that refusing or withdrawing his or her consent may affect the Employee&#8217;s ability to<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.5pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 345.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.56pt;">participate in the Plan. For more information on the consequences of the Employee&#8217;s<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.56pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 359.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.58pt;">refusal to consent or withdrawal of consent, the Employee understands that he or she<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.58pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 372.23pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 297.44pt;">may contact his or her local human resources representative.<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 438.95pt; width: 594.72pt;"><div style="font-size: 0pt; left: 30.24pt; position: absolute; top: 0pt; width: 535.5pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 82.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 453pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 107.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 82.5pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 82.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre; width: 15.27pt;">2.4<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 82.5pt; position: absolute; top: 0pt; width: 453pt;"><div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 2.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.49pt;">Upon request of the Company, the Employee agrees to provide a separate executed data<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.49pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 15.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.47pt;">privacy consent form (or any other agreements or consents that may be required by the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.47pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 29.03pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.5pt;">Company) that the Company may deem necessary to obtain from the Employee for the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.5pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 42.23pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.52pt;">purpose of administering his or her participation in the Plan in compliance with the data<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.52pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 55.43pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.58pt;">privacy laws in the Employee&#8217;s country, either now or in the future. The Employee<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.58pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 68.63pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 438.58pt;">understands and agrees that he or she will not be able to participate in the Plan if the<font style="display: inline-block; height: 8pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 438.58pt; position: absolute; white-space: pre; width: 3.05pt;"> <font style="display: inline-block; height: 8pt;"></font></font></div><div style="line-height: 8pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 81.83pt; width: 453pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 11pt; font-style: normal; font-weight: normal; left: 0pt; position: absolute; white-space: pre; width: 416.97pt;">Employee fails to provide any such consent or agreement requested by the Company.<font style="display: inline-block; height: 8pt;"></font></font></div></div></div></td></tr></table></div></div></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>agl-20250630xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie026700ebdf5484fb869bbc96344ed68_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Benjamin Shaker, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of agilon health, inc. for the period ended June&#160;30, 2025&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; August&#160;4, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; BENJAMIN SHAKER</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Benjamin Shaker</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Chief Markets Officer and Member of the Office of the Chairman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Interim Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>agl-20250630xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2fc0c7c087ab4dddade2cc551d9389bf_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeffrey Schwaneke, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of agilon health, inc. for the period ended June&#160;30, 2025&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; August&#160;4, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; JEFFREY SCHWANEKE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Jeffrey Schwaneke</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Chief Financial Officer and Member of the Office of the Chairman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Financial Officer and Interim Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>agl-20250630xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i580e2bd0427240fbaef54a5ffcd6135f_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of agilon health, inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June&#160;30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Benjamin Shaker, Chief Markets Officer and Member of the Office of the Chairman of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; August&#160;4, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; BENJAMIN SHAKER</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Benjamin Shaker</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Chief Markets Officer and Member of the Office of the Chairman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Interim Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>agl-20250630xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ibd988bdf3c7f4d6ab6fb3d9320e84585_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of agilon health, inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June&#160;30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jeffrey Schwaneke, Chief Financial Officer and Member of the Office of the Chairman of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; August&#160;4, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; JEFFREY SCHWANEKE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Jeffrey Schwaneke</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Chief Financial Officer and Member of the Office of the Chairman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Financial Officer and Interim Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>agl-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:13b764c6-a2b0-4a9c-9408-254f78400ab0,g:a48cf18d-4f3e-446d-9d3f-633818f822f0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:agl="http://agilonhealth.com/20250630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://agilonhealth.com/20250630">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agl-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agl-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agl-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agl-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://agilonhealth.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Business" roleURI="http://agilonhealth.com/role/Business">
        <link:definition>9952157 - Disclosure - Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://agilonhealth.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReceivablesandConcentrationofCreditRisk" roleURI="http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRisk">
        <link:definition>9952159 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurements" roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurements">
        <link:definition>9952160 - Disclosure - Marketable Securities and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssets" roleURI="http://agilonhealth.com/role/OtherAssets">
        <link:definition>9952161 - Disclosure - Other Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandRelatedPayables" roleURI="http://agilonhealth.com/role/MedicalClaimsandRelatedPayables">
        <link:definition>9952162 - Disclosure - Medical Claims and Related Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilities" roleURI="http://agilonhealth.com/role/OtherLiabilities">
        <link:definition>9952163 - Disclosure - Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://agilonhealth.com/role/Debt">
        <link:definition>9952164 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://agilonhealth.com/role/CommitmentsandContingencies">
        <link:definition>9952165 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://agilonhealth.com/role/CommonStock">
        <link:definition>9952166 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerCommonShare" roleURI="http://agilonhealth.com/role/NetIncomeLossPerCommonShare">
        <link:definition>9952167 - Disclosure - Net Income (Loss) Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandAmortizableIntangibleAssets" roleURI="http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssets">
        <link:definition>9952168 - Disclosure - Goodwill and Amortizable Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://agilonhealth.com/role/SupplementalCashFlowInformation">
        <link:definition>9952169 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntities" roleURI="http://agilonhealth.com/role/VariableInterestEntities">
        <link:definition>9952170 - Disclosure - Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://agilonhealth.com/role/DiscontinuedOperations">
        <link:definition>9952171 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReceivablesandConcentrationofCreditRiskTables" roleURI="http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskTables">
        <link:definition>9955512 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsTables" roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables">
        <link:definition>9955513 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssetsTables" roleURI="http://agilonhealth.com/role/OtherAssetsTables">
        <link:definition>9955514 - Disclosure - Other Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandRelatedPayablesTables" roleURI="http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesTables">
        <link:definition>9955515 - Disclosure - Medical Claims and Related Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilitiesTables" roleURI="http://agilonhealth.com/role/OtherLiabilitiesTables">
        <link:definition>9955516 - Disclosure - Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerCommonShareTables" roleURI="http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables">
        <link:definition>9955517 - Disclosure - Net Income (Loss) Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://agilonhealth.com/role/SupplementalCashFlowInformationTables">
        <link:definition>9955518 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesTables" roleURI="http://agilonhealth.com/role/VariableInterestEntitiesTables">
        <link:definition>9955519 - Disclosure - Variable Interest Entities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsTables" roleURI="http://agilonhealth.com/role/DiscontinuedOperationsTables">
        <link:definition>9955520 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessDetails" roleURI="http://agilonhealth.com/role/BusinessDetails">
        <link:definition>9955521 - Disclosure - Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9955522 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReceivablesandConcentrationofCreditRiskDetails" roleURI="http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails">
        <link:definition>9955523 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails">
        <link:definition>9955524 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsNarrativeDetails" roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails">
        <link:definition>9955525 - Disclosure - Marketable Securities and Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails" roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails">
        <link:definition>9955526 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails" roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails">
        <link:definition>9955527 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities, Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails" roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails">
        <link:definition>9955528 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Fair Value Assets Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssetsDetails" roleURI="http://agilonhealth.com/role/OtherAssetsDetails">
        <link:definition>9955529 - Disclosure - Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssetsNarrativeDetails" roleURI="http://agilonhealth.com/role/OtherAssetsNarrativeDetails">
        <link:definition>9955530 - Disclosure - Other Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails" roleURI="http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails">
        <link:definition>9955531 - Disclosure - Medical Claims and Related Payables - Schedule Changes in Medical Claims and Related Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandRelatedPayablesNarrativeDetails" roleURI="http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesNarrativeDetails">
        <link:definition>9955532 - Disclosure - Medical Claims and Related Payables - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilitiesScheduleofOtherLiabilitiesDetails" roleURI="http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails">
        <link:definition>9955533 - Disclosure - Other Liabilities - Schedule of Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilitiesNarrativeDetails" roleURI="http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails">
        <link:definition>9955534 - Disclosure - Other Liabilities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://agilonhealth.com/role/DebtDetails">
        <link:definition>9955535 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://agilonhealth.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9955536 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetails" roleURI="http://agilonhealth.com/role/CommonStockDetails">
        <link:definition>9955537 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails" roleURI="http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails">
        <link:definition>9955538 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Computation of Basic and Diluted EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" roleURI="http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails">
        <link:definition>9955539 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandAmortizableIntangibleAssetsDetails" roleURI="http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails">
        <link:definition>9955540 - Disclosure - Goodwill and Amortizable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails" roleURI="http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails">
        <link:definition>9955541 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails" roleURI="http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails">
        <link:definition>9955542 - Disclosure - Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" roleURI="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails">
        <link:definition>9955543 - Disclosure - Variable Interest Entities - Schedule of Consolidated Asset and Liabilities Include VIE Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesNarrativeDetails" roleURI="http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails">
        <link:definition>9955544 - Disclosure - Variable Interest Entities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails" roleURI="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails">
        <link:definition>9955545 - Disclosure - Variable Interest Entities - Schedule of Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesScheduleofOperatingResultsDetails" roleURI="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails">
        <link:definition>9955546 - Disclosure - Variable Interest Entities - Schedule of Operating Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesScheduleBalanceSheetDetails" roleURI="http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails">
        <link:definition>9955547 - Disclosure - Variable Interest Entities - Schedule Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsDetails" roleURI="http://agilonhealth.com/role/DiscontinuedOperationsDetails">
        <link:definition>9955548 - Disclosure - Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="agl_MedicalServicesMember" abstract="true" name="MedicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_OtherOperatingMember" abstract="true" name="OtherOperatingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_DistributionsOfEarningsFromEquityMethodInvestments" abstract="false" name="DistributionsOfEarningsFromEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_PaymentsToAcquireLoansReceivableAndOther" abstract="false" name="PaymentsToAcquireLoansReceivableAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans" abstract="false" name="NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agl_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="agl_PlatformSupportCostsMember" abstract="true" name="PlatformSupportCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agl_PayorAMember" abstract="true" name="PayorAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_PayorBMember" abstract="true" name="PayorBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_PayorCMember" abstract="true" name="PayorCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_PayorDMember" abstract="true" name="PayorDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_PayorEMember" abstract="true" name="PayorEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo" abstract="false" name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree" abstract="false" name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour" abstract="false" name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_LoansToPhysiciansPartners" abstract="false" name="LoansToPhysiciansPartners" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_HealthPlanDepositsNoncurrent" abstract="false" name="HealthPlanDepositsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable" abstract="false" name="LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable" abstract="false" name="LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_EquityMethodLiabilitiesNoncurrent" abstract="false" name="EquityMethodLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_OtherLiabilitiesTable" abstract="true" name="OtherLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="agl_OtherLiabilitiesLineItems" abstract="true" name="OtherLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agl_SecuredTermLoanFacilityMember" abstract="true" name="SecuredTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_SecuredRevolvingFacilityMember" abstract="true" name="SecuredRevolvingFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit" abstract="false" name="LineOfCreditFacilityAccordionFeatureIncreaseLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_ExtendedTermOfLettersOfCredit" abstract="false" name="ExtendedTermOfLettersOfCredit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="agl_ConsolidatedSecuritiesMatterMember" abstract="true" name="ConsolidatedSecuritiesMatterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_DerivativeMattersMember" abstract="true" name="DerivativeMattersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_NumberOfWhollyOwnedRiskBearingEntities" abstract="false" name="NumberOfWhollyOwnedRiskBearingEntities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agl_NumberOfEquityMethodInvestments" abstract="false" name="NumberOfEquityMethodInvestments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agl_NumberOfDirectContractingEntities" abstract="false" name="NumberOfDirectContractingEntities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agl_NumberOfPhysicianGroupPartners" abstract="false" name="NumberOfPhysicianGroupPartners" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agl_NumberOfGeographicalLocation" abstract="false" name="NumberOfGeographicalLocation" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agl_OtherEquityMethodInvestmentsMember" abstract="true" name="OtherEquityMethodInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_ACOREACHMember" abstract="true" name="ACOREACHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agl_EquityMethodLiabilities" abstract="false" name="EquityMethodLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_PhysicianCompensationExpense" abstract="false" name="PhysicianCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>agl-20250630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:13b764c6-a2b0-4a9c-9408-254f78400ab0,g:a48cf18d-4f3e-446d-9d3f-633818f822f0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="agl-20250630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a4cf1b9b-1c4c-4b26-ba9c-cc4f71d30eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_810122eb-e0ad-498e-b0fe-ce9c103c40e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a4cf1b9b-1c4c-4b26-ba9c-cc4f71d30eb0" xlink:to="loc_us-gaap_LongTermDebtCurrent_810122eb-e0ad-498e-b0fe-ce9c103c40e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_cc66ca26-11c6-4c03-b4eb-e493eee4764c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a4cf1b9b-1c4c-4b26-ba9c-cc4f71d30eb0" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_cc66ca26-11c6-4c03-b4eb-e493eee4764c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_22c84bf2-74f2-46e8-962b-9cdd025031fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a4cf1b9b-1c4c-4b26-ba9c-cc4f71d30eb0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_22c84bf2-74f2-46e8-962b-9cdd025031fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_33bbba68-38bf-4918-bc94-08232256e9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ac0c9362-6b8d-45e0-87f4-b5d876c74d55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_33bbba68-38bf-4918-bc94-08232256e9b4" xlink:to="loc_us-gaap_Liabilities_ac0c9362-6b8d-45e0-87f4-b5d876c74d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_24029ec9-ebfa-4422-9550-5dbff209d1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_33bbba68-38bf-4918-bc94-08232256e9b4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_24029ec9-ebfa-4422-9550-5dbff209d1cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3256beea-a2cb-42ec-b698-4894e26aec2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_33bbba68-38bf-4918-bc94-08232256e9b4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3256beea-a2cb-42ec-b698-4894e26aec2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73797bf8-f6d1-4c9e-9916-9085995c0c83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9c9a19cc-34fa-4c49-9718-b3ac98c4511a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73797bf8-f6d1-4c9e-9916-9085995c0c83" xlink:to="loc_us-gaap_CommonStockValue_9c9a19cc-34fa-4c49-9718-b3ac98c4511a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4c1ee530-f53b-46c3-859e-da4e74d0c52a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73797bf8-f6d1-4c9e-9916-9085995c0c83" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4c1ee530-f53b-46c3-859e-da4e74d0c52a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_512bb3f4-4151-4575-814b-4d1bb5f908ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73797bf8-f6d1-4c9e-9916-9085995c0c83" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_512bb3f4-4151-4575-814b-4d1bb5f908ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c2ed4a18-7668-49b6-9f6e-3b8039cc48c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73797bf8-f6d1-4c9e-9916-9085995c0c83" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c2ed4a18-7668-49b6-9f6e-3b8039cc48c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_94bf7ec6-bb4f-4533-a1fb-c465bb7af2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c399d36b-11ec-4fd7-aab9-a4a4cc504c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_94bf7ec6-bb4f-4533-a1fb-c465bb7af2b2" xlink:to="loc_us-gaap_AssetsCurrent_c399d36b-11ec-4fd7-aab9-a4a4cc504c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d9c0b931-d7bf-4d07-8224-f58b86f01de0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_94bf7ec6-bb4f-4533-a1fb-c465bb7af2b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d9c0b931-d7bf-4d07-8224-f58b86f01de0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_13641bd2-732e-4b91-8b7d-9259f38887ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_94bf7ec6-bb4f-4533-a1fb-c465bb7af2b2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_13641bd2-732e-4b91-8b7d-9259f38887ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ba8cddb8-491b-49e0-8ef1-11d7cffb9567" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_94bf7ec6-bb4f-4533-a1fb-c465bb7af2b2" xlink:to="loc_us-gaap_Goodwill_ba8cddb8-491b-49e0-8ef1-11d7cffb9567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7409011a-1e11-403a-b4b9-1d15fd0e717f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_94bf7ec6-bb4f-4533-a1fb-c465bb7af2b2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7409011a-1e11-403a-b4b9-1d15fd0e717f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d3f5490f-308e-4b86-87ce-4debc8ad27ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b4c2627c-4722-4d8f-aba8-b8ed22aace58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d3f5490f-308e-4b86-87ce-4debc8ad27ca" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b4c2627c-4722-4d8f-aba8-b8ed22aace58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_b1786555-404f-44ff-b4a0-ed9275901ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d3f5490f-308e-4b86-87ce-4debc8ad27ca" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_b1786555-404f-44ff-b4a0-ed9275901ed3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e961c7d4-6be0-4154-a767-6f6c8fabcceb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d3f5490f-308e-4b86-87ce-4debc8ad27ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e961c7d4-6be0-4154-a767-6f6c8fabcceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_54c4928c-27c2-4d4d-a8db-e9f2afe034bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d3f5490f-308e-4b86-87ce-4debc8ad27ca" xlink:to="loc_us-gaap_ReceivablesNetCurrent_54c4928c-27c2-4d4d-a8db-e9f2afe034bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1183c465-8f92-4070-919e-0ae57e93219e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d3f5490f-308e-4b86-87ce-4debc8ad27ca" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1183c465-8f92-4070-919e-0ae57e93219e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cda825ae-a7cc-4195-b450-6bebe41d1ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3bf18300-7840-4213-b6f7-4090b37ad316" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cda825ae-a7cc-4195-b450-6bebe41d1ae8" xlink:to="loc_us-gaap_LiabilitiesCurrent_3bf18300-7840-4213-b6f7-4090b37ad316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b8e1f404-5fae-4df0-ae93-f0a917432f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cda825ae-a7cc-4195-b450-6bebe41d1ae8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b8e1f404-5fae-4df0-ae93-f0a917432f4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1950dbe2-234e-4c27-9d48-d1b40d1cf0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cda825ae-a7cc-4195-b450-6bebe41d1ae8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1950dbe2-234e-4c27-9d48-d1b40d1cf0e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="agl-20250630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1be4a786-2ef4-4043-af26-093e68074880" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4d519060-c91e-4e07-aee9-7fab52209b10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1be4a786-2ef4-4043-af26-093e68074880" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4d519060-c91e-4e07-aee9-7fab52209b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a3e9c856-723b-4123-af1d-3771164c4e49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1be4a786-2ef4-4043-af26-093e68074880" xlink:to="loc_us-gaap_CostsAndExpenses_a3e9c856-723b-4123-af1d-3771164c4e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9b8e4d0d-29d3-4812-84e7-4241c3fb364a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_bf4b8e6f-45ae-4b2a-89f3-20ee7da5e6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_9b8e4d0d-29d3-4812-84e7-4241c3fb364a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_bf4b8e6f-45ae-4b2a-89f3-20ee7da5e6ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_a1cccf3c-0077-4c0c-82e9-cbad343862f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_9b8e4d0d-29d3-4812-84e7-4241c3fb364a" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_a1cccf3c-0077-4c0c-82e9-cbad343862f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ee5b549a-c941-4aaf-b30e-5ce98029dcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d1e79d09-5d43-48d5-a24d-d13d32523f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ee5b549a-c941-4aaf-b30e-5ce98029dcf5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d1e79d09-5d43-48d5-a24d-d13d32523f4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_d55a1f3b-e1db-4a3b-b16b-3b8ee9231cda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ee5b549a-c941-4aaf-b30e-5ce98029dcf5" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_d55a1f3b-e1db-4a3b-b16b-3b8ee9231cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_f079a615-7a10-4729-9b72-295bb78a6ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ee5b549a-c941-4aaf-b30e-5ce98029dcf5" xlink:to="loc_us-gaap_DepreciationAndAmortization_f079a615-7a10-4729-9b72-295bb78a6ab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d19f59da-3983-49a9-a756-070e08c17c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_875e7cc4-8bef-42e8-848a-174d5a307e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d19f59da-3983-49a9-a756-070e08c17c2a" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_875e7cc4-8bef-42e8-848a-174d5a307e3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_f84ce364-9233-476e-9f41-5a89c1f6d0af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d19f59da-3983-49a9-a756-070e08c17c2a" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_f84ce364-9233-476e-9f41-5a89c1f6d0af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac4973d3-7cdf-4ae2-8bea-cc0e3dc7fc10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_37a663f2-19e7-4d32-9ba7-0e6205ecce7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac4973d3-7cdf-4ae2-8bea-cc0e3dc7fc10" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_37a663f2-19e7-4d32-9ba7-0e6205ecce7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_21272191-7d6b-4cdf-b789-9d4f649e7271" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac4973d3-7cdf-4ae2-8bea-cc0e3dc7fc10" xlink:to="loc_us-gaap_OperatingIncomeLoss_21272191-7d6b-4cdf-b789-9d4f649e7271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e4dc33a5-867d-4e1f-a62c-6b2bf093303c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac4973d3-7cdf-4ae2-8bea-cc0e3dc7fc10" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e4dc33a5-867d-4e1f-a62c-6b2bf093303c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_1e7ffa22-67a7-4ea8-8f82-a3100bef170c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac4973d3-7cdf-4ae2-8bea-cc0e3dc7fc10" xlink:to="loc_us-gaap_InterestExpenseNonoperating_1e7ffa22-67a7-4ea8-8f82-a3100bef170c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b2e69dd5-f73c-46e5-8bc0-2e8afb4e5e79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3c54970e-be46-457b-9510-c680a944cf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b2e69dd5-f73c-46e5-8bc0-2e8afb4e5e79" xlink:to="loc_us-gaap_ProfitLoss_3c54970e-be46-457b-9510-c680a944cf8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_78e8b03b-07a9-41a5-8a4e-688c1ce50f49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b2e69dd5-f73c-46e5-8bc0-2e8afb4e5e79" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_78e8b03b-07a9-41a5-8a4e-688c1ce50f49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d09e7d42-a7d0-454c-8684-6eb4d6ae9e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_757ec100-4d5a-41b9-8eab-ea0a55183c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d09e7d42-a7d0-454c-8684-6eb4d6ae9e7a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_757ec100-4d5a-41b9-8eab-ea0a55183c0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_052c8017-201b-4c51-9b4a-3c877a53d8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d09e7d42-a7d0-454c-8684-6eb4d6ae9e7a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_052c8017-201b-4c51-9b4a-3c877a53d8bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="agl-20250630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4bbc25ec-dc16-4861-9aef-36a6e34490c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_016774e2-395d-4b26-ac71-4bfa81c3d1da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4bbc25ec-dc16-4861-9aef-36a6e34490c7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_016774e2-395d-4b26-ac71-4bfa81c3d1da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2c431561-463f-4cd4-b119-b1f6ca24be51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4bbc25ec-dc16-4861-9aef-36a6e34490c7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2c431561-463f-4cd4-b119-b1f6ca24be51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5bcf63a5-8784-47f8-9b93-4e9f7030a2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4bbc25ec-dc16-4861-9aef-36a6e34490c7" xlink:to="loc_us-gaap_ProfitLoss_5bcf63a5-8784-47f8-9b93-4e9f7030a2e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f938138a-f182-453b-8577-4af5eb00c732" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b4ffe3cc-df63-43cb-ae42-65bd28c76af8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f938138a-f182-453b-8577-4af5eb00c732" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b4ffe3cc-df63-43cb-ae42-65bd28c76af8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6823c6bd-c9ec-4a9e-a039-0bed4cbf57f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f938138a-f182-453b-8577-4af5eb00c732" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6823c6bd-c9ec-4a9e-a039-0bed4cbf57f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="agl-20250630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e57adf5-f3a7-4554-a981-365f253c3b90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c4c10d23-b937-4b8d-aa94-10b8ac50f4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e57adf5-f3a7-4554-a981-365f253c3b90" xlink:to="loc_us-gaap_ProfitLoss_c4c10d23-b937-4b8d-aa94-10b8ac50f4b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c36a36b6-aee0-4eed-beeb-5286bc884bab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e57adf5-f3a7-4554-a981-365f253c3b90" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c36a36b6-aee0-4eed-beeb-5286bc884bab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_acd451fc-24e6-4596-9470-ab69e6086f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e57adf5-f3a7-4554-a981-365f253c3b90" xlink:to="loc_us-gaap_ShareBasedCompensation_acd451fc-24e6-4596-9470-ab69e6086f8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3ed35d93-bd13-42c1-8f44-d8280585414a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e57adf5-f3a7-4554-a981-365f253c3b90" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3ed35d93-bd13-42c1-8f44-d8280585414a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_62a62d46-ace3-4808-a148-bbda374c3e78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e57adf5-f3a7-4554-a981-365f253c3b90" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_62a62d46-ace3-4808-a148-bbda374c3e78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_914b0aee-c258-4ef5-aff8-efea817be0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e57adf5-f3a7-4554-a981-365f253c3b90" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_914b0aee-c258-4ef5-aff8-efea817be0d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_c1ec408e-6463-4104-a70c-8f97d26bba32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e57adf5-f3a7-4554-a981-365f253c3b90" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_c1ec408e-6463-4104-a70c-8f97d26bba32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DistributionsOfEarningsFromEquityMethodInvestments_a2727cb0-b6dc-40b8-aebd-0a5f5279c756" xlink:href="agl-20250630.xsd#agl_DistributionsOfEarningsFromEquityMethodInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e57adf5-f3a7-4554-a981-365f253c3b90" xlink:to="loc_agl_DistributionsOfEarningsFromEquityMethodInvestments_a2727cb0-b6dc-40b8-aebd-0a5f5279c756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8632f305-7ba2-400f-afe2-06bf835bbc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7784f445-eda7-41a7-ab76-60abc9adf58f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8632f305-7ba2-400f-afe2-06bf835bbc3e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7784f445-eda7-41a7-ab76-60abc9adf58f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_46780a7a-d0fc-4074-a460-54c3261375be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8632f305-7ba2-400f-afe2-06bf835bbc3e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_46780a7a-d0fc-4074-a460-54c3261375be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f7b8a08-2c2e-4d00-b755-f85c67144ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8632f305-7ba2-400f-afe2-06bf835bbc3e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f7b8a08-2c2e-4d00-b755-f85c67144ff5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b46e6914-bc5f-4b9d-b0f6-e117cfc12ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_282c8abe-0322-4485-9548-a77952183cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b46e6914-bc5f-4b9d-b0f6-e117cfc12ec5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_282c8abe-0322-4485-9548-a77952183cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_bf48833a-ee3d-4c98-a3ee-2838a88efb48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b46e6914-bc5f-4b9d-b0f6-e117cfc12ec5" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_bf48833a-ee3d-4c98-a3ee-2838a88efb48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PaymentsToAcquireLoansReceivableAndOther_3d3840aa-4e58-4c5a-a124-adf462dcd71d" xlink:href="agl-20250630.xsd#agl_PaymentsToAcquireLoansReceivableAndOther"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b46e6914-bc5f-4b9d-b0f6-e117cfc12ec5" xlink:to="loc_agl_PaymentsToAcquireLoansReceivableAndOther_3d3840aa-4e58-4c5a-a124-adf462dcd71d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_93b48606-dfe1-42ae-b4d6-281e9b3fb74a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b46e6914-bc5f-4b9d-b0f6-e117cfc12ec5" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_93b48606-dfe1-42ae-b4d6-281e9b3fb74a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ba0c2970-a702-49a7-9356-2ffbafe048be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b46e6914-bc5f-4b9d-b0f6-e117cfc12ec5" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ba0c2970-a702-49a7-9356-2ffbafe048be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a4a8603a-7aa3-45a1-b212-7462be4f3ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepurchaseOfEquity_cd77781e-f0de-4143-9da5-43c6c49632a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepurchaseOfEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a4a8603a-7aa3-45a1-b212-7462be4f3ea3" xlink:to="loc_us-gaap_ProceedsFromRepurchaseOfEquity_cd77781e-f0de-4143-9da5-43c6c49632a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f5bdc431-e3f7-459d-954c-bd3861a73b57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a4a8603a-7aa3-45a1-b212-7462be4f3ea3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f5bdc431-e3f7-459d-954c-bd3861a73b57" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_eeef0bef-3006-42fe-9b48-9ee081f8772f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_670e3bf0-2e33-4d6c-a94d-86609801d710" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_eeef0bef-3006-42fe-9b48-9ee081f8772f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_670e3bf0-2e33-4d6c-a94d-86609801d710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d761c91-b0d3-4220-82c8-1d004c9b4ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_eeef0bef-3006-42fe-9b48-9ee081f8772f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d761c91-b0d3-4220-82c8-1d004c9b4ef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3c0032a4-9f61-4671-81e5-ad542f1fe39c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_eeef0bef-3006-42fe-9b48-9ee081f8772f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3c0032a4-9f61-4671-81e5-ad542f1fe39c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"/>
  <link:calculationLink xlink:role="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b214070c-b1ff-4fdb-9ed0-f74b15181f05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_498c5e9b-5c47-4477-83ed-7523da492e59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b214070c-b1ff-4fdb-9ed0-f74b15181f05" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_498c5e9b-5c47-4477-83ed-7523da492e59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo_2e402336-b16a-4634-84ed-263e2c43cf30" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b214070c-b1ff-4fdb-9ed0-f74b15181f05" xlink:to="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo_2e402336-b16a-4634-84ed-263e2c43cf30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree_e5c51c68-1a73-45cd-81c2-7e4cba3b46b3" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b214070c-b1ff-4fdb-9ed0-f74b15181f05" xlink:to="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree_e5c51c68-1a73-45cd-81c2-7e4cba3b46b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour_1391e1e3-a5b5-4dda-acda-f9e330f82ddd" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b214070c-b1ff-4fdb-9ed0-f74b15181f05" xlink:to="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour_1391e1e3-a5b5-4dda-acda-f9e330f82ddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_43c5565a-ebf2-49ef-8b87-05bf807a6789" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_124b67f5-5758-47df-a7ad-39046c316600" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_43c5565a-ebf2-49ef-8b87-05bf807a6789" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_124b67f5-5758-47df-a7ad-39046c316600" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_3fa23d6d-41d8-4d85-aa2c-945b48ef4419" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_43c5565a-ebf2-49ef-8b87-05bf807a6789" xlink:to="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_3fa23d6d-41d8-4d85-aa2c-945b48ef4419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree_914ab9eb-7dce-462a-9454-6e070fafc602" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_43c5565a-ebf2-49ef-8b87-05bf807a6789" xlink:to="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree_914ab9eb-7dce-462a-9454-6e070fafc602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour_8c0315ec-ea42-426f-a158-5d90d923be44" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_43c5565a-ebf2-49ef-8b87-05bf807a6789" xlink:to="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour_8c0315ec-ea42-426f-a158-5d90d923be44" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/OtherAssetsDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#OtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://agilonhealth.com/role/OtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b41e7b44-c1d3-4658-85e6-ea867e0edd47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a9217869-77c2-4d99-853a-9b13337c02ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_b41e7b44-c1d3-4658-85e6-ea867e0edd47" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a9217869-77c2-4d99-853a-9b13337c02ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_02cee426-1ca9-4a1a-9a21-f632f030290e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_b41e7b44-c1d3-4658-85e6-ea867e0edd47" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_02cee426-1ca9-4a1a-9a21-f632f030290e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_6f2f6a86-a0de-4c30-b471-251f4e48d89f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_b41e7b44-c1d3-4658-85e6-ea867e0edd47" xlink:to="loc_us-gaap_EquityMethodInvestments_6f2f6a86-a0de-4c30-b471-251f4e48d89f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_LoansToPhysiciansPartners_698624ee-c3d7-4135-b937-9677f52eaf27" xlink:href="agl-20250630.xsd#agl_LoansToPhysiciansPartners"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_b41e7b44-c1d3-4658-85e6-ea867e0edd47" xlink:to="loc_agl_LoansToPhysiciansPartners_698624ee-c3d7-4135-b937-9677f52eaf27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_HealthPlanDepositsNoncurrent_1160b904-73a7-4518-a9c7-e2e4008081f1" xlink:href="agl-20250630.xsd#agl_HealthPlanDepositsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_b41e7b44-c1d3-4658-85e6-ea867e0edd47" xlink:to="loc_agl_HealthPlanDepositsNoncurrent_1160b904-73a7-4518-a9c7-e2e4008081f1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails"/>
  <link:calculationLink xlink:role="http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_bc778410-ca47-4d64-b7e6-2113cd84ccbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_ecb2d81f-7da1-41ca-9355-c0e8a75f7d97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_bc778410-ca47-4d64-b7e6-2113cd84ccbb" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_ecb2d81f-7da1-41ca-9355-c0e8a75f7d97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_f1608423-78d0-4260-a858-77cb77756919" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_bc778410-ca47-4d64-b7e6-2113cd84ccbb" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_f1608423-78d0-4260-a858-77cb77756919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_118eb6fa-7f0e-4d7b-92ca-e5b24522f914" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_5c960d51-3b4e-4cc1-9edb-8276f9836c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_118eb6fa-7f0e-4d7b-92ca-e5b24522f914" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_5c960d51-3b4e-4cc1-9edb-8276f9836c6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_13c6f264-0f0d-474f-87af-794fcf299b26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_118eb6fa-7f0e-4d7b-92ca-e5b24522f914" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_13c6f264-0f0d-474f-87af-794fcf299b26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#OtherLiabilitiesScheduleofOtherLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0f23abd7-d1a6-466c-bceb-314c7e8f7b24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_97f6b906-2463-415d-8fef-957dd2938213" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_0f23abd7-d1a6-466c-bceb-314c7e8f7b24" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_97f6b906-2463-415d-8fef-957dd2938213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_32a097df-1bf4-422f-817c-3882cb5b8ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_0f23abd7-d1a6-466c-bceb-314c7e8f7b24" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_32a097df-1bf4-422f-817c-3882cb5b8ff3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_EquityMethodLiabilitiesNoncurrent_90d7f514-7180-4da8-9d6a-6ed652f1a09e" xlink:href="agl-20250630.xsd#agl_EquityMethodLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_0f23abd7-d1a6-466c-bceb-314c7e8f7b24" xlink:to="loc_agl_EquityMethodLiabilitiesNoncurrent_90d7f514-7180-4da8-9d6a-6ed652f1a09e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_07e02134-6b7c-4a4b-953b-179fa51b7d03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_0f23abd7-d1a6-466c-bceb-314c7e8f7b24" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_07e02134-6b7c-4a4b-953b-179fa51b7d03" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_e873c0b5-b23a-4638-b355-4c66a55a71a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_af8af3b8-8d80-4c21-aa3b-4b45e3166dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_e873c0b5-b23a-4638-b355-4c66a55a71a3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_af8af3b8-8d80-4c21-aa3b-4b45e3166dc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_40ece0bc-6567-416c-9de3-13a264c71dac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_e873c0b5-b23a-4638-b355-4c66a55a71a3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_40ece0bc-6567-416c-9de3-13a264c71dac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_32441522-d90d-4135-a1dc-fc43a47a66b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_d60e3a21-6ad0-4d85-99ac-66de238b7aed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_32441522-d90d-4135-a1dc-fc43a47a66b9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_d60e3a21-6ad0-4d85-99ac-66de238b7aed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_df437930-d80e-4c47-9baf-96715a0c44be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_32441522-d90d-4135-a1dc-fc43a47a66b9" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_df437930-d80e-4c47-9baf-96715a0c44be" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails"/>
  <link:calculationLink xlink:role="http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a51f8cfd-4798-4af2-aaa8-1ba35fad6ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_758771f1-6be6-4679-bfbb-2c40d5400c35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a51f8cfd-4798-4af2-aaa8-1ba35fad6ec4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_758771f1-6be6-4679-bfbb-2c40d5400c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_f418905c-789c-4afb-ba58-3daacdddbfd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a51f8cfd-4798-4af2-aaa8-1ba35fad6ec4" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_f418905c-789c-4afb-ba58-3daacdddbfd7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#VariableInterestEntitiesScheduleBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c22a98e9-2000-4a59-aa0f-097e2f3aa43e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_e459a9a1-895d-4787-a662-f1f333c3e93f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c22a98e9-2000-4a59-aa0f-097e2f3aa43e" xlink:to="loc_us-gaap_AssetsNoncurrent_e459a9a1-895d-4787-a662-f1f333c3e93f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e686a12d-07a1-4d0a-9665-e840bb3cde6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c22a98e9-2000-4a59-aa0f-097e2f3aa43e" xlink:to="loc_us-gaap_AssetsCurrent_e686a12d-07a1-4d0a-9665-e840bb3cde6c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/DiscontinuedOperationsDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#DiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://agilonhealth.com/role/DiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f941f761-c694-482b-a9aa-704cab9d5d00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_52f533f7-fba7-435e-898e-0222765ea302" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f941f761-c694-482b-a9aa-704cab9d5d00" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_52f533f7-fba7-435e-898e-0222765ea302" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_821fcb6d-db79-421e-83df-4300e1ded820" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f941f761-c694-482b-a9aa-704cab9d5d00" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_821fcb6d-db79-421e-83df-4300e1ded820" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_0fac071e-22cb-4dc7-8d4d-2a9b320aa452" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments_7b7610c6-61c0-44e3-878f-76d75623cf3e" xlink:href="agl-20250630.xsd#agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_0fac071e-22cb-4dc7-8d4d-2a9b320aa452" xlink:to="loc_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments_7b7610c6-61c0-44e3-878f-76d75623cf3e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>agl-20250630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:13b764c6-a2b0-4a9c-9408-254f78400ab0,g:a48cf18d-4f3e-446d-9d3f-633818f822f0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="agl-20250630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4d9f332c-3ed5-4691-a4ec-4457f3e8a040" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:to="loc_us-gaap_StatementTable_4d9f332c-3ed5-4691-a4ec-4457f3e8a040" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_13533f6e-126c-4f70-ace4-461c1bdd79f2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4d9f332c-3ed5-4691-a4ec-4457f3e8a040" xlink:to="loc_srt_ConsolidatedEntitiesAxis_13533f6e-126c-4f70-ace4-461c1bdd79f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_13533f6e-126c-4f70-ace4-461c1bdd79f2_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_13533f6e-126c-4f70-ace4-461c1bdd79f2" xlink:to="loc_srt_ConsolidatedEntitiesDomain_13533f6e-126c-4f70-ace4-461c1bdd79f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c8dd414c-7642-426d-a73d-570e0c59a873" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_13533f6e-126c-4f70-ace4-461c1bdd79f2" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c8dd414c-7642-426d-a73d-570e0c59a873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_f1846f8c-765a-4e12-9580-d8d7102a2c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c8dd414c-7642-426d-a73d-570e0c59a873" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_f1846f8c-765a-4e12-9580-d8d7102a2c1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f42975d6-15fb-4346-98bc-a859fccca5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f42975d6-15fb-4346-98bc-a859fccca5f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a10bc1ac-7aca-4349-85c6-18f16e69955c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a10bc1ac-7aca-4349-85c6-18f16e69955c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_45fa961c-2645-43be-a412-3ac5026c3881" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:to="loc_us-gaap_CommonStockSharesIssued_45fa961c-2645-43be-a412-3ac5026c3881" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9859dcc1-76c0-446a-97eb-e0b919b97cac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9859dcc1-76c0-446a-97eb-e0b919b97cac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b587f29e-8d12-441a-aef9-eeea9c91ee43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:to="loc_us-gaap_Assets_b587f29e-8d12-441a-aef9-eeea9c91ee43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5fba432e-db82-408a-a894-ac3c76843454" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:to="loc_us-gaap_Liabilities_5fba432e-db82-408a-a894-ac3c76843454" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="agl-20250630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f55344e4-2f82-4cf0-9ab0-ca2282fa6132" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_StatementTable_f55344e4-2f82-4cf0-9ab0-ca2282fa6132" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_01ad3894-5411-47d2-94bf-aa74018009e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f55344e4-2f82-4cf0-9ab0-ca2282fa6132" xlink:to="loc_srt_ProductOrServiceAxis_01ad3894-5411-47d2-94bf-aa74018009e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_01ad3894-5411-47d2-94bf-aa74018009e3_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_01ad3894-5411-47d2-94bf-aa74018009e3" xlink:to="loc_srt_ProductsAndServicesDomain_01ad3894-5411-47d2-94bf-aa74018009e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a76400c1-a401-4db9-8adb-a47b042dfc2c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_01ad3894-5411-47d2-94bf-aa74018009e3" xlink:to="loc_srt_ProductsAndServicesDomain_a76400c1-a401-4db9-8adb-a47b042dfc2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_MedicalServicesMember_585e57d7-bb9f-49dd-a53b-2763af887e7a" xlink:href="agl-20250630.xsd#agl_MedicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a76400c1-a401-4db9-8adb-a47b042dfc2c" xlink:to="loc_agl_MedicalServicesMember_585e57d7-bb9f-49dd-a53b-2763af887e7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherOperatingMember_9df1b09a-178d-42d3-bb7c-e8d1bf0825d1" xlink:href="agl-20250630.xsd#agl_OtherOperatingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a76400c1-a401-4db9-8adb-a47b042dfc2c" xlink:to="loc_agl_OtherOperatingMember_9df1b09a-178d-42d3-bb7c-e8d1bf0825d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_146c2098-9be2-4d49-bd73-1ece8b86eab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_RevenuesAbstract_146c2098-9be2-4d49-bd73-1ece8b86eab7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d7e3f364-2dd2-410b-be46-16c3da281633" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_146c2098-9be2-4d49-bd73-1ece8b86eab7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d7e3f364-2dd2-410b-be46-16c3da281633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_aa8c37e3-7b95-495b-96fb-9af5e6c38f73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_aa8c37e3-7b95-495b-96fb-9af5e6c38f73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_9dc0bc78-3073-4498-bda8-5596b293cf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_aa8c37e3-7b95-495b-96fb-9af5e6c38f73" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_9dc0bc78-3073-4498-bda8-5596b293cf9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5f176812-d6a3-42f0-9c57-045ca84342b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_aa8c37e3-7b95-495b-96fb-9af5e6c38f73" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5f176812-d6a3-42f0-9c57-045ca84342b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_5d132a4e-b5f1-41c1-9606-78fe5d80e2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_aa8c37e3-7b95-495b-96fb-9af5e6c38f73" xlink:to="loc_us-gaap_DepreciationAndAmortization_5d132a4e-b5f1-41c1-9606-78fe5d80e2d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cfc5ed24-b75d-4800-98a1-d23e773da9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_aa8c37e3-7b95-495b-96fb-9af5e6c38f73" xlink:to="loc_us-gaap_CostsAndExpenses_cfc5ed24-b75d-4800-98a1-d23e773da9aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e499bef0-1bd4-4131-af48-279c6fbb4c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_OperatingIncomeLoss_e499bef0-1bd4-4131-af48-279c6fbb4c4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_646025f7-afd7-4eb8-b769-e0b1adfb606f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_646025f7-afd7-4eb8-b769-e0b1adfb606f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dbc526dc-7da0-43bf-974e-150798b818a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_646025f7-afd7-4eb8-b769-e0b1adfb606f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dbc526dc-7da0-43bf-974e-150798b818a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_81faa544-df7b-4396-a85a-5ef56f64c3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_646025f7-afd7-4eb8-b769-e0b1adfb606f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_81faa544-df7b-4396-a85a-5ef56f64c3a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_b1ae7418-b09a-4dc0-9b96-b5f9e4df82c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_646025f7-afd7-4eb8-b769-e0b1adfb606f" xlink:to="loc_us-gaap_InterestExpenseNonoperating_b1ae7418-b09a-4dc0-9b96-b5f9e4df82c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82071b28-dbbe-40dc-a872-3f67501d2043" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82071b28-dbbe-40dc-a872-3f67501d2043" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_08336336-4dca-4ba5-bc29-b5b96fed5e11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_08336336-4dca-4ba5-bc29-b5b96fed5e11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_28f96250-8b56-4c94-b29d-fa1e41f0b1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_28f96250-8b56-4c94-b29d-fa1e41f0b1fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_492183ac-b28a-47a7-adcb-6e33309dbb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_492183ac-b28a-47a7-adcb-6e33309dbb5f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_8ebf44d1-6b99-4f19-884a-2a399f89923e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_492183ac-b28a-47a7-adcb-6e33309dbb5f" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_8ebf44d1-6b99-4f19-884a-2a399f89923e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_e0ff0648-985a-465c-a829-1f925bd8adb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_492183ac-b28a-47a7-adcb-6e33309dbb5f" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_e0ff0648-985a-465c-a829-1f925bd8adb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_07895ca0-62d1-4216-9159-69492a426021" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_492183ac-b28a-47a7-adcb-6e33309dbb5f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_07895ca0-62d1-4216-9159-69492a426021" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_186c50c2-f379-4b2a-9dd6-f2cb7d371374" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_ProfitLoss_186c50c2-f379-4b2a-9dd6-f2cb7d371374" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9791fa1f-4f72-4631-869a-032989a68d81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9791fa1f-4f72-4631-869a-032989a68d81" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_85209b1d-7189-4f1b-971e-cab4b28ae684" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_NetIncomeLoss_85209b1d-7189-4f1b-971e-cab4b28ae684" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b08984b9-df7e-4831-bc8c-bf2b65a2f545" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b08984b9-df7e-4831-bc8c-bf2b65a2f545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_34854b8c-6669-4366-8a2d-ad9996ca3d33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_34854b8c-6669-4366-8a2d-ad9996ca3d33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_9eef6121-6e11-4a10-9655-fcd3f04419e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_9eef6121-6e11-4a10-9655-fcd3f04419e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_e530e197-26dd-47c2-a3a6-f376b01af905" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_e530e197-26dd-47c2-a3a6-f376b01af905" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1dc3d74f-c058-4f44-b596-92c9a2ab0137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1dc3d74f-c058-4f44-b596-92c9a2ab0137" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e0136294-8238-454a-bd92-192a2a7d2446" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e0136294-8238-454a-bd92-192a2a7d2446" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="agl-20250630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_af7ef48d-c696-4711-a3ec-4706eaf0d30b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5c74e4d1-9298-459b-ade3-3676f9608cad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_af7ef48d-c696-4711-a3ec-4706eaf0d30b" xlink:to="loc_us-gaap_StatementTable_5c74e4d1-9298-459b-ade3-3676f9608cad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ec554ea4-8335-4cfa-a105-83bc4312ff31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5c74e4d1-9298-459b-ade3-3676f9608cad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ec554ea4-8335-4cfa-a105-83bc4312ff31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ec554ea4-8335-4cfa-a105-83bc4312ff31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ec554ea4-8335-4cfa-a105-83bc4312ff31" xlink:to="loc_us-gaap_EquityComponentDomain_ec554ea4-8335-4cfa-a105-83bc4312ff31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ec554ea4-8335-4cfa-a105-83bc4312ff31" xlink:to="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f4f6a8f3-1ce0-4a3c-ba1e-f52a12e881a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:to="loc_us-gaap_CommonStockMember_f4f6a8f3-1ce0-4a3c-ba1e-f52a12e881a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_caf13f0f-645c-4b47-a4f4-b4829078408a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_caf13f0f-645c-4b47-a4f4-b4829078408a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bc373ce7-e899-4601-a543-4c5919666d25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:to="loc_us-gaap_RetainedEarningsMember_bc373ce7-e899-4601-a543-4c5919666d25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96316cd7-6b05-4068-9ec6-e2c118678382" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96316cd7-6b05-4068-9ec6-e2c118678382" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d5ec224f-cb07-4add-8bdc-58c0b8d943ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d5ec224f-cb07-4add-8bdc-58c0b8d943ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_af7ef48d-c696-4711-a3ec-4706eaf0d30b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f63aac52-6260-4e10-96b9-571f8b0b1500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f63aac52-6260-4e10-96b9-571f8b0b1500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87771689-39ee-4a9c-9268-5f5dbfcaaa59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87771689-39ee-4a9c-9268-5f5dbfcaaa59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_877a597d-0ab6-4719-b292-bc72739f719c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_ProfitLoss_877a597d-0ab6-4719-b292-bc72739f719c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f014447-0e2c-4840-a550-ea78b5b637a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f014447-0e2c-4840-a550-ea78b5b637a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_78f30cf0-0862-4d97-8674-3fba6b2e8df0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_78f30cf0-0862-4d97-8674-3fba6b2e8df0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cb3690fd-4476-47ce-a0ec-a5c5e39bb8be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cb3690fd-4476-47ce-a0ec-a5c5e39bb8be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_918305cd-e233-40f6-bc55-cd233bf0bfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_918305cd-e233-40f6-bc55-cd233bf0bfd4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2f5ba5c1-24ff-4a5c-b54e-2d60589e702a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2f5ba5c1-24ff-4a5c-b54e-2d60589e702a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d302280c-6c5e-4137-96f6-f1aa24731019" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d302280c-6c5e-4137-96f6-f1aa24731019" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_64152a1e-c8f4-4c67-8f97-e9daaadca7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_64152a1e-c8f4-4c67-8f97-e9daaadca7a6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_32f6ebd2-0176-447a-bcb0-83fbeeb85305" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_32f6ebd2-0176-447a-bcb0-83fbeeb85305" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1bd3a70f-9681-49ae-8fa0-46e247f82043" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1bd3a70f-9681-49ae-8fa0-46e247f82043" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_71379a8e-a9fb-448b-b462-d7ff6667cd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_71379a8e-a9fb-448b-b462-d7ff6667cd0c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_377041ad-bdb6-4aec-9e49-30dbb4c2f93e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d38dd19f-37c5-4963-943a-83cfa6efef39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:href="agl-20250630.xsd#agl_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_SummaryOfSignificantAccountingPoliciesTable_7f522c79-2006-4ed8-908e-07a8aeb8c913" xlink:href="agl-20250630.xsd#agl_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:to="loc_agl_SummaryOfSignificantAccountingPoliciesTable_7f522c79-2006-4ed8-908e-07a8aeb8c913" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_176394c9-672b-4227-bc0a-525c1d05ff8a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesTable_7f522c79-2006-4ed8-908e-07a8aeb8c913" xlink:to="loc_srt_ProductOrServiceAxis_176394c9-672b-4227-bc0a-525c1d05ff8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_176394c9-672b-4227-bc0a-525c1d05ff8a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_176394c9-672b-4227-bc0a-525c1d05ff8a" xlink:to="loc_srt_ProductsAndServicesDomain_176394c9-672b-4227-bc0a-525c1d05ff8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_24a7cf22-b97c-442a-87a5-ce3f8091e6ed" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_176394c9-672b-4227-bc0a-525c1d05ff8a" xlink:to="loc_srt_ProductsAndServicesDomain_24a7cf22-b97c-442a-87a5-ce3f8091e6ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PlatformSupportCostsMember_df1fc4e1-1a8a-4926-90df-4302053836f7" xlink:href="agl-20250630.xsd#agl_PlatformSupportCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_24a7cf22-b97c-442a-87a5-ce3f8091e6ed" xlink:to="loc_agl_PlatformSupportCostsMember_df1fc4e1-1a8a-4926-90df-4302053836f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d9e0faa3-e733-4b62-830d-a3af0dc620e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesTable_7f522c79-2006-4ed8-908e-07a8aeb8c913" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d9e0faa3-e733-4b62-830d-a3af0dc620e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d9e0faa3-e733-4b62-830d-a3af0dc620e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d9e0faa3-e733-4b62-830d-a3af0dc620e3" xlink:to="loc_us-gaap_SegmentDomain_d9e0faa3-e733-4b62-830d-a3af0dc620e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_55b45e5a-e738-4073-9271-7dcf9c4fcfea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d9e0faa3-e733-4b62-830d-a3af0dc620e3" xlink:to="loc_us-gaap_SegmentDomain_55b45e5a-e738-4073-9271-7dcf9c4fcfea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_ReportableSegmentMember_a2ba6d38-8316-4001-b626-b346fdf33fdc" xlink:href="agl-20250630.xsd#agl_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_55b45e5a-e738-4073-9271-7dcf9c4fcfea" xlink:to="loc_agl_ReportableSegmentMember_a2ba6d38-8316-4001-b626-b346fdf33fdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a03ed188-fe1b-4aa9-8a8a-0358250f7c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a03ed188-fe1b-4aa9-8a8a-0358250f7c2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f396d570-2cd1-4a2d-9f37-29f7d9e33e10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f396d570-2cd1-4a2d-9f37-29f7d9e33e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_35839d8f-8b5e-4094-9e6b-0b26f88604d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:to="loc_us-gaap_Depreciation_35839d8f-8b5e-4094-9e6b-0b26f88604d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a167234b-7dec-49e9-880c-42da772a3aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a167234b-7dec-49e9-880c-42da772a3aa1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_5e4b40a4-4974-4c54-86eb-02c99fe49180" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_5e4b40a4-4974-4c54-86eb-02c99fe49180" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#RevenueReceivablesandConcentrationofCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_665d1717-ac8d-4064-b04f-54182d568168" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_19f034f9-ed00-4537-9ed0-04108b217d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_665d1717-ac8d-4064-b04f-54182d568168" xlink:to="loc_us-gaap_ConcentrationRiskTable_19f034f9-ed00-4537-9ed0-04108b217d6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ffcf8223-07fa-4f13-9450-990b9cb437ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_19f034f9-ed00-4537-9ed0-04108b217d6a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ffcf8223-07fa-4f13-9450-990b9cb437ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ffcf8223-07fa-4f13-9450-990b9cb437ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ffcf8223-07fa-4f13-9450-990b9cb437ce" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ffcf8223-07fa-4f13-9450-990b9cb437ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_15f6ff78-2d22-4fe7-afdf-b3e0ebb0667d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ffcf8223-07fa-4f13-9450-990b9cb437ce" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_15f6ff78-2d22-4fe7-afdf-b3e0ebb0667d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_b8f1ab33-71f6-4674-b92c-df6cf119c92a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_15f6ff78-2d22-4fe7-afdf-b3e0ebb0667d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_b8f1ab33-71f6-4674-b92c-df6cf119c92a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0c09ca74-2708-4b79-ab34-b5c0916774bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_15f6ff78-2d22-4fe7-afdf-b3e0ebb0667d" xlink:to="loc_us-gaap_AccountsReceivableMember_0c09ca74-2708-4b79-ab34-b5c0916774bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d0603888-6edc-4dd4-ad0c-c33b7ab3935e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_19f034f9-ed00-4537-9ed0-04108b217d6a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d0603888-6edc-4dd4-ad0c-c33b7ab3935e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d0603888-6edc-4dd4-ad0c-c33b7ab3935e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d0603888-6edc-4dd4-ad0c-c33b7ab3935e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d0603888-6edc-4dd4-ad0c-c33b7ab3935e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a660ecef-3826-4d8b-bed1-3f362897fc45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d0603888-6edc-4dd4-ad0c-c33b7ab3935e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a660ecef-3826-4d8b-bed1-3f362897fc45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c86812d4-459a-4b21-b368-8f8684dbc3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a660ecef-3826-4d8b-bed1-3f362897fc45" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c86812d4-459a-4b21-b368-8f8684dbc3a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7f58765c-4605-4c8f-bf78-f8020a176641" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_19f034f9-ed00-4537-9ed0-04108b217d6a" xlink:to="loc_srt_MajorCustomersAxis_7f58765c-4605-4c8f-bf78-f8020a176641" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7f58765c-4605-4c8f-bf78-f8020a176641_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7f58765c-4605-4c8f-bf78-f8020a176641" xlink:to="loc_srt_NameOfMajorCustomerDomain_7f58765c-4605-4c8f-bf78-f8020a176641_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7f58765c-4605-4c8f-bf78-f8020a176641" xlink:to="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorAMember_df2f5e7d-1ff5-4801-a27d-08e800b35259" xlink:href="agl-20250630.xsd#agl_PayorAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:to="loc_agl_PayorAMember_df2f5e7d-1ff5-4801-a27d-08e800b35259" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorBMember_16acf450-7e72-4416-a6ab-e249b296d13a" xlink:href="agl-20250630.xsd#agl_PayorBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:to="loc_agl_PayorBMember_16acf450-7e72-4416-a6ab-e249b296d13a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorCMember_a1dfe306-cbcc-475e-90a4-39e4ad68ad44" xlink:href="agl-20250630.xsd#agl_PayorCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:to="loc_agl_PayorCMember_a1dfe306-cbcc-475e-90a4-39e4ad68ad44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorDMember_7f552e1c-756c-46c5-97a6-60a7eef22c4d" xlink:href="agl-20250630.xsd#agl_PayorDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:to="loc_agl_PayorDMember_7f552e1c-756c-46c5-97a6-60a7eef22c4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorEMember_755f484d-a15f-4642-b3b4-e60e016554b6" xlink:href="agl-20250630.xsd#agl_PayorEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:to="loc_agl_PayorEMember_755f484d-a15f-4642-b3b4-e60e016554b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7c10aef4-c695-4c76-812a-33f4d309605b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_665d1717-ac8d-4064-b04f-54182d568168" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7c10aef4-c695-4c76-812a-33f4d309605b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_ed21c875-63f0-4ce0-8f40-d04b0a79b755" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_a6350e95-89b2-44a3-be60-1caffbadd29d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_ed21c875-63f0-4ce0-8f40-d04b0a79b755" xlink:to="loc_us-gaap_MarketableSecuritiesTable_a6350e95-89b2-44a3-be60-1caffbadd29d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8fab48b5-d4fd-4f6c-848b-7855fbd8442e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_a6350e95-89b2-44a3-be60-1caffbadd29d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8fab48b5-d4fd-4f6c-848b-7855fbd8442e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fab48b5-d4fd-4f6c-848b-7855fbd8442e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8fab48b5-d4fd-4f6c-848b-7855fbd8442e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fab48b5-d4fd-4f6c-848b-7855fbd8442e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1334c8d-1a07-47ba-9431-abb1c732834a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8fab48b5-d4fd-4f6c-848b-7855fbd8442e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1334c8d-1a07-47ba-9431-abb1c732834a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_71857615-7b43-4c04-9545-a24352b990c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1334c8d-1a07-47ba-9431-abb1c732834a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_71857615-7b43-4c04-9545-a24352b990c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b9178bd6-7d77-49d2-95f4-fe4e6cd49e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1334c8d-1a07-47ba-9431-abb1c732834a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b9178bd6-7d77-49d2-95f4-fe4e6cd49e7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_2013a388-e561-489d-87be-746f71245ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_ed21c875-63f0-4ce0-8f40-d04b0a79b755" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_2013a388-e561-489d-87be-746f71245ae9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f3406641-bb52-482d-bf31-e68c69620764" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_ed21c875-63f0-4ce0-8f40-d04b0a79b755" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f3406641-bb52-482d-bf31-e68c69620764" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d393486e-7aca-40f2-9219-12f5545ffab3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_ed21c875-63f0-4ce0-8f40-d04b0a79b755" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d393486e-7aca-40f2-9219-12f5545ffab3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_f0ae6c71-9549-4993-a099-ef5b8404c3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_ed21c875-63f0-4ce0-8f40-d04b0a79b755" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_f0ae6c71-9549-4993-a099-ef5b8404c3e2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ffc692a2-0ec7-40d8-a173-32ac0d2b0348" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_31d5c0c4-38b3-41fa-9754-881d76b4bce9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ffc692a2-0ec7-40d8-a173-32ac0d2b0348" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_31d5c0c4-38b3-41fa-9754-881d76b4bce9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_91aa572b-99d4-4cf6-9bce-c616e76a8b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_31d5c0c4-38b3-41fa-9754-881d76b4bce9" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_91aa572b-99d4-4cf6-9bce-c616e76a8b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91aa572b-99d4-4cf6-9bce-c616e76a8b1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_91aa572b-99d4-4cf6-9bce-c616e76a8b1e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91aa572b-99d4-4cf6-9bce-c616e76a8b1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7c5d3592-628e-4c90-bbe8-a24aa6b3d5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_91aa572b-99d4-4cf6-9bce-c616e76a8b1e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7c5d3592-628e-4c90-bbe8-a24aa6b3d5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_73839db0-0b04-41fc-9def-052df67ae090" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7c5d3592-628e-4c90-bbe8-a24aa6b3d5ea" xlink:to="loc_us-gaap_DebtSecuritiesMember_73839db0-0b04-41fc-9def-052df67ae090" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_df1993ba-949a-46f9-91a1-1a7ff4a20d06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7c5d3592-628e-4c90-bbe8-a24aa6b3d5ea" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_df1993ba-949a-46f9-91a1-1a7ff4a20d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_396d2c32-a8b6-49e2-bfb8-ce8cc49943c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ffc692a2-0ec7-40d8-a173-32ac0d2b0348" xlink:to="loc_us-gaap_InvestmentIncomeNet_396d2c32-a8b6-49e2-bfb8-ce8cc49943c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_943184b3-bf64-4737-af1c-5eb95e1fe7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ffc692a2-0ec7-40d8-a173-32ac0d2b0348" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_943184b3-bf64-4737-af1c-5eb95e1fe7e4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8587b129-f9e2-4519-87ba-a0c8a2b2a1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_83d30b49-e7fc-4385-a9b0-85f70fb8d484" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8587b129-f9e2-4519-87ba-a0c8a2b2a1f9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_83d30b49-e7fc-4385-a9b0-85f70fb8d484" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f89e2345-c74c-4337-90e7-116daf589d75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_83d30b49-e7fc-4385-a9b0-85f70fb8d484" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f89e2345-c74c-4337-90e7-116daf589d75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f89e2345-c74c-4337-90e7-116daf589d75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f89e2345-c74c-4337-90e7-116daf589d75" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f89e2345-c74c-4337-90e7-116daf589d75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5970053c-c99d-4d22-885c-fcfe8fb9537a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f89e2345-c74c-4337-90e7-116daf589d75" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5970053c-c99d-4d22-885c-fcfe8fb9537a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ca0fa131-4f86-4783-a9be-42f7d7723daf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5970053c-c99d-4d22-885c-fcfe8fb9537a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ca0fa131-4f86-4783-a9be-42f7d7723daf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a3a839d6-0de0-4def-aa2c-0c31b014ec54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5970053c-c99d-4d22-885c-fcfe8fb9537a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a3a839d6-0de0-4def-aa2c-0c31b014ec54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_71f3bcd3-64d7-4276-a67f-13d9844b3355" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8587b129-f9e2-4519-87ba-a0c8a2b2a1f9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_71f3bcd3-64d7-4276-a67f-13d9844b3355" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_80a2a15c-2d78-4756-961e-64056b7a0d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_71f3bcd3-64d7-4276-a67f-13d9844b3355" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_80a2a15c-2d78-4756-961e-64056b7a0d1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_66587002-5c06-4459-8ac5-086d101731c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_71f3bcd3-64d7-4276-a67f-13d9844b3355" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_66587002-5c06-4459-8ac5-086d101731c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b5dc127c-bff5-4ebd-8a74-3803768f3da2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8587b129-f9e2-4519-87ba-a0c8a2b2a1f9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b5dc127c-bff5-4ebd-8a74-3803768f3da2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_33b130eb-8511-49fe-9266-0bc38d00fa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b5dc127c-bff5-4ebd-8a74-3803768f3da2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_33b130eb-8511-49fe-9266-0bc38d00fa9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_75c95fd2-1b24-4e5e-bf50-296c9120ed4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b5dc127c-bff5-4ebd-8a74-3803768f3da2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_75c95fd2-1b24-4e5e-bf50-296c9120ed4d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d755c645-e29d-46e3-a7a0-9424ab791125" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77955e00-facc-49e4-877c-c6e496e032c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d755c645-e29d-46e3-a7a0-9424ab791125" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77955e00-facc-49e4-877c-c6e496e032c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6decf53e-2d8c-4ab4-8e4f-8c0434df9906" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77955e00-facc-49e4-877c-c6e496e032c2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6decf53e-2d8c-4ab4-8e4f-8c0434df9906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6decf53e-2d8c-4ab4-8e4f-8c0434df9906_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6decf53e-2d8c-4ab4-8e4f-8c0434df9906" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6decf53e-2d8c-4ab4-8e4f-8c0434df9906_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a65b33ba-ec82-4f32-a9e5-cacb6163dc87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6decf53e-2d8c-4ab4-8e4f-8c0434df9906" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a65b33ba-ec82-4f32-a9e5-cacb6163dc87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3c3da7b3-56a0-441b-a1e9-af916af6f55c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a65b33ba-ec82-4f32-a9e5-cacb6163dc87" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3c3da7b3-56a0-441b-a1e9-af916af6f55c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_54948da7-344a-45fb-909d-823b40d45a02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a65b33ba-ec82-4f32-a9e5-cacb6163dc87" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_54948da7-344a-45fb-909d-823b40d45a02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1547ddaa-73eb-4c00-8b8c-e1eb0fe17cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77955e00-facc-49e4-877c-c6e496e032c2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1547ddaa-73eb-4c00-8b8c-e1eb0fe17cb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1547ddaa-73eb-4c00-8b8c-e1eb0fe17cb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1547ddaa-73eb-4c00-8b8c-e1eb0fe17cb5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1547ddaa-73eb-4c00-8b8c-e1eb0fe17cb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ed21e26-eade-4854-b98e-0af3ab2a6881" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1547ddaa-73eb-4c00-8b8c-e1eb0fe17cb5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ed21e26-eade-4854-b98e-0af3ab2a6881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_285ddf1e-0f5d-4c1c-bfaa-a8decfb185f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ed21e26-eade-4854-b98e-0af3ab2a6881" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_285ddf1e-0f5d-4c1c-bfaa-a8decfb185f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_38af8ecd-0604-40a7-a8c0-a1c4a617cf09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ed21e26-eade-4854-b98e-0af3ab2a6881" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_38af8ecd-0604-40a7-a8c0-a1c4a617cf09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8ef6cbad-647b-402a-9541-78b3770ac15f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ed21e26-eade-4854-b98e-0af3ab2a6881" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8ef6cbad-647b-402a-9541-78b3770ac15f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_24171445-6fe4-4c92-b83f-86e5ece5f751" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d755c645-e29d-46e3-a7a0-9424ab791125" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_24171445-6fe4-4c92-b83f-86e5ece5f751" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#OtherLiabilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherLiabilitiesLineItems_636caa3a-0a6b-4b4b-8fbf-3dc1c66a9afb" xlink:href="agl-20250630.xsd#agl_OtherLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherLiabilitiesTable_3108fc66-293c-4235-a3b7-04ae50467632" xlink:href="agl-20250630.xsd#agl_OtherLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agl_OtherLiabilitiesLineItems_636caa3a-0a6b-4b4b-8fbf-3dc1c66a9afb" xlink:to="loc_agl_OtherLiabilitiesTable_3108fc66-293c-4235-a3b7-04ae50467632" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_064bb2dd-5461-4df5-9daa-e6bf6c4646e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agl_OtherLiabilitiesTable_3108fc66-293c-4235-a3b7-04ae50467632" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_064bb2dd-5461-4df5-9daa-e6bf6c4646e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_064bb2dd-5461-4df5-9daa-e6bf6c4646e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_064bb2dd-5461-4df5-9daa-e6bf6c4646e9" xlink:to="loc_us-gaap_LossContingencyNatureDomain_064bb2dd-5461-4df5-9daa-e6bf6c4646e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_d8836f1b-960b-4372-ac57-19e353a6943c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_064bb2dd-5461-4df5-9daa-e6bf6c4646e9" xlink:to="loc_us-gaap_LossContingencyNatureDomain_d8836f1b-960b-4372-ac57-19e353a6943c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnassertedClaimMember_c12eb9ef-f32f-4555-b5ed-bee3dc2dddc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnassertedClaimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d8836f1b-960b-4372-ac57-19e353a6943c" xlink:to="loc_us-gaap_UnassertedClaimMember_c12eb9ef-f32f-4555-b5ed-bee3dc2dddc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_ed852704-3f93-4143-8c9e-4f91ae422989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agl_OtherLiabilitiesLineItems_636caa3a-0a6b-4b4b-8fbf-3dc1c66a9afb" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_ed852704-3f93-4143-8c9e-4f91ae422989" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/DebtDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5d45b191-86e0-42fd-8280-027f49a3abd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_DebtInstrumentTable_5d45b191-86e0-42fd-8280-027f49a3abd2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0d0fb1bc-439e-41ce-a2d4-b24c262e8577" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5d45b191-86e0-42fd-8280-027f49a3abd2" xlink:to="loc_us-gaap_CreditFacilityAxis_0d0fb1bc-439e-41ce-a2d4-b24c262e8577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0d0fb1bc-439e-41ce-a2d4-b24c262e8577_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_0d0fb1bc-439e-41ce-a2d4-b24c262e8577" xlink:to="loc_us-gaap_CreditFacilityDomain_0d0fb1bc-439e-41ce-a2d4-b24c262e8577_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2b71fc58-25c6-4cc9-a550-937215492f00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_0d0fb1bc-439e-41ce-a2d4-b24c262e8577" xlink:to="loc_us-gaap_CreditFacilityDomain_2b71fc58-25c6-4cc9-a550-937215492f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_SecuredTermLoanFacilityMember_77f9ccb4-d673-47ea-955a-d6b53a80467f" xlink:href="agl-20250630.xsd#agl_SecuredTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2b71fc58-25c6-4cc9-a550-937215492f00" xlink:to="loc_agl_SecuredTermLoanFacilityMember_77f9ccb4-d673-47ea-955a-d6b53a80467f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_SecuredRevolvingFacilityMember_489a0dff-7ae7-4b7b-b0a4-321f5a43bf7a" xlink:href="agl-20250630.xsd#agl_SecuredRevolvingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2b71fc58-25c6-4cc9-a550-937215492f00" xlink:to="loc_agl_SecuredRevolvingFacilityMember_489a0dff-7ae7-4b7b-b0a4-321f5a43bf7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_16dd59c9-5fbc-4ba3-b4dd-f1d742c5b9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2b71fc58-25c6-4cc9-a550-937215492f00" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_16dd59c9-5fbc-4ba3-b4dd-f1d742c5b9f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8ed95c03-9df4-4897-8a91-73c5855fad11" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5d45b191-86e0-42fd-8280-027f49a3abd2" xlink:to="loc_srt_RangeAxis_8ed95c03-9df4-4897-8a91-73c5855fad11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ed95c03-9df4-4897-8a91-73c5855fad11_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8ed95c03-9df4-4897-8a91-73c5855fad11" xlink:to="loc_srt_RangeMember_8ed95c03-9df4-4897-8a91-73c5855fad11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76328ebe-bc46-4dce-bca7-8b891170656c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8ed95c03-9df4-4897-8a91-73c5855fad11" xlink:to="loc_srt_RangeMember_76328ebe-bc46-4dce-bca7-8b891170656c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bf4cc8f9-2d48-49a7-8a66-e6d7be9db1f8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_76328ebe-bc46-4dce-bca7-8b891170656c" xlink:to="loc_srt_MaximumMember_bf4cc8f9-2d48-49a7-8a66-e6d7be9db1f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_da0ae479-5480-43b7-b35c-9ddb0d6d7bff" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_76328ebe-bc46-4dce-bca7-8b891170656c" xlink:to="loc_srt_MinimumMember_da0ae479-5480-43b7-b35c-9ddb0d6d7bff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bd12c67b-25f6-4b65-94a5-2bd22d34dd95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5d45b191-86e0-42fd-8280-027f49a3abd2" xlink:to="loc_us-gaap_VariableRateAxis_bd12c67b-25f6-4b65-94a5-2bd22d34dd95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_bd12c67b-25f6-4b65-94a5-2bd22d34dd95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_bd12c67b-25f6-4b65-94a5-2bd22d34dd95" xlink:to="loc_us-gaap_VariableRateDomain_bd12c67b-25f6-4b65-94a5-2bd22d34dd95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_354791df-aa5b-4eeb-ac05-dfeb509c3121" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_bd12c67b-25f6-4b65-94a5-2bd22d34dd95" xlink:to="loc_us-gaap_VariableRateDomain_354791df-aa5b-4eeb-ac05-dfeb509c3121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_5982f5b2-f655-44a9-b73a-5aa1b59ede6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_354791df-aa5b-4eeb-ac05-dfeb509c3121" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_5982f5b2-f655-44a9-b73a-5aa1b59ede6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_7c5a8e4f-ef14-4020-8d3c-cb921bd63f74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_354791df-aa5b-4eeb-ac05-dfeb509c3121" xlink:to="loc_us-gaap_BaseRateMember_7c5a8e4f-ef14-4020-8d3c-cb921bd63f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_98b203ba-d24e-480a-919f-72332456ef49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_354791df-aa5b-4eeb-ac05-dfeb509c3121" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_98b203ba-d24e-480a-919f-72332456ef49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ed3bd3a9-b10b-478e-bdbb-61e2efb2f88e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ed3bd3a9-b10b-478e-bdbb-61e2efb2f88e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit_7dc82714-f23c-4d1d-b424-cfdf3e162300" xlink:href="agl-20250630.xsd#agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit_7dc82714-f23c-4d1d-b424-cfdf3e162300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_15d86cf6-b5a9-4371-b09c-93e870793b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_LongTermDebt_15d86cf6-b5a9-4371-b09c-93e870793b5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_598fbf19-4079-46b6-9cef-de5cf442b22f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_598fbf19-4079-46b6-9cef-de5cf442b22f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_3c244ecb-fc27-465d-a83d-1e87e8ff7a45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_3c244ecb-fc27-465d-a83d-1e87e8ff7a45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_ExtendedTermOfLettersOfCredit_3218caf2-d301-4b44-bccd-5ac48f0bffee" xlink:href="agl-20250630.xsd#agl_ExtendedTermOfLettersOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_agl_ExtendedTermOfLettersOfCredit_3218caf2-d301-4b44-bccd-5ac48f0bffee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_802d26fb-f7a3-4894-8090-e55d46cfda38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_802d26fb-f7a3-4894-8090-e55d46cfda38" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_e976d10c-08f5-4cd2-a1e9-403b9f75aed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_e976d10c-08f5-4cd2-a1e9-403b9f75aed8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_0618da17-290d-4254-84d2-b3ef06aaa2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_0618da17-290d-4254-84d2-b3ef06aaa2fe" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b8526eeb-22ef-44e3-931c-4d0e3f168b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_a1e32222-b000-4164-b453-1bdedfe75964" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_b8526eeb-22ef-44e3-931c-4d0e3f168b1b" xlink:to="loc_us-gaap_LossContingenciesTable_a1e32222-b000-4164-b453-1bdedfe75964" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_82ecfd96-eba9-4c14-a446-4ecadc55d4a5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_a1e32222-b000-4164-b453-1bdedfe75964" xlink:to="loc_srt_LitigationCaseAxis_82ecfd96-eba9-4c14-a446-4ecadc55d4a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_82ecfd96-eba9-4c14-a446-4ecadc55d4a5_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_82ecfd96-eba9-4c14-a446-4ecadc55d4a5" xlink:to="loc_srt_LitigationCaseTypeDomain_82ecfd96-eba9-4c14-a446-4ecadc55d4a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_92fb7985-1598-4248-b8e4-a2b5a26f1f26" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_82ecfd96-eba9-4c14-a446-4ecadc55d4a5" xlink:to="loc_srt_LitigationCaseTypeDomain_92fb7985-1598-4248-b8e4-a2b5a26f1f26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_ConsolidatedSecuritiesMatterMember_8e7dd34e-7695-4206-aa87-0074fe862403" xlink:href="agl-20250630.xsd#agl_ConsolidatedSecuritiesMatterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_92fb7985-1598-4248-b8e4-a2b5a26f1f26" xlink:to="loc_agl_ConsolidatedSecuritiesMatterMember_8e7dd34e-7695-4206-aa87-0074fe862403" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DerivativeMattersMember_8ac0b900-f7e1-4382-9acd-337eed5ceffa" xlink:href="agl-20250630.xsd#agl_DerivativeMattersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_92fb7985-1598-4248-b8e4-a2b5a26f1f26" xlink:to="loc_agl_DerivativeMattersMember_8ac0b900-f7e1-4382-9acd-337eed5ceffa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_6b5a1496-a080-411a-83c6-4f1cca3703c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b8526eeb-22ef-44e3-931c-4d0e3f168b1b" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_6b5a1496-a080-411a-83c6-4f1cca3703c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CommonStockDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#CommonStockDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_7f4e37ac-eee8-483b-84c5-ad440a16d27a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_91fd798d-0704-46dc-bfed-efd6c3b5a9de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7f4e37ac-eee8-483b-84c5-ad440a16d27a" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_91fd798d-0704-46dc-bfed-efd6c3b5a9de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b6c8b768-a695-4836-8532-896be255aeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_91fd798d-0704-46dc-bfed-efd6c3b5a9de" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b6c8b768-a695-4836-8532-896be255aeb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b6c8b768-a695-4836-8532-896be255aeb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b6c8b768-a695-4836-8532-896be255aeb7" xlink:to="loc_us-gaap_EquityComponentDomain_b6c8b768-a695-4836-8532-896be255aeb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_beaf2841-7dfa-4ebb-a836-78116b10453e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b6c8b768-a695-4836-8532-896be255aeb7" xlink:to="loc_us-gaap_EquityComponentDomain_beaf2841-7dfa-4ebb-a836-78116b10453e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_870d71a3-b891-4475-a590-cfae98453048" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_beaf2841-7dfa-4ebb-a836-78116b10453e" xlink:to="loc_us-gaap_CommonStockMember_870d71a3-b891-4475-a590-cfae98453048" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4e3a448d-10ec-4fd7-924a-fd74e76220de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7f4e37ac-eee8-483b-84c5-ad440a16d27a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4e3a448d-10ec-4fd7-924a-fd74e76220de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_8e89afa8-2077-4876-855e-97f9fbc3c590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7f4e37ac-eee8-483b-84c5-ad440a16d27a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_8e89afa8-2077-4876-855e-97f9fbc3c590" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a9415aa1-0df0-4d14-b867-fb8c6889bceb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_01f2c7b1-352b-449f-9671-a937daf45e93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a9415aa1-0df0-4d14-b867-fb8c6889bceb" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_01f2c7b1-352b-449f-9671-a937daf45e93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bac2d596-0ca8-4664-be6b-ebab9f7c525d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_01f2c7b1-352b-449f-9671-a937daf45e93" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bac2d596-0ca8-4664-be6b-ebab9f7c525d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bac2d596-0ca8-4664-be6b-ebab9f7c525d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bac2d596-0ca8-4664-be6b-ebab9f7c525d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bac2d596-0ca8-4664-be6b-ebab9f7c525d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4de612b8-3ef0-43c2-9066-c92697e87bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bac2d596-0ca8-4664-be6b-ebab9f7c525d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4de612b8-3ef0-43c2-9066-c92697e87bbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1b6d7457-a97e-45dd-808b-400ce99ab3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4de612b8-3ef0-43c2-9066-c92697e87bbd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1b6d7457-a97e-45dd-808b-400ce99ab3bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5f5bb431-b80d-4e20-89e7-3e228e869606" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4de612b8-3ef0-43c2-9066-c92697e87bbd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5f5bb431-b80d-4e20-89e7-3e228e869606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_768f3fa3-21fd-4c7a-98b6-d50d3e844e18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a9415aa1-0df0-4d14-b867-fb8c6889bceb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_768f3fa3-21fd-4c7a-98b6-d50d3e844e18" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_a6569eb8-895e-4c33-9d36-b08883871104" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_af14a8da-4d8e-4dfb-880c-6475d10d3124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a6569eb8-895e-4c33-9d36-b08883871104" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_af14a8da-4d8e-4dfb-880c-6475d10d3124" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_3ada4c46-83c4-4841-936a-b8039c687833" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_af14a8da-4d8e-4dfb-880c-6475d10d3124" xlink:to="loc_srt_ConsolidatedEntitiesAxis_3ada4c46-83c4-4841-936a-b8039c687833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3ada4c46-83c4-4841-936a-b8039c687833_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3ada4c46-83c4-4841-936a-b8039c687833" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3ada4c46-83c4-4841-936a-b8039c687833_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a9baf6d4-767b-4039-b936-421dc3658962" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3ada4c46-83c4-4841-936a-b8039c687833" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a9baf6d4-767b-4039-b936-421dc3658962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_d949a21c-8383-4cdd-8ab6-90a864205652" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a9baf6d4-767b-4039-b936-421dc3658962" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_d949a21c-8383-4cdd-8ab6-90a864205652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a6569eb8-895e-4c33-9d36-b08883871104" xlink:to="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b314a833-ea6b-4f73-bc7d-59773a216d83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b314a833-ea6b-4f73-bc7d-59773a216d83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalents_14ac37f8-b52f-4fbe-9117-c003ff1f8a57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_RestrictedCashEquivalents_14ac37f8-b52f-4fbe-9117-c003ff1f8a57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_d9b4daf4-18d5-48c3-9b72-4544213aa23d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_ReceivablesNetCurrent_d9b4daf4-18d5-48c3-9b72-4544213aa23d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1497cdd5-010b-4d45-856d-5db0a5a1d98c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1497cdd5-010b-4d45-856d-5db0a5a1d98c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_92ba50b6-0617-465a-9b73-e16bde2a1a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_92ba50b6-0617-465a-9b73-e16bde2a1a4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9bdfff60-29f1-4d01-8779-beb5a3d4b099" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9bdfff60-29f1-4d01-8779-beb5a3d4b099" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_4a97f023-43c7-4322-ae43-b0f2e386cc85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_OtherAssets_4a97f023-43c7-4322-ae43-b0f2e386cc85" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_672683dd-af05-4575-b41e-f31063f889c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a6569eb8-895e-4c33-9d36-b08883871104" xlink:to="loc_us-gaap_LiabilitiesAbstract_672683dd-af05-4575-b41e-f31063f889c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_63f08b6a-d116-45d6-836e-13a3467ae46d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_672683dd-af05-4575-b41e-f31063f889c2" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_63f08b6a-d116-45d6-836e-13a3467ae46d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a7ba96d-1b71-4b68-a85b-1e8de11a1d99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_672683dd-af05-4575-b41e-f31063f889c2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a7ba96d-1b71-4b68-a85b-1e8de11a1d99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_d9deeed6-1690-4b87-bd5a-49097ca83e15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_672683dd-af05-4575-b41e-f31063f889c2" xlink:to="loc_us-gaap_OtherLiabilities_d9deeed6-1690-4b87-bd5a-49097ca83e15" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#VariableInterestEntitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_347be536-9356-4a75-b1d5-7b13cbcf5669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_347be536-9356-4a75-b1d5-7b13cbcf5669" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_ca8f9d7a-6534-4c20-92ef-d60bec14aab0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_347be536-9356-4a75-b1d5-7b13cbcf5669" xlink:to="loc_srt_ConsolidatedEntitiesAxis_ca8f9d7a-6534-4c20-92ef-d60bec14aab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ca8f9d7a-6534-4c20-92ef-d60bec14aab0_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ca8f9d7a-6534-4c20-92ef-d60bec14aab0" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ca8f9d7a-6534-4c20-92ef-d60bec14aab0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_26963940-e60e-403b-9e44-dce8ed38f891" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ca8f9d7a-6534-4c20-92ef-d60bec14aab0" xlink:to="loc_srt_ConsolidatedEntitiesDomain_26963940-e60e-403b-9e44-dce8ed38f891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_9e0b5a55-e8af-4b2f-b4bb-86372446b2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_26963940-e60e-403b-9e44-dce8ed38f891" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_9e0b5a55-e8af-4b2f-b4bb-86372446b2b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_b67d98e3-a2aa-491a-9693-10a3d45aaf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_26963940-e60e-403b-9e44-dce8ed38f891" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_b67d98e3-a2aa-491a-9693-10a3d45aaf7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_037bb399-3b67-4d3a-8e84-910804159ade" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_347be536-9356-4a75-b1d5-7b13cbcf5669" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_037bb399-3b67-4d3a-8e84-910804159ade" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_037bb399-3b67-4d3a-8e84-910804159ade_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_037bb399-3b67-4d3a-8e84-910804159ade" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_037bb399-3b67-4d3a-8e84-910804159ade_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cac2da54-4938-4413-a3d9-fc50f5c5de28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_037bb399-3b67-4d3a-8e84-910804159ade" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cac2da54-4938-4413-a3d9-fc50f5c5de28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuretyBondMember_815e164c-01e2-4fc4-a18d-4d8ad26f8bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuretyBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cac2da54-4938-4413-a3d9-fc50f5c5de28" xlink:to="loc_us-gaap_SuretyBondMember_815e164c-01e2-4fc4-a18d-4d8ad26f8bd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfWhollyOwnedRiskBearingEntities_dbff4191-3c68-4381-a2bf-57327b4edf0f" xlink:href="agl-20250630.xsd#agl_NumberOfWhollyOwnedRiskBearingEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:to="loc_agl_NumberOfWhollyOwnedRiskBearingEntities_dbff4191-3c68-4381-a2bf-57327b4edf0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfEquityMethodInvestments_210bb424-caa3-423d-a1ae-840639ae509a" xlink:href="agl-20250630.xsd#agl_NumberOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:to="loc_agl_NumberOfEquityMethodInvestments_210bb424-caa3-423d-a1ae-840639ae509a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfDirectContractingEntities_521a73fb-1cde-452d-ae38-fa2a94fcc951" xlink:href="agl-20250630.xsd#agl_NumberOfDirectContractingEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:to="loc_agl_NumberOfDirectContractingEntities_521a73fb-1cde-452d-ae38-fa2a94fcc951" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7c8758ad-926a-4b10-8eba-4e675f2af91f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:to="loc_us-gaap_LongTermDebt_7c8758ad-926a-4b10-8eba-4e675f2af91f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfPhysicianGroupPartners_e5910ad5-c664-428a-877e-059cbcd89f31" xlink:href="agl-20250630.xsd#agl_NumberOfPhysicianGroupPartners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:to="loc_agl_NumberOfPhysicianGroupPartners_e5910ad5-c664-428a-877e-059cbcd89f31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfGeographicalLocation_dd809150-a66f-4926-b6aa-7f8fbd003ca0" xlink:href="agl-20250630.xsd#agl_NumberOfGeographicalLocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:to="loc_agl_NumberOfGeographicalLocation_dd809150-a66f-4926-b6aa-7f8fbd003ca0" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_a768c2d8-afe0-4de4-abac-3b6daa1b6380" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a9858e9a-6a14-45e5-aa0f-551461791859" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a768c2d8-afe0-4de4-abac-3b6daa1b6380" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a9858e9a-6a14-45e5-aa0f-551461791859" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2c41a4de-76f9-40c7-a9f3-08d170f724f7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a9858e9a-6a14-45e5-aa0f-551461791859" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2c41a4de-76f9-40c7-a9f3-08d170f724f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2c41a4de-76f9-40c7-a9f3-08d170f724f7_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2c41a4de-76f9-40c7-a9f3-08d170f724f7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2c41a4de-76f9-40c7-a9f3-08d170f724f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f0d64419-6cc5-42ea-b86d-2850100c7ee2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2c41a4de-76f9-40c7-a9f3-08d170f724f7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f0d64419-6cc5-42ea-b86d-2850100c7ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherEquityMethodInvestmentsMember_82fe36cf-3641-4b8e-8fd4-1062c85ffb93" xlink:href="agl-20250630.xsd#agl_OtherEquityMethodInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f0d64419-6cc5-42ea-b86d-2850100c7ee2" xlink:to="loc_agl_OtherEquityMethodInvestmentsMember_82fe36cf-3641-4b8e-8fd4-1062c85ffb93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_ACOREACHMember_d8fc371a-72fd-4b04-9102-1834739323d4" xlink:href="agl-20250630.xsd#agl_ACOREACHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f0d64419-6cc5-42ea-b86d-2850100c7ee2" xlink:to="loc_agl_ACOREACHMember_d8fc371a-72fd-4b04-9102-1834739323d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_bb268952-0321-4c68-bf6f-6d7b0c674c33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a768c2d8-afe0-4de4-abac-3b6daa1b6380" xlink:to="loc_us-gaap_EquityMethodInvestments_bb268952-0321-4c68-bf6f-6d7b0c674c33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_EquityMethodLiabilities_bb628ba2-7610-49cc-aac7-9aad7ecedaaa" xlink:href="agl-20250630.xsd#agl_EquityMethodLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a768c2d8-afe0-4de4-abac-3b6daa1b6380" xlink:to="loc_agl_EquityMethodLiabilities_bb628ba2-7610-49cc-aac7-9aad7ecedaaa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#VariableInterestEntitiesScheduleofOperatingResultsDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ed16fe59-dd92-4897-83e8-31444601ff88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ed16fe59-dd92-4897-83e8-31444601ff88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d314e81d-1e76-4332-a0ac-2c76f4ca5d2b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ed16fe59-dd92-4897-83e8-31444601ff88" xlink:to="loc_srt_ProductOrServiceAxis_d314e81d-1e76-4332-a0ac-2c76f4ca5d2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d314e81d-1e76-4332-a0ac-2c76f4ca5d2b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d314e81d-1e76-4332-a0ac-2c76f4ca5d2b" xlink:to="loc_srt_ProductsAndServicesDomain_d314e81d-1e76-4332-a0ac-2c76f4ca5d2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4c8bd373-64b4-472d-8b34-888aa6c4caee" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d314e81d-1e76-4332-a0ac-2c76f4ca5d2b" xlink:to="loc_srt_ProductsAndServicesDomain_4c8bd373-64b4-472d-8b34-888aa6c4caee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_MedicalServicesMember_4aba600f-c71a-4a8d-8941-26fa1ef29be7" xlink:href="agl-20250630.xsd#agl_MedicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4c8bd373-64b4-472d-8b34-888aa6c4caee" xlink:to="loc_agl_MedicalServicesMember_4aba600f-c71a-4a8d-8941-26fa1ef29be7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherOperatingMember_d54d571f-01a4-47c1-a3a0-bc03762a15ae" xlink:href="agl-20250630.xsd#agl_OtherOperatingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4c8bd373-64b4-472d-8b34-888aa6c4caee" xlink:to="loc_agl_OtherOperatingMember_d54d571f-01a4-47c1-a3a0-bc03762a15ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1d05a804-909b-46ae-9c5b-618ee8520858" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ed16fe59-dd92-4897-83e8-31444601ff88" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1d05a804-909b-46ae-9c5b-618ee8520858" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1d05a804-909b-46ae-9c5b-618ee8520858_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1d05a804-909b-46ae-9c5b-618ee8520858" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1d05a804-909b-46ae-9c5b-618ee8520858_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_88682889-9a81-4a43-ba56-0ea966e56636" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1d05a804-909b-46ae-9c5b-618ee8520858" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_88682889-9a81-4a43-ba56-0ea966e56636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_d4a99a03-3587-478f-8300-b63c2cbd3cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_88682889-9a81-4a43-ba56-0ea966e56636" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_d4a99a03-3587-478f-8300-b63c2cbd3cc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc94ee9b-75e6-4024-9866-7ca7eb6ab7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc94ee9b-75e6-4024-9866-7ca7eb6ab7ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_4b56916a-428e-48d3-bcb0-cd6c9b82857f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_4b56916a-428e-48d3-bcb0-cd6c9b82857f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_73846bee-e3b3-447a-9fa0-7d6e36f4677b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:to="loc_us-gaap_OperatingIncomeLoss_73846bee-e3b3-447a-9fa0-7d6e36f4677b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f96c6aa6-a52a-46f9-9d8f-7760d70279df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:to="loc_us-gaap_NetIncomeLoss_f96c6aa6-a52a-46f9-9d8f-7760d70279df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PhysicianCompensationExpense_405821ab-3a37-4d35-b38d-ac1f45321594" xlink:href="agl-20250630.xsd#agl_PhysicianCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:to="loc_agl_PhysicianCompensationExpense_405821ab-3a37-4d35-b38d-ac1f45321594" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_20eccfb4-2417-4389-bda3-3661992417e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:to="loc_us-gaap_OperatingExpenses_20eccfb4-2417-4389-bda3-3661992417e5" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#VariableInterestEntitiesScheduleBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_6a44c368-756e-442c-8915-71b87f5e6468" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4eb3a338-2c68-40ea-bfee-e341277d1e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6a44c368-756e-442c-8915-71b87f5e6468" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4eb3a338-2c68-40ea-bfee-e341277d1e4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_5b570ef2-e573-4b86-b555-94e0748c92d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4eb3a338-2c68-40ea-bfee-e341277d1e4d" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_5b570ef2-e573-4b86-b555-94e0748c92d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_5b570ef2-e573-4b86-b555-94e0748c92d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_5b570ef2-e573-4b86-b555-94e0748c92d2" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_5b570ef2-e573-4b86-b555-94e0748c92d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a60029d7-ba8e-4a1d-9473-10715e1e89be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_5b570ef2-e573-4b86-b555-94e0748c92d2" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a60029d7-ba8e-4a1d-9473-10715e1e89be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_47f126ee-38de-45de-b1b2-181aa45f177b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a60029d7-ba8e-4a1d-9473-10715e1e89be" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_47f126ee-38de-45de-b1b2-181aa45f177b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d99eac25-9a47-4a25-9778-632e0ae77d97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6a44c368-756e-442c-8915-71b87f5e6468" xlink:to="loc_us-gaap_AssetsCurrent_d99eac25-9a47-4a25-9778-632e0ae77d97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_99b9a62b-eb2b-448b-8c0c-7f08994d39ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6a44c368-756e-442c-8915-71b87f5e6468" xlink:to="loc_us-gaap_AssetsNoncurrent_99b9a62b-eb2b-448b-8c0c-7f08994d39ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5ef4839a-3a18-4425-b3fb-441f49f6b0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6a44c368-756e-442c-8915-71b87f5e6468" xlink:to="loc_us-gaap_Assets_5ef4839a-3a18-4425-b3fb-441f49f6b0fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_406ec1ab-908c-44a7-b2a5-640a2447ca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6a44c368-756e-442c-8915-71b87f5e6468" xlink:to="loc_us-gaap_Liabilities_406ec1ab-908c-44a7-b2a5-640a2447ca5d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/DiscontinuedOperationsDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#DiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://agilonhealth.com/role/DiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_900951ef-3092-48a3-b27a-53887ca2f084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d0972e57-2e93-490f-a98e-6459d5af2033" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_900951ef-3092-48a3-b27a-53887ca2f084" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d0972e57-2e93-490f-a98e-6459d5af2033" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9d50ad38-0358-4691-a721-285e7f8aae4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d0972e57-2e93-490f-a98e-6459d5af2033" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9d50ad38-0358-4691-a721-285e7f8aae4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9d50ad38-0358-4691-a721-285e7f8aae4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9d50ad38-0358-4691-a721-285e7f8aae4a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9d50ad38-0358-4691-a721-285e7f8aae4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a927d34d-006b-44fb-9933-09b97afc27f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9d50ad38-0358-4691-a721-285e7f8aae4a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a927d34d-006b-44fb-9933-09b97afc27f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_cb9b9ef4-068f-4fb5-a021-389015e46096" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a927d34d-006b-44fb-9933-09b97afc27f8" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_cb9b9ef4-068f-4fb5-a021-389015e46096" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments_cfd4467b-8c31-4198-95f9-00f417493ca6" xlink:href="agl-20250630.xsd#agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_900951ef-3092-48a3-b27a-53887ca2f084" xlink:to="loc_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments_cfd4467b-8c31-4198-95f9-00f417493ca6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_194852e8-60ad-4f49-a898-ee23e3948607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_900951ef-3092-48a3-b27a-53887ca2f084" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_194852e8-60ad-4f49-a898-ee23e3948607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_162a700f-e10b-41e3-951a-69fc4c86de37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_900951ef-3092-48a3-b27a-53887ca2f084" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_162a700f-e10b-41e3-951a-69fc4c86de37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b007d550-3214-4adb-a3b2-c02eee5a6fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_900951ef-3092-48a3-b27a-53887ca2f084" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b007d550-3214-4adb-a3b2-c02eee5a6fe4" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>agl-20250630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:13b764c6-a2b0-4a9c-9408-254f78400ab0,g:a48cf18d-4f3e-446d-9d3f-633818f822f0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromRepurchaseOfEquity_5e573bd0-5a49-45d5-99fe-ce66a8b03fff_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepurchaseOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from (payments for) equity issuances, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepurchaseOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepurchaseOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Repurchase of) Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepurchaseOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepurchaseOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepurchaseOfEquity" xlink:to="lab_us-gaap_ProceedsFromRepurchaseOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6ce65614-d2c5-47ee-9e9f-3aa3574a7910_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_80f1a6dc-2c9a-4a6e-bd69-5d419d4912c4_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b5575a03-e25d-4578-9253-2ce338081f29_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_142728b9-be0d-4f75-b771-22875fa5d45b_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_5e71ce80-2615-4d48-8aab-febf109ce949_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_70a94438-b92e-452d-947b-eaafdc64721e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross carrying amount of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_78c2a5f1-4188-429f-82d5-5b3265b19adc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0666d8fb-7c9b-4915-85ef-279bd5f61eb6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d41fe8fc-23a0-4532-a14b-9e6ed2b2e068_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8bd31593-ae66-49e2-8f48-77d5ee675705_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_dc98c41e-ca5c-40a7-82af-ae149c6386f2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss (income) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable_ad28d567-cdf2-4695-a38e-76684be79a42_terseLabel_en-US" xlink:label="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related payables associated with retained liability</link:label>
    <link:label id="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable_label_en-US" xlink:label="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense, Amounts Recoverable</link:label>
    <link:label id="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable_documentation_en-US" xlink:label="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense, Amounts Recoverable under risk sharing arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable" xlink:href="agl-20250630.xsd#agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable" xlink:to="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2a2c2041-84c8-44e9-bd5b-0cc96dde2268_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_421df106-e58c-4df7-920e-e62b9d1948ec_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_b959d5b5-4bcf-4b90-9ad2-b5880edc7df1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Statements Related to Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_3d252c38-17d9-432c-91ca-347147c5cc83_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_67732d22-ea45-4839-bded-f76940334fe1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Shares withheld related to net share settlement</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_99be5ea0-36f8-4fc5-bd53-729237a6f4d6_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_c76566f6-aaa8-471e-a423-3e9c253d246b_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight Federal Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_7a086dd7-4943-4600-b062-fc9a7c253d39_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesAbstract_1ca4afee-d4f0-4270-a604-318daa7dfb60_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5c3c1fb0-c012-4006-b7f9-042092ec5571_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_63aff3a0-49d4-45ca-af80-3ed419d96999_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_727261b9-e757-47cf-a8a9-8e0d85e363a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents from Continuing Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_c41688c8-807b-4bf4-85cb-b1ddb4718622_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_d6b208a7-4043-40ef-8282-c90481d4522d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8f7fd631-a1ff-4bcd-a060-ec7bd309c8d2_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a7a5c6b6-1ffb-473a-9524-ff9e58b5b04f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b6489f07-f8b8-4309-b59c-0776a601cd81_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_92a31e28-ccdc-45a7-aa17-1a113e8e5a7b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_93697406-eda6-43b5-87a8-ce723274be70_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_60605363-9519-49a0-8a54-42ae9c71741b_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d65c4f2-5004-4080-a122-7dc1c1699931_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_e4f7c3c4-21de-4700-b716-91c7c583a172_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1ac56456-7fde-4311-a894-85d084b3f43d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_404d53b5-3067-4f65-acfb-7d3262f15d43_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuretyBondMember_a1288394-24e0-4315-ab65-0084f0ba17c2_terseLabel_en-US" xlink:label="lab_us-gaap_SuretyBondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Surety Bond</link:label>
    <link:label id="lab_us-gaap_SuretyBondMember_label_en-US" xlink:label="lab_us-gaap_SuretyBondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surety Bond [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuretyBondMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuretyBondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuretyBondMember" xlink:to="lab_us-gaap_SuretyBondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_09807f0f-7492-4cfe-800d-c5e8bad1efcb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4e81c222-b58b-43fb-8f47-4181b5d96cbf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_63ba6f22-e06c-4849-a71d-2ece0b50e421_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_03d3fb63-7d27-4792-96fa-1400704d1c16_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_99ad74f2-b916-4290-996d-c5b56fb7ca18_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_f8adbb3b-6b35-40de-8944-5d84fb244c73_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1f527b3e-e322-45fe-8f4c-34598304838e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash and equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_e53e4580-ddb6-4e00-87c4-00a1fe4d3bb2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash and equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d950f651-f664-4924-9f97-4bc34aebc55f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_14879aca-7858-4515-a2ad-47d0d22b91fb_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1dfe6e09-1d75-4a37-817a-8bf0ea3b803b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4a59b27c-2db7-489a-8f34-774a29baef5f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0eafb619-d664-4958-83e5-c5abe68da45a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests&#8217; share in (earnings) loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_84361f19-c0e9-4a22-8d2b-ec8dcc9eb550_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests&#8217; share in (earnings) loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f9b30ac0-44be-450d-a250-ffb806216dcf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_4f83260b-0031-4222-abfd-43b668ec4f2c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_b3666e69-810d-4cc1-9d69-4c1d907956a1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_0acbc29a-3b60-435d-8d96-cf5a8accf07a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Receivables, and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_OtherEquityMethodInvestmentsMember_92633a76-bb74-48ac-a0ec-f78bbe7ebf4a_terseLabel_en-US" xlink:label="lab_agl_OtherEquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Equity Methods</link:label>
    <link:label id="lab_agl_OtherEquityMethodInvestmentsMember_label_en-US" xlink:label="lab_agl_OtherEquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Method Investments [Member]</link:label>
    <link:label id="lab_agl_OtherEquityMethodInvestmentsMember_documentation_en-US" xlink:label="lab_agl_OtherEquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherEquityMethodInvestmentsMember" xlink:href="agl-20250630.xsd#agl_OtherEquityMethodInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_OtherEquityMethodInvestmentsMember" xlink:to="lab_agl_OtherEquityMethodInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_707bef3f-8d8c-4b50-8d1d-9b875cc5d251_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e2ef9916-fa6d-440f-9a3c-4409ceaf2d53_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_8d13ddd2-a4a3-4bc2-9e2d-f4cf6438d0d5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued to settle liabilities (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_025a781d-8697-4746-9899-ae4133000687_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_2ac4b200-715d-41a6-a3f9-35bb82e60038_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5feeca01-9497-4a2a-88ef-5b7856f59417_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c902d681-762d-4d43-b051-e70dbf8dbb5c_verboseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_727eff63-c19d-43e6-bb88-4dc767c6abe5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6822f78b-8831-423e-827b-f31a9fca4fdf_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1caa3bc9-95ac-473b-8496-da9b5a9c308d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_bc5dea62-9313-42b5-a8a5-20d384260727_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_eace663d-f97f-49c8-9df8-07ff4da12e7e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_37f4d87f-1ad1-4f31-9b76-93667b09aaea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_d49385d9-c747-41ad-bd99-a5c796df7d9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_8d9e334d-e2b0-4865-b37d-4f667d021f8c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_188fd044-f668-4788-bc01-0f55245f7de2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f04d39fa-3861-4c92-bbd8-9482bdb63a22_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive (income) loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_429901f9-d1ca-46fa-bada-d6d781428aa8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income (loss) attributable to agilon health, inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit_424bea54-a962-40ee-b9d6-0f53af1b859d_terseLabel_en-US" xlink:label="lab_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, accordion feature, increase limit</link:label>
    <link:label id="lab_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit_label_en-US" xlink:label="lab_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Accordion Feature, Increase Limit</link:label>
    <link:label id="lab_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit_documentation_en-US" xlink:label="lab_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Accordion Feature, Increase Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit" xlink:href="agl-20250630.xsd#agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit" xlink:to="lab_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_edf1da77-b125-4c6f-83ec-a3f33f1ee712_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to common stockholders before discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_ExtendedTermOfLettersOfCredit_9941d986-b08e-44ef-96b4-7ee62ac8e683_terseLabel_en-US" xlink:label="lab_agl_ExtendedTermOfLettersOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extended term of letters of credit</link:label>
    <link:label id="lab_agl_ExtendedTermOfLettersOfCredit_label_en-US" xlink:label="lab_agl_ExtendedTermOfLettersOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extended Term Of Letters Of Credit</link:label>
    <link:label id="lab_agl_ExtendedTermOfLettersOfCredit_documentation_en-US" xlink:label="lab_agl_ExtendedTermOfLettersOfCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extended term of letters of credit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_ExtendedTermOfLettersOfCredit" xlink:href="agl-20250630.xsd#agl_ExtendedTermOfLettersOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_ExtendedTermOfLettersOfCredit" xlink:to="lab_agl_ExtendedTermOfLettersOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f7efe369-7065-4a16-8222-3fb8ca2998bc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_93994bcd-6501-4055-9f74-9e431bb088ef_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_65bb9b0c-766c-4a52-b842-1d1f6d1a8120_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_89aacadc-b4cf-48fb-bfb2-2395b9be63aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_9487e6b3-1654-4523-a6ed-116e3222edae_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_a8999695-f65d-492b-9ea3-59d2ad8b573f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_7ae661ca-4d36-49d1-a93a-01a9858f25fa_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_fdbc5d3b-4a4f-49e7-812c-89e8279e11f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations, basic (US dollar per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b8ce8ab4-6a04-42e0-889b-91e6a2897c9a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share from continuing operations, basic (US dollar per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_fdcdd57a-07f8-48d9-af90-61ccf3a91f7b_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_3e1ddf97-19d0-4c70-a525-dd00ce71d250_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_bf6b2eca-b1d8-4fb4-8a89-0bd95a1e677a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_119c5472-4e09-4971-b6e9-b5ce216625d4_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_4e811f2f-e1ad-4376-bc96-04dca58d7f5a_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2d7014b9-00a9-4c94-8e5c-67309b8ccccf_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_SummaryOfSignificantAccountingPoliciesTable_f87f1740-2514-4751-9b21-e41c32ffd95a_terseLabel_en-US" xlink:label="lab_agl_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_agl_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_agl_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_agl_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_agl_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_SummaryOfSignificantAccountingPoliciesTable" xlink:href="agl-20250630.xsd#agl_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_agl_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_381eaa09-988e-487f-b510-0723eff64e7e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued under share-based awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_6c6a1863-beb4-42db-948c-c6580d6f1ea4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d3efdd10-de61-41bb-8d37-e888c191a063_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d25de65f-b7bf-4a1f-b9c8-6b696dc9ec4d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_4263870a-59a5-46b3-82dc-97a937f34d1f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment items</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_cc69eb60-7413-4ee2-9a0f-6f41089129af_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4500ce38-418c-4ac3-8f16-8c5e724ade2a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_74a0c1ab-fae5-49c4-a846-bb8d68056fab_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_50a9de09-7cac-4e1b-b96f-353b6a8a168c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_4640a035-b48c-4fd5-966d-d00872f97274_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d5d93f9e-7e2c-4c92-9d3e-50b68de1ef41_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e0153642-40de-4f1f-bdfe-f9d7eab67be7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset obtained in exchange for new operating lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3fc25c18-41cd-4111-acee-90b4159ac12e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0b77356d-3988-4761-80f6-7f7170da303d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_8b66c58b-7db3-4278-b32c-c449e1a46c77_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d3c35fc2-0ff5-47d4-affb-8793ecc9df87_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c0258260-d27a-47ab-b3bd-c502747217ba_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bdf5474c-ffaf-4cbb-8e53-9f8214c33ced_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_83b7d72d-f74c-46be-bd53-7ad7f0d00acc_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_ReportableSegmentMember_e0d08034-c0f8-4b61-8bc4-a876c2c25c9e_terseLabel_en-US" xlink:label="lab_agl_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_agl_ReportableSegmentMember_label_en-US" xlink:label="lab_agl_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_agl_ReportableSegmentMember_documentation_en-US" xlink:label="lab_agl_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_ReportableSegmentMember" xlink:href="agl-20250630.xsd#agl_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_ReportableSegmentMember" xlink:to="lab_agl_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_2459f656-28cc-4728-867a-467edee52bcf_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2d671517-7a1e-458c-a41a-1e47e0a5515e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_97892607-90e9-4b69-8596-9a5c9e0081e0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_f03dda46-f3c8-4098-8c79-173d6a0e65bc_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Claims paid related</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9044a7c6-72ea-4d9a-99e8-6120327fd94b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets, net</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0cd6eda9-38f2-477d-8966-110d590d479e_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets, net</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_d185811a-2b04-420e-b379-20e240c8dc77_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations, diluted (US dollar per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_ab34f2dd-9c69-4190-a90a-9f4ffff9cb17_verboseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share from discontinued operations, diluted (US dollar per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e4474122-6bf3-4ed3-8c02-a686865bd952_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42d73523-4898-4927-937a-e53d09939706_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_bad61f1e-bafb-49bc-95fd-3bbf097088b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_df0ef8fe-45e8-48c1-b879-0cf50979fab2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_552669de-333d-4176-8e8c-94b64801e07d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans_7764673f-6343-42d9-a3ef-b43273fbf4a3_terseLabel_en-US" xlink:label="lab_agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of medicare advantage members enrolled with private health plans</link:label>
    <link:label id="lab_agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans_label_en-US" xlink:label="lab_agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Medicare Advantage Members Enrolled With Private Health Plans</link:label>
    <link:label id="lab_agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans_documentation_en-US" xlink:label="lab_agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Medicare Advantage members enrolled with private health plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans" xlink:href="agl-20250630.xsd#agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans" xlink:to="lab_agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_211ce069-be77-4ced-9c7a-d6d6b47b977a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1dd807ee-6b32-43b1-ba99-1ff4b0a302ec_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_e942900a-b2a6-4a17-bb25-7099faf07b07_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets, net</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ccf9ce3f-3d49-46a6-8015-fe10b2026da9_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ddcd55c2-0add-4e1e-afe2-fa758838b43a_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b57ffa11-747f-4734-acb7-9893c92f8414_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_048f1013-7ac9-4d7f-bd9b-121365822766_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_9644087a-161c-46cf-b215-4eb374e9c144_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare Advantage Payors</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_26d6623f-1ff1-451f-a307-a4605ec5c50a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross carrying amount of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_fbab8c35-59c4-40ac-be84-136f9a08ce5a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of incurred costs related to:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_8c896cbc-e346-424f-8ecb-7ef7adf1d290_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations, diluted (US dollar per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_bb3a1e6a-b2a1-461b-8cc8-d5ff5234fd57_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share from continuing operations, diluted (US dollar per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_7c5343a6-b5fc-48b1-aff3-08eca12a4f5a_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_5d02c6c1-ec80-4840-ac05-5ebff56d14cf_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2755bb2a-9f72-4e48-a443-fcccdecf1430_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_PayorEMember_f8d1c73d-ba27-479f-ba22-bed0e47dd8f5_terseLabel_en-US" xlink:label="lab_agl_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payor E</link:label>
    <link:label id="lab_agl_PayorEMember_label_en-US" xlink:label="lab_agl_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payor E [Member]</link:label>
    <link:label id="lab_agl_PayorEMember_documentation_en-US" xlink:label="lab_agl_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payor e.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorEMember" xlink:href="agl-20250630.xsd#agl_PayorEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_PayorEMember" xlink:to="lab_agl_PayorEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_DerivativeMattersMember_36048f81-d945-4a33-bc06-4bfd89d0d194_terseLabel_en-US" xlink:label="lab_agl_DerivativeMattersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Matters</link:label>
    <link:label id="lab_agl_DerivativeMattersMember_label_en-US" xlink:label="lab_agl_DerivativeMattersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Matters [Member]</link:label>
    <link:label id="lab_agl_DerivativeMattersMember_documentation_en-US" xlink:label="lab_agl_DerivativeMattersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Matters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DerivativeMattersMember" xlink:href="agl-20250630.xsd#agl_DerivativeMattersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_DerivativeMattersMember" xlink:to="lab_agl_DerivativeMattersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_59b1faa5-bdc2-4239-b7ff-4b8a1c776364_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7feabb0-503c-462c-b447-4a90535180ad_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree_74d21485-9694-46cd-b901-6b7cba3de636_terseLabel_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree_label_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Three</link:label>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree_documentation_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree" xlink:to="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ae109263-986a-4802-88cd-c955a530d003_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_2fc181b9-6b05-4414-b3e7-399a0541950e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5bc4647-2d85-4c62-aaf7-a4f060bd4118_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour_dff74ac5-8bf1-4963-ae18-79b3baaa8e9d_terseLabel_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour_label_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Four</link:label>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour_documentation_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour" xlink:to="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_215dd3e0-b253-45db-9f66-22bbc257274b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5b239e2f-0306-47aa-bdc9-b6378bf16751_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_e1ed8739-2ebf-415d-a566-fca04e36d8df_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_fb55863e-f72c-41fe-8815-d6889425db88_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_5a33251d-2b91-469d-a4d2-bb1053cd123c_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_69bd9b68-ac1b-4c68-bf1b-f54daa6909ef_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f8e11d69-918f-471e-a38c-c7eaa5a6130d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_66fd3c6d-8818-484e-993f-a949b0f2523f_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_44cf340a-801d-453c-b6ae-b6b4078f9332_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_b0f2fd30-d2e8-4d1e-868e-073253f6caef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_b42aab90-28b7-4d02-a6d1-386122e91649_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_fb5888ba-5503-4ade-a2d6-397eee73034c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_23df2774-3c05-4f52-97b3-d7cfd516a9ca_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_1b6b5fe9-579d-4b4c-9a9d-82c4fce15444_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_db991f28-cd6e-4b68-a46e-cabef7af163c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_983c991c-82e9-4646-8d8e-8da35d8f337b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9fde02ff-e585-4261-bb88-cfd006a6b0e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Cash Equivalents from Continuing Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6815500f-546f-45e8-87ac-fd5bade0cc88_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_db64790d-19da-4968-844b-e7576d66ebec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_EquityMethodLiabilitiesNoncurrent_f33c2fcf-b51b-4341-9d24-1b44685deecd_terseLabel_en-US" xlink:label="lab_agl_EquityMethodLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method liabilities &#8211; CMS ACO Models</link:label>
    <link:label id="lab_agl_EquityMethodLiabilitiesNoncurrent_label_en-US" xlink:label="lab_agl_EquityMethodLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Liabilities, Noncurrent</link:label>
    <link:label id="lab_agl_EquityMethodLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_agl_EquityMethodLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_EquityMethodLiabilitiesNoncurrent" xlink:href="agl-20250630.xsd#agl_EquityMethodLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_EquityMethodLiabilitiesNoncurrent" xlink:to="lab_agl_EquityMethodLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cb150d9d-3b12-4d59-8319-ab77f2bcda4f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_PaymentsToAcquireLoansReceivableAndOther_43e46073-e125-4201-b10a-cea9bf4b9ad6_negatedLabel_en-US" xlink:label="lab_agl_PaymentsToAcquireLoansReceivableAndOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Investment in loans receivable and other</link:label>
    <link:label id="lab_agl_PaymentsToAcquireLoansReceivableAndOther_label_en-US" xlink:label="lab_agl_PaymentsToAcquireLoansReceivableAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Loans Receivable And Other</link:label>
    <link:label id="lab_agl_PaymentsToAcquireLoansReceivableAndOther_documentation_en-US" xlink:label="lab_agl_PaymentsToAcquireLoansReceivableAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Acquire Loans Receivable And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PaymentsToAcquireLoansReceivableAndOther" xlink:href="agl-20250630.xsd#agl_PaymentsToAcquireLoansReceivableAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_PaymentsToAcquireLoansReceivableAndOther" xlink:to="lab_agl_PaymentsToAcquireLoansReceivableAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_993fe385-415d-48a7-9117-972e2ee9191e_terseLabel_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_label_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Two</link:label>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_documentation_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:to="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_SecuredTermLoanFacilityMember_e37accf9-ba13-491b-be6e-982884270822_terseLabel_en-US" xlink:label="lab_agl_SecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Term Loan Facility</link:label>
    <link:label id="lab_agl_SecuredTermLoanFacilityMember_label_en-US" xlink:label="lab_agl_SecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Term Loan Facility [Member]</link:label>
    <link:label id="lab_agl_SecuredTermLoanFacilityMember_documentation_en-US" xlink:label="lab_agl_SecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_SecuredTermLoanFacilityMember" xlink:href="agl-20250630.xsd#agl_SecuredTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_SecuredTermLoanFacilityMember" xlink:to="lab_agl_SecuredTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_02468f03-b9ee-4202-b563-a3901e6a21d3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_02eb8fc7-b269-4e87-ba94-4019a2d41b21_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_9b8c16c6-9cf3-4ded-9b3a-0abbd232817d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_44e86796-b8f1-49b4-9118-1303fe34e777_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2891f6de-7e06-4e44-b009-d1ae56fc1b6f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3c37edc5-14ae-4ca1-963a-415176727cc8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_43a51ffe-7163-4c72-8d5a-fd7e96ffc5eb_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e9944498-3481-4334-9d41-9881b23f0c97_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_3d5734e9-4648-4898-a786-2bf02e7510fa_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments_f48b5544-f600-4f6d-bd31-d9034dac4289_terseLabel_en-US" xlink:label="lab_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments_label_en-US" xlink:label="lab_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General And Administrative Expense, Net Of Adjustments</link:label>
    <link:label id="lab_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments_documentation_en-US" xlink:label="lab_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General And Administrative Expense, Net Of Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments" xlink:href="agl-20250630.xsd#agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments" xlink:to="lab_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_5007caa1-1c44-419e-86dd-a41be5840aaa_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_4b0d754d-fdb1-4cf9-94d0-dfd0008837f9_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61eadd11-30a9-4cbb-b81e-49ff88465ccb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_87fc3236-15f6-4cf7-9020-fbc7ce470d70_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_fb20c60e-f47b-45ba-b667-31dfa477f2c9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical Services Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_09b2b1ae-2540-4ea0-a053-e3899a7457f0_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49553911-6e17-4f96-8eab-52b4f5cb1030_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_a28c5c7a-b259-4764-92a3-6c127fb1db17_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_c965d17a-ac24-40c4-9805-6d1911cbf48b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bfdbeb94-8a19-4869-a987-ffae6dc0f2fd_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6720003f-d9f2-460e-aaae-37139c0dd12e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_07853c53-dedb-4229-89b8-20e4187f15e3_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_bfa6c6a6-e5b1-4fe0-a7d0-3dff251b4502_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_74de633e-9bfe-4768-bf6f-d319822613d5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_a2851953-8276-44d5-ad45-95aff5f76396_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c4b0e60a-3f62-4289-9def-47ae575be8d9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Incurred cost related to claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_PayorDMember_b80ddea2-e367-4c01-9697-37f6879d82a9_terseLabel_en-US" xlink:label="lab_agl_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payor D</link:label>
    <link:label id="lab_agl_PayorDMember_label_en-US" xlink:label="lab_agl_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payor D [Member]</link:label>
    <link:label id="lab_agl_PayorDMember_documentation_en-US" xlink:label="lab_agl_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payor D.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorDMember" xlink:href="agl-20250630.xsd#agl_PayorDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_PayorDMember" xlink:to="lab_agl_PayorDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_5d8f7ea1-bf70-443b-8120-824f632c75e6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_66f669ba-b9c1-4610-8884-1b1346a14d3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Results</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Operating Cost and Expense, by Component [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_PayorAMember_8edfc14e-3f6b-4263-99c9-0aed794e9f05_terseLabel_en-US" xlink:label="lab_agl_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payor A</link:label>
    <link:label id="lab_agl_PayorAMember_label_en-US" xlink:label="lab_agl_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payor A [Member]</link:label>
    <link:label id="lab_agl_PayorAMember_documentation_en-US" xlink:label="lab_agl_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payor A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorAMember" xlink:href="agl-20250630.xsd#agl_PayorAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_PayorAMember" xlink:to="lab_agl_PayorAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_a6047c5c-6c86-4186-b8ed-725f7a73f1a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ba3bfb8b-635b-4638-9e93-cb2a221aa2bb_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_884a118d-0630-4d85-958c-3142f5b2e105_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo_135f8494-95ee-4d46-92dd-ef8179e5a447_terseLabel_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo_label_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Two</link:label>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo_documentation_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:to="lab_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_PayorCMember_e2c884a2-90d7-48d2-b3ae-835afa75dd80_terseLabel_en-US" xlink:label="lab_agl_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payor C</link:label>
    <link:label id="lab_agl_PayorCMember_label_en-US" xlink:label="lab_agl_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payor C [Member]</link:label>
    <link:label id="lab_agl_PayorCMember_documentation_en-US" xlink:label="lab_agl_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payor C.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorCMember" xlink:href="agl-20250630.xsd#agl_PayorCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_PayorCMember" xlink:to="lab_agl_PayorCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_8271c318-1dbb-4b78-8ccb-d15215b24524_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments on sale of assets, net</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4962472d-a300-4b8a-8814-50e38084de50_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_32b12c21-26cb-4a44-a492-8e25165ec323_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_593c865d-4215-46ef-b2ea-27e5325a6763_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_b4d13fe9-0182-4bbe-ba89-d8b99a05d280_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_ACOREACHMember_7cbe8848-70f5-4ad9-8842-134313c4b105_terseLabel_en-US" xlink:label="lab_agl_ACOREACHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACO REACH</link:label>
    <link:label id="lab_agl_ACOREACHMember_label_en-US" xlink:label="lab_agl_ACOREACHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ACO REACH [Member]</link:label>
    <link:label id="lab_agl_ACOREACHMember_documentation_en-US" xlink:label="lab_agl_ACOREACHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ACO REACH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_ACOREACHMember" xlink:href="agl-20250630.xsd#agl_ACOREACHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_ACOREACHMember" xlink:to="lab_agl_ACOREACHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansAndLeasesReceivableRelatedParties_d0049e07-bb00-4d28-a002-8e18bdc54932_terseLabel_en-US" xlink:label="lab_us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans receivable</link:label>
    <link:label id="lab_us-gaap_LoansAndLeasesReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans and Leases Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:to="lab_us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_4e465d22-a834-4514-986a-dda127e26d95_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7d93e23d-8b27-4297-a80a-12b9a412cb78_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_205e7265-34a1-4c0b-9688-988eae1676d3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e7a1723a-2afa-4167-abbb-031d4ccaa329_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_34e16f71-8d19-49f7-a7b7-c4fdf3e24dde_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_e5d0de13-d870-4fe4-8e0a-908bea8ce222_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5180b44c-0f14-4d00-b4b6-effe92855959_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_144069b6-fcea-4965-913e-ce481baf697c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Shares withheld related to net share settlement (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_5d9375c5-af55-4755-b0f0-1d47e4dee2fc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of liabilities through issuance of stock</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_PayorBMember_56f9b942-efb8-40ba-874b-2dd3d6a25333_terseLabel_en-US" xlink:label="lab_agl_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payor B</link:label>
    <link:label id="lab_agl_PayorBMember_label_en-US" xlink:label="lab_agl_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payor B [Member]</link:label>
    <link:label id="lab_agl_PayorBMember_documentation_en-US" xlink:label="lab_agl_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payor B.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorBMember" xlink:href="agl-20250630.xsd#agl_PayorBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_PayorBMember" xlink:to="lab_agl_PayorBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_NumberOfEquityMethodInvestments_1a058166-545f-4e1a-9d06-58764249ea06_terseLabel_en-US" xlink:label="lab_agl_NumberOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of equity method investments for VIEs</link:label>
    <link:label id="lab_agl_NumberOfEquityMethodInvestments_label_en-US" xlink:label="lab_agl_NumberOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Equity Method Investments</link:label>
    <link:label id="lab_agl_NumberOfEquityMethodInvestments_documentation_en-US" xlink:label="lab_agl_NumberOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of equity method investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfEquityMethodInvestments" xlink:href="agl-20250630.xsd#agl_NumberOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_NumberOfEquityMethodInvestments" xlink:to="lab_agl_NumberOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_12b75102-fc8a-4242-9cdd-d257bbdb678c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_84e57195-a5a9-45a0-a53e-a79f91d49b9c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour_5ab99cb2-2d98-4986-9473-02b373314f0c_terseLabel_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour_label_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Four</link:label>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour_documentation_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour" xlink:to="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_OtherOperatingMember_af33e125-3524-4d39-9e89-041cbabd6dce_terseLabel_en-US" xlink:label="lab_agl_OtherOperatingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating revenue</link:label>
    <link:label id="lab_agl_OtherOperatingMember_label_en-US" xlink:label="lab_agl_OtherOperatingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating [Member]</link:label>
    <link:label id="lab_agl_OtherOperatingMember_documentation_en-US" xlink:label="lab_agl_OtherOperatingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other operating revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherOperatingMember" xlink:href="agl-20250630.xsd#agl_OtherOperatingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_OtherOperatingMember" xlink:to="lab_agl_OtherOperatingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_2b8ca1bd-c691-4705-8e71-454dc5aefec5_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e2919200-13c1-411a-ad94-24892aa6f8c6_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_8e44c731-a68b-4139-8585-ea56d02e44c5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less Than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_NumberOfDirectContractingEntities_554cd1cd-3191-423f-95ff-fdae2392beef_terseLabel_en-US" xlink:label="lab_agl_NumberOfDirectContractingEntities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of direct contracting entities</link:label>
    <link:label id="lab_agl_NumberOfDirectContractingEntities_label_en-US" xlink:label="lab_agl_NumberOfDirectContractingEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Direct Contracting Entities</link:label>
    <link:label id="lab_agl_NumberOfDirectContractingEntities_documentation_en-US" xlink:label="lab_agl_NumberOfDirectContractingEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Direct Contracting Entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfDirectContractingEntities" xlink:href="agl-20250630.xsd#agl_NumberOfDirectContractingEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_NumberOfDirectContractingEntities" xlink:to="lab_agl_NumberOfDirectContractingEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_2a9fa6c2-e61a-423d-b240-9e5b1f30f58e_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total outstanding letters of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_3442826d-e07c-4578-b990-01a797668ef6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_46d4786c-1576-4ea0-b657-db6c7e5dcebe_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments on sale of assets, net</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_EquityMethodLiabilities_c406bc34-825d-43aa-9d01-99041709e28a_negatedLabel_en-US" xlink:label="lab_agl_EquityMethodLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity method liabilities</link:label>
    <link:label id="lab_agl_EquityMethodLiabilities_label_en-US" xlink:label="lab_agl_EquityMethodLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Liabilities</link:label>
    <link:label id="lab_agl_EquityMethodLiabilities_documentation_en-US" xlink:label="lab_agl_EquityMethodLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_EquityMethodLiabilities" xlink:href="agl-20250630.xsd#agl_EquityMethodLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_EquityMethodLiabilities" xlink:to="lab_agl_EquityMethodLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bbf19391-be0c-4396-8234-e65844d49614_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_aede9463-2e1a-48a0-a828-6b330aae1ffc_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other noncash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_1e382dc3-8eb8-4f9c-adb7-b00a7f668ad1_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_bd05d2b7-83ae-4e94-9c88-73b51484b60f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Changes in Medical Claims and Related Payables</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1482c9e1-177f-4200-963e-d6945361a4ea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_PlatformSupportCostsMember_4885b381-1bd7-4c25-96ca-63b5d0795ab5_terseLabel_en-US" xlink:label="lab_agl_PlatformSupportCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Platform Support Costs</link:label>
    <link:label id="lab_agl_PlatformSupportCostsMember_label_en-US" xlink:label="lab_agl_PlatformSupportCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Platform Support Costs [Member]</link:label>
    <link:label id="lab_agl_PlatformSupportCostsMember_documentation_en-US" xlink:label="lab_agl_PlatformSupportCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Platform Support Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PlatformSupportCostsMember" xlink:href="agl-20250630.xsd#agl_PlatformSupportCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_PlatformSupportCostsMember" xlink:to="lab_agl_PlatformSupportCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_b330ca76-0e2e-47b7-92d0-d25121f81f38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_c4598000-a96c-47e8-9b3f-e2296044c848_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_8f8435d8-37dc-4568-8313-cbeea5b01517_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_60611154-cbb6-47ef-b4d7-8b75cb6bd66c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_NumberOfWhollyOwnedRiskBearingEntities_b331adce-3a94-496f-957d-36f7ffdd5a4b_terseLabel_en-US" xlink:label="lab_agl_NumberOfWhollyOwnedRiskBearingEntities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of wholly-owned risk-bearing entities</link:label>
    <link:label id="lab_agl_NumberOfWhollyOwnedRiskBearingEntities_label_en-US" xlink:label="lab_agl_NumberOfWhollyOwnedRiskBearingEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Wholly Owned Risk Bearing Entities</link:label>
    <link:label id="lab_agl_NumberOfWhollyOwnedRiskBearingEntities_documentation_en-US" xlink:label="lab_agl_NumberOfWhollyOwnedRiskBearingEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of wholly-owned risk-bearing entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfWhollyOwnedRiskBearingEntities" xlink:href="agl-20250630.xsd#agl_NumberOfWhollyOwnedRiskBearingEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_NumberOfWhollyOwnedRiskBearingEntities" xlink:to="lab_agl_NumberOfWhollyOwnedRiskBearingEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eac4bcac-6c80-4c9a-a8fa-ce4e6e8dcc88_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_733dbb9d-84e5-484d-81ae-ab64b8c68a86_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c31f69a-d0be-4360-b2e5-13cb29054a5a_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_SummaryOfSignificantAccountingPoliciesLineItems_e98d3e91-c4e0-406e-9121-6bf7e8580c18_terseLabel_en-US" xlink:label="lab_agl_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_agl_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_agl_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_agl_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_agl_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="agl-20250630.xsd#agl_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_agl_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_96e215c0-986c-4da8-9011-12b8c5d2bf91_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_e49a92bd-8a2a-49ec-981a-b4f7470214fc_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_d6d81079-39ee-4f8b-a199-3bd30219965a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_f8ad1b21-04e2-45b7-9bc2-f1c5afb0d37f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7a7c89bd-dd06-42c3-bf28-e37ad3646e1c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07e29f38-f1fc-4315-bb34-5200d3e1fcfe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_72ee7b0d-920a-4328-88d7-77dd654bb542_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_HealthPlanDepositsNoncurrent_a20127ba-2507-457f-b698-9c190720d6b9_terseLabel_en-US" xlink:label="lab_agl_HealthPlanDepositsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Health plan deposits</link:label>
    <link:label id="lab_agl_HealthPlanDepositsNoncurrent_label_en-US" xlink:label="lab_agl_HealthPlanDepositsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Health Plan Deposits, Noncurrent</link:label>
    <link:label id="lab_agl_HealthPlanDepositsNoncurrent_documentation_en-US" xlink:label="lab_agl_HealthPlanDepositsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Health Plan Deposits, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_HealthPlanDepositsNoncurrent" xlink:href="agl-20250630.xsd#agl_HealthPlanDepositsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_HealthPlanDepositsNoncurrent" xlink:to="lab_agl_HealthPlanDepositsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_185c7d56-6acf-45c8-9d4c-ffbc93c9058b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_511ba9e0-397b-4b0e-9530-ebf796337ba8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_480ce2e0-7118-4246-ba8a-43801e0e79e0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_88782b1d-c675-49b4-a4dd-d0a81ca830ca_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Accrual, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2a773110-afbc-4ab8-90d1-def21ab734f8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value: 2,000,000 shares authorized; 414,283 and 412,194 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_39ea2cbe-1cc6-485e-b278-8521a9e95f38_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7c41356e-cf5e-4dd0-b876-2694d2ae8bea_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnassertedClaimMember_45136aeb-d921-4d35-89c2-550223cb7d79_terseLabel_en-US" xlink:label="lab_us-gaap_UnassertedClaimMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unasserted Claim</link:label>
    <link:label id="lab_us-gaap_UnassertedClaimMember_label_en-US" xlink:label="lab_us-gaap_UnassertedClaimMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unasserted Claim [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnassertedClaimMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnassertedClaimMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnassertedClaimMember" xlink:to="lab_us-gaap_UnassertedClaimMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_18b868da-e046-4013-9cb9-6e4e29c3a4d1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_020a615e-b962-45f7-8353-e535d67efbcc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_ConsolidatedSecuritiesMatterMember_3de6d97d-f2f7-45d3-81be-f371bfbb9618_terseLabel_en-US" xlink:label="lab_agl_ConsolidatedSecuritiesMatterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Securities Matter</link:label>
    <link:label id="lab_agl_ConsolidatedSecuritiesMatterMember_label_en-US" xlink:label="lab_agl_ConsolidatedSecuritiesMatterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Securities Matter [Member]</link:label>
    <link:label id="lab_agl_ConsolidatedSecuritiesMatterMember_documentation_en-US" xlink:label="lab_agl_ConsolidatedSecuritiesMatterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Securities Matter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_ConsolidatedSecuritiesMatterMember" xlink:href="agl-20250630.xsd#agl_ConsolidatedSecuritiesMatterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_ConsolidatedSecuritiesMatterMember" xlink:to="lab_agl_ConsolidatedSecuritiesMatterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_de9d5729-46da-4323-bf67-10de0cebd5d0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7fa4df95-c00e-49b4-8ee4-a4d26683c82f_verboseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_ac2d34cf-3e43-44a3-be12-ebaa72747bf9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8b87ee81-032b-417c-81f6-e632932699e4_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_OtherLiabilitiesLineItems_aeda3b55-1969-4fac-9199-7493d31a65c9_terseLabel_en-US" xlink:label="lab_agl_OtherLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities [Line Items]</link:label>
    <link:label id="lab_agl_OtherLiabilitiesLineItems_label_en-US" xlink:label="lab_agl_OtherLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Line Items]</link:label>
    <link:label id="lab_agl_OtherLiabilitiesLineItems_documentation_en-US" xlink:label="lab_agl_OtherLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherLiabilitiesLineItems" xlink:href="agl-20250630.xsd#agl_OtherLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_OtherLiabilitiesLineItems" xlink:to="lab_agl_OtherLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_d81bcf71-dc11-4e6f-9ceb-1c5fa75452b1_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk as a Percentage of Revenues and Receivables</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0be2611c-6420-4762-9053-99818e572597_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_fdeb2ec5-e759-476b-bef6-395eaac1900b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_30e5d04b-56f6-4373-b02e-eb6bed6bd4f6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3aae6e27-feb9-45d1-86b5-50e64b3ede95_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_6d613a1e-cb9b-4fa0-a118-9ea8c48c4bb2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="lab_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_5a7bf0ff-cbc2-4188-b699-bb5fe154304b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, and Marketable Security [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_89d194fd-9fab-4e4e-bac4-0783ab5f06c3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3c58689a-dadb-4e31-936e-4ab39ca983c7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94693f46-a8d3-436f-ab8a-ea72b9097d33_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f806581b-9e2b-405a-824c-bcc652f26350_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_NumberOfGeographicalLocation_aa919f86-8a96-4593-9d99-e66e6c145c8a_terseLabel_en-US" xlink:label="lab_agl_NumberOfGeographicalLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of geographies</link:label>
    <link:label id="lab_agl_NumberOfGeographicalLocation_label_en-US" xlink:label="lab_agl_NumberOfGeographicalLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Geographical Location</link:label>
    <link:label id="lab_agl_NumberOfGeographicalLocation_documentation_en-US" xlink:label="lab_agl_NumberOfGeographicalLocation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of geographical location.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfGeographicalLocation" xlink:href="agl-20250630.xsd#agl_NumberOfGeographicalLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_NumberOfGeographicalLocation" xlink:to="lab_agl_NumberOfGeographicalLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_c226d41f-2e72-4ba7-a71b-7ed926b37abd_terseLabel_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0f9193c0-58af-4b32-9aed-7e8318f5ae67_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2bac5e1d-7db6-421d-b39a-1ff4dac3c6dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_fd7f6de1-9d8b-4c47-93f7-1cd006dbf996_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_22245e71-c50a-4a23-8c0b-8b677bd18f42_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_058992eb-3b50-4178-85e3-1bc765623946_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical Claims and Related Payables</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_8345bc53-2c45-4cc4-95c9-869eb5286536_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_54dcf86f-1051-4e04-bb59-82ae56ec43f3_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_56679e0d-0e98-4e47-b0d1-80cc39e4bb35_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_54f6b834-196e-4a30-94c4-c995fe866f7a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_75737216-e0e6-4205-a702-bf767fd6ff16_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e940c578-a08f-4909-9e02-8a69e6d438e4_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_95c5b399-ed23-4e71-96ad-8497d7384502_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a1d88ca2-1c53-4280-ae4e-a14dac009989_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_446ea7a6-301b-409c-a759-1b0d1de480a4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_8541060a-7666-478b-abc3-7fedf2009be1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c2a29499-ce57-4a6b-8c83-c17a3d5d5e96_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_88604432-acce-4f15-8ba2-ac74c2214352_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalents_f333f050-8fd7-478c-b036-bcf232b27894_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_83257d60-b1ac-4852-a788-8924d191e783_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_aca7ab60-c63e-446a-a2f8-62b8b78dc846_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_78f8bffd-2cdf-422a-9ac2-b88a6f922176_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, new claims filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_c76eeec5-4bdb-4416-b0dd-3dbfba970218_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_5ff45cac-25d8-456c-b0fd-9e1f6d906ccc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_0407f9f1-5507-4415-ac5a-33d5daf9314a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash and equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash Equivalent, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_76734643-f933-424b-a804-9340346c694d_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before gain (loss) on sales</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_214ad248-6fe3-42f9-b6e5-8be197823366_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d9e4f55b-35bc-4368-9d78-2f9f28da5090_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c5c8471f-2334-4a45-adc5-0d5b76ef0c9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_ee8a9fa8-5e8f-4ee9-bd8f-ef774dc432e9_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments on sale of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsAbstract_fcfd0b94-4112-4242-8d88-6c8688b38451_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_OtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsAbstract" xlink:to="lab_us-gaap_OtherAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_62ef4e27-6326-4e7e-a609-14d2d193f936_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_21ce9a46-bd62-42ef-9437-fa7e7b462845_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9129400f-800c-499d-8841-43d5534a95cf_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e95bd5f3-050f-44a5-99d8-c0307dc8d85e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_d5445a6f-4d55-483e-b7cc-3ed7f8f22eb1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_SecuredRevolvingFacilityMember_799fb0c9-4ac4-4675-8d81-98afc0d549ce_terseLabel_en-US" xlink:label="lab_agl_SecuredRevolvingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Revolving Facility</link:label>
    <link:label id="lab_agl_SecuredRevolvingFacilityMember_label_en-US" xlink:label="lab_agl_SecuredRevolvingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Revolving Facility [Member]</link:label>
    <link:label id="lab_agl_SecuredRevolvingFacilityMember_documentation_en-US" xlink:label="lab_agl_SecuredRevolvingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured Revolving Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_SecuredRevolvingFacilityMember" xlink:href="agl-20250630.xsd#agl_SecuredRevolvingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_SecuredRevolvingFacilityMember" xlink:to="lab_agl_SecuredRevolvingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3629fe78-ccb7-40e7-bfb6-6e1bf00d7901_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share, basic and diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_6c148ebd-56ce-4dd1-b400-2db6515b4648_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Claims paid related to:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_62696538-510e-457f-91ca-5b1060d38801_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_bf6e8a95-0ccf-4236-b8ee-e8eef2eaa0e5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) from discontinued operations attributable to common shares</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ba51e110-c349-4695-bcc8-3a201b4f17af_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_ee2927d0-d1e4-4256-9bff-94903f4fe9aa_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9a989d9a-1014-466a-adf4-f5d4b8880ecc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_75d8522a-61ad-4da0-9a7b-2f0932dadb66_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2bdfbd4b-6592-43f2-8730-524a6b446a59_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ff17f232-8d08-4961-ae11-1ce79fd3a147_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to common shares</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a8bbf3ad-9402-456b-96f2-02e69be99da2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_990019a2-be31-4e20-a45b-496d9a0b944b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Marketable Securities, Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_001f4fce-fedd-499c-8c85-935c35e101da_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_988c0fb7-ba19-407c-8919-a9c7faccfb30_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations, basic (US dollar per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_5d612a96-768b-4b9a-8c6a-a283c7c1e4c2_verboseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share from discontinued operations, basic (US dollar per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_OtherLiabilitiesTable_c77a243d-7bee-49ce-bfb0-4d32f33956a1_terseLabel_en-US" xlink:label="lab_agl_OtherLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities [Table]</link:label>
    <link:label id="lab_agl_OtherLiabilitiesTable_label_en-US" xlink:label="lab_agl_OtherLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Table]</link:label>
    <link:label id="lab_agl_OtherLiabilitiesTable_documentation_en-US" xlink:label="lab_agl_OtherLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherLiabilitiesTable" xlink:href="agl-20250630.xsd#agl_OtherLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_OtherLiabilitiesTable" xlink:to="lab_agl_OtherLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d8a8dec5-7898-4bf7-8f95-5e3c4ec06189_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_b4a76069-d730-4368-bcb8-b3122384a286_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4e55a8eb-0047-43b8-b567-6cc520a13b74_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4be109f7-f75a-4433-b9e5-d3bea7b92017_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_dc0bb51f-f193-4ed8-bfbe-d429b8690624_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate Loans</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_38146b1b-2f4b-438a-af8a-48657a6ff98c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_283d6c9e-8033-4225-99de-672487519471_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4f32f391-43ed-4e39-9a7c-eae0bd602d98_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_863d0d78-96c5-4d9d-967f-da7e7cef194a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_12f159c7-33e7-4e71-bb8e-80aaab60e0b4_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3df40c24-7a64-42ca-b898-67c35be36d73_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_807e0fda-0df3-4ba6-a4e5-9723e1c3ec6a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_LoansToPhysiciansPartners_28b3d8e8-679f-4bb8-8a84-1b083c53e990_terseLabel_en-US" xlink:label="lab_agl_LoansToPhysiciansPartners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans to physician partners</link:label>
    <link:label id="lab_agl_LoansToPhysiciansPartners_label_en-US" xlink:label="lab_agl_LoansToPhysiciansPartners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans To Physicians Partners</link:label>
    <link:label id="lab_agl_LoansToPhysiciansPartners_documentation_en-US" xlink:label="lab_agl_LoansToPhysiciansPartners" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loans To Physicians Partners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_LoansToPhysiciansPartners" xlink:href="agl-20250630.xsd#agl_LoansToPhysiciansPartners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_LoansToPhysiciansPartners" xlink:to="lab_agl_LoansToPhysiciansPartners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_73c1e085-2c60-44bf-a8a1-731f22eb4c5f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_8560dc38-f0f1-4035-befd-2197f59c85ff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1f7b02e9-a5e7-4478-af59-863cbb50305b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_41ae7168-b846-42ee-ab50-adb0c030fc0c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_c360572d-f804-4baa-bc35-92eae60ca6ef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less Than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_46e17d8c-6a6c-4805-8899-5376acdf96c2_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9cd82b74-6382-4fc8-9994-15a08703c215_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_882923b9-cfbd-44a7-babc-46c4f8b4f491_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36d14bb1-0121-47d6-b0e8-e020459cbb59_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_MedicalServicesMember_a9e665ae-ee69-4b02-85cb-86dce0a5189f_terseLabel_en-US" xlink:label="lab_agl_MedicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical services revenue</link:label>
    <link:label id="lab_agl_MedicalServicesMember_label_en-US" xlink:label="lab_agl_MedicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Services [Member]</link:label>
    <link:label id="lab_agl_MedicalServicesMember_documentation_en-US" xlink:label="lab_agl_MedicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical services revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_MedicalServicesMember" xlink:href="agl-20250630.xsd#agl_MedicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_MedicalServicesMember" xlink:to="lab_agl_MedicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_61179426-f6d0-41dd-93f4-07cb68a4b9e9_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_cf479216-ddc2-4627-9cf4-486fa2da3355_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_56369f09-7ce2-413c-bab6-4b8282735ebf_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_e04d8fc5-3b09-4972-889e-6da10678d8d1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f578e3c5-39cb-485a-92b1-f67bbf277e5c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_65baff25-7f85-475c-a382-718aae2ffd9f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d51435d0-dbba-42c6-94b3-84217da68792_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8f7760f5-14e6-41a6-b1ec-14a947e38aa2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c5f26af3-a3f0-46ba-ae75-437b4cbbd644_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical claims and related payables</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9eca5e2a-f434-4a0d-9705-4fb9ceab7a7a_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Medical claims and related payables</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_PhysicianCompensationExpense_fd0dc8e6-5307-4954-902f-a7baca74c1d7_terseLabel_en-US" xlink:label="lab_agl_PhysicianCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Physician compensation expense</link:label>
    <link:label id="lab_agl_PhysicianCompensationExpense_label_en-US" xlink:label="lab_agl_PhysicianCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Physician Compensation Expense</link:label>
    <link:label id="lab_agl_PhysicianCompensationExpense_documentation_en-US" xlink:label="lab_agl_PhysicianCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Physician compensation expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PhysicianCompensationExpense" xlink:href="agl-20250630.xsd#agl_PhysicianCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_PhysicianCompensationExpense" xlink:to="lab_agl_PhysicianCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_688cb24b-2c93-4d62-b1ed-8c6a70821ea6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree_8e5cc418-a2e5-4fe0-9262-69654ea6b5e5_terseLabel_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree_label_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Three</link:label>
    <link:label id="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree_documentation_en-US" xlink:label="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree" xlink:to="lab_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable_6be1bed5-32d7-4536-8b3b-157b35454ba7_periodStartLabel_en-US" xlink:label="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Medical claims and related payables, beginning of the year</link:label>
    <link:label id="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable_a9c0c4cc-432a-4e9b-a226-325a3711e853_periodEndLabel_en-US" xlink:label="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Medical claims and related payables, end of the period</link:label>
    <link:label id="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable_label_en-US" xlink:label="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense, Including Amounts Recoverable</link:label>
    <link:label id="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable_documentation_en-US" xlink:label="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense, Including Amounts Recoverable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable" xlink:href="agl-20250630.xsd#agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable" xlink:to="lab_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_DistributionsOfEarningsFromEquityMethodInvestments_4c4e1a1b-3158-4e56-954c-22f12d1f63d0_negatedTerseLabel_en-US" xlink:label="lab_agl_DistributionsOfEarningsFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Distributions of earnings from equity method investments</link:label>
    <link:label id="lab_agl_DistributionsOfEarningsFromEquityMethodInvestments_label_en-US" xlink:label="lab_agl_DistributionsOfEarningsFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributions Of Earnings From Equity Method Investments</link:label>
    <link:label id="lab_agl_DistributionsOfEarningsFromEquityMethodInvestments_documentation_en-US" xlink:label="lab_agl_DistributionsOfEarningsFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributions Of Earnings From Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DistributionsOfEarningsFromEquityMethodInvestments" xlink:href="agl-20250630.xsd#agl_DistributionsOfEarningsFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_DistributionsOfEarningsFromEquityMethodInvestments" xlink:to="lab_agl_DistributionsOfEarningsFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_d5c354ca-5a4c-4056-9a39-0abad4da65d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1cac5cbd-4711-4262-b8e8-f6431491d1f4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8cf82de6-0e93-4394-865f-1d797ceb80bf_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_e71aa14c-41ef-41a5-a33d-2a5761a9fe01_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_e1ed9941-74a0-476d-8d33-5aba64c6d547_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_e930745e-9770-4e57-af77-1220b366e40b_negatedLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_c605e4a7-e135-41a9-bb0a-a7244828084e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ed8c5d67-1156-4908-b417-62cd10b81787_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Computation of Basic and Diluted EPS</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_d95da1d9-33fe-425f-9604-4a8c21454c17_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_700a1aad-e354-4190-b36d-d22d4a882eb2_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ba9c7946-bbf3-46a9-8f12-c3a9b07db77c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_f14f322b-93af-44f6-bd33-176919554de6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Consolidated Asset and Liabilities Include VIE Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7c6bc1c3-5184-4973-9045-2448307dad8f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_2ef3657b-facd-4255-a4ef-a1c10293b837_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9b2a7e7c-2608-428f-9005-6e5756fe9688_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_29ec83e4-d0ca-4946-80c1-ab7dbd5bdf40_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Amortizable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agl_NumberOfPhysicianGroupPartners_a5c64112-80f0-4e12-a30b-790e02417615_terseLabel_en-US" xlink:label="lab_agl_NumberOfPhysicianGroupPartners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of physician group partners</link:label>
    <link:label id="lab_agl_NumberOfPhysicianGroupPartners_label_en-US" xlink:label="lab_agl_NumberOfPhysicianGroupPartners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Physician Group Partners</link:label>
    <link:label id="lab_agl_NumberOfPhysicianGroupPartners_documentation_en-US" xlink:label="lab_agl_NumberOfPhysicianGroupPartners" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of physician group partners.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfPhysicianGroupPartners" xlink:href="agl-20250630.xsd#agl_NumberOfPhysicianGroupPartners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agl_NumberOfPhysicianGroupPartners" xlink:to="lab_agl_NumberOfPhysicianGroupPartners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_03a35323-9bd6-4c72-80ce-095bb63569bd_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_eed9e0ce-cd6b-44f8-8aaa-c8e6c5443c27_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_21614f76-8f99-430c-aed5-91fc75bf1b7d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f714cf0e-d00f-429b-b731-d93f7e8b6376_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_508dfb22-e237-4669-bb22-94748de22adc_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_e68e7598-5a2d-4ec4-a105-82d00681bafb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowances for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_143c7dc8-0bd4-488d-8f15-14f89ac35f0c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_c5d1355b-da79-4e94-8890-555e6d598479_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_fd8939d5-6188-4997-bcda-7906f50a50fc_verboseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current and total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_74b4892a-9b5a-44bf-96ab-d38880e5b7a8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1d7c2bf5-9bad-4b8a-b8bd-6918c6520847_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_32860d25-7197-42ef-aeef-9b7ea045da40_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_0caf8dab-522a-4004-891f-f8611d8b5ba6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_f9173fbb-0fa7-4bd7-a74b-1bd933b36808_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of marketable securities and other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6de3dcf3-6c18-4214-a176-de544d8c57d7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0125e8e7-304a-432f-b5cf-da909f87a361_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_820a3e1d-7802-4135-9c2f-36b5e4561de9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_723ec620-86df-4a01-93cc-329020d8137a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_74e744b9-88b2-42b4-9a27-e38dc6c73169_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_2b781423-37b1-49e0-9907-efb82c182219_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8923f038-433f-4a42-a2f9-339d7b2ae26b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAbstract_6fb6f0ac-3304-4cbd-b014-c315a5d973ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ed053de7-d369-4e70-88d0-fdb3eb1a8b01_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_80c9e6e5-bc58-48d6-9725-0a588f365a2b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_d64a35e2-35ff-41ae-a4b0-4ad88aef670b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_d7454f04-1fb6-4158-89ce-e1f4f8de71b6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_29bfe110-61d4-495d-8d0b-21d63813a64c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>agl-20250630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:13b764c6-a2b0-4a9c-9408-254f78400ab0,g:a48cf18d-4f3e-446d-9d3f-633818f822f0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://agilonhealth.com/role/CoverPage" xlink:type="simple" xlink:href="agl-20250630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ec4276d1-ccfd-4813-b2e3-0511d412d790" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_DocumentType_ec4276d1-ccfd-4813-b2e3-0511d412d790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_f0cc4ced-d7f3-429b-9a11-c0331cb59fcf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_DocumentQuarterlyReport_f0cc4ced-d7f3-429b-9a11-c0331cb59fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_37eabc05-8c29-41bd-b3c5-77043f06418a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_DocumentPeriodEndDate_37eabc05-8c29-41bd-b3c5-77043f06418a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_133316bd-c93a-4a80-9301-5194c14c809b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_DocumentTransitionReport_133316bd-c93a-4a80-9301-5194c14c809b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_50e7cf13-7ddc-4883-aa98-8e602432c66d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityFileNumber_50e7cf13-7ddc-4883-aa98-8e602432c66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d3796f48-bae4-4ffa-ab3c-a74a32a77c22" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityRegistrantName_d3796f48-bae4-4ffa-ab3c-a74a32a77c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3936a460-02a9-4ef8-9d30-29e7a2b2085f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3936a460-02a9-4ef8-9d30-29e7a2b2085f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_07dd3cde-367f-4f11-b0ec-6d572b86e38b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityTaxIdentificationNumber_07dd3cde-367f-4f11-b0ec-6d572b86e38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a3bcff72-ccc9-42a5-813f-08ab4fb2c01d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityAddressAddressLine1_a3bcff72-ccc9-42a5-813f-08ab4fb2c01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_8b7d3655-b473-4951-8dfe-c68462ae021f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityAddressAddressLine2_8b7d3655-b473-4951-8dfe-c68462ae021f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cdbd2b84-ed94-41a9-b955-293e66f61bf4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityAddressCityOrTown_cdbd2b84-ed94-41a9-b955-293e66f61bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_29be5f94-fe10-4fe3-b559-a689e5cabf16" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityAddressStateOrProvince_29be5f94-fe10-4fe3-b559-a689e5cabf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_43d2d457-577b-4906-842a-df84e97ceee5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityAddressPostalZipCode_43d2d457-577b-4906-842a-df84e97ceee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6e9bbc0a-0393-4984-85a6-aa6cc803ef51" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_CityAreaCode_6e9bbc0a-0393-4984-85a6-aa6cc803ef51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_63d85234-bf10-479b-bfc1-baa067490e59" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_LocalPhoneNumber_63d85234-bf10-479b-bfc1-baa067490e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c52cc688-15c7-4d6e-8d5e-a97d545e2548" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_Security12bTitle_c52cc688-15c7-4d6e-8d5e-a97d545e2548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_125cc0d6-8cfe-4c64-bef1-eb5744cf02d3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_TradingSymbol_125cc0d6-8cfe-4c64-bef1-eb5744cf02d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1c51ebc1-ebb5-4b77-9d39-3034f6601a0e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_SecurityExchangeName_1c51ebc1-ebb5-4b77-9d39-3034f6601a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1125f51e-5a96-452e-9fe5-9f9c43379c4a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityCurrentReportingStatus_1125f51e-5a96-452e-9fe5-9f9c43379c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_170a6150-4052-4fe2-ab11-d5b51b9d5c4b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityInteractiveDataCurrent_170a6150-4052-4fe2-ab11-d5b51b9d5c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_89fc41cd-4039-40c5-920a-0f5c75fdd11e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityFilerCategory_89fc41cd-4039-40c5-920a-0f5c75fdd11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_aebb87f7-5d51-40cd-a5ec-da885e357927" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntitySmallBusiness_aebb87f7-5d51-40cd-a5ec-da885e357927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3db82bdb-1175-4e8f-ae3c-5fa384df4235" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityEmergingGrowthCompany_3db82bdb-1175-4e8f-ae3c-5fa384df4235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ab066977-24e7-4496-b7b8-5af261d7580e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityShellCompany_ab066977-24e7-4496-b7b8-5af261d7580e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_69e05944-1e70-438e-a7d0-46c8a1d5dc95" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_69e05944-1e70-438e-a7d0-46c8a1d5dc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8cc9a5d6-5c39-4d4e-898f-5aebaae13bd5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_EntityCentralIndexKey_8cc9a5d6-5c39-4d4e-898f-5aebaae13bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9b9f1095-6524-4e65-9331-3ab9a5c82af6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_CurrentFiscalYearEndDate_9b9f1095-6524-4e65-9331-3ab9a5c82af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b72b8a10-59ba-4ad5-9f98-4aabbd9bc080" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_DocumentFiscalYearFocus_b72b8a10-59ba-4ad5-9f98-4aabbd9bc080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a829d24f-a805-4afc-abed-1b6c6094fa68" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a829d24f-a805-4afc-abed-1b6c6094fa68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_44f0d2e8-8140-41e9-9ed1-3cd3a7c47d33" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c8952e8-8752-41eb-bb6f-506f8351c1ea" xlink:to="loc_dei_AmendmentFlag_44f0d2e8-8140-41e9-9ed1-3cd3a7c47d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="agl-20250630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a760ea93-9525-4c37-94b1-c24baae72e73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_327f5d98-f615-4eb3-93e6-64735c112e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a760ea93-9525-4c37-94b1-c24baae72e73" xlink:to="loc_us-gaap_AssetsAbstract_327f5d98-f615-4eb3-93e6-64735c112e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f6f88d0a-abaf-4985-b018-75f2fc9e8913" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_327f5d98-f615-4eb3-93e6-64735c112e4e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f6f88d0a-abaf-4985-b018-75f2fc9e8913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6cb38aa1-bc60-481c-810f-00c1628d65de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6f88d0a-abaf-4985-b018-75f2fc9e8913" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6cb38aa1-bc60-481c-810f-00c1628d65de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_353446e5-36e4-4a7f-924d-6b8d05dd1310" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6f88d0a-abaf-4985-b018-75f2fc9e8913" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_353446e5-36e4-4a7f-924d-6b8d05dd1310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_7c2d886b-bade-476e-9bd9-5493c161cc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6f88d0a-abaf-4985-b018-75f2fc9e8913" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_7c2d886b-bade-476e-9bd9-5493c161cc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_f6f6e18c-344f-4456-b6a7-4e3b15bd0ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6f88d0a-abaf-4985-b018-75f2fc9e8913" xlink:to="loc_us-gaap_ReceivablesNetCurrent_f6f6e18c-344f-4456-b6a7-4e3b15bd0ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_86dc2729-8965-44e0-b626-1ecc0046890f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6f88d0a-abaf-4985-b018-75f2fc9e8913" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_86dc2729-8965-44e0-b626-1ecc0046890f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_858b95a3-94fc-44af-b940-333a66b99dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6f88d0a-abaf-4985-b018-75f2fc9e8913" xlink:to="loc_us-gaap_AssetsCurrent_858b95a3-94fc-44af-b940-333a66b99dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9763da82-b52d-4b66-9b99-7508462d350b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_327f5d98-f615-4eb3-93e6-64735c112e4e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9763da82-b52d-4b66-9b99-7508462d350b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_277602f5-3665-4a7e-9bb0-339b0c61b002" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_327f5d98-f615-4eb3-93e6-64735c112e4e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_277602f5-3665-4a7e-9bb0-339b0c61b002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_56ae052b-2073-44d7-a55f-ebce0fc92ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_327f5d98-f615-4eb3-93e6-64735c112e4e" xlink:to="loc_us-gaap_Goodwill_56ae052b-2073-44d7-a55f-ebce0fc92ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c5f0ad8a-a147-4671-930a-525ac02403cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_327f5d98-f615-4eb3-93e6-64735c112e4e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c5f0ad8a-a147-4671-930a-525ac02403cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e146bd19-0a1f-4c9c-a639-f555a6be3f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_327f5d98-f615-4eb3-93e6-64735c112e4e" xlink:to="loc_us-gaap_Assets_e146bd19-0a1f-4c9c-a639-f555a6be3f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d26870ee-1dc6-4596-a45e-e7fc91116bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a760ea93-9525-4c37-94b1-c24baae72e73" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d26870ee-1dc6-4596-a45e-e7fc91116bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f346f930-ed85-41b3-bf89-2cdd974b2f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d26870ee-1dc6-4596-a45e-e7fc91116bc7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f346f930-ed85-41b3-bf89-2cdd974b2f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f563ab18-1312-4c68-9292-a54245f683e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f346f930-ed85-41b3-bf89-2cdd974b2f4b" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f563ab18-1312-4c68-9292-a54245f683e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_034e0752-6471-4e49-b658-ea55fd6cfa80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f346f930-ed85-41b3-bf89-2cdd974b2f4b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_034e0752-6471-4e49-b658-ea55fd6cfa80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ca352703-e91b-4430-98d2-3d5ecfb96a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f346f930-ed85-41b3-bf89-2cdd974b2f4b" xlink:to="loc_us-gaap_LongTermDebtCurrent_ca352703-e91b-4430-98d2-3d5ecfb96a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_72183c7d-481c-425c-a193-5f5b44de0cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f346f930-ed85-41b3-bf89-2cdd974b2f4b" xlink:to="loc_us-gaap_LiabilitiesCurrent_72183c7d-481c-425c-a193-5f5b44de0cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5c196294-b23f-4bed-bb28-f622c1c9abe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d26870ee-1dc6-4596-a45e-e7fc91116bc7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5c196294-b23f-4bed-bb28-f622c1c9abe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0391bb8b-3632-40bf-9a09-7c46e4eb8c11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d26870ee-1dc6-4596-a45e-e7fc91116bc7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0391bb8b-3632-40bf-9a09-7c46e4eb8c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f779be73-4fe9-4644-8348-929b314a4735" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d26870ee-1dc6-4596-a45e-e7fc91116bc7" xlink:to="loc_us-gaap_Liabilities_f779be73-4fe9-4644-8348-929b314a4735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c0d6498f-99e4-4ab6-8abe-4ba98d40430b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d26870ee-1dc6-4596-a45e-e7fc91116bc7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c0d6498f-99e4-4ab6-8abe-4ba98d40430b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_733cb06c-7d0c-4298-8880-4105e044d4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d26870ee-1dc6-4596-a45e-e7fc91116bc7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_733cb06c-7d0c-4298-8880-4105e044d4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f2060f09-771f-43ed-8b30-25ac1382394b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_733cb06c-7d0c-4298-8880-4105e044d4ec" xlink:to="loc_us-gaap_CommonStockValue_f2060f09-771f-43ed-8b30-25ac1382394b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_12999dc3-ae5e-4f2e-8530-30c732984031" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_733cb06c-7d0c-4298-8880-4105e044d4ec" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_12999dc3-ae5e-4f2e-8530-30c732984031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d9d70039-ffd6-41f1-b8bd-25c65e7dc0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_733cb06c-7d0c-4298-8880-4105e044d4ec" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d9d70039-ffd6-41f1-b8bd-25c65e7dc0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9d6156af-396f-4947-a1ca-53c6f1190a35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_733cb06c-7d0c-4298-8880-4105e044d4ec" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9d6156af-396f-4947-a1ca-53c6f1190a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_06d3a52b-b181-4aed-ac8f-f165e7e9397c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_733cb06c-7d0c-4298-8880-4105e044d4ec" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_06d3a52b-b181-4aed-ac8f-f165e7e9397c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_75960ce9-5203-4417-a992-5a001fc2b8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d26870ee-1dc6-4596-a45e-e7fc91116bc7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_75960ce9-5203-4417-a992-5a001fc2b8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="agl-20250630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4832491f-d6d9-496e-9a62-9bc53312176e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4d9f332c-3ed5-4691-a4ec-4457f3e8a040" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4832491f-d6d9-496e-9a62-9bc53312176e" xlink:to="loc_us-gaap_StatementTable_4d9f332c-3ed5-4691-a4ec-4457f3e8a040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_13533f6e-126c-4f70-ace4-461c1bdd79f2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4d9f332c-3ed5-4691-a4ec-4457f3e8a040" xlink:to="loc_srt_ConsolidatedEntitiesAxis_13533f6e-126c-4f70-ace4-461c1bdd79f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c8dd414c-7642-426d-a73d-570e0c59a873" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_13533f6e-126c-4f70-ace4-461c1bdd79f2" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c8dd414c-7642-426d-a73d-570e0c59a873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_f1846f8c-765a-4e12-9580-d8d7102a2c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c8dd414c-7642-426d-a73d-570e0c59a873" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_f1846f8c-765a-4e12-9580-d8d7102a2c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4d9f332c-3ed5-4691-a4ec-4457f3e8a040" xlink:to="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f42975d6-15fb-4346-98bc-a859fccca5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f42975d6-15fb-4346-98bc-a859fccca5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a10bc1ac-7aca-4349-85c6-18f16e69955c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a10bc1ac-7aca-4349-85c6-18f16e69955c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_45fa961c-2645-43be-a412-3ac5026c3881" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:to="loc_us-gaap_CommonStockSharesIssued_45fa961c-2645-43be-a412-3ac5026c3881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9859dcc1-76c0-446a-97eb-e0b919b97cac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9859dcc1-76c0-446a-97eb-e0b919b97cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b587f29e-8d12-441a-aef9-eeea9c91ee43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:to="loc_us-gaap_Assets_b587f29e-8d12-441a-aef9-eeea9c91ee43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5fba432e-db82-408a-a894-ac3c76843454" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81bad9f8-6d12-4158-b3b4-3e12d008fe26" xlink:to="loc_us-gaap_Liabilities_5fba432e-db82-408a-a894-ac3c76843454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="agl-20250630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_347f3fc4-4c70-4267-aab5-39db13f4ad92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f55344e4-2f82-4cf0-9ab0-ca2282fa6132" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_347f3fc4-4c70-4267-aab5-39db13f4ad92" xlink:to="loc_us-gaap_StatementTable_f55344e4-2f82-4cf0-9ab0-ca2282fa6132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_01ad3894-5411-47d2-94bf-aa74018009e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f55344e4-2f82-4cf0-9ab0-ca2282fa6132" xlink:to="loc_srt_ProductOrServiceAxis_01ad3894-5411-47d2-94bf-aa74018009e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a76400c1-a401-4db9-8adb-a47b042dfc2c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_01ad3894-5411-47d2-94bf-aa74018009e3" xlink:to="loc_srt_ProductsAndServicesDomain_a76400c1-a401-4db9-8adb-a47b042dfc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_MedicalServicesMember_585e57d7-bb9f-49dd-a53b-2763af887e7a" xlink:href="agl-20250630.xsd#agl_MedicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a76400c1-a401-4db9-8adb-a47b042dfc2c" xlink:to="loc_agl_MedicalServicesMember_585e57d7-bb9f-49dd-a53b-2763af887e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherOperatingMember_9df1b09a-178d-42d3-bb7c-e8d1bf0825d1" xlink:href="agl-20250630.xsd#agl_OtherOperatingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a76400c1-a401-4db9-8adb-a47b042dfc2c" xlink:to="loc_agl_OtherOperatingMember_9df1b09a-178d-42d3-bb7c-e8d1bf0825d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f55344e4-2f82-4cf0-9ab0-ca2282fa6132" xlink:to="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_146c2098-9be2-4d49-bd73-1ece8b86eab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_RevenuesAbstract_146c2098-9be2-4d49-bd73-1ece8b86eab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d7e3f364-2dd2-410b-be46-16c3da281633" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_146c2098-9be2-4d49-bd73-1ece8b86eab7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d7e3f364-2dd2-410b-be46-16c3da281633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_aa8c37e3-7b95-495b-96fb-9af5e6c38f73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_aa8c37e3-7b95-495b-96fb-9af5e6c38f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_9dc0bc78-3073-4498-bda8-5596b293cf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_aa8c37e3-7b95-495b-96fb-9af5e6c38f73" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_9dc0bc78-3073-4498-bda8-5596b293cf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5f176812-d6a3-42f0-9c57-045ca84342b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_aa8c37e3-7b95-495b-96fb-9af5e6c38f73" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5f176812-d6a3-42f0-9c57-045ca84342b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_5d132a4e-b5f1-41c1-9606-78fe5d80e2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_aa8c37e3-7b95-495b-96fb-9af5e6c38f73" xlink:to="loc_us-gaap_DepreciationAndAmortization_5d132a4e-b5f1-41c1-9606-78fe5d80e2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cfc5ed24-b75d-4800-98a1-d23e773da9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_aa8c37e3-7b95-495b-96fb-9af5e6c38f73" xlink:to="loc_us-gaap_CostsAndExpenses_cfc5ed24-b75d-4800-98a1-d23e773da9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e499bef0-1bd4-4131-af48-279c6fbb4c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_OperatingIncomeLoss_e499bef0-1bd4-4131-af48-279c6fbb4c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_646025f7-afd7-4eb8-b769-e0b1adfb606f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_646025f7-afd7-4eb8-b769-e0b1adfb606f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dbc526dc-7da0-43bf-974e-150798b818a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_646025f7-afd7-4eb8-b769-e0b1adfb606f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dbc526dc-7da0-43bf-974e-150798b818a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_81faa544-df7b-4396-a85a-5ef56f64c3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_646025f7-afd7-4eb8-b769-e0b1adfb606f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_81faa544-df7b-4396-a85a-5ef56f64c3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_b1ae7418-b09a-4dc0-9b96-b5f9e4df82c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_646025f7-afd7-4eb8-b769-e0b1adfb606f" xlink:to="loc_us-gaap_InterestExpenseNonoperating_b1ae7418-b09a-4dc0-9b96-b5f9e4df82c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82071b28-dbbe-40dc-a872-3f67501d2043" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_82071b28-dbbe-40dc-a872-3f67501d2043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_08336336-4dca-4ba5-bc29-b5b96fed5e11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_08336336-4dca-4ba5-bc29-b5b96fed5e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_28f96250-8b56-4c94-b29d-fa1e41f0b1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_28f96250-8b56-4c94-b29d-fa1e41f0b1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_492183ac-b28a-47a7-adcb-6e33309dbb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_492183ac-b28a-47a7-adcb-6e33309dbb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_8ebf44d1-6b99-4f19-884a-2a399f89923e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_492183ac-b28a-47a7-adcb-6e33309dbb5f" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_8ebf44d1-6b99-4f19-884a-2a399f89923e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_e0ff0648-985a-465c-a829-1f925bd8adb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_492183ac-b28a-47a7-adcb-6e33309dbb5f" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_e0ff0648-985a-465c-a829-1f925bd8adb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_07895ca0-62d1-4216-9159-69492a426021" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_492183ac-b28a-47a7-adcb-6e33309dbb5f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_07895ca0-62d1-4216-9159-69492a426021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_186c50c2-f379-4b2a-9dd6-f2cb7d371374" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_ProfitLoss_186c50c2-f379-4b2a-9dd6-f2cb7d371374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9791fa1f-4f72-4631-869a-032989a68d81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9791fa1f-4f72-4631-869a-032989a68d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_85209b1d-7189-4f1b-971e-cab4b28ae684" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_NetIncomeLoss_85209b1d-7189-4f1b-971e-cab4b28ae684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3b9a50e-c5f3-4a87-8a88-522b8579488c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b08984b9-df7e-4831-bc8c-bf2b65a2f545" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b08984b9-df7e-4831-bc8c-bf2b65a2f545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_34854b8c-6669-4366-8a2d-ad9996ca3d33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_34854b8c-6669-4366-8a2d-ad9996ca3d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_9eef6121-6e11-4a10-9655-fcd3f04419e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_9eef6121-6e11-4a10-9655-fcd3f04419e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_e530e197-26dd-47c2-a3a6-f376b01af905" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_e530e197-26dd-47c2-a3a6-f376b01af905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1dc3d74f-c058-4f44-b596-92c9a2ab0137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1dc3d74f-c058-4f44-b596-92c9a2ab0137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e0136294-8238-454a-bd92-192a2a7d2446" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_047d5360-092f-4c49-9a36-a2f89be16992" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e0136294-8238-454a-bd92-192a2a7d2446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="agl-20250630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_98f2ff15-2090-426f-b65b-183993a68f62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f02b6276-361a-481d-abe7-b959f6e7cd51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_98f2ff15-2090-426f-b65b-183993a68f62" xlink:to="loc_us-gaap_ProfitLoss_f02b6276-361a-481d-abe7-b959f6e7cd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9de6b5ae-f13d-4d7f-9d53-22f4a827cd96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_98f2ff15-2090-426f-b65b-183993a68f62" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9de6b5ae-f13d-4d7f-9d53-22f4a827cd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a0c81da4-1929-4494-886a-634f7f5448ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9de6b5ae-f13d-4d7f-9d53-22f4a827cd96" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a0c81da4-1929-4494-886a-634f7f5448ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7b2bdba8-d53d-4a21-b3dd-d00a1dc5e285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9de6b5ae-f13d-4d7f-9d53-22f4a827cd96" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7b2bdba8-d53d-4a21-b3dd-d00a1dc5e285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_56c30669-abeb-49ad-acac-066cb5bad567" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_98f2ff15-2090-426f-b65b-183993a68f62" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_56c30669-abeb-49ad-acac-066cb5bad567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_569c4756-044b-4d4c-9d72-d8b856ba9eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_98f2ff15-2090-426f-b65b-183993a68f62" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_569c4756-044b-4d4c-9d72-d8b856ba9eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cd3d7624-87d2-4602-afa1-53087c422cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_98f2ff15-2090-426f-b65b-183993a68f62" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_cd3d7624-87d2-4602-afa1-53087c422cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="agl-20250630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9a996058-b5bf-42fd-b414-57e7debf7d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5c74e4d1-9298-459b-ade3-3676f9608cad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9a996058-b5bf-42fd-b414-57e7debf7d9c" xlink:to="loc_us-gaap_StatementTable_5c74e4d1-9298-459b-ade3-3676f9608cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ec554ea4-8335-4cfa-a105-83bc4312ff31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5c74e4d1-9298-459b-ade3-3676f9608cad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ec554ea4-8335-4cfa-a105-83bc4312ff31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ec554ea4-8335-4cfa-a105-83bc4312ff31" xlink:to="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f4f6a8f3-1ce0-4a3c-ba1e-f52a12e881a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:to="loc_us-gaap_CommonStockMember_f4f6a8f3-1ce0-4a3c-ba1e-f52a12e881a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_caf13f0f-645c-4b47-a4f4-b4829078408a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_caf13f0f-645c-4b47-a4f4-b4829078408a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bc373ce7-e899-4601-a543-4c5919666d25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:to="loc_us-gaap_RetainedEarningsMember_bc373ce7-e899-4601-a543-4c5919666d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96316cd7-6b05-4068-9ec6-e2c118678382" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96316cd7-6b05-4068-9ec6-e2c118678382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d5ec224f-cb07-4add-8bdc-58c0b8d943ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fe032fb-b522-4a43-a6aa-490e0d0f1b9f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d5ec224f-cb07-4add-8bdc-58c0b8d943ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_af7ef48d-c696-4711-a3ec-4706eaf0d30b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5c74e4d1-9298-459b-ade3-3676f9608cad" xlink:to="loc_us-gaap_StatementLineItems_af7ef48d-c696-4711-a3ec-4706eaf0d30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_af7ef48d-c696-4711-a3ec-4706eaf0d30b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f63aac52-6260-4e10-96b9-571f8b0b1500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f63aac52-6260-4e10-96b9-571f8b0b1500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87771689-39ee-4a9c-9268-5f5dbfcaaa59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87771689-39ee-4a9c-9268-5f5dbfcaaa59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_877a597d-0ab6-4719-b292-bc72739f719c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_ProfitLoss_877a597d-0ab6-4719-b292-bc72739f719c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f014447-0e2c-4840-a550-ea78b5b637a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f014447-0e2c-4840-a550-ea78b5b637a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_78f30cf0-0862-4d97-8674-3fba6b2e8df0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_78f30cf0-0862-4d97-8674-3fba6b2e8df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cb3690fd-4476-47ce-a0ec-a5c5e39bb8be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cb3690fd-4476-47ce-a0ec-a5c5e39bb8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_918305cd-e233-40f6-bc55-cd233bf0bfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_918305cd-e233-40f6-bc55-cd233bf0bfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2f5ba5c1-24ff-4a5c-b54e-2d60589e702a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2f5ba5c1-24ff-4a5c-b54e-2d60589e702a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d302280c-6c5e-4137-96f6-f1aa24731019" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d302280c-6c5e-4137-96f6-f1aa24731019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_64152a1e-c8f4-4c67-8f97-e9daaadca7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_64152a1e-c8f4-4c67-8f97-e9daaadca7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_32f6ebd2-0176-447a-bcb0-83fbeeb85305" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_32f6ebd2-0176-447a-bcb0-83fbeeb85305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1bd3a70f-9681-49ae-8fa0-46e247f82043" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1bd3a70f-9681-49ae-8fa0-46e247f82043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_71379a8e-a9fb-448b-b462-d7ff6667cd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_71379a8e-a9fb-448b-b462-d7ff6667cd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_377041ad-bdb6-4aec-9e49-30dbb4c2f93e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_377041ad-bdb6-4aec-9e49-30dbb4c2f93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d38dd19f-37c5-4963-943a-83cfa6efef39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3fc4011-16a2-439b-8183-1142a9be9ca2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d38dd19f-37c5-4963-943a-83cfa6efef39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="agl-20250630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4daf1578-1ab7-4986-a0b9-17fcfc612641" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64064e75-685f-4447-baf2-813cbd8be089" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4daf1578-1ab7-4986-a0b9-17fcfc612641" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64064e75-685f-4447-baf2-813cbd8be089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1ce7598a-cdb4-4a12-8385-3d0703c7ba62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64064e75-685f-4447-baf2-813cbd8be089" xlink:to="loc_us-gaap_ProfitLoss_1ce7598a-cdb4-4a12-8385-3d0703c7ba62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c9f330f-9963-4953-8d5a-23df6bec4331" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64064e75-685f-4447-baf2-813cbd8be089" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c9f330f-9963-4953-8d5a-23df6bec4331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_201e1e71-5f2f-41ca-8be1-fe39e3480087" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c9f330f-9963-4953-8d5a-23df6bec4331" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_201e1e71-5f2f-41ca-8be1-fe39e3480087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bc1a2637-a15f-4a72-961c-b753a9e77a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c9f330f-9963-4953-8d5a-23df6bec4331" xlink:to="loc_us-gaap_ShareBasedCompensation_bc1a2637-a15f-4a72-961c-b753a9e77a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_13486f4d-48e8-4400-a192-40b9887017b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c9f330f-9963-4953-8d5a-23df6bec4331" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_13486f4d-48e8-4400-a192-40b9887017b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DistributionsOfEarningsFromEquityMethodInvestments_883acc0f-c2c5-4b44-8034-05ee9c723cc6" xlink:href="agl-20250630.xsd#agl_DistributionsOfEarningsFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c9f330f-9963-4953-8d5a-23df6bec4331" xlink:to="loc_agl_DistributionsOfEarningsFromEquityMethodInvestments_883acc0f-c2c5-4b44-8034-05ee9c723cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_809f018d-0d62-46c9-a7a8-ade50851e8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c9f330f-9963-4953-8d5a-23df6bec4331" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_809f018d-0d62-46c9-a7a8-ade50851e8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_15033a63-9640-4198-86ea-69045fea8ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c9f330f-9963-4953-8d5a-23df6bec4331" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_15033a63-9640-4198-86ea-69045fea8ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_5930a2fd-0db4-4ccf-ae6d-55b802ee2ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64064e75-685f-4447-baf2-813cbd8be089" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_5930a2fd-0db4-4ccf-ae6d-55b802ee2ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5afce856-28d9-4082-8d74-002df4116867" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_64064e75-685f-4447-baf2-813cbd8be089" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5afce856-28d9-4082-8d74-002df4116867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a46312bb-7265-49c9-9cbc-7fa7b374a2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4daf1578-1ab7-4986-a0b9-17fcfc612641" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a46312bb-7265-49c9-9cbc-7fa7b374a2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_561bf77a-cea8-48f3-b889-a217fd17c215" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a46312bb-7265-49c9-9cbc-7fa7b374a2d3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_561bf77a-cea8-48f3-b889-a217fd17c215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5725ff90-7f4b-4198-b9c8-6473f6707388" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a46312bb-7265-49c9-9cbc-7fa7b374a2d3" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5725ff90-7f4b-4198-b9c8-6473f6707388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PaymentsToAcquireLoansReceivableAndOther_4de0a1c3-de58-49a3-a6b9-7599145b7d65" xlink:href="agl-20250630.xsd#agl_PaymentsToAcquireLoansReceivableAndOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a46312bb-7265-49c9-9cbc-7fa7b374a2d3" xlink:to="loc_agl_PaymentsToAcquireLoansReceivableAndOther_4de0a1c3-de58-49a3-a6b9-7599145b7d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4be401eb-40c7-4e6c-be13-a701569ec100" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a46312bb-7265-49c9-9cbc-7fa7b374a2d3" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4be401eb-40c7-4e6c-be13-a701569ec100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0185b092-6b2d-47e6-bdef-2062f47e17e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a46312bb-7265-49c9-9cbc-7fa7b374a2d3" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0185b092-6b2d-47e6-bdef-2062f47e17e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7b8f3a9-16c5-43af-bd3b-6c66a54653c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a46312bb-7265-49c9-9cbc-7fa7b374a2d3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7b8f3a9-16c5-43af-bd3b-6c66a54653c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_46c27722-5461-41ab-8b14-d7717a0aae21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4daf1578-1ab7-4986-a0b9-17fcfc612641" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_46c27722-5461-41ab-8b14-d7717a0aae21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepurchaseOfEquity_f8bdc021-3969-44f3-8de2-a86900784cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepurchaseOfEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_46c27722-5461-41ab-8b14-d7717a0aae21" xlink:to="loc_us-gaap_ProceedsFromRepurchaseOfEquity_f8bdc021-3969-44f3-8de2-a86900784cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9f9f20f1-c4b6-43a3-8c35-cad5f729624d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_46c27722-5461-41ab-8b14-d7717a0aae21" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9f9f20f1-c4b6-43a3-8c35-cad5f729624d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_465a4ef5-24ad-48c4-b68a-1f7f262d9d51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_46c27722-5461-41ab-8b14-d7717a0aae21" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_465a4ef5-24ad-48c4-b68a-1f7f262d9d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_81d76106-9b17-4a69-a6cb-7fc353c7f2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4daf1578-1ab7-4986-a0b9-17fcfc612641" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_81d76106-9b17-4a69-a6cb-7fc353c7f2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_243cb4ba-b0bf-4c99-a0c1-f086e320327a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4daf1578-1ab7-4986-a0b9-17fcfc612641" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_243cb4ba-b0bf-4c99-a0c1-f086e320327a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_e6e372f8-e989-40ac-9882-e13955308756" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4daf1578-1ab7-4986-a0b9-17fcfc612641" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_e6e372f8-e989-40ac-9882-e13955308756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/Business" xlink:type="simple" xlink:href="agl-20250630.xsd#Business"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/Business" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90289dac-7e50-447d-98f2-e78bfb9b4c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_95b336c7-5a5b-4e86-b284-3608fc41326f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90289dac-7e50-447d-98f2-e78bfb9b4c6e" xlink:to="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_95b336c7-5a5b-4e86-b284-3608fc41326f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="agl-20250630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b1065bbc-c980-47bc-8eaf-6ff282e77ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_99c918fc-170a-4c42-8e71-b63df7c174a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1065bbc-c980-47bc-8eaf-6ff282e77ddc" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_99c918fc-170a-4c42-8e71-b63df7c174a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRisk" xlink:type="simple" xlink:href="agl-20250630.xsd#RevenueReceivablesandConcentrationofCreditRisk"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRisk" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_baab05f5-4736-492d-9043-233a05841a52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_7011cc83-3196-400e-937b-ab4f2a53a711" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_baab05f5-4736-492d-9043-233a05841a52" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_7011cc83-3196-400e-937b-ab4f2a53a711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="simple" xlink:href="agl-20250630.xsd#MarketableSecuritiesandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_015d1d64-25de-4273-81a7-114648137470" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_9488403b-5c3f-4933-8687-4b5b090ced88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_015d1d64-25de-4273-81a7-114648137470" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_9488403b-5c3f-4933-8687-4b5b090ced88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/OtherAssets" xlink:type="simple" xlink:href="agl-20250630.xsd#OtherAssets"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/OtherAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsAbstract_638eeeca-2481-489f-b531-efcde9a565f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_33828fb1-466c-4fd7-8117-d380b7df9ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_638eeeca-2481-489f-b531-efcde9a565f7" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_33828fb1-466c-4fd7-8117-d380b7df9ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MedicalClaimsandRelatedPayables" xlink:type="simple" xlink:href="agl-20250630.xsd#MedicalClaimsandRelatedPayables"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/MedicalClaimsandRelatedPayables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_2c59d357-3860-4e5e-b384-ba5b35506b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_9b389479-33a6-4970-8de1-38e129638605" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_2c59d357-3860-4e5e-b384-ba5b35506b0a" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_9b389479-33a6-4970-8de1-38e129638605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/OtherLiabilities" xlink:type="simple" xlink:href="agl-20250630.xsd#OtherLiabilities"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/OtherLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesAbstract_8817b56c-af16-40ea-9e2a-67b197384072" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_5aab5eae-204f-4b7a-8004-d0b86a7bbd90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_8817b56c-af16-40ea-9e2a-67b197384072" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_5aab5eae-204f-4b7a-8004-d0b86a7bbd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/Debt" xlink:type="simple" xlink:href="agl-20250630.xsd#Debt"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9b798755-a5a2-41af-afba-b8d2a76ed78d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2da6d17b-de24-4440-b5dc-ca33cf8c0c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9b798755-a5a2-41af-afba-b8d2a76ed78d" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_2da6d17b-de24-4440-b5dc-ca33cf8c0c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="agl-20250630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db9058d1-85dc-4a3f-a9db-9ce0b8874bde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8690c45f-a840-4c1e-9612-9ee7cd7b3c24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db9058d1-85dc-4a3f-a9db-9ce0b8874bde" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8690c45f-a840-4c1e-9612-9ee7cd7b3c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CommonStock" xlink:type="simple" xlink:href="agl-20250630.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fdb047dc-1318-403d-bb36-899ae81f256c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_be52b461-5c56-4814-b0cb-f3a6d146d683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fdb047dc-1318-403d-bb36-899ae81f256c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_be52b461-5c56-4814-b0cb-f3a6d146d683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/NetIncomeLossPerCommonShare" xlink:type="simple" xlink:href="agl-20250630.xsd#NetIncomeLossPerCommonShare"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/NetIncomeLossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c89fa5b1-36fb-4e26-8333-2ec3ba78e943" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7bab4481-6c12-4e9d-8612-8d6eadcb4605" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c89fa5b1-36fb-4e26-8333-2ec3ba78e943" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7bab4481-6c12-4e9d-8612-8d6eadcb4605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssets" xlink:type="simple" xlink:href="agl-20250630.xsd#GoodwillandAmortizableIntangibleAssets"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d560a9f-27ea-43d7-b09d-a02fda06f32e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a239065a-556b-46a3-80a3-fffa23fd530e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d560a9f-27ea-43d7-b09d-a02fda06f32e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a239065a-556b-46a3-80a3-fffa23fd530e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="agl-20250630.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_ea1d20cb-9ad0-439e-bc6a-efdd78d159d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_840bf393-3be0-4863-a512-7eba91e72e10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_ea1d20cb-9ad0-439e-bc6a-efdd78d159d6" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_840bf393-3be0-4863-a512-7eba91e72e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/VariableInterestEntities" xlink:type="simple" xlink:href="agl-20250630.xsd#VariableInterestEntities"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/VariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e19b92e-3f4d-45d0-b15d-74b4a22e8d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_3c64fcde-8fc6-4bc5-bef7-9bcb0cb9cf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e19b92e-3f4d-45d0-b15d-74b4a22e8d2b" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_3c64fcde-8fc6-4bc5-bef7-9bcb0cb9cf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="agl-20250630.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e6afb15b-6413-4907-814b-b578304d8ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_d2b3ad88-00e1-438c-8b1f-b80576d04e31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e6afb15b-6413-4907-814b-b578304d8ce3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_d2b3ad88-00e1-438c-8b1f-b80576d04e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="agl-20250630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_43f7a90d-d53f-443f-97b2-91c797015502" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_97d835c7-2f45-4bb6-a22f-67fa50d5cbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43f7a90d-d53f-443f-97b2-91c797015502" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_97d835c7-2f45-4bb6-a22f-67fa50d5cbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e6622b66-0153-427e-b11f-8ebbe33cef75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43f7a90d-d53f-443f-97b2-91c797015502" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e6622b66-0153-427e-b11f-8ebbe33cef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_23ee77c0-157b-401e-b7ee-5dfbcb1beb09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43f7a90d-d53f-443f-97b2-91c797015502" xlink:to="loc_us-gaap_UseOfEstimates_23ee77c0-157b-401e-b7ee-5dfbcb1beb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_0659445d-e88f-4959-85d0-22e884b38dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43f7a90d-d53f-443f-97b2-91c797015502" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_0659445d-e88f-4959-85d0-22e884b38dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_16ceec07-c46f-49c9-a503-7e6a3764215b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43f7a90d-d53f-443f-97b2-91c797015502" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_16ceec07-c46f-49c9-a503-7e6a3764215b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_51564831-198f-4d72-a81b-87a876ec8e22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43f7a90d-d53f-443f-97b2-91c797015502" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_51564831-198f-4d72-a81b-87a876ec8e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_207215ae-281d-4bbc-9ec8-6ec486b16703" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43f7a90d-d53f-443f-97b2-91c797015502" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_207215ae-281d-4bbc-9ec8-6ec486b16703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_18e46a02-9f84-4317-9d6f-0a342e6f53fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43f7a90d-d53f-443f-97b2-91c797015502" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_18e46a02-9f84-4317-9d6f-0a342e6f53fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskTables" xlink:type="simple" xlink:href="agl-20250630.xsd#RevenueReceivablesandConcentrationofCreditRiskTables"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_7762ae5e-226d-4f00-859e-a97f4ec95b39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c38ba5c4-e608-4720-a898-51bd18e0bb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_7762ae5e-226d-4f00-859e-a97f4ec95b39" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c38ba5c4-e608-4720-a898-51bd18e0bb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="simple" xlink:href="agl-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_80df408c-1791-4ba2-888c-11e9a3fe8898" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_4ac1bfed-b28c-4b29-ba13-a1935c1b638d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_80df408c-1791-4ba2-888c-11e9a3fe8898" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_4ac1bfed-b28c-4b29-ba13-a1935c1b638d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_edcfeced-6265-4a03-be0c-d135c9f676d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_80df408c-1791-4ba2-888c-11e9a3fe8898" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_edcfeced-6265-4a03-be0c-d135c9f676d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_95041254-5d96-4ce4-93a1-2f75b2138273" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_80df408c-1791-4ba2-888c-11e9a3fe8898" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_95041254-5d96-4ce4-93a1-2f75b2138273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/OtherAssetsTables" xlink:type="simple" xlink:href="agl-20250630.xsd#OtherAssetsTables"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/OtherAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsAbstract_2c0389a5-8760-4978-8902-9f62ca7748b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_dc293867-2170-4a09-a67f-3cf15ad02568" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_2c0389a5-8760-4978-8902-9f62ca7748b4" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_dc293867-2170-4a09-a67f-3cf15ad02568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesTables" xlink:type="simple" xlink:href="agl-20250630.xsd#MedicalClaimsandRelatedPayablesTables"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_4153ad8d-d7c7-4e94-9148-5b5467bfaab5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_25e49c8c-4f6a-47a5-8242-222b9923519e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_4153ad8d-d7c7-4e94-9148-5b5467bfaab5" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_25e49c8c-4f6a-47a5-8242-222b9923519e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/OtherLiabilitiesTables" xlink:type="simple" xlink:href="agl-20250630.xsd#OtherLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/OtherLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesAbstract_89bfbfff-d9ec-447e-8a41-53c29cd46b90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock_8ef574b8-3f35-4402-8129-b4dab1e173e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_89bfbfff-d9ec-447e-8a41-53c29cd46b90" xlink:to="loc_us-gaap_OtherLiabilitiesTableTextBlock_8ef574b8-3f35-4402-8129-b4dab1e173e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables" xlink:type="simple" xlink:href="agl-20250630.xsd#NetIncomeLossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_28e7a114-0d09-4b49-ae9b-7fec54efa794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_83d4ea4e-f82c-4a0e-a3f0-0df72bba7215" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_28e7a114-0d09-4b49-ae9b-7fec54efa794" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_83d4ea4e-f82c-4a0e-a3f0-0df72bba7215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_875e4121-a5e4-4ce4-9c1c-fadb76d72c79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_28e7a114-0d09-4b49-ae9b-7fec54efa794" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_875e4121-a5e4-4ce4-9c1c-fadb76d72c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="agl-20250630.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_db9bf81f-65b1-45eb-b386-d77922b9faee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_1dca8871-e8a5-4419-84b3-24bfc09e6668" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_db9bf81f-65b1-45eb-b386-d77922b9faee" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_1dca8871-e8a5-4419-84b3-24bfc09e6668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_439079f7-98b9-46a6-9c62-83740874c58e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_db9bf81f-65b1-45eb-b386-d77922b9faee" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_439079f7-98b9-46a6-9c62-83740874c58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_c5d08e3b-8e4d-4b31-929e-89cc28703f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_db9bf81f-65b1-45eb-b386-d77922b9faee" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_c5d08e3b-8e4d-4b31-929e-89cc28703f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/VariableInterestEntitiesTables" xlink:type="simple" xlink:href="agl-20250630.xsd#VariableInterestEntitiesTables"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/VariableInterestEntitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_43f7e18b-8034-4edc-ac90-2f0c0dc93b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_c8f258aa-e874-4477-a516-c21a71a0bd77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_43f7e18b-8034-4edc-ac90-2f0c0dc93b2f" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_c8f258aa-e874-4477-a516-c21a71a0bd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_dd440591-1115-4985-a920-ce9ee1757ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_43f7e18b-8034-4edc-ac90-2f0c0dc93b2f" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_dd440591-1115-4985-a920-ce9ee1757ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_88608e1e-263a-4020-8811-5028638ed184" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_43f7e18b-8034-4edc-ac90-2f0c0dc93b2f" xlink:to="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_88608e1e-263a-4020-8811-5028638ed184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_a001ea39-b163-4ffa-bf35-cfabc568b4bd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_43f7e18b-8034-4edc-ac90-2f0c0dc93b2f" xlink:to="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_a001ea39-b163-4ffa-bf35-cfabc568b4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="agl-20250630.xsd#DiscontinuedOperationsTables"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/DiscontinuedOperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6764dc18-7394-484b-b087-ce0b061d6009" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_c6a1575b-269b-4545-a47a-58106bbd8853" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6764dc18-7394-484b-b087-ce0b061d6009" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_c6a1575b-269b-4545-a47a-58106bbd8853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/BusinessDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#BusinessDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/BusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e1883177-fd5a-48e4-8af3-8c34e2370e69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans_28b5089a-465b-43b9-b5dd-d5d6303f0d69" xlink:href="agl-20250630.xsd#agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e1883177-fd5a-48e4-8af3-8c34e2370e69" xlink:to="loc_agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans_28b5089a-465b-43b9-b5dd-d5d6303f0d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_49d2406d-6f47-4a6c-8b27-4b68a7a16f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_SummaryOfSignificantAccountingPoliciesTable_7f522c79-2006-4ed8-908e-07a8aeb8c913" xlink:href="agl-20250630.xsd#agl_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49d2406d-6f47-4a6c-8b27-4b68a7a16f6e" xlink:to="loc_agl_SummaryOfSignificantAccountingPoliciesTable_7f522c79-2006-4ed8-908e-07a8aeb8c913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_176394c9-672b-4227-bc0a-525c1d05ff8a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesTable_7f522c79-2006-4ed8-908e-07a8aeb8c913" xlink:to="loc_srt_ProductOrServiceAxis_176394c9-672b-4227-bc0a-525c1d05ff8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_24a7cf22-b97c-442a-87a5-ce3f8091e6ed" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_176394c9-672b-4227-bc0a-525c1d05ff8a" xlink:to="loc_srt_ProductsAndServicesDomain_24a7cf22-b97c-442a-87a5-ce3f8091e6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PlatformSupportCostsMember_df1fc4e1-1a8a-4926-90df-4302053836f7" xlink:href="agl-20250630.xsd#agl_PlatformSupportCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_24a7cf22-b97c-442a-87a5-ce3f8091e6ed" xlink:to="loc_agl_PlatformSupportCostsMember_df1fc4e1-1a8a-4926-90df-4302053836f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d9e0faa3-e733-4b62-830d-a3af0dc620e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesTable_7f522c79-2006-4ed8-908e-07a8aeb8c913" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d9e0faa3-e733-4b62-830d-a3af0dc620e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_55b45e5a-e738-4073-9271-7dcf9c4fcfea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d9e0faa3-e733-4b62-830d-a3af0dc620e3" xlink:to="loc_us-gaap_SegmentDomain_55b45e5a-e738-4073-9271-7dcf9c4fcfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_ReportableSegmentMember_a2ba6d38-8316-4001-b626-b346fdf33fdc" xlink:href="agl-20250630.xsd#agl_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_55b45e5a-e738-4073-9271-7dcf9c4fcfea" xlink:to="loc_agl_ReportableSegmentMember_a2ba6d38-8316-4001-b626-b346fdf33fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:href="agl-20250630.xsd#agl_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesTable_7f522c79-2006-4ed8-908e-07a8aeb8c913" xlink:to="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a03ed188-fe1b-4aa9-8a8a-0358250f7c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a03ed188-fe1b-4aa9-8a8a-0358250f7c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f396d570-2cd1-4a2d-9f37-29f7d9e33e10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f396d570-2cd1-4a2d-9f37-29f7d9e33e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_35839d8f-8b5e-4094-9e6b-0b26f88604d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:to="loc_us-gaap_Depreciation_35839d8f-8b5e-4094-9e6b-0b26f88604d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a167234b-7dec-49e9-880c-42da772a3aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a167234b-7dec-49e9-880c-42da772a3aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_5e4b40a4-4974-4c54-86eb-02c99fe49180" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agl_SummaryOfSignificantAccountingPoliciesLineItems_3e381148-e34e-43ac-9337-855019fb750f" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_5e4b40a4-4974-4c54-86eb-02c99fe49180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#RevenueReceivablesandConcentrationofCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_62e58f2d-ec45-4e85-b6e0-b69b2178f782" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_19f034f9-ed00-4537-9ed0-04108b217d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_62e58f2d-ec45-4e85-b6e0-b69b2178f782" xlink:to="loc_us-gaap_ConcentrationRiskTable_19f034f9-ed00-4537-9ed0-04108b217d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ffcf8223-07fa-4f13-9450-990b9cb437ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_19f034f9-ed00-4537-9ed0-04108b217d6a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ffcf8223-07fa-4f13-9450-990b9cb437ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_15f6ff78-2d22-4fe7-afdf-b3e0ebb0667d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ffcf8223-07fa-4f13-9450-990b9cb437ce" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_15f6ff78-2d22-4fe7-afdf-b3e0ebb0667d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_b8f1ab33-71f6-4674-b92c-df6cf119c92a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_15f6ff78-2d22-4fe7-afdf-b3e0ebb0667d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_b8f1ab33-71f6-4674-b92c-df6cf119c92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0c09ca74-2708-4b79-ab34-b5c0916774bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_15f6ff78-2d22-4fe7-afdf-b3e0ebb0667d" xlink:to="loc_us-gaap_AccountsReceivableMember_0c09ca74-2708-4b79-ab34-b5c0916774bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d0603888-6edc-4dd4-ad0c-c33b7ab3935e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_19f034f9-ed00-4537-9ed0-04108b217d6a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d0603888-6edc-4dd4-ad0c-c33b7ab3935e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a660ecef-3826-4d8b-bed1-3f362897fc45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d0603888-6edc-4dd4-ad0c-c33b7ab3935e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a660ecef-3826-4d8b-bed1-3f362897fc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c86812d4-459a-4b21-b368-8f8684dbc3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a660ecef-3826-4d8b-bed1-3f362897fc45" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c86812d4-459a-4b21-b368-8f8684dbc3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7f58765c-4605-4c8f-bf78-f8020a176641" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_19f034f9-ed00-4537-9ed0-04108b217d6a" xlink:to="loc_srt_MajorCustomersAxis_7f58765c-4605-4c8f-bf78-f8020a176641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7f58765c-4605-4c8f-bf78-f8020a176641" xlink:to="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorAMember_df2f5e7d-1ff5-4801-a27d-08e800b35259" xlink:href="agl-20250630.xsd#agl_PayorAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:to="loc_agl_PayorAMember_df2f5e7d-1ff5-4801-a27d-08e800b35259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorBMember_16acf450-7e72-4416-a6ab-e249b296d13a" xlink:href="agl-20250630.xsd#agl_PayorBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:to="loc_agl_PayorBMember_16acf450-7e72-4416-a6ab-e249b296d13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorCMember_a1dfe306-cbcc-475e-90a4-39e4ad68ad44" xlink:href="agl-20250630.xsd#agl_PayorCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:to="loc_agl_PayorCMember_a1dfe306-cbcc-475e-90a4-39e4ad68ad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorDMember_7f552e1c-756c-46c5-97a6-60a7eef22c4d" xlink:href="agl-20250630.xsd#agl_PayorDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:to="loc_agl_PayorDMember_7f552e1c-756c-46c5-97a6-60a7eef22c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PayorEMember_755f484d-a15f-4642-b3b4-e60e016554b6" xlink:href="agl-20250630.xsd#agl_PayorEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a116d85c-47f1-4960-8de1-2bbb962ff426" xlink:to="loc_agl_PayorEMember_755f484d-a15f-4642-b3b4-e60e016554b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_665d1717-ac8d-4064-b04f-54182d568168" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_19f034f9-ed00-4537-9ed0-04108b217d6a" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_665d1717-ac8d-4064-b04f-54182d568168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7c10aef4-c695-4c76-812a-33f4d309605b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_665d1717-ac8d-4064-b04f-54182d568168" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7c10aef4-c695-4c76-812a-33f4d309605b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_6390b3b9-faa7-4e06-9747-943947f80015" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_a6350e95-89b2-44a3-be60-1caffbadd29d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_6390b3b9-faa7-4e06-9747-943947f80015" xlink:to="loc_us-gaap_MarketableSecuritiesTable_a6350e95-89b2-44a3-be60-1caffbadd29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8fab48b5-d4fd-4f6c-848b-7855fbd8442e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_a6350e95-89b2-44a3-be60-1caffbadd29d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8fab48b5-d4fd-4f6c-848b-7855fbd8442e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1334c8d-1a07-47ba-9431-abb1c732834a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8fab48b5-d4fd-4f6c-848b-7855fbd8442e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1334c8d-1a07-47ba-9431-abb1c732834a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_71857615-7b43-4c04-9545-a24352b990c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1334c8d-1a07-47ba-9431-abb1c732834a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_71857615-7b43-4c04-9545-a24352b990c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b9178bd6-7d77-49d2-95f4-fe4e6cd49e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1334c8d-1a07-47ba-9431-abb1c732834a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b9178bd6-7d77-49d2-95f4-fe4e6cd49e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_ed21c875-63f0-4ce0-8f40-d04b0a79b755" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_a6350e95-89b2-44a3-be60-1caffbadd29d" xlink:to="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_ed21c875-63f0-4ce0-8f40-d04b0a79b755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_2013a388-e561-489d-87be-746f71245ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_ed21c875-63f0-4ce0-8f40-d04b0a79b755" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_2013a388-e561-489d-87be-746f71245ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f3406641-bb52-482d-bf31-e68c69620764" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_ed21c875-63f0-4ce0-8f40-d04b0a79b755" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f3406641-bb52-482d-bf31-e68c69620764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d393486e-7aca-40f2-9219-12f5545ffab3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_ed21c875-63f0-4ce0-8f40-d04b0a79b755" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d393486e-7aca-40f2-9219-12f5545ffab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_f0ae6c71-9549-4993-a099-ef5b8404c3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_ed21c875-63f0-4ce0-8f40-d04b0a79b755" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_f0ae6c71-9549-4993-a099-ef5b8404c3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_09221d7d-5ced-4915-aa41-e1a6d6471474" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_31d5c0c4-38b3-41fa-9754-881d76b4bce9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_09221d7d-5ced-4915-aa41-e1a6d6471474" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_31d5c0c4-38b3-41fa-9754-881d76b4bce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_91aa572b-99d4-4cf6-9bce-c616e76a8b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_31d5c0c4-38b3-41fa-9754-881d76b4bce9" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_91aa572b-99d4-4cf6-9bce-c616e76a8b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7c5d3592-628e-4c90-bbe8-a24aa6b3d5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_91aa572b-99d4-4cf6-9bce-c616e76a8b1e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7c5d3592-628e-4c90-bbe8-a24aa6b3d5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_73839db0-0b04-41fc-9def-052df67ae090" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7c5d3592-628e-4c90-bbe8-a24aa6b3d5ea" xlink:to="loc_us-gaap_DebtSecuritiesMember_73839db0-0b04-41fc-9def-052df67ae090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_df1993ba-949a-46f9-91a1-1a7ff4a20d06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7c5d3592-628e-4c90-bbe8-a24aa6b3d5ea" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_df1993ba-949a-46f9-91a1-1a7ff4a20d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ffc692a2-0ec7-40d8-a173-32ac0d2b0348" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_31d5c0c4-38b3-41fa-9754-881d76b4bce9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ffc692a2-0ec7-40d8-a173-32ac0d2b0348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_396d2c32-a8b6-49e2-bfb8-ce8cc49943c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ffc692a2-0ec7-40d8-a173-32ac0d2b0348" xlink:to="loc_us-gaap_InvestmentIncomeNet_396d2c32-a8b6-49e2-bfb8-ce8cc49943c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_943184b3-bf64-4737-af1c-5eb95e1fe7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ffc692a2-0ec7-40d8-a173-32ac0d2b0348" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_943184b3-bf64-4737-af1c-5eb95e1fe7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_8438ff4b-bad9-49ba-8f7b-7cad3d67b661" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2c6494f2-5e43-46fa-9d8e-d21f5a9bfba8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_8438ff4b-bad9-49ba-8f7b-7cad3d67b661" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2c6494f2-5e43-46fa-9d8e-d21f5a9bfba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_ffdabc48-61bd-4bb8-8a5c-a35630c5c651" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2c6494f2-5e43-46fa-9d8e-d21f5a9bfba8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_ffdabc48-61bd-4bb8-8a5c-a35630c5c651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo_b63d88c9-1b98-45f3-80a9-769bbe9380b9" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2c6494f2-5e43-46fa-9d8e-d21f5a9bfba8" xlink:to="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo_b63d88c9-1b98-45f3-80a9-769bbe9380b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree_4a4e28a5-37a7-4788-a55c-5ee2f5cd5cd9" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2c6494f2-5e43-46fa-9d8e-d21f5a9bfba8" xlink:to="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree_4a4e28a5-37a7-4788-a55c-5ee2f5cd5cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour_265c38b7-743b-47b7-b0f2-480e2a4b501f" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2c6494f2-5e43-46fa-9d8e-d21f5a9bfba8" xlink:to="loc_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour_265c38b7-743b-47b7-b0f2-480e2a4b501f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_754a587b-571f-4833-b414-e672badf4616" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2c6494f2-5e43-46fa-9d8e-d21f5a9bfba8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_754a587b-571f-4833-b414-e672badf4616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_d18de8f4-2dab-403f-a103-178cbeb21c18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_8438ff4b-bad9-49ba-8f7b-7cad3d67b661" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_d18de8f4-2dab-403f-a103-178cbeb21c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4ac42e16-e9b7-4b46-8723-c82e9a4dd792" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_d18de8f4-2dab-403f-a103-178cbeb21c18" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4ac42e16-e9b7-4b46-8723-c82e9a4dd792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_458290b5-b06c-406b-8af3-ef9e7df048d2" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_d18de8f4-2dab-403f-a103-178cbeb21c18" xlink:to="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo_458290b5-b06c-406b-8af3-ef9e7df048d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree_d2f68dba-ff12-4e3b-9d62-1a114956f3d2" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_d18de8f4-2dab-403f-a103-178cbeb21c18" xlink:to="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree_d2f68dba-ff12-4e3b-9d62-1a114956f3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour_41ae46bf-48c3-4843-8a4f-690b7a49d11a" xlink:href="agl-20250630.xsd#agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_d18de8f4-2dab-403f-a103-178cbeb21c18" xlink:to="loc_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour_41ae46bf-48c3-4843-8a4f-690b7a49d11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_87d4da62-8c0b-4d64-acf0-e4849aef1ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_d18de8f4-2dab-403f-a103-178cbeb21c18" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_87d4da62-8c0b-4d64-acf0-e4849aef1ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_5395914c-80f9-46a4-91bc-8c0448db546e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_83d30b49-e7fc-4385-a9b0-85f70fb8d484" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5395914c-80f9-46a4-91bc-8c0448db546e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_83d30b49-e7fc-4385-a9b0-85f70fb8d484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f89e2345-c74c-4337-90e7-116daf589d75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_83d30b49-e7fc-4385-a9b0-85f70fb8d484" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f89e2345-c74c-4337-90e7-116daf589d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5970053c-c99d-4d22-885c-fcfe8fb9537a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f89e2345-c74c-4337-90e7-116daf589d75" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5970053c-c99d-4d22-885c-fcfe8fb9537a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ca0fa131-4f86-4783-a9be-42f7d7723daf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5970053c-c99d-4d22-885c-fcfe8fb9537a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ca0fa131-4f86-4783-a9be-42f7d7723daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a3a839d6-0de0-4def-aa2c-0c31b014ec54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5970053c-c99d-4d22-885c-fcfe8fb9537a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a3a839d6-0de0-4def-aa2c-0c31b014ec54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8587b129-f9e2-4519-87ba-a0c8a2b2a1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_83d30b49-e7fc-4385-a9b0-85f70fb8d484" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8587b129-f9e2-4519-87ba-a0c8a2b2a1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_71f3bcd3-64d7-4276-a67f-13d9844b3355" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8587b129-f9e2-4519-87ba-a0c8a2b2a1f9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_71f3bcd3-64d7-4276-a67f-13d9844b3355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_80a2a15c-2d78-4756-961e-64056b7a0d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_71f3bcd3-64d7-4276-a67f-13d9844b3355" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_80a2a15c-2d78-4756-961e-64056b7a0d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_66587002-5c06-4459-8ac5-086d101731c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_71f3bcd3-64d7-4276-a67f-13d9844b3355" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_66587002-5c06-4459-8ac5-086d101731c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b5dc127c-bff5-4ebd-8a74-3803768f3da2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_8587b129-f9e2-4519-87ba-a0c8a2b2a1f9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b5dc127c-bff5-4ebd-8a74-3803768f3da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_33b130eb-8511-49fe-9266-0bc38d00fa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b5dc127c-bff5-4ebd-8a74-3803768f3da2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_33b130eb-8511-49fe-9266-0bc38d00fa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_75c95fd2-1b24-4e5e-bf50-296c9120ed4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b5dc127c-bff5-4ebd-8a74-3803768f3da2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_75c95fd2-1b24-4e5e-bf50-296c9120ed4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_90d240d5-3e89-4b30-8ac1-9ec44311beb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77955e00-facc-49e4-877c-c6e496e032c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_90d240d5-3e89-4b30-8ac1-9ec44311beb9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77955e00-facc-49e4-877c-c6e496e032c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6decf53e-2d8c-4ab4-8e4f-8c0434df9906" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77955e00-facc-49e4-877c-c6e496e032c2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6decf53e-2d8c-4ab4-8e4f-8c0434df9906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a65b33ba-ec82-4f32-a9e5-cacb6163dc87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6decf53e-2d8c-4ab4-8e4f-8c0434df9906" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a65b33ba-ec82-4f32-a9e5-cacb6163dc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3c3da7b3-56a0-441b-a1e9-af916af6f55c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a65b33ba-ec82-4f32-a9e5-cacb6163dc87" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3c3da7b3-56a0-441b-a1e9-af916af6f55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_54948da7-344a-45fb-909d-823b40d45a02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a65b33ba-ec82-4f32-a9e5-cacb6163dc87" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_54948da7-344a-45fb-909d-823b40d45a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1547ddaa-73eb-4c00-8b8c-e1eb0fe17cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77955e00-facc-49e4-877c-c6e496e032c2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1547ddaa-73eb-4c00-8b8c-e1eb0fe17cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ed21e26-eade-4854-b98e-0af3ab2a6881" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1547ddaa-73eb-4c00-8b8c-e1eb0fe17cb5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ed21e26-eade-4854-b98e-0af3ab2a6881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_285ddf1e-0f5d-4c1c-bfaa-a8decfb185f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ed21e26-eade-4854-b98e-0af3ab2a6881" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_285ddf1e-0f5d-4c1c-bfaa-a8decfb185f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_38af8ecd-0604-40a7-a8c0-a1c4a617cf09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ed21e26-eade-4854-b98e-0af3ab2a6881" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_38af8ecd-0604-40a7-a8c0-a1c4a617cf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8ef6cbad-647b-402a-9541-78b3770ac15f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ed21e26-eade-4854-b98e-0af3ab2a6881" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8ef6cbad-647b-402a-9541-78b3770ac15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d755c645-e29d-46e3-a7a0-9424ab791125" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77955e00-facc-49e4-877c-c6e496e032c2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d755c645-e29d-46e3-a7a0-9424ab791125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_24171445-6fe4-4c92-b83f-86e5ece5f751" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d755c645-e29d-46e3-a7a0-9424ab791125" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_24171445-6fe4-4c92-b83f-86e5ece5f751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/OtherAssetsDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#OtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/OtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsAbstract_f955dcbc-dd10-4815-91e3-5ff1f817e493" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_LoansToPhysiciansPartners_ea24c915-bef0-478d-8507-eda8ca8fd69c" xlink:href="agl-20250630.xsd#agl_LoansToPhysiciansPartners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_f955dcbc-dd10-4815-91e3-5ff1f817e493" xlink:to="loc_agl_LoansToPhysiciansPartners_ea24c915-bef0-478d-8507-eda8ca8fd69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_HealthPlanDepositsNoncurrent_8d4c7893-5be9-467b-b15e-e59c6e32e50c" xlink:href="agl-20250630.xsd#agl_HealthPlanDepositsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_f955dcbc-dd10-4815-91e3-5ff1f817e493" xlink:to="loc_agl_HealthPlanDepositsNoncurrent_8d4c7893-5be9-467b-b15e-e59c6e32e50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_62f564b9-1288-4e09-bba4-21b30daf6adc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_f955dcbc-dd10-4815-91e3-5ff1f817e493" xlink:to="loc_us-gaap_EquityMethodInvestments_62f564b9-1288-4e09-bba4-21b30daf6adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_06cfc4c8-4d15-46bf-bafe-28c3e6a34280" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_f955dcbc-dd10-4815-91e3-5ff1f817e493" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_06cfc4c8-4d15-46bf-bafe-28c3e6a34280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_407cf965-8b9f-4601-8320-e61b12d9363e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_f955dcbc-dd10-4815-91e3-5ff1f817e493" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_407cf965-8b9f-4601-8320-e61b12d9363e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c2a4930f-cc8a-4c9b-8d53-6b519d2415e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_f955dcbc-dd10-4815-91e3-5ff1f817e493" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c2a4930f-cc8a-4c9b-8d53-6b519d2415e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/OtherAssetsNarrativeDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#OtherAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/OtherAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsAbstract_eba0fa31-e389-4bd8-b979-9142db4a1f47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansAndLeasesReceivableRelatedParties_c2857fd2-7049-4403-b59f-751f51fc700b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_eba0fa31-e389-4bd8-b979-9142db4a1f47" xlink:to="loc_us-gaap_LoansAndLeasesReceivableRelatedParties_c2857fd2-7049-4403-b59f-751f51fc700b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_8c848600-4b1b-4509-ac10-83fd840bf394" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_81a92ff1-9323-42c6-a576-2b41456c998f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_8c848600-4b1b-4509-ac10-83fd840bf394" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_81a92ff1-9323-42c6-a576-2b41456c998f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable_bfd8dbc7-8726-465e-9e11-434aad891616" xlink:href="agl-20250630.xsd#agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_81a92ff1-9323-42c6-a576-2b41456c998f" xlink:to="loc_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable_bfd8dbc7-8726-465e-9e11-434aad891616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0f1bc2f5-2c4c-42e3-a641-c1ab30b7d276" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_81a92ff1-9323-42c6-a576-2b41456c998f" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0f1bc2f5-2c4c-42e3-a641-c1ab30b7d276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_9188c353-cd73-4e3e-8112-fd73c82fca3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0f1bc2f5-2c4c-42e3-a641-c1ab30b7d276" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_9188c353-cd73-4e3e-8112-fd73c82fca3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_432a4c92-bc16-4ffc-80e0-0d7a80cc8c38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0f1bc2f5-2c4c-42e3-a641-c1ab30b7d276" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_432a4c92-bc16-4ffc-80e0-0d7a80cc8c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_4f48ecc6-2bb3-403e-b650-e8f7896b530e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_0f1bc2f5-2c4c-42e3-a641-c1ab30b7d276" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_4f48ecc6-2bb3-403e-b650-e8f7896b530e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_979aa3d1-55c9-4450-922e-2de7683c7488" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_81a92ff1-9323-42c6-a576-2b41456c998f" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_979aa3d1-55c9-4450-922e-2de7683c7488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_2ccad92a-41b1-4562-bf21-5e81d98807b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_979aa3d1-55c9-4450-922e-2de7683c7488" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_2ccad92a-41b1-4562-bf21-5e81d98807b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_420b521d-af7b-499b-910d-f647c40a7595" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_979aa3d1-55c9-4450-922e-2de7683c7488" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_420b521d-af7b-499b-910d-f647c40a7595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_76a59fa0-0f1f-4cb2-abe7-659fa025d7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_979aa3d1-55c9-4450-922e-2de7683c7488" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_76a59fa0-0f1f-4cb2-abe7-659fa025d7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable_cf55d26d-ff5a-4056-ad9f-b6647c4536ac" xlink:href="agl-20250630.xsd#agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_81a92ff1-9323-42c6-a576-2b41456c998f" xlink:to="loc_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable_cf55d26d-ff5a-4056-ad9f-b6647c4536ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesNarrativeDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#MedicalClaimsandRelatedPayablesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_ba6a9a9f-12ac-425b-be52-d19fb3e76217" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable_4ce5d55b-c277-4210-84f3-f1e80a4d1a35" xlink:href="agl-20250630.xsd#agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_ba6a9a9f-12ac-425b-be52-d19fb3e76217" xlink:to="loc_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable_4ce5d55b-c277-4210-84f3-f1e80a4d1a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#OtherLiabilitiesScheduleofOtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesAbstract_871da406-1f7c-4ca4-992e-45779b647362" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_39a86719-4c9b-45dc-83f7-5a785bb35fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_871da406-1f7c-4ca4-992e-45779b647362" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_39a86719-4c9b-45dc-83f7-5a785bb35fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_abd4f2d7-19e6-41a1-862c-59d5946141e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_871da406-1f7c-4ca4-992e-45779b647362" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_abd4f2d7-19e6-41a1-862c-59d5946141e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_1c50d736-f898-4a06-b267-449e6d777e44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_abd4f2d7-19e6-41a1-862c-59d5946141e4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_1c50d736-f898-4a06-b267-449e6d777e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_EquityMethodLiabilitiesNoncurrent_7d1df499-fa1c-4bc0-ac9d-1b2007bf42f2" xlink:href="agl-20250630.xsd#agl_EquityMethodLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_871da406-1f7c-4ca4-992e-45779b647362" xlink:to="loc_agl_EquityMethodLiabilitiesNoncurrent_7d1df499-fa1c-4bc0-ac9d-1b2007bf42f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_44123b50-1e79-4ee7-bfc2-3c39d5bee877" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_871da406-1f7c-4ca4-992e-45779b647362" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_44123b50-1e79-4ee7-bfc2-3c39d5bee877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_63ed33c1-db54-4543-a22d-11498b3facfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_871da406-1f7c-4ca4-992e-45779b647362" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_63ed33c1-db54-4543-a22d-11498b3facfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#OtherLiabilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesAbstract_00f8118e-815f-4312-b9e1-8d39b01bc643" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherLiabilitiesTable_3108fc66-293c-4235-a3b7-04ae50467632" xlink:href="agl-20250630.xsd#agl_OtherLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_00f8118e-815f-4312-b9e1-8d39b01bc643" xlink:to="loc_agl_OtherLiabilitiesTable_3108fc66-293c-4235-a3b7-04ae50467632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_064bb2dd-5461-4df5-9daa-e6bf6c4646e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agl_OtherLiabilitiesTable_3108fc66-293c-4235-a3b7-04ae50467632" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_064bb2dd-5461-4df5-9daa-e6bf6c4646e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_d8836f1b-960b-4372-ac57-19e353a6943c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_064bb2dd-5461-4df5-9daa-e6bf6c4646e9" xlink:to="loc_us-gaap_LossContingencyNatureDomain_d8836f1b-960b-4372-ac57-19e353a6943c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnassertedClaimMember_c12eb9ef-f32f-4555-b5ed-bee3dc2dddc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnassertedClaimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d8836f1b-960b-4372-ac57-19e353a6943c" xlink:to="loc_us-gaap_UnassertedClaimMember_c12eb9ef-f32f-4555-b5ed-bee3dc2dddc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherLiabilitiesLineItems_636caa3a-0a6b-4b4b-8fbf-3dc1c66a9afb" xlink:href="agl-20250630.xsd#agl_OtherLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agl_OtherLiabilitiesTable_3108fc66-293c-4235-a3b7-04ae50467632" xlink:to="loc_agl_OtherLiabilitiesLineItems_636caa3a-0a6b-4b4b-8fbf-3dc1c66a9afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_ed852704-3f93-4143-8c9e-4f91ae422989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agl_OtherLiabilitiesLineItems_636caa3a-0a6b-4b4b-8fbf-3dc1c66a9afb" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_ed852704-3f93-4143-8c9e-4f91ae422989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/DebtDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5c105b58-305b-4813-8ed0-56026e5d48e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5d45b191-86e0-42fd-8280-027f49a3abd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5c105b58-305b-4813-8ed0-56026e5d48e8" xlink:to="loc_us-gaap_DebtInstrumentTable_5d45b191-86e0-42fd-8280-027f49a3abd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0d0fb1bc-439e-41ce-a2d4-b24c262e8577" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5d45b191-86e0-42fd-8280-027f49a3abd2" xlink:to="loc_us-gaap_CreditFacilityAxis_0d0fb1bc-439e-41ce-a2d4-b24c262e8577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2b71fc58-25c6-4cc9-a550-937215492f00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_0d0fb1bc-439e-41ce-a2d4-b24c262e8577" xlink:to="loc_us-gaap_CreditFacilityDomain_2b71fc58-25c6-4cc9-a550-937215492f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_SecuredTermLoanFacilityMember_77f9ccb4-d673-47ea-955a-d6b53a80467f" xlink:href="agl-20250630.xsd#agl_SecuredTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2b71fc58-25c6-4cc9-a550-937215492f00" xlink:to="loc_agl_SecuredTermLoanFacilityMember_77f9ccb4-d673-47ea-955a-d6b53a80467f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_SecuredRevolvingFacilityMember_489a0dff-7ae7-4b7b-b0a4-321f5a43bf7a" xlink:href="agl-20250630.xsd#agl_SecuredRevolvingFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2b71fc58-25c6-4cc9-a550-937215492f00" xlink:to="loc_agl_SecuredRevolvingFacilityMember_489a0dff-7ae7-4b7b-b0a4-321f5a43bf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_16dd59c9-5fbc-4ba3-b4dd-f1d742c5b9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2b71fc58-25c6-4cc9-a550-937215492f00" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_16dd59c9-5fbc-4ba3-b4dd-f1d742c5b9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8ed95c03-9df4-4897-8a91-73c5855fad11" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5d45b191-86e0-42fd-8280-027f49a3abd2" xlink:to="loc_srt_RangeAxis_8ed95c03-9df4-4897-8a91-73c5855fad11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76328ebe-bc46-4dce-bca7-8b891170656c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8ed95c03-9df4-4897-8a91-73c5855fad11" xlink:to="loc_srt_RangeMember_76328ebe-bc46-4dce-bca7-8b891170656c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bf4cc8f9-2d48-49a7-8a66-e6d7be9db1f8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_76328ebe-bc46-4dce-bca7-8b891170656c" xlink:to="loc_srt_MaximumMember_bf4cc8f9-2d48-49a7-8a66-e6d7be9db1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_da0ae479-5480-43b7-b35c-9ddb0d6d7bff" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_76328ebe-bc46-4dce-bca7-8b891170656c" xlink:to="loc_srt_MinimumMember_da0ae479-5480-43b7-b35c-9ddb0d6d7bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bd12c67b-25f6-4b65-94a5-2bd22d34dd95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5d45b191-86e0-42fd-8280-027f49a3abd2" xlink:to="loc_us-gaap_VariableRateAxis_bd12c67b-25f6-4b65-94a5-2bd22d34dd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_354791df-aa5b-4eeb-ac05-dfeb509c3121" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_bd12c67b-25f6-4b65-94a5-2bd22d34dd95" xlink:to="loc_us-gaap_VariableRateDomain_354791df-aa5b-4eeb-ac05-dfeb509c3121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_5982f5b2-f655-44a9-b73a-5aa1b59ede6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_354791df-aa5b-4eeb-ac05-dfeb509c3121" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_5982f5b2-f655-44a9-b73a-5aa1b59ede6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_7c5a8e4f-ef14-4020-8d3c-cb921bd63f74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_354791df-aa5b-4eeb-ac05-dfeb509c3121" xlink:to="loc_us-gaap_BaseRateMember_7c5a8e4f-ef14-4020-8d3c-cb921bd63f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_98b203ba-d24e-480a-919f-72332456ef49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_354791df-aa5b-4eeb-ac05-dfeb509c3121" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_98b203ba-d24e-480a-919f-72332456ef49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5d45b191-86e0-42fd-8280-027f49a3abd2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ed3bd3a9-b10b-478e-bdbb-61e2efb2f88e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ed3bd3a9-b10b-478e-bdbb-61e2efb2f88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit_7dc82714-f23c-4d1d-b424-cfdf3e162300" xlink:href="agl-20250630.xsd#agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit_7dc82714-f23c-4d1d-b424-cfdf3e162300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_15d86cf6-b5a9-4371-b09c-93e870793b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_LongTermDebt_15d86cf6-b5a9-4371-b09c-93e870793b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_598fbf19-4079-46b6-9cef-de5cf442b22f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_598fbf19-4079-46b6-9cef-de5cf442b22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_3c244ecb-fc27-465d-a83d-1e87e8ff7a45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_3c244ecb-fc27-465d-a83d-1e87e8ff7a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_ExtendedTermOfLettersOfCredit_3218caf2-d301-4b44-bccd-5ac48f0bffee" xlink:href="agl-20250630.xsd#agl_ExtendedTermOfLettersOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_agl_ExtendedTermOfLettersOfCredit_3218caf2-d301-4b44-bccd-5ac48f0bffee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_802d26fb-f7a3-4894-8090-e55d46cfda38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_802d26fb-f7a3-4894-8090-e55d46cfda38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_e976d10c-08f5-4cd2-a1e9-403b9f75aed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_e976d10c-08f5-4cd2-a1e9-403b9f75aed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_0618da17-290d-4254-84d2-b3ef06aaa2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60b95ab4-b54a-44ef-b591-977e2a98bfeb" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_0618da17-290d-4254-84d2-b3ef06aaa2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_87e6bde4-a63e-4558-9e71-dca0c9b35e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_a1e32222-b000-4164-b453-1bdedfe75964" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_87e6bde4-a63e-4558-9e71-dca0c9b35e1b" xlink:to="loc_us-gaap_LossContingenciesTable_a1e32222-b000-4164-b453-1bdedfe75964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_82ecfd96-eba9-4c14-a446-4ecadc55d4a5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a1e32222-b000-4164-b453-1bdedfe75964" xlink:to="loc_srt_LitigationCaseAxis_82ecfd96-eba9-4c14-a446-4ecadc55d4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_92fb7985-1598-4248-b8e4-a2b5a26f1f26" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_82ecfd96-eba9-4c14-a446-4ecadc55d4a5" xlink:to="loc_srt_LitigationCaseTypeDomain_92fb7985-1598-4248-b8e4-a2b5a26f1f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_ConsolidatedSecuritiesMatterMember_8e7dd34e-7695-4206-aa87-0074fe862403" xlink:href="agl-20250630.xsd#agl_ConsolidatedSecuritiesMatterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_92fb7985-1598-4248-b8e4-a2b5a26f1f26" xlink:to="loc_agl_ConsolidatedSecuritiesMatterMember_8e7dd34e-7695-4206-aa87-0074fe862403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DerivativeMattersMember_8ac0b900-f7e1-4382-9acd-337eed5ceffa" xlink:href="agl-20250630.xsd#agl_DerivativeMattersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_92fb7985-1598-4248-b8e4-a2b5a26f1f26" xlink:to="loc_agl_DerivativeMattersMember_8ac0b900-f7e1-4382-9acd-337eed5ceffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b8526eeb-22ef-44e3-931c-4d0e3f168b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a1e32222-b000-4164-b453-1bdedfe75964" xlink:to="loc_us-gaap_LossContingenciesLineItems_b8526eeb-22ef-44e3-931c-4d0e3f168b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_6b5a1496-a080-411a-83c6-4f1cca3703c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b8526eeb-22ef-44e3-931c-4d0e3f168b1b" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_6b5a1496-a080-411a-83c6-4f1cca3703c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/CommonStockDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#CommonStockDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_56f841a2-c018-4fd0-bdd2-515b3529b1be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_91fd798d-0704-46dc-bfed-efd6c3b5a9de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_56f841a2-c018-4fd0-bdd2-515b3529b1be" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_91fd798d-0704-46dc-bfed-efd6c3b5a9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b6c8b768-a695-4836-8532-896be255aeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_91fd798d-0704-46dc-bfed-efd6c3b5a9de" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b6c8b768-a695-4836-8532-896be255aeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_beaf2841-7dfa-4ebb-a836-78116b10453e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b6c8b768-a695-4836-8532-896be255aeb7" xlink:to="loc_us-gaap_EquityComponentDomain_beaf2841-7dfa-4ebb-a836-78116b10453e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_870d71a3-b891-4475-a590-cfae98453048" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_beaf2841-7dfa-4ebb-a836-78116b10453e" xlink:to="loc_us-gaap_CommonStockMember_870d71a3-b891-4475-a590-cfae98453048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_7f4e37ac-eee8-483b-84c5-ad440a16d27a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_91fd798d-0704-46dc-bfed-efd6c3b5a9de" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_7f4e37ac-eee8-483b-84c5-ad440a16d27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4e3a448d-10ec-4fd7-924a-fd74e76220de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7f4e37ac-eee8-483b-84c5-ad440a16d27a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4e3a448d-10ec-4fd7-924a-fd74e76220de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_8e89afa8-2077-4876-855e-97f9fbc3c590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7f4e37ac-eee8-483b-84c5-ad440a16d27a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_8e89afa8-2077-4876-855e-97f9fbc3c590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1402a9a2-f3bd-4bac-afbf-9ce28e69fdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_78e67d18-168f-4446-9f2f-7e6f9edc078e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1402a9a2-f3bd-4bac-afbf-9ce28e69fdf1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_78e67d18-168f-4446-9f2f-7e6f9edc078e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_22a6c9b8-0d79-4ecf-b249-26401727e68e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_78e67d18-168f-4446-9f2f-7e6f9edc078e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_22a6c9b8-0d79-4ecf-b249-26401727e68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_95ac9494-57f1-4b92-9462-434fe487aac6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_78e67d18-168f-4446-9f2f-7e6f9edc078e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_95ac9494-57f1-4b92-9462-434fe487aac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_ac8902bb-e2fd-4c0d-bd10-daf7fca9cef4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_78e67d18-168f-4446-9f2f-7e6f9edc078e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_ac8902bb-e2fd-4c0d-bd10-daf7fca9cef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c5dbf178-a3ca-4131-aaa7-d1460ee4fad0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_78e67d18-168f-4446-9f2f-7e6f9edc078e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c5dbf178-a3ca-4131-aaa7-d1460ee4fad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9984df48-26bf-4aed-8b00-215836ea9158" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_78e67d18-168f-4446-9f2f-7e6f9edc078e" xlink:to="loc_us-gaap_NetIncomeLoss_9984df48-26bf-4aed-8b00-215836ea9158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_57304d6b-df0c-44d6-b405-0bc80e65a285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1402a9a2-f3bd-4bac-afbf-9ce28e69fdf1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_57304d6b-df0c-44d6-b405-0bc80e65a285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5ef73366-7148-4718-8b38-7962f1a33276" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_57304d6b-df0c-44d6-b405-0bc80e65a285" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5ef73366-7148-4718-8b38-7962f1a33276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_26a7f4e3-4e1f-4cab-bff5-16a79e7764c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_57304d6b-df0c-44d6-b405-0bc80e65a285" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_26a7f4e3-4e1f-4cab-bff5-16a79e7764c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_15b5a425-1d44-40e4-add3-92be1d17386f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1402a9a2-f3bd-4bac-afbf-9ce28e69fdf1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_15b5a425-1d44-40e4-add3-92be1d17386f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c034e5ef-7420-4ded-a670-8e646cd5c625" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_15b5a425-1d44-40e4-add3-92be1d17386f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c034e5ef-7420-4ded-a670-8e646cd5c625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_96cdf304-0558-4ea4-952d-a56257c97b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_15b5a425-1d44-40e4-add3-92be1d17386f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_96cdf304-0558-4ea4-952d-a56257c97b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_5fbd9c74-2903-4ab3-98ae-955c308cb2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_15b5a425-1d44-40e4-add3-92be1d17386f" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_5fbd9c74-2903-4ab3-98ae-955c308cb2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_5b521229-29a2-4b8f-a870-f814bf3dc1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_15b5a425-1d44-40e4-add3-92be1d17386f" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_5b521229-29a2-4b8f-a870-f814bf3dc1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d4aae856-ce18-4ccb-876d-b107706176aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_01f2c7b1-352b-449f-9671-a937daf45e93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d4aae856-ce18-4ccb-876d-b107706176aa" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_01f2c7b1-352b-449f-9671-a937daf45e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bac2d596-0ca8-4664-be6b-ebab9f7c525d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_01f2c7b1-352b-449f-9671-a937daf45e93" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bac2d596-0ca8-4664-be6b-ebab9f7c525d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4de612b8-3ef0-43c2-9066-c92697e87bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bac2d596-0ca8-4664-be6b-ebab9f7c525d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4de612b8-3ef0-43c2-9066-c92697e87bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1b6d7457-a97e-45dd-808b-400ce99ab3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4de612b8-3ef0-43c2-9066-c92697e87bbd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1b6d7457-a97e-45dd-808b-400ce99ab3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5f5bb431-b80d-4e20-89e7-3e228e869606" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4de612b8-3ef0-43c2-9066-c92697e87bbd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5f5bb431-b80d-4e20-89e7-3e228e869606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a9415aa1-0df0-4d14-b867-fb8c6889bceb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_01f2c7b1-352b-449f-9671-a937daf45e93" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a9415aa1-0df0-4d14-b867-fb8c6889bceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_768f3fa3-21fd-4c7a-98b6-d50d3e844e18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a9415aa1-0df0-4d14-b867-fb8c6889bceb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_768f3fa3-21fd-4c7a-98b6-d50d3e844e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#GoodwillandAmortizableIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_008a8374-be6d-47ff-8654-68e8e7377bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_af9aa397-6a6e-4748-8035-39c02647867d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_008a8374-be6d-47ff-8654-68e8e7377bcd" xlink:to="loc_us-gaap_Goodwill_af9aa397-6a6e-4748-8035-39c02647867d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c7a60e7d-a2ff-4873-a3b0-fc6c25a6f833" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_008a8374-be6d-47ff-8654-68e8e7377bcd" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c7a60e7d-a2ff-4873-a3b0-fc6c25a6f833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_99a60302-ae76-4a79-9c2c-fd4d1edf8946" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_008a8374-be6d-47ff-8654-68e8e7377bcd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_99a60302-ae76-4a79-9c2c-fd4d1edf8946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_295733d2-7770-4ded-866a-8e5fc4f06710" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_008a8374-be6d-47ff-8654-68e8e7377bcd" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_295733d2-7770-4ded-866a-8e5fc4f06710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_68dba1c6-eb7f-41b9-a9db-c5ed0b203dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e34c95b-b710-4e73-a4db-e8ded4953bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_68dba1c6-eb7f-41b9-a9db-c5ed0b203dbc" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e34c95b-b710-4e73-a4db-e8ded4953bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_2a4e7332-156d-470d-82a3-972d782999f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e34c95b-b710-4e73-a4db-e8ded4953bfc" xlink:to="loc_us-gaap_InterestPaidNet_2a4e7332-156d-470d-82a3-972d782999f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_4a7966c2-7d9b-4e62-9131-43f767462fee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e34c95b-b710-4e73-a4db-e8ded4953bfc" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_4a7966c2-7d9b-4e62-9131-43f767462fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0bd91228-eed6-4206-b30a-0f64ad97bd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_68dba1c6-eb7f-41b9-a9db-c5ed0b203dbc" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0bd91228-eed6-4206-b30a-0f64ad97bd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8b3f5bf7-b49d-473a-9370-268106e6b44a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0bd91228-eed6-4206-b30a-0f64ad97bd6e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8b3f5bf7-b49d-473a-9370-268106e6b44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_4ea54f69-8e87-4ccc-b199-270f94b415be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0bd91228-eed6-4206-b30a-0f64ad97bd6e" xlink:to="loc_us-gaap_StockIssued1_4ea54f69-8e87-4ccc-b199-270f94b415be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_ae4a30cc-2c1d-4cb6-afd9-40d94407dde0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e486840-f5b3-4688-8274-03a322b9600d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_ae4a30cc-2c1d-4cb6-afd9-40d94407dde0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e486840-f5b3-4688-8274-03a322b9600d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_9fc021df-a4bf-4199-9023-8263ad8e1b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_ae4a30cc-2c1d-4cb6-afd9-40d94407dde0" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_9fc021df-a4bf-4199-9023-8263ad8e1b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aac1b6bf-0816-4fd6-b490-3ce28c2a2731" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_ae4a30cc-2c1d-4cb6-afd9-40d94407dde0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aac1b6bf-0816-4fd6-b490-3ce28c2a2731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e3d0e750-c459-4137-938b-0fff2a9d4029" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_af14a8da-4d8e-4dfb-880c-6475d10d3124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e3d0e750-c459-4137-938b-0fff2a9d4029" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_af14a8da-4d8e-4dfb-880c-6475d10d3124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_3ada4c46-83c4-4841-936a-b8039c687833" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_af14a8da-4d8e-4dfb-880c-6475d10d3124" xlink:to="loc_srt_ConsolidatedEntitiesAxis_3ada4c46-83c4-4841-936a-b8039c687833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a9baf6d4-767b-4039-b936-421dc3658962" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3ada4c46-83c4-4841-936a-b8039c687833" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a9baf6d4-767b-4039-b936-421dc3658962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_d949a21c-8383-4cdd-8ab6-90a864205652" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a9baf6d4-767b-4039-b936-421dc3658962" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_d949a21c-8383-4cdd-8ab6-90a864205652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_a6569eb8-895e-4c33-9d36-b08883871104" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_af14a8da-4d8e-4dfb-880c-6475d10d3124" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_a6569eb8-895e-4c33-9d36-b08883871104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a6569eb8-895e-4c33-9d36-b08883871104" xlink:to="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b314a833-ea6b-4f73-bc7d-59773a216d83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b314a833-ea6b-4f73-bc7d-59773a216d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalents_14ac37f8-b52f-4fbe-9117-c003ff1f8a57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_RestrictedCashEquivalents_14ac37f8-b52f-4fbe-9117-c003ff1f8a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_d9b4daf4-18d5-48c3-9b72-4544213aa23d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_ReceivablesNetCurrent_d9b4daf4-18d5-48c3-9b72-4544213aa23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1497cdd5-010b-4d45-856d-5db0a5a1d98c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1497cdd5-010b-4d45-856d-5db0a5a1d98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_92ba50b6-0617-465a-9b73-e16bde2a1a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_92ba50b6-0617-465a-9b73-e16bde2a1a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9bdfff60-29f1-4d01-8779-beb5a3d4b099" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9bdfff60-29f1-4d01-8779-beb5a3d4b099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_4a97f023-43c7-4322-ae43-b0f2e386cc85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_367c4c45-65e0-4fe9-bf30-aa25816e478b" xlink:to="loc_us-gaap_OtherAssets_4a97f023-43c7-4322-ae43-b0f2e386cc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_672683dd-af05-4575-b41e-f31063f889c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a6569eb8-895e-4c33-9d36-b08883871104" xlink:to="loc_us-gaap_LiabilitiesAbstract_672683dd-af05-4575-b41e-f31063f889c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_63f08b6a-d116-45d6-836e-13a3467ae46d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_672683dd-af05-4575-b41e-f31063f889c2" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_63f08b6a-d116-45d6-836e-13a3467ae46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a7ba96d-1b71-4b68-a85b-1e8de11a1d99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_672683dd-af05-4575-b41e-f31063f889c2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a7ba96d-1b71-4b68-a85b-1e8de11a1d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_d9deeed6-1690-4b87-bd5a-49097ca83e15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_672683dd-af05-4575-b41e-f31063f889c2" xlink:to="loc_us-gaap_OtherLiabilities_d9deeed6-1690-4b87-bd5a-49097ca83e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#VariableInterestEntitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4f2916b7-c870-4564-8081-ac97c3b80fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_347be536-9356-4a75-b1d5-7b13cbcf5669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4f2916b7-c870-4564-8081-ac97c3b80fdc" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_347be536-9356-4a75-b1d5-7b13cbcf5669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_ca8f9d7a-6534-4c20-92ef-d60bec14aab0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_347be536-9356-4a75-b1d5-7b13cbcf5669" xlink:to="loc_srt_ConsolidatedEntitiesAxis_ca8f9d7a-6534-4c20-92ef-d60bec14aab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_26963940-e60e-403b-9e44-dce8ed38f891" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ca8f9d7a-6534-4c20-92ef-d60bec14aab0" xlink:to="loc_srt_ConsolidatedEntitiesDomain_26963940-e60e-403b-9e44-dce8ed38f891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_9e0b5a55-e8af-4b2f-b4bb-86372446b2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_26963940-e60e-403b-9e44-dce8ed38f891" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_9e0b5a55-e8af-4b2f-b4bb-86372446b2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_b67d98e3-a2aa-491a-9693-10a3d45aaf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_26963940-e60e-403b-9e44-dce8ed38f891" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_b67d98e3-a2aa-491a-9693-10a3d45aaf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_037bb399-3b67-4d3a-8e84-910804159ade" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_347be536-9356-4a75-b1d5-7b13cbcf5669" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_037bb399-3b67-4d3a-8e84-910804159ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cac2da54-4938-4413-a3d9-fc50f5c5de28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_037bb399-3b67-4d3a-8e84-910804159ade" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cac2da54-4938-4413-a3d9-fc50f5c5de28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuretyBondMember_815e164c-01e2-4fc4-a18d-4d8ad26f8bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuretyBondMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cac2da54-4938-4413-a3d9-fc50f5c5de28" xlink:to="loc_us-gaap_SuretyBondMember_815e164c-01e2-4fc4-a18d-4d8ad26f8bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_347be536-9356-4a75-b1d5-7b13cbcf5669" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfWhollyOwnedRiskBearingEntities_dbff4191-3c68-4381-a2bf-57327b4edf0f" xlink:href="agl-20250630.xsd#agl_NumberOfWhollyOwnedRiskBearingEntities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:to="loc_agl_NumberOfWhollyOwnedRiskBearingEntities_dbff4191-3c68-4381-a2bf-57327b4edf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfEquityMethodInvestments_210bb424-caa3-423d-a1ae-840639ae509a" xlink:href="agl-20250630.xsd#agl_NumberOfEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:to="loc_agl_NumberOfEquityMethodInvestments_210bb424-caa3-423d-a1ae-840639ae509a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfDirectContractingEntities_521a73fb-1cde-452d-ae38-fa2a94fcc951" xlink:href="agl-20250630.xsd#agl_NumberOfDirectContractingEntities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:to="loc_agl_NumberOfDirectContractingEntities_521a73fb-1cde-452d-ae38-fa2a94fcc951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7c8758ad-926a-4b10-8eba-4e675f2af91f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:to="loc_us-gaap_LongTermDebt_7c8758ad-926a-4b10-8eba-4e675f2af91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfPhysicianGroupPartners_e5910ad5-c664-428a-877e-059cbcd89f31" xlink:href="agl-20250630.xsd#agl_NumberOfPhysicianGroupPartners"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:to="loc_agl_NumberOfPhysicianGroupPartners_e5910ad5-c664-428a-877e-059cbcd89f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_NumberOfGeographicalLocation_dd809150-a66f-4926-b6aa-7f8fbd003ca0" xlink:href="agl-20250630.xsd#agl_NumberOfGeographicalLocation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d26c459d-17e8-411e-a9f3-b6ec50ce90bd" xlink:to="loc_agl_NumberOfGeographicalLocation_dd809150-a66f-4926-b6aa-7f8fbd003ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_919bab09-2d74-4cab-88bf-8a990e5e8c59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a9858e9a-6a14-45e5-aa0f-551461791859" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_919bab09-2d74-4cab-88bf-8a990e5e8c59" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a9858e9a-6a14-45e5-aa0f-551461791859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2c41a4de-76f9-40c7-a9f3-08d170f724f7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a9858e9a-6a14-45e5-aa0f-551461791859" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2c41a4de-76f9-40c7-a9f3-08d170f724f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f0d64419-6cc5-42ea-b86d-2850100c7ee2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2c41a4de-76f9-40c7-a9f3-08d170f724f7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f0d64419-6cc5-42ea-b86d-2850100c7ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherEquityMethodInvestmentsMember_82fe36cf-3641-4b8e-8fd4-1062c85ffb93" xlink:href="agl-20250630.xsd#agl_OtherEquityMethodInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f0d64419-6cc5-42ea-b86d-2850100c7ee2" xlink:to="loc_agl_OtherEquityMethodInvestmentsMember_82fe36cf-3641-4b8e-8fd4-1062c85ffb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_ACOREACHMember_d8fc371a-72fd-4b04-9102-1834739323d4" xlink:href="agl-20250630.xsd#agl_ACOREACHMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f0d64419-6cc5-42ea-b86d-2850100c7ee2" xlink:to="loc_agl_ACOREACHMember_d8fc371a-72fd-4b04-9102-1834739323d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_a768c2d8-afe0-4de4-abac-3b6daa1b6380" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a9858e9a-6a14-45e5-aa0f-551461791859" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_a768c2d8-afe0-4de4-abac-3b6daa1b6380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_bb268952-0321-4c68-bf6f-6d7b0c674c33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a768c2d8-afe0-4de4-abac-3b6daa1b6380" xlink:to="loc_us-gaap_EquityMethodInvestments_bb268952-0321-4c68-bf6f-6d7b0c674c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_EquityMethodLiabilities_bb628ba2-7610-49cc-aac7-9aad7ecedaaa" xlink:href="agl-20250630.xsd#agl_EquityMethodLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a768c2d8-afe0-4de4-abac-3b6daa1b6380" xlink:to="loc_agl_EquityMethodLiabilities_bb628ba2-7610-49cc-aac7-9aad7ecedaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#VariableInterestEntitiesScheduleofOperatingResultsDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7c3b68d2-307b-4783-9fdb-137c7dc9ae9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ed16fe59-dd92-4897-83e8-31444601ff88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7c3b68d2-307b-4783-9fdb-137c7dc9ae9c" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ed16fe59-dd92-4897-83e8-31444601ff88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d314e81d-1e76-4332-a0ac-2c76f4ca5d2b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ed16fe59-dd92-4897-83e8-31444601ff88" xlink:to="loc_srt_ProductOrServiceAxis_d314e81d-1e76-4332-a0ac-2c76f4ca5d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4c8bd373-64b4-472d-8b34-888aa6c4caee" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d314e81d-1e76-4332-a0ac-2c76f4ca5d2b" xlink:to="loc_srt_ProductsAndServicesDomain_4c8bd373-64b4-472d-8b34-888aa6c4caee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_MedicalServicesMember_4aba600f-c71a-4a8d-8941-26fa1ef29be7" xlink:href="agl-20250630.xsd#agl_MedicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4c8bd373-64b4-472d-8b34-888aa6c4caee" xlink:to="loc_agl_MedicalServicesMember_4aba600f-c71a-4a8d-8941-26fa1ef29be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_OtherOperatingMember_d54d571f-01a4-47c1-a3a0-bc03762a15ae" xlink:href="agl-20250630.xsd#agl_OtherOperatingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4c8bd373-64b4-472d-8b34-888aa6c4caee" xlink:to="loc_agl_OtherOperatingMember_d54d571f-01a4-47c1-a3a0-bc03762a15ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1d05a804-909b-46ae-9c5b-618ee8520858" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ed16fe59-dd92-4897-83e8-31444601ff88" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1d05a804-909b-46ae-9c5b-618ee8520858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_88682889-9a81-4a43-ba56-0ea966e56636" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1d05a804-909b-46ae-9c5b-618ee8520858" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_88682889-9a81-4a43-ba56-0ea966e56636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_d4a99a03-3587-478f-8300-b63c2cbd3cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_88682889-9a81-4a43-ba56-0ea966e56636" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_d4a99a03-3587-478f-8300-b63c2cbd3cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ed16fe59-dd92-4897-83e8-31444601ff88" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc94ee9b-75e6-4024-9866-7ca7eb6ab7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc94ee9b-75e6-4024-9866-7ca7eb6ab7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_4b56916a-428e-48d3-bcb0-cd6c9b82857f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_4b56916a-428e-48d3-bcb0-cd6c9b82857f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_73846bee-e3b3-447a-9fa0-7d6e36f4677b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:to="loc_us-gaap_OperatingIncomeLoss_73846bee-e3b3-447a-9fa0-7d6e36f4677b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f96c6aa6-a52a-46f9-9d8f-7760d70279df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:to="loc_us-gaap_NetIncomeLoss_f96c6aa6-a52a-46f9-9d8f-7760d70279df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_PhysicianCompensationExpense_405821ab-3a37-4d35-b38d-ac1f45321594" xlink:href="agl-20250630.xsd#agl_PhysicianCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:to="loc_agl_PhysicianCompensationExpense_405821ab-3a37-4d35-b38d-ac1f45321594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_20eccfb4-2417-4389-bda3-3661992417e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_9fe773e8-7e4f-4ac8-bb2c-bd87b3293085" xlink:to="loc_us-gaap_OperatingExpenses_20eccfb4-2417-4389-bda3-3661992417e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#VariableInterestEntitiesScheduleBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5aab5794-e78e-44f9-8c1c-977d3b5758a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4eb3a338-2c68-40ea-bfee-e341277d1e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5aab5794-e78e-44f9-8c1c-977d3b5758a0" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4eb3a338-2c68-40ea-bfee-e341277d1e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_5b570ef2-e573-4b86-b555-94e0748c92d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4eb3a338-2c68-40ea-bfee-e341277d1e4d" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_5b570ef2-e573-4b86-b555-94e0748c92d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a60029d7-ba8e-4a1d-9473-10715e1e89be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_5b570ef2-e573-4b86-b555-94e0748c92d2" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a60029d7-ba8e-4a1d-9473-10715e1e89be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_47f126ee-38de-45de-b1b2-181aa45f177b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a60029d7-ba8e-4a1d-9473-10715e1e89be" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_47f126ee-38de-45de-b1b2-181aa45f177b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_6a44c368-756e-442c-8915-71b87f5e6468" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_4eb3a338-2c68-40ea-bfee-e341277d1e4d" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_6a44c368-756e-442c-8915-71b87f5e6468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d99eac25-9a47-4a25-9778-632e0ae77d97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6a44c368-756e-442c-8915-71b87f5e6468" xlink:to="loc_us-gaap_AssetsCurrent_d99eac25-9a47-4a25-9778-632e0ae77d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_99b9a62b-eb2b-448b-8c0c-7f08994d39ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6a44c368-756e-442c-8915-71b87f5e6468" xlink:to="loc_us-gaap_AssetsNoncurrent_99b9a62b-eb2b-448b-8c0c-7f08994d39ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5ef4839a-3a18-4425-b3fb-441f49f6b0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6a44c368-756e-442c-8915-71b87f5e6468" xlink:to="loc_us-gaap_Assets_5ef4839a-3a18-4425-b3fb-441f49f6b0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_406ec1ab-908c-44a7-b2a5-640a2447ca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_6a44c368-756e-442c-8915-71b87f5e6468" xlink:to="loc_us-gaap_Liabilities_406ec1ab-908c-44a7-b2a5-640a2447ca5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agilonhealth.com/role/DiscontinuedOperationsDetails" xlink:type="simple" xlink:href="agl-20250630.xsd#DiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://agilonhealth.com/role/DiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_321291a9-43e3-4c53-bde2-fb8ded1c0de9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d0972e57-2e93-490f-a98e-6459d5af2033" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_321291a9-43e3-4c53-bde2-fb8ded1c0de9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d0972e57-2e93-490f-a98e-6459d5af2033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9d50ad38-0358-4691-a721-285e7f8aae4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d0972e57-2e93-490f-a98e-6459d5af2033" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9d50ad38-0358-4691-a721-285e7f8aae4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a927d34d-006b-44fb-9933-09b97afc27f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9d50ad38-0358-4691-a721-285e7f8aae4a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a927d34d-006b-44fb-9933-09b97afc27f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_cb9b9ef4-068f-4fb5-a021-389015e46096" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a927d34d-006b-44fb-9933-09b97afc27f8" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_cb9b9ef4-068f-4fb5-a021-389015e46096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_900951ef-3092-48a3-b27a-53887ca2f084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d0972e57-2e93-490f-a98e-6459d5af2033" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_900951ef-3092-48a3-b27a-53887ca2f084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments_cfd4467b-8c31-4198-95f9-00f417493ca6" xlink:href="agl-20250630.xsd#agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_900951ef-3092-48a3-b27a-53887ca2f084" xlink:to="loc_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments_cfd4467b-8c31-4198-95f9-00f417493ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_194852e8-60ad-4f49-a898-ee23e3948607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_900951ef-3092-48a3-b27a-53887ca2f084" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_194852e8-60ad-4f49-a898-ee23e3948607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_162a700f-e10b-41e3-951a-69fc4c86de37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_900951ef-3092-48a3-b27a-53887ca2f084" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_162a700f-e10b-41e3-951a-69fc4c86de37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b007d550-3214-4adb-a3b2-c02eee5a6fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_900951ef-3092-48a3-b27a-53887ca2f084" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b007d550-3214-4adb-a3b2-c02eee5a6fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">agilon health, inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">37-1915147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">440 Polaris Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Westerville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">43082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">256-3800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AGL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,423,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001831097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 171,416<span></span>
</td>
<td class="nump">$ 188,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted cash and equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="nump">155,585<span></span>
</td>
<td class="nump">211,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables, net</a></td>
<td class="nump">1,047,164<span></span>
</td>
<td class="nump">1,017,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets, net</a></td>
<td class="nump">78,495<span></span>
</td>
<td class="nump">35,137<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,452,660<span></span>
</td>
<td class="nump">1,457,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">27,410<span></span>
</td>
<td class="nump">28,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">65,595<span></span>
</td>
<td class="nump">72,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">24,133<span></span>
</td>
<td class="nump">24,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">143,097<span></span>
</td>
<td class="nump">151,136<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,712,895<span></span>
</td>
<td class="nump">1,733,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and related payables</a></td>
<td class="nump">1,042,257<span></span>
</td>
<td class="nump">931,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">171,886<span></span>
</td>
<td class="nump">220,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current debt</a></td>
<td class="nump">34,945<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,249,088<span></span>
</td>
<td class="nump">1,152,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">54,878<span></span>
</td>
<td class="nump">76,121<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,303,966<span></span>
</td>
<td class="nump">1,263,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value: 2,000,000 shares authorized; 414,283 and 412,194 shares issued and outstanding, respectively</a></td>
<td class="nump">4,143<span></span>
</td>
<td class="nump">4,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,083,234<span></span>
</td>
<td class="nump">2,053,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,679,235)<span></span>
</td>
<td class="num">(1,586,977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">787<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">408,929<span></span>
</td>
<td class="nump">470,952<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 1,712,895<span></span>
</td>
<td class="nump">$ 1,733,983<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-9E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalent restricted as to withdrawal or usage, classified as current. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">414,283,000<span></span>
</td>
<td class="nump">412,194,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">414,283,000<span></span>
</td>
<td class="nump">412,194,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 1,712,895<span></span>
</td>
<td class="nump">$ 1,733,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">1,303,966<span></span>
</td>
<td class="nump">1,263,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">1,190,000<span></span>
</td>
<td class="nump">1,170,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,130,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,394,982<span></span>
</td>
<td class="nump">$ 1,482,758<span></span>
</td>
<td class="nump">$ 2,927,764<span></span>
</td>
<td class="nump">$ 3,087,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">56,281<span></span>
</td>
<td class="nump">69,612<span></span>
</td>
<td class="nump">122,237<span></span>
</td>
<td class="nump">146,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,319<span></span>
</td>
<td class="nump">5,907<span></span>
</td>
<td class="nump">14,195<span></span>
</td>
<td class="nump">11,751<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">1,511,009<span></span>
</td>
<td class="nump">1,526,102<span></span>
</td>
<td class="nump">3,065,901<span></span>
</td>
<td class="nump">3,137,634<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(116,027)<span></span>
</td>
<td class="num">(43,344)<span></span>
</td>
<td class="num">(138,137)<span></span>
</td>
<td class="num">(50,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="nump">5,412<span></span>
</td>
<td class="nump">9,955<span></span>
</td>
<td class="nump">18,084<span></span>
</td>
<td class="nump">15,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">7,879<span></span>
</td>
<td class="nump">4,841<span></span>
</td>
<td class="nump">17,140<span></span>
</td>
<td class="nump">10,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(1,572)<span></span>
</td>
<td class="num">(1,697)<span></span>
</td>
<td class="num">(3,087)<span></span>
</td>
<td class="num">(2,981)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(104,308)<span></span>
</td>
<td class="num">(30,245)<span></span>
</td>
<td class="num">(106,000)<span></span>
</td>
<td class="num">(27,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(417)<span></span>
</td>
<td class="num">(258)<span></span>
</td>
<td class="num">(284)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (loss) from continuing operations</a></td>
<td class="num">(104,370)<span></span>
</td>
<td class="num">(30,662)<span></span>
</td>
<td class="num">(106,258)<span></span>
</td>
<td class="num">(27,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract', window );"><strong>Discontinued operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Income (loss) before gain (loss) on sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Adjustments on sale of assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="num">(8,763)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Total discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="num">(9,281)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(104,370)<span></span>
</td>
<td class="num">(30,662)<span></span>
</td>
<td class="num">(92,258)<span></span>
</td>
<td class="num">(36,696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Noncontrolling interests&#8217; share in (earnings) loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shares</a></td>
<td class="num">$ (104,370)<span></span>
</td>
<td class="num">$ (30,682)<span></span>
</td>
<td class="num">$ (92,258)<span></span>
</td>
<td class="num">$ (36,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per common share, basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations, basic (US dollar per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations, diluted (US dollar per share)</a></td>
<td class="num">(0.25)<span></span>
</td>
<td class="num">(0.07)<span></span>
</td>
<td class="num">(0.25)<span></span>
</td>
<td class="num">(0.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Discontinued operations, basic (US dollar per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="num">(0.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Discontinued operations, diluted (US dollar per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">413,836,000<span></span>
</td>
<td class="nump">411,271,000<span></span>
</td>
<td class="nump">413,388,000<span></span>
</td>
<td class="nump">409,152,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">413,836,000<span></span>
</td>
<td class="nump">411,271,000<span></span>
</td>
<td class="nump">413,388,000<span></span>
</td>
<td class="nump">409,152,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agl_MedicalServicesMember', window );">Medical services revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,392,039<span></span>
</td>
<td class="nump">$ 1,479,579<span></span>
</td>
<td class="nump">$ 2,921,918<span></span>
</td>
<td class="nump">$ 3,080,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Expenses</a></td>
<td class="nump">1,445,245<span></span>
</td>
<td class="nump">1,374,060<span></span>
</td>
<td class="nump">2,847,112<span></span>
</td>
<td class="nump">2,817,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agl_OtherOperatingMember', window );">Other operating revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,943<span></span>
</td>
<td class="nump">3,179<span></span>
</td>
<td class="nump">5,846<span></span>
</td>
<td class="nump">6,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Expenses</a></td>
<td class="nump">$ 2,164<span></span>
</td>
<td class="nump">$ 76,523<span></span>
</td>
<td class="nump">$ 82,357<span></span>
</td>
<td class="nump">$ 161,947<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agl_MedicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agl_MedicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agl_OtherOperatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agl_OtherOperatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (104,370)<span></span>
</td>
<td class="num">$ (30,662)<span></span>
</td>
<td class="num">$ (92,258)<span></span>
</td>
<td class="num">$ (36,696)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on marketable securities, net of tax</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">822<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income (loss)</a></td>
<td class="num">(104,126)<span></span>
</td>
<td class="num">(30,362)<span></span>
</td>
<td class="num">(91,383)<span></span>
</td>
<td class="num">(36,845)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive (income) loss attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss) attributable to agilon health, inc.</a></td>
<td class="num">$ (104,126)<span></span>
</td>
<td class="num">$ (30,382)<span></span>
</td>
<td class="num">$ (91,383)<span></span>
</td>
<td class="num">$ (36,895)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 661,021<span></span>
</td>
<td class="nump">$ 4,064<span></span>
</td>
<td class="nump">$ 1,986,899<span></span>
</td>
<td class="num">$ (1,326,826)<span></span>
</td>
<td class="num">$ (2,298)<span></span>
</td>
<td class="num">$ (818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(36,696)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,626<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement</a></td>
<td class="num">(1,281)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">(1,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">15,230<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">15,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">35,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">675,867<span></span>
</td>
<td class="nump">$ 4,114<span></span>
</td>
<td class="nump">2,038,540<span></span>
</td>
<td class="num">(1,363,572)<span></span>
</td>
<td class="num">(2,447)<span></span>
</td>
<td class="num">(768)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="nump">688,486<span></span>
</td>
<td class="nump">$ 4,108<span></span>
</td>
<td class="nump">2,020,803<span></span>
</td>
<td class="num">(1,332,890)<span></span>
</td>
<td class="num">(2,747)<span></span>
</td>
<td class="num">(788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(30,662)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement</a></td>
<td class="num">(635)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(634)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">18,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">$ 675,867<span></span>
</td>
<td class="nump">$ 4,114<span></span>
</td>
<td class="nump">2,038,540<span></span>
</td>
<td class="num">(1,363,572)<span></span>
</td>
<td class="num">(2,447)<span></span>
</td>
<td class="num">$ (768)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">412,194<span></span>
</td>
<td class="nump">412,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 470,952<span></span>
</td>
<td class="nump">$ 4,122<span></span>
</td>
<td class="nump">2,053,895<span></span>
</td>
<td class="num">(1,586,977)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(92,258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement</a></td>
<td class="num">(2,851)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">(2,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 32,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, (in shares) at Jun. 30, 2025</a></td>
<td class="nump">414,283<span></span>
</td>
<td class="nump">414,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">$ 408,929<span></span>
</td>
<td class="nump">$ 4,143<span></span>
</td>
<td class="nump">2,083,234<span></span>
</td>
<td class="num">(1,679,235)<span></span>
</td>
<td class="nump">787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2025</a></td>
<td class="nump">500,254<span></span>
</td>
<td class="nump">$ 4,130<span></span>
</td>
<td class="nump">2,070,446<span></span>
</td>
<td class="num">(1,574,865)<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(104,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement</a></td>
<td class="num">(2,690)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">(2,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 15,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, (in shares) at Jun. 30, 2025</a></td>
<td class="nump">414,283<span></span>
</td>
<td class="nump">414,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">$ 408,929<span></span>
</td>
<td class="nump">$ 4,143<span></span>
</td>
<td class="nump">$ 2,083,234<span></span>
</td>
<td class="num">$ (1,679,235)<span></span>
</td>
<td class="nump">$ 787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (92,258,000)<span></span>
</td>
<td class="num">$ (36,696,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">14,195,000<span></span>
</td>
<td class="nump">11,751,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">32,101,000<span></span>
</td>
<td class="nump">35,116,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss (income) from equity method investments</a></td>
<td class="num">(18,084,000)<span></span>
</td>
<td class="num">(15,639,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_DistributionsOfEarningsFromEquityMethodInvestments', window );">Distributions of earnings from equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,340,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Adjustments on sale of assets, net</a></td>
<td class="num">(14,000,000)<span></span>
</td>
<td class="nump">3,784,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other noncash items</a></td>
<td class="num">(3,107,000)<span></span>
</td>
<td class="num">(837,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Changes in operating assets and liabilities</a></td>
<td class="nump">14,081,000<span></span>
</td>
<td class="num">(67,312,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(67,072,000)<span></span>
</td>
<td class="num">(66,493,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(7,099,000)<span></span>
</td>
<td class="num">(6,451,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(9,717,000)<span></span>
</td>
<td class="num">(17,893,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_PaymentsToAcquireLoansReceivableAndOther', window );">Investment in loans receivable and other</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="num">(9,742,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Investments in marketable securities</a></td>
<td class="num">(60,154,000)<span></span>
</td>
<td class="num">(12,006,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities and other</a></td>
<td class="nump">125,339,000<span></span>
</td>
<td class="nump">115,747,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">47,369,000<span></span>
</td>
<td class="nump">69,655,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepurchaseOfEquity', window );">Proceeds from (payments for) equity issuances, net</a></td>
<td class="num">(2,741,000)<span></span>
</td>
<td class="nump">1,345,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,500,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(2,741,000)<span></span>
</td>
<td class="num">(1,155,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents</a></td>
<td class="num">(22,444,000)<span></span>
</td>
<td class="nump">2,007,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash and equivalents, beginning of period</a></td>
<td class="nump">193,860,000<span></span>
</td>
<td class="nump">114,329,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash and equivalents, end of period</a></td>
<td class="nump">$ 171,416,000<span></span>
</td>
<td class="nump">$ 116,336,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_DistributionsOfEarningsFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distributions Of Earnings From Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_DistributionsOfEarningsFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_PaymentsToAcquireLoansReceivableAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Loans Receivable And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_PaymentsToAcquireLoansReceivableAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in asset and (increase) decrease in liability, used in operating activity in reconciling net income to reflect cash provided by (used in) operating activity when indirect cash flow method is applied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow resulting from the entity's share transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Business</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. Business</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agilon health, inc., together with its consolidated subsidiaries and VIEs (the &#8220;Company&#8221;), through its partnerships and platform, provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. As of June&#160;30, 2025, the Company, through its contracted physician networks, provided care to approximately 497,500 Medicare Advantage members enrolled with private health plans. Additionally, the Company participates in the Centers for Medicare &amp; Medicaid Services' (&#8220;CMS&#8221;) Accountable Care Organization Realizing Equity, Access, and Community Health (&#8220;ACO REACH&#8221;) Model and Medicare Shared Savings Program (&#8220;MSSP,&#8221; and together with ACO REACH, the &#8220;CMS ACO Models&#8221;) through its equity method investments.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 14 for additional discussions related to the Company&#8217;s involvement with VIEs. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s largest shareholder is an investment fund associated with Clayton Dubilier &amp; Rice, LLC (&#8220;CD&amp;R&#8221;), a private equity firm. All funds affiliated with CD&amp;R are considered related parties.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:24pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. Summary of Significant Accounting Policies</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included. Operating results for the three and six months ended June&#160;30, 2025 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2025. The accompanying condensed consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December&#160;31, 2024 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission.</span></div><div style="margin-bottom:12pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported (&#8220;IBNR&#8221;) claims), and the valuation and related recognition of impairments of long-lived assets, including goodwill. Management&#8217;s estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025 and December&#160;31, 2024, the Company&#8217;s gross carrying amount of property and equipment was $58.6 million and $52.9 million, with accumulated depreciation of $31.2 million and $24.7 million, respectively.  For the three months ended June 30, 2025 and 2024, the Company recognized $3.9 million and $2.9 million, respectively, in depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recognized $7.7 million and $5.8 million, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">respectively, in depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the income tax provision for interim periods using an estimate of the Company&#8217;s annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the &#8220;One Big Beautiful Bill Act&#8221; was signed into law in the U.S., which contains a broad range of tax reform provisions. The Company is evaluating the provisions of the legislation and the potential effects on its estimated annual effective tax rate, financial position, results of operations, and cash flows. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates a Medicare-centric, capitated line of business and is organized as a single operating and reportable segment based on the manner in which the Chief Executive Officer, who is the Chief Operating Decision Maker (&#8220;CODM&#8221;), evaluates performance and makes decisions about how to allocate resources. Segment asset information, which is presented on the consolidated balance sheet, is not used by the CODM to assess performance and make decisions about how to allocate resources. The Company's segment measure of profit or loss is consolidated net income (loss). The CODM uses the segment measure of profit or loss to assess performance and make resource allocation decisions, primarily through periodic budgeting and company performance reviews. Significant expense categories included within the segment measure of profit or loss that are regularly provided to the CODM include medical services expense, other medical expense, and platform support costs. Medical services expense and other medical expense amounts are included in the consolidated statements of operations. Platform support costs were $37.4 million and $41.7 million for the three months ended June 30, 2025 and 2024, respectively. For the three months ended June 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $14.5 million and $21.2 million, respectively. Platform support costs were $81.7 million and $87.4 million for the six months ended June 30, 2025 and 2024, respectively. For the six months ended June 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $8.9 million and $56.6 million, respectively. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-09&#8221;), which amends certain disclosure requirements related to income taxes. The amendments in ASU 2023-09 require public business entities on an annual basis to: (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The amendments in ASU 2023-09 can be applied on a prospective basis or retrospective application. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on its disclosures.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2024-03&#8221;). In January 2025, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2025-01, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2025-01&#8221;). The amendments in ASU 2024-03 require public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement expense line items by breaking down certain expense line items into specified natural expense categories, including purchases of inventory, employee compensation, deprecation, intangible asset amortization, and depletion. The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The amendments in </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2024-03 can be applied on a prospective basis or retrospective basis and early adoption is permitted. The amendments in ASU 2025-01 clarify the effective date of ASU 2024-03 stating that all public business entities are required to adopt the update in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. ASU 2025-01 does not change the effective date of ASU 2024-03 but was issued to provide clarity on the effective date for public business entities that do not have a calendar year-end. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 and ASU 2025-01 on its disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue, Receivables, and Concentration of Credit Risk<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Revenue, Receivables, and Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:24pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. Revenue, Receivables, and Concentration of Credit Risk</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Services Revenue</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors (&#8220;payors&#8221;). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month (&#8220;PMPM&#8221;) fees to provide a defined range of healthcare services for Medicare Advantage health plan members (&#8220;members&#8221;) attributed to the Company&#8217;s contracted primary care physicians. In certain of the Company&#8217;s payor arrangements, it is also financially responsible for Medicare Part D pharmaceutical costs for prescriptions rendered to members. PMPM fees are determined as a percent of the premium payors receive from CMS for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are generally recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification (&#8220;ASC&#8221;) 606, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price for the Company&#8217;s capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS&#8217;s risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member&#8217;s health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company&#8217;s contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of incentive revenue will not occur once any uncertainty is resolved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management&#8217;s estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company contracts with various payors whereby the Company is entitled to monthly PMPM fees to provide a defined range of healthcare services for members attributed to its contracted primary care physicians. The Company generally accepts full financial risk for such members and therefore is responsible for the cost of all healthcare services required by them. Substantially all of the Company&#8217;s receivable balances are from a small number of payors. Revenue from Medicare Advantage payors constitutes substantially all of the Company&#8217;s total revenue for the three and six months ended June&#160;30, 2025 and 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the Company&#8217;s revenue concentration with respect to major payors as a percentage of the Company&#8217;s total revenues: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt">Less than 10% of total revenues.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the Company&#8217;s concentration of credit risk with respect to major payors as a percentage of receivables, net:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt">Less than 10% of total receivables.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-3A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Debt Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Marketable Securities and Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. Marketable Securities and Fair Value Measurements</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s marketable securities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">128,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">154,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155,585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">211,879&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(417)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">211,737&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2025, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $3.6 million, of which $2.6 million was related to its marketable securities investments and $1.0 million was related to interest on cash and cash equivalent balances. For the three months ended June 30, 2024, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $4.8&#160;million, of which $3.3&#160;million was related to its marketable securities investments and $1.5&#160;million was related to interest on cash and cash equivalent balances. For the six months ended June 30, 2025, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $7.9&#160;million, of which $5.7&#160;million was related to its marketable securities investments and $2.2&#160;million was related to interest on cash and cash equivalent balances. For the six months ended June 30, 2024, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $10.2&#160;million, of which $7.2&#160;million was related to its marketable securities investments and $3.0&#160;million was related to interest on cash and cash equivalent balances. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s marketable securities maturity as of June&#160;30, 2025 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40,260&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">154,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155,585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of June&#160;30, 2025 (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,360&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of December&#160;31, 2024 (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">73,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">111,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">313&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unrealized losses from marketable securities as of June&#160;30, 2025 and December&#160;31, 2024 were caused primarily by interest rate increases. As of June&#160;30, 2025, all of the Company&#8217;s marketable securities carry an investment grade rating by nationally recognized statistical rating organizations. The Company does not intend to sell marketable securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. There was no allowance for credit losses on available-for-sale marketable securities at June&#160;30, 2025 or December&#160;31, 2024.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash and equivalents, marketable securities, receivables, other liabilities, accounts payable, certain accrued expenses, and borrowings which consist of a term loan and a revolving credit facility. The carrying values of the financial instruments classified as current in the consolidated balance sheets approximate their fair values due to their short-term maturities. The Company's cash and cash equivalents are classified within Level 1 of the fair value hierarchy. The carrying values of the term loan and revolving credit facility are a reasonable estimate of fair value because the interest rates on such borrowings approximate market rates as of the reporting date. Such borrowings are classified within Level 2 of the fair value hierarchy. During the three and six months ended June&#160;30, 2025 and 2024, there were no material transfers of financial assets or liabilities within the fair value hierarchy. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">unobservable inputs reflect the Company&#8217;s market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1&#8212;quoted prices for identical instruments in active markets; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2&#8212;quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3&#8212;fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,228&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101,030&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110,707&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Other Assets</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:12pt;padding-right:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. Other Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s other assets (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loans to physician partners</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Health plan deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">77,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">143,097&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">151,136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">See Note 14 for additional discussion related to the Company's equity method investments.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loans to Physician Partners</span></div>Loans to physician partners primarily represent loans in connection with taxes payable on shares distributed to them in connection with the IPO. These loans mature between 2026 and 2031 with nominal interest compounding annually and no prepayment penalties. At June&#160;30, 2025, $21.4 million of these loans were reclassed to Prepaid expenses and other current assets, net on the condensed consolidated balance sheet as the maturities were less than 12 months. Such loans are stated at the amount expected to be collected.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Related Payables<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock', window );">Medical Claims and Related Payables</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. Medical Claims and Related Payables</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense represents costs incurred for medical services provided to members by physicians, hospitals and other ancillary providers for which the Company is financially responsible and are paid by payors with whom the Company has contracted. Medical services expenses are recognized in the period in which services are provided and include estimates of claims that have been incurred but have either not yet been received, processed, or paid and as such, not reported.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Such estimates are developed using actuarial methods commonly used by health insurance actuaries that include a number of factors and assumptions including medical service utilization trends, changes in membership, observed medical </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cost trends, historical claim payment patterns and other factors. Generally, for the most recent months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average PMPM medical costs incurred in prior months for which more complete claims data are available.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each period, the Company re-examines previously established medical claims payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claims information becomes available, the Company adjusts its estimates and recognizes those changes in estimates in the period in which the change is identified. The difference between the estimated liability and the actual settlements of claims is recognized in the period the claims are settled. The Company&#8217;s medical claims payable balance represents management&#8217;s best estimate of its liability for unpaid medical costs as of June&#160;30, 2025 and 2024. The Company uses judgment to determine the appropriate assumptions for developing the required estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of changes in medical claims and related payables (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Medical claims and related payables, beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">918,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">723,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Components of incurred costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,810,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,802,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,847,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,817,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,821,175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,806,692)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(930,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(650,106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,751,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,456,798)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Medical claims and related payables, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,013,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,084,175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical claims and related payables also include $28.5 million and $13.3 million, as of June&#160;30, 2025 and December&#160;31, 2024, respectively, that is recoverable from other parties under risk sharing arrangements and is presented as prepaid expenses and other current assets, net in the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/944-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesAbstract', window );"><strong>Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Liabilities</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. Other Liabilities</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s other liabilities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term contingencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">L<span style="-sec-ix-hidden:f-577"><span style="-sec-ix-hidden:f-578">ease liabilities, long-term</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method liabilities &#8211; CMS ACO Models</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">See Note 14 for additional discussion related to the Company's equity method liabilities related to its CMS ACO Models investments.</span></div>As of June&#160;30, 2025 and December&#160;31, 2024, the Company&#8217;s accruals for contingent liabilities related to unasserted claims were $35.0 million and $49.0 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. Debt</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;18, 2021, the Company executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021 and the Second Amendment to Credit Agreement, dated as of May 25, 2023, the &#8220;Credit Facility&#8221;). The Credit Facility includes: (i) a $100.0&#160;million secured term loan facility (the &#8220;Secured Term Loan </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility&#8221;) and (ii) a $100.0&#160;million senior secured revolving credit facility (the &#8220;Secured Revolving Facility&#8221;) with a capacity to issue standby letters of credit in certain circumstances up to a maximum of $100.0&#160;million. Subject to specified conditions and receipt of commitments, the Secured Term Loan Facility may be expanded (or a new term loan facility, revolving credit facility or letter of credit facility added) by up to (i) $50.0&#160;million plus (ii) an additional amount determined in accordance with a formula tied to repayment of certain of the Company&#8217;s indebtedness. The maturity date of the Credit Facility is February&#160;18, 2026.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company had $35.0 million outstanding under the Secured Term Loan Facility and availability under the Secured Revolving Facility was $19.4 million, as the Company had outstanding letters of credit totaling $80.6 million. The standby letters of credit are automatically extended without amendment for one-year periods, unless the Company notifies the institution in advance of the expiration date that the letter will be terminated. No amounts have been drawn on the outstanding letters of credit as of June&#160;30, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective with the Second Amendment to Credit Agreement on May 25, 2023, the Company transitioned to the Secured Overnight Financing Rate (&#8220;SOFR&#8221;) as a benchmark interest rate used in the Credit Agreement. At the Company&#8217;s option, borrowings under the Credit Facility can be either: (i) SOFR Rate Loans, (ii) Daily Simple SOFR Rate Loans, or (iii) Base Rate Loans. Daily Simple SOFR Rate Loans and SOFR Rate Loans bear interest at a rate equal to the sum of 3.50% and the higher of (a) SOFR, as defined in the Credit Agreement, and (b) 0%. Base Rate Loans bear interest at a rate equal to the sum of 2.50% and the highest of: (a) 0.50% in excess of the overnight federal funds rate, (b) the prime rate established by the administrative agent from time to time, (c) the one-month SOFR rate (adjusted for maximum reserves) plus 1.00% and (d) 0%. Additionally, the Company pays a commitment fee on the unfunded Secured Revolving Facility amount of 0.375%. The Company must also pay customary letter of credit fees. As of June&#160;30, 2025, the effective interest rate on the Secured Term Loan Facility was 8.279%.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility is guaranteed by certain of the Company&#8217;s subsidiaries, including those identified as VIEs, and contain customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios. Failure to meet any of these covenants could result in an event of default under the Credit Agreement. If an event of default occurs, the lenders could elect to declare all amounts outstanding under the Credit Agreement to be immediately due and payable. The Company was in compliance with all covenants under the Credit Facility.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;padding-right:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. Commitments and Contingencies</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to, or has a significant relationship to, legal proceedings, lawsuits, and other claims that arise in the ordinary course of the Company's business. Except as described in this Note 9, the Company is not aware of any other legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company's business, prospects, financial condition, results of operations or cash flows. The Company&#8217;s policy is to expense legal costs as they are incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February and March 2024, three class action lawsuits were filed and later consolidated as one matter captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re agilon health, inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, 1:24-cv-00297 (W.D. Tex.) (the &#8220;Consolidated Securities Matter&#8221;). The Consolidated Securities Matter names the Company and certain current and former members of the Company&#8217;s executive team and Board of Directors as defendants, among others. The Consolidated Securities Matter generally asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in connection with statements made between April 2021 and February 2024 in the Company&#8217;s annual and quarterly reports, investor presentations, and earnings releases related to, among other things, the Company&#8217;s financial guidance, medical margin and Adjusted EBITDA results, growth strategy, and data management. The Consolidated Securities Matter seeks compensatory damages, judgment interest, attorney&#8217;s fees and costs, and other unspecified equitable and/or injunctive relief.&#8239;The Company and other defendants filed motions to dismiss the complaint on November 8, 2024, and the motion is now fully submitted and pending before the Court. The Company intends to vigorously oppose the complaint, but is unable to predict the outcome or estimate any ultimate individual or aggregate amount of monetary liability or financial impact due to the early stages of the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May and October 2024, two putative stockholder derivative class action lawsuits were filed: (1) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Douglas v. Steven J. Sell et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, 1:24-cv-00531 (W.D. Tex.) and (2) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bingham v. Steven J. Sell et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, 1:24-cv-01181 (W.D. Tex.) (the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Derivative Matters&#8221;). The Derivative Matters name the Company and certain current and former members of the Company&#8217;s executive team and Board of Directors as defendants. The Derivative Matters generally assert claims under Sections 14(a) and 10(b) of the Exchange Act, as well as common law claims including breach of fiduciary duty, among others, in connection with statements made between April 2021 and February 2024 in the Company&#8217;s annual and quarterly reports, investor presentations, and earnings releases related to, among other things, the Company&#8217;s financial guidance, medical margin and Adjusted EBITDA results, growth strategy, and data management. The </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Douglas</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit also asserts claims under Section 20(a) of the Exchange Act in connection with the same allegations and seeks contribution under Section 11(f) of the Securities Act and Section 21D of the Exchange Act. The Derivative Matters seek compensatory damages, restitution, punitive damages, attorney&#8217;s fees and costs, and other relief.&#8239;The plaintiff in the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Douglas</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> action also seeks corporate governance reforms. The Derivative Matters were consolidated in November 2024 into </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In Re agilon health, inc. Shareholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, 1:24-cv-00531-DII. The consolidated derivative matter is currently stayed, pending resolution of the motion to dismiss in the Consolidated Securities Matter. The Company intends to vigorously oppose the complaint, but is unable to predict the outcome or estimate any ultimate individual or aggregate amount of monetary liability or financial impact due to the early stage of the litigation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. Common Stock</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. During the three months ended June 30, 2025, the Company issued approximately 1.3&#160;million shares of common stock primarily in connection with vesting of stock-based awards. During the six months ended June 30, 2025, the Company issued approximately 2.1&#160;million shares of common stock primarily in connection with vesting of stock-based awards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. During the three months ended June 30, 2024, the Company issued approximately 0.6&#160;million shares of common stock primarily in connection with exercises and vesting of stock-based awards. During the six months ended June 30, 2024, the Company issued approximately 3.1&#160;million shares of common stock primarily in connection with exercises and vesting of stock-based awards. Additionally, during the six months ended June 30, 2024, the Company issued approximately 2.0&#160;million shares of common stock to settle liabilities related to the exchange of common stock for reduced physician partner compensation percentage in certain ACO REACH entities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Common Share</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. Net Income (Loss) Per Common Share</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share (&#8220;EPS&#8221;) is computed based upon the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed based upon the weighted average number of common shares outstanding plus the impact of common shares issuable from the assumed conversion of stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on basic net income (loss) per share are included in diluted net income (loss) per share during the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(104,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(106,258)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27,415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests&#8217; share in (earnings) loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to common stockholders before discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(104,370)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30,682)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(106,258)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27,465)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9,281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(104,370)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30,682)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(92,258)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(36,746)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding &#8211; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">413,836</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">411,271</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">413,388</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">409,152</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) per share attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per common share from continuing operations, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per common share from discontinued operations, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,980</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,421</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25,623</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,177</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Amortizable Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Amortizable Intangible Assets</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. Goodwill and Amortizable Intangible Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of both June&#160;30, 2025 and December&#160;31, 2024, the Company&#8217;s goodwill balance was $24.1 million. There were no events or circumstances that warranted an interim impairment test for goodwill during the six months ended June&#160;30, 2025. </span></div>As of June&#160;30, 2025 and December&#160;31, 2024, the Company&#8217;s gross carrying amount of amortizable intangible assets was $122.8 million and $123.8 million, respectively, with accumulated amortization of $57.2 million and $51.0 million, respectively. For the three months ended June 30, 2025 and 2024, the Company recognized $3.4 million and $3.0 million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recognized $6.5 million and $6.0 million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. Supplemental Cash Flow Information</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental cash flow information (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use asset obtained in exchange for new operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Settlement of liabilities through issuance of stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">188,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and equivalents</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">193,860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span>Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/230/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14. Variable Interest Entities</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agilon health, inc.&#8217;s consolidated assets and liabilities as of June&#160;30, 2025 and December&#160;31, 2024 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to agilon health, inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agilon health, inc.&#8217;s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">78,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,046,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,015,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical claims and related payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,042,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">931,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">154,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">199,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-bearing Entities.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> At June&#160;30, 2025, the Company operates 33 wholly-owned risk-bearing entities (&#8220;RBEs&#8221;) for the purpose of entering into risk-bearing contracts with payors. Each RBE&#8217;s equity at risk is considered insufficient to </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">finance its activities without additional support, and, therefore, each RBE is considered a VIE. The Company consolidates the RBEs as it has determined that it is the primary beneficiary because it has: (i) the ability to control the activities that most significantly impact the RBEs&#8217; economic performance; and (ii) the obligation to absorb losses or right to receive benefits that could potentially be significant to the RBEs. Specifically, the Company has the unilateral ability and authority, through the RBE governance and management agreements, to make significant decisions about strategic and operating activities of the RBEs, including negotiating and entering into risk-bearing contracts with payors, and approving the RBEs&#8217; annual operating budgets. The Company also has the obligation to fund losses of the RBEs and the right to receive a significant percentage of any financial surplus generated by the RBEs. The assets of the RBEs primarily consist of cash and cash equivalents, receivables, net, intangible assets, net, and other assets. Its obligations primarily consist of medical claims and related payables as well as operating expenses of the RBEs (accounts payable and accrued expenses), including incentive compensation obligations to the Company&#8217;s physician partners. On February 18, 2021, the Company executed the Credit Facility, which is guaranteed by certain of the Company&#8217;s VIEs. Assets generated by the RBEs (primarily from medical services revenues) may be used, in certain limited circumstances, to settle the Company&#8217;s contractual debt obligations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company had 12 equity method investments (liabilities), including 10 wholly-owned CMS ACO Models entities discussed below, that were deemed to be VIEs. The Company has determined that the activities that most significantly impact the performance of these VIEs consist of the allocation of resources to and other decisions related to clinical activities and provider contracting decisions. Because the Company does not have the ability to control these activities due to another party&#8217;s control of the VIEs&#8217; board of directors, the Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs. The Company provided support to assist its CMS ACO Models investments in obtaining surety bonds related to risk-bearing capital contributions to CMS. As of June&#160;30, 2025 and December&#160;31, 2024, the CMS ACO Models investments had $131.6 million and $65.2 million, respectively, of outstanding surety bonds. The Company's maximum loss exposure as a result of the Company&#8217;s involvement with the unconsolidated VIEs cannot be quantified as the Company has the obligation to provide ongoing operational support to the unconsolidated VIEs, as needed.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s equity method investees (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments - Other</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments - CMS ACO Models</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">68,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method liabilities - CMS ACO Models</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(12,290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Other assets, net in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Other liabilities in the condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a partner in 10 wholly-owned CMS ACO Models investments in collaboration with 13 of its physician group partners operating in 12 geographies. The combined summarized operating results of the Company&#8217;s CMS ACO Models investments are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">434,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">446,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">848,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">887,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(401,902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(406,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(753,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(805,713)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(17,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(22,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(47,673)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from operations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:26.68pt">The three months ended June 30, 2025 and 2024, includes physician incentive expenses of $8.8 million and $13.7 million, respectively. The six months ended June 30, 2025 and 2024, includes physician incentive expenses of $36.6 million and $30.4 million, respectively. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">The three months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $4.3 million and $1.3 million, respectively. The six months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $8.5 million and $2.6 million, respectively. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Income (loss) from equity method investments in the condensed consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The combined summarized balance sheet of the Company&#8217;s CMS ACO Models investments are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">524,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">444,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">526,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">446,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current and total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">467,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">406,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15. Discontinued Operations</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations is a component of an entity that has either been disposed of or is deemed held-for-sale and, (i) the operations and cash flows of the component have been or will be eliminated from ongoing operations as a result of the disposal transaction, and (ii) the entity will not have any significant continuing involvement in the operations of the component after the disposal transaction. On October 31, 2023, the Company completed the disposition of MDX Hawaii, Inc. and its related operations. The Company&#8217;s decision to exit Hawaii and the Independent Practice Association line of business represents a strategic shift that will have a major effect on its operations and financial results. As such, the Company&#8217;s Hawaii operations are reflected in the condensed consolidated financial statements as discontinued operations for all periods presented. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results of discontinued operations are as follows (in thousands): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(518)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments on sale of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) from discontinued operations attributable to common shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9,281)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (104,370)<span></span>
</td>
<td class="num">$ (30,682)<span></span>
</td>
<td class="num">$ (92,258)<span></span>
</td>
<td class="num">$ (36,746)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div>The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text">The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported (&#8220;IBNR&#8221;) claims), and the valuation and related recognition of impairments of long-lived assets, including goodwill. Management&#8217;s estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the income tax provision for interim periods using an estimate of the Company&#8217;s annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.</span></div>On July 4, 2025, the &#8220;One Big Beautiful Bill Act&#8221; was signed into law in the U.S., which contains a broad range of tax reform provisions. The Company is evaluating the provisions of the legislation and the potential effects on its estimated annual effective tax rate, financial position, results of operations, and cash flows.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div>The Company operates a Medicare-centric, capitated line of business and is organized as a single operating and reportable segment based on the manner in which the Chief Executive Officer, who is the Chief Operating Decision Maker (&#8220;CODM&#8221;), evaluates performance and makes decisions about how to allocate resources. Segment asset information, which is presented on the consolidated balance sheet, is not used by the CODM to assess performance and make decisions about how to allocate resources. The Company's segment measure of profit or loss is consolidated net income (loss). The CODM uses the segment measure of profit or loss to assess performance and make resource allocation decisions, primarily through periodic budgeting and company performance reviews. Significant expense categories included within the segment measure of profit or loss that are regularly provided to the CODM include medical services expense, other medical expense, and platform support costs. Medical services expense and other medical expense amounts are included in the consolidated statements of operations. Platform support costs were $37.4 million and $41.7 million for the three months ended June 30, 2025 and 2024, respectively. For the three months ended June 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $14.5 million and $21.2 million, respectively. Platform support costs were $81.7 million and $87.4 million for the six months ended June 30, 2025 and 2024, respectively. For the six months ended June 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $8.9 million and $56.6 million, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-09&#8221;), which amends certain disclosure requirements related to income taxes. The amendments in ASU 2023-09 require public business entities on an annual basis to: (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The amendments in ASU 2023-09 can be applied on a prospective basis or retrospective application. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on its disclosures.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2024-03&#8221;). In January 2025, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2025-01, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2025-01&#8221;). The amendments in ASU 2024-03 require public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement expense line items by breaking down certain expense line items into specified natural expense categories, including purchases of inventory, employee compensation, deprecation, intangible asset amortization, and depletion. The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The amendments in </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2024-03 can be applied on a prospective basis or retrospective basis and early adoption is permitted. The amendments in ASU 2025-01 clarify the effective date of ASU 2024-03 stating that all public business entities are required to adopt the update in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. ASU 2025-01 does not change the effective date of ASU 2024-03 but was issued to provide clarity on the effective date for public business entities that do not have a calendar year-end. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 and ASU 2025-01 on its disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Medical Services Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Services Revenue</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors (&#8220;payors&#8221;). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month (&#8220;PMPM&#8221;) fees to provide a defined range of healthcare services for Medicare Advantage health plan members (&#8220;members&#8221;) attributed to the Company&#8217;s contracted primary care physicians. In certain of the Company&#8217;s payor arrangements, it is also financially responsible for Medicare Part D pharmaceutical costs for prescriptions rendered to members. PMPM fees are determined as a percent of the premium payors receive from CMS for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are generally recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification (&#8220;ASC&#8221;) 606, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price for the Company&#8217;s capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS&#8217;s risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member&#8217;s health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company&#8217;s contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of incentive revenue will not occur once any uncertainty is resolved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span></div>Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management&#8217;s estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue, Receivables, and Concentration of Credit Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk as a Percentage of Revenues and Receivables</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the Company&#8217;s revenue concentration with respect to major payors as a percentage of the Company&#8217;s total revenues: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt">Less than 10% of total revenues.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the Company&#8217;s concentration of credit risk with respect to major payors as a percentage of receivables, net:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt">Less than 10% of total receivables.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Debt Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s marketable securities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">128,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">154,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155,585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">211,879&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(417)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">211,737&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s marketable securities maturity as of June&#160;30, 2025 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40,260&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">154,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155,585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Marketable Securities, Unrealized Loss Position</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of June&#160;30, 2025 (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,360&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of December&#160;31, 2024 (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">73,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">111,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">313&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,228&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101,030&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110,707&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Other Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s other assets (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loans to physician partners</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Health plan deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">77,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">143,097&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">151,136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">See Note 14 for additional discussion related to the Company's equity method investments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Related Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule Changes in Medical Claims and Related Payables</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of changes in medical claims and related payables (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Medical claims and related payables, beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">918,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">723,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Components of incurred costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,810,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,802,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,847,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,817,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,821,175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,806,692)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(930,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(650,106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,751,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2,456,798)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Medical claims and related payables, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,013,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,084,175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesAbstract', window );"><strong>Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Schedule of Other Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s other liabilities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term contingencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">L<span style="-sec-ix-hidden:f-577"><span style="-sec-ix-hidden:f-578">ease liabilities, long-term</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method liabilities &#8211; CMS ACO Models</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">See Note 14 for additional discussion related to the Company's equity method liabilities related to its CMS ACO Models investments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted EPS</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(104,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(106,258)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27,415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests&#8217; share in (earnings) loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to common stockholders before discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(104,370)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30,682)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(106,258)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27,465)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9,281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(104,370)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30,682)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(92,258)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(36,746)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding &#8211; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">413,836</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">411,271</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">413,388</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">409,152</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) per share attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per common share from continuing operations, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per common share from discontinued operations, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,980</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,421</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25,623</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,177</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental cash flow information (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use asset obtained in exchange for new operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Settlement of liabilities through issuance of stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash Equivalents from Continuing Operations</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">188,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and equivalents</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">193,860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span>Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents from Continuing Operations</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">188,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and equivalents</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">193,860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span>Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Consolidated Asset and Liabilities Include VIE Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agilon health, inc.&#8217;s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">78,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,046,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,015,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical claims and related payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,042,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">931,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">154,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">199,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s equity method investees (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments - Other</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments - CMS ACO Models</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">68,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity method liabilities - CMS ACO Models</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(12,290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Other assets, net in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Other liabilities in the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock', window );">Schedule of Operating Results</a></td>
<td class="text">The combined summarized operating results of the Company&#8217;s CMS ACO Models investments are as follows (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">434,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">446,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">848,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">887,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medical services expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(401,902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(406,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(753,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(805,713)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other medical expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(17,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(22,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(47,673)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from operations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:26.68pt">The three months ended June 30, 2025 and 2024, includes physician incentive expenses of $8.8 million and $13.7 million, respectively. The six months ended June 30, 2025 and 2024, includes physician incentive expenses of $36.6 million and $30.4 million, respectively. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">The three months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $4.3 million and $1.3 million, respectively. The six months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $8.5 million and $2.6 million, respectively. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Included in Income (loss) from equity method investments in the condensed consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of Balance Sheet</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The combined summarized balance sheet of the Company&#8217;s CMS ACO Models investments are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">524,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">444,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">526,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">446,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current and total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">467,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">406,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-9<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Financial Statements Related to Discontinued Operations</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results of discontinued operations are as follows (in thousands): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(518)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments on sale of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss) from discontinued operations attributable to common shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9,281)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>member</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans', window );">Number of medicare advantage members enrolled with private health plans</a></td>
<td class="nump">497,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Medicare Advantage members enrolled with private health plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross carrying amount of property and equipment</a></td>
<td class="nump">$ 58,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated amortization</a></td>
<td class="nump">31,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">56,281<span></span>
</td>
<td class="nump">69,612<span></span>
</td>
<td class="nump">122,237<span></span>
</td>
<td class="nump">146,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=agl_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">14,500<span></span>
</td>
<td class="nump">21,200<span></span>
</td>
<td class="nump">8,900<span></span>
</td>
<td class="nump">56,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agl_PlatformSupportCostsMember', window );">Platform Support Costs | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 37,400<span></span>
</td>
<td class="nump">$ 41,700<span></span>
</td>
<td class="nump">$ 81,700<span></span>
</td>
<td class="nump">$ 87,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=agl_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=agl_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agl_PlatformSupportCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agl_PlatformSupportCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue, Receivables, and Concentration of Credit Risk (Details) - Medicare Advantage Payors<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Payor A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Payor B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Payor C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Payor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Payor E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables | Payor B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables | Payor C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables | Payor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables | Payor E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=agl_PayorAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=agl_PayorAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=agl_PayorBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=agl_PayorBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=agl_PayorCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=agl_PayorCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=agl_PayorDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=agl_PayorDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=agl_PayorEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=agl_PayorEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Marketable debt securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 154,905<span></span>
</td>
<td class="nump">$ 211,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">155,585<span></span>
</td>
<td class="nump">211,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Marketable debt securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">26,330<span></span>
</td>
<td class="nump">110,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">26,357<span></span>
</td>
<td class="nump">110,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Marketable debt securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">128,575<span></span>
</td>
<td class="nump">101,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 129,228<span></span>
</td>
<td class="nump">$ 101,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowances for credit losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DebtSecuritiesMember', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">2025</a></td>
<td class="nump">$ 40,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo', window );">2026</a></td>
<td class="nump">62,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree', window );">2027</a></td>
<td class="nump">27,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour', window );">2028</a></td>
<td class="nump">24,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">154,905<span></span>
</td>
<td class="nump">$ 211,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">2025</a></td>
<td class="nump">40,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo', window );">2026</a></td>
<td class="nump">62,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree', window );">2027</a></td>
<td class="nump">28,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour', window );">2028</a></td>
<td class="nump">24,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 155,585<span></span>
</td>
<td class="nump">$ 211,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities, Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">$ 26,360<span></span>
</td>
<td class="nump">$ 25,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater</a></td>
<td class="nump">16,984<span></span>
</td>
<td class="nump">111,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">747<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater</a></td>
<td class="nump">3,999<span></span>
</td>
<td class="nump">73,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">25,613<span></span>
</td>
<td class="nump">25,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater</a></td>
<td class="nump">12,985<span></span>
</td>
<td class="nump">38,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Schedule of Fair Value Assets Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 155,585<span></span>
</td>
<td class="nump">$ 211,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">129,228<span></span>
</td>
<td class="nump">101,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">26,357<span></span>
</td>
<td class="nump">110,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">26,357<span></span>
</td>
<td class="nump">110,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">26,357<span></span>
</td>
<td class="nump">110,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">129,228<span></span>
</td>
<td class="nump">101,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">129,228<span></span>
</td>
<td class="nump">101,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_LoansToPhysiciansPartners', window );">Loans to physician partners</a></td>
<td class="nump">$ 39,381<span></span>
</td>
<td class="nump">$ 63,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_HealthPlanDepositsNoncurrent', window );">Health plan deposits</a></td>
<td class="nump">2,051<span></span>
</td>
<td class="nump">2,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">77,906<span></span>
</td>
<td class="nump">61,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use lease assets</a></td>
<td class="nump">8,838<span></span>
</td>
<td class="nump">8,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other</a></td>
<td class="nump">14,921<span></span>
</td>
<td class="nump">15,391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 143,097<span></span>
</td>
<td class="nump">$ 151,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_HealthPlanDepositsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Plan Deposits, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_HealthPlanDepositsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_LoansToPhysiciansPartners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loans To Physicians Partners</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_LoansToPhysiciansPartners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableRelatedParties', window );">Loans receivable</a></td>
<td class="nump">$ 21.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAndLeasesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Related Payables - Schedule Changes in Medical Claims and Related Payables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable', window );">Medical claims and related payables, beginning of the year</a></td>
<td class="nump">$ 918,395<span></span>
</td>
<td class="nump">$ 723,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Components of incurred costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">2,810,528<span></span>
</td>
<td class="nump">2,802,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="nump">36,584<span></span>
</td>
<td class="nump">15,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Incurred cost related to claims</a></td>
<td class="nump">2,847,112<span></span>
</td>
<td class="nump">2,817,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Claims paid related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="num">(1,821,175)<span></span>
</td>
<td class="num">(1,806,692)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="num">(930,606)<span></span>
</td>
<td class="num">(650,106)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Claims paid related</a></td>
<td class="num">(2,751,781)<span></span>
</td>
<td class="num">(2,456,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable', window );">Medical claims and related payables, end of the period</a></td>
<td class="nump">$ 1,013,726<span></span>
</td>
<td class="nump">$ 1,084,175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Claims And Claims Adjustment Expense, Including Amounts Recoverable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Medical Claims and Related Payables - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable', window );">Related payables associated with retained liability</a></td>
<td class="nump">$ 28.5<span></span>
</td>
<td class="nump">$ 13.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Claims And Claims Adjustment Expense, Amounts Recoverable under risk sharing arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities - Schedule of Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesAbstract', window );"><strong>Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueNoncurrent', window );">Other long-term contingencies</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, long-term</a></td>
<td class="nump">$ 6,428<span></span>
</td>
<td class="nump">$ 6,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_EquityMethodLiabilitiesNoncurrent', window );">Equity method liabilities &#8211; CMS ACO Models</a></td>
<td class="nump">$ 10,355<span></span>
</td>
<td class="nump">$ 12,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">3,095<span></span>
</td>
<td class="nump">8,232<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">$ 54,878<span></span>
</td>
<td class="nump">$ 76,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_EquityMethodLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_EquityMethodLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_OtherLiabilitiesLineItems', window );"><strong>Other Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueNoncurrent', window );">Other long-term contingencies</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnassertedClaimMember', window );">Unasserted Claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_OtherLiabilitiesLineItems', window );"><strong>Other Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueNoncurrent', window );">Other long-term contingencies</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_OtherLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_OtherLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnassertedClaimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnassertedClaimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 25, 2023</div></th>
<th class="th"><div>Feb. 18, 2021</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=agl_SecuredTermLoanFacilityMember', window );">Secured Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit', window );">Line of credit facility, accordion feature, increase limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.279%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=agl_SecuredTermLoanFacilityMember', window );">Secured Term Loan Facility | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=agl_SecuredTermLoanFacilityMember', window );">Secured Term Loan Facility | Overnight Federal Funds Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=agl_SecuredTermLoanFacilityMember', window );">Secured Term Loan Facility | Maximum | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=agl_SecuredTermLoanFacilityMember', window );">Secured Term Loan Facility | Maximum | Base Rate Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=agl_SecuredTermLoanFacilityMember', window );">Secured Term Loan Facility | Minimum | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=agl_SecuredTermLoanFacilityMember', window );">Secured Term Loan Facility | Minimum | Base Rate Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=agl_SecuredRevolvingFacilityMember', window );">Secured Revolving Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Credit facility remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=agl_SecuredRevolvingFacilityMember', window );">Secured Revolving Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit facility, unused capacity, commitment fee percentage</a></td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Total outstanding letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_ExtendedTermOfLettersOfCredit', window );">Extended term of letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_ExtendedTermOfLettersOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended term of letters of credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_ExtendedTermOfLettersOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Accordion Feature, Increase Limit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=agl_SecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=agl_SecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=agl_SecuredRevolvingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=agl_SecuredRevolvingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - lawsuit<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=agl_ConsolidatedSecuritiesMatterMember', window );">Consolidated Securities Matter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, new claims filed</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=agl_DerivativeMattersMember', window );">Derivative Matters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, new claims filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=agl_ConsolidatedSecuritiesMatterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=agl_ConsolidatedSecuritiesMatterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=agl_DerivativeMattersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=agl_DerivativeMattersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - Common Stock - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Number of shares issued under share-based awards (in shares)</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares issued to settle liabilities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Common Share - Schedule of Computation of Basic and Diluted EPS (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (loss) from continuing operations</a></td>
<td class="num">$ (104,370)<span></span>
</td>
<td class="num">$ (30,662)<span></span>
</td>
<td class="num">$ (106,258)<span></span>
</td>
<td class="num">$ (27,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Noncontrolling interests&#8217; share in (earnings) loss from continuing operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income (loss) attributable to common stockholders before discontinued operations</a></td>
<td class="num">(104,370)<span></span>
</td>
<td class="num">(30,682)<span></span>
</td>
<td class="num">(106,258)<span></span>
</td>
<td class="num">(27,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="num">(9,281)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shares</a></td>
<td class="num">$ (104,370)<span></span>
</td>
<td class="num">$ (30,682)<span></span>
</td>
<td class="num">$ (92,258)<span></span>
</td>
<td class="num">$ (36,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">413,836,000<span></span>
</td>
<td class="nump">411,271,000<span></span>
</td>
<td class="nump">413,388,000<span></span>
</td>
<td class="nump">409,152,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">413,836,000<span></span>
</td>
<td class="nump">411,271,000<span></span>
</td>
<td class="nump">413,388,000<span></span>
</td>
<td class="nump">409,152,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Net income (loss) per share attributable to common stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net income (loss) per common share from continuing operations, basic (US dollar per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net income (loss) per common share from continuing operations, diluted (US dollar per share)</a></td>
<td class="num">(0.25)<span></span>
</td>
<td class="num">(0.07)<span></span>
</td>
<td class="num">(0.25)<span></span>
</td>
<td class="num">(0.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Net income (loss) per common share from discontinued operations, basic (US dollar per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="num">(0.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Net income (loss) per common share from discontinued operations, diluted (US dollar per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Common Share - Schedule of Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">20,980<span></span>
</td>
<td class="nump">17,421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">25,623<span></span>
</td>
<td class="nump">20,177<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Amortizable Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 24,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross carrying amount of amortizable intangible assets</a></td>
<td class="nump">122,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">57,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 2,659<span></span>
</td>
<td class="nump">$ 1,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for new operating lease liability</a></td>
<td class="nump">1,602<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Settlement of liabilities through issuance of stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 171,416<span></span>
</td>
<td class="nump">$ 188,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted cash and equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,629<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents</a></td>
<td class="nump">$ 171,416<span></span>
</td>
<td class="nump">$ 193,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalent restricted as to withdrawal or usage, classified as current. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities - Schedule of Consolidated Asset and Liabilities Include VIE Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 171,416<span></span>
</td>
<td class="nump">$ 188,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables, net</a></td>
<td class="nump">1,047,164<span></span>
</td>
<td class="nump">1,017,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets, net</a></td>
<td class="nump">78,495<span></span>
</td>
<td class="nump">35,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">27,410<span></span>
</td>
<td class="nump">28,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">65,595<span></span>
</td>
<td class="nump">72,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and related payables</a></td>
<td class="nump">1,042,257<span></span>
</td>
<td class="nump">931,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">171,886<span></span>
</td>
<td class="nump">220,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">57,361<span></span>
</td>
<td class="nump">78,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalents', window );">Restricted cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables, net</a></td>
<td class="nump">1,046,335<span></span>
</td>
<td class="nump">1,015,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets, net</a></td>
<td class="nump">31,599<span></span>
</td>
<td class="nump">17,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">43,651<span></span>
</td>
<td class="nump">49,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets, net</a></td>
<td class="nump">5,584<span></span>
</td>
<td class="nump">4,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and related payables</a></td>
<td class="nump">1,042,257<span></span>
</td>
<td class="nump">931,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">154,932<span></span>
</td>
<td class="nump">199,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 1,381<span></span>
</td>
<td class="nump">$ 2,270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-7<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-9E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalent restricted as to withdrawal or usage. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>investment </div>
<div>entity </div>
<div>partner </div>
<div>geography</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_NumberOfGeographicalLocation', window );">Number of geographies | geography</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_NumberOfWhollyOwnedRiskBearingEntities', window );">Number of wholly-owned risk-bearing entities</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_NumberOfDirectContractingEntities', window );">Number of direct contracting entities</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_NumberOfPhysicianGroupPartners', window );">Number of physician group partners | partner</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_NumberOfEquityMethodInvestments', window );">Number of equity method investments for VIEs | investment</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Surety Bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt | $</a></td>
<td class="nump">$ 131.6<span></span>
</td>
<td class="nump">$ 65.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_NumberOfDirectContractingEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Direct Contracting Entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_NumberOfDirectContractingEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_NumberOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_NumberOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_NumberOfGeographicalLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of geographical location.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_NumberOfGeographicalLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_NumberOfPhysicianGroupPartners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of physician group partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_NumberOfPhysicianGroupPartners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_NumberOfWhollyOwnedRiskBearingEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of wholly-owned risk-bearing entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_NumberOfWhollyOwnedRiskBearingEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SuretyBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SuretyBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities - Schedule of Equity Method Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">$ 77,906<span></span>
</td>
<td class="nump">$ 61,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_EquityMethodLiabilities', window );">Equity method liabilities</a></td>
<td class="num">(10,355)<span></span>
</td>
<td class="num">(12,290)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=agl_OtherEquityMethodInvestmentsMember', window );">Other Equity Methods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">9,378<span></span>
</td>
<td class="nump">9,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=agl_ACOREACHMember', window );">ACO REACH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">$ 68,528<span></span>
</td>
<td class="nump">$ 52,391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_EquityMethodLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_EquityMethodLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=agl_OtherEquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=agl_OtherEquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=agl_ACOREACHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=agl_ACOREACHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities - Schedule of Operating Results (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,394,982<span></span>
</td>
<td class="nump">$ 1,482,758<span></span>
</td>
<td class="nump">$ 2,927,764<span></span>
</td>
<td class="nump">$ 3,087,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(116,027)<span></span>
</td>
<td class="num">(43,344)<span></span>
</td>
<td class="num">(138,137)<span></span>
</td>
<td class="num">(50,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(104,370)<span></span>
</td>
<td class="num">(30,682)<span></span>
</td>
<td class="num">(92,258)<span></span>
</td>
<td class="num">(36,746)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Equity Method Investment, Nonconsolidated Investee or Group of Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">6,396<span></span>
</td>
<td class="nump">11,325<span></span>
</td>
<td class="nump">22,609<span></span>
</td>
<td class="nump">20,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">5,395<span></span>
</td>
<td class="nump">9,921<span></span>
</td>
<td class="nump">18,072<span></span>
</td>
<td class="nump">15,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_PhysicianCompensationExpense', window );">Physician compensation expense</a></td>
<td class="nump">8,800<span></span>
</td>
<td class="nump">13,700<span></span>
</td>
<td class="nump">36,600<span></span>
</td>
<td class="nump">30,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agl_MedicalServicesMember', window );">Medical services revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,392,039<span></span>
</td>
<td class="nump">1,479,579<span></span>
</td>
<td class="nump">2,921,918<span></span>
</td>
<td class="nump">3,080,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Expenses</a></td>
<td class="num">(1,445,245)<span></span>
</td>
<td class="num">(1,374,060)<span></span>
</td>
<td class="num">(2,847,112)<span></span>
</td>
<td class="num">(2,817,902)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agl_MedicalServicesMember', window );">Medical services revenue | Equity Method Investment, Nonconsolidated Investee or Group of Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">434,806<span></span>
</td>
<td class="nump">446,914<span></span>
</td>
<td class="nump">848,271<span></span>
</td>
<td class="nump">887,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Expenses</a></td>
<td class="num">(401,902)<span></span>
</td>
<td class="num">(406,921)<span></span>
</td>
<td class="num">(753,755)<span></span>
</td>
<td class="num">(805,713)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agl_OtherOperatingMember', window );">Other operating revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,943<span></span>
</td>
<td class="nump">3,179<span></span>
</td>
<td class="nump">5,846<span></span>
</td>
<td class="nump">6,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Expenses</a></td>
<td class="num">(2,164)<span></span>
</td>
<td class="num">(76,523)<span></span>
</td>
<td class="num">(82,357)<span></span>
</td>
<td class="num">(161,947)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agl_OtherOperatingMember', window );">Other operating revenue | Equity Method Investment, Nonconsolidated Investee or Group of Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Expenses</a></td>
<td class="num">$ (17,848)<span></span>
</td>
<td class="num">$ (22,268)<span></span>
</td>
<td class="num">$ (54,090)<span></span>
</td>
<td class="num">$ (47,673)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_PhysicianCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Physician compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_PhysicianCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agl_MedicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agl_MedicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agl_OtherOperatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agl_OtherOperatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities - Schedule Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">$ 1,452,660<span></span>
</td>
<td class="nump">$ 1,457,774<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,712,895<span></span>
</td>
<td class="nump">1,733,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Current and total liabilities</a></td>
<td class="nump">1,303,966<span></span>
</td>
<td class="nump">1,263,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Equity Method Investment, Nonconsolidated Investee or Group of Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">524,238<span></span>
</td>
<td class="nump">444,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Noncurrent assets</a></td>
<td class="nump">1,894<span></span>
</td>
<td class="nump">1,894<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">526,132<span></span>
</td>
<td class="nump">446,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Current and total liabilities</a></td>
<td class="nump">$ 467,959<span></span>
</td>
<td class="nump">$ 406,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Details) - Discontinued Operations, Disposed of by Sale - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments', window );">General and administrative</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 518<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Adjustments on sale of assets, net</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="num">(8,763)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income (loss) from discontinued operations attributable to common shares</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="num">$ (9,281)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, General And Administrative Expense, Net Of Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>171</ContextCount>
  <ElementCount>241</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRisk</Role>
      <ShortName>Revenue, Receivables, and Concentration of Credit Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Marketable Securities and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurements</Role>
      <ShortName>Marketable Securities and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/OtherAssets</Role>
      <ShortName>Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Medical Claims and Related Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/MedicalClaimsandRelatedPayables</Role>
      <ShortName>Medical Claims and Related Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/OtherLiabilities</Role>
      <ShortName>Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Net Income (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/NetIncomeLossPerCommonShare</Role>
      <ShortName>Net Income (Loss) Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Goodwill and Amortizable Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssets</Role>
      <ShortName>Goodwill and Amortizable Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/VariableInterestEntities</Role>
      <ShortName>Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskTables</Role>
      <ShortName>Revenue, Receivables, and Concentration of Credit Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRisk</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/OtherAssetsTables</Role>
      <ShortName>Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/OtherAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Medical Claims and Related Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesTables</Role>
      <ShortName>Medical Claims and Related Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/MedicalClaimsandRelatedPayables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/OtherLiabilitiesTables</Role>
      <ShortName>Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/OtherLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Net Income (Loss) Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables</Role>
      <ShortName>Net Income (Loss) Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/NetIncomeLossPerCommonShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Variable Interest Entities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/VariableInterestEntitiesTables</Role>
      <ShortName>Variable Interest Entities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/VariableInterestEntities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/DiscontinuedOperations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/BusinessDetails</Role>
      <ShortName>Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/Business</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails</Role>
      <ShortName>Revenue, Receivables, and Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Marketable Securities and Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities, Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities, Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Fair Value Assets Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Schedule of Fair Value Assets Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/OtherAssetsDetails</Role>
      <ShortName>Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/OtherAssetsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Other Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/OtherAssetsNarrativeDetails</Role>
      <ShortName>Other Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Medical Claims and Related Payables - Schedule Changes in Medical Claims and Related Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails</Role>
      <ShortName>Medical Claims and Related Payables - Schedule Changes in Medical Claims and Related Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Medical Claims and Related Payables - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesNarrativeDetails</Role>
      <ShortName>Medical Claims and Related Payables - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Other Liabilities - Schedule of Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails</Role>
      <ShortName>Other Liabilities - Schedule of Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Other Liabilities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails</Role>
      <ShortName>Other Liabilities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/Debt</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/CommitmentsandContingencies</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/CommonStock</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Computation of Basic and Diluted EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails</Role>
      <ShortName>Net Income (Loss) Per Common Share - Schedule of Computation of Basic and Diluted EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Income (Loss) Per Common Share - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Goodwill and Amortizable Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Amortizable Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssets</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails</Role>
      <ShortName>Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Variable Interest Entities - Schedule of Consolidated Asset and Liabilities Include VIE Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails</Role>
      <ShortName>Variable Interest Entities - Schedule of Consolidated Asset and Liabilities Include VIE Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Variable Interest Entities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails</Role>
      <ShortName>Variable Interest Entities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Variable Interest Entities - Schedule of Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails</Role>
      <ShortName>Variable Interest Entities - Schedule of Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Variable Interest Entities - Schedule of Operating Results (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails</Role>
      <ShortName>Variable Interest Entities - Schedule of Operating Results (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Variable Interest Entities - Schedule Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails</Role>
      <ShortName>Variable Interest Entities - Schedule Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="agl-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agilonhealth.com/role/DiscontinuedOperationsDetails</Role>
      <ShortName>Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agilonhealth.com/role/DiscontinuedOperationsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="agl-20250630.htm">agl-20250630.htm</File>
    <File>agl-20250630.xsd</File>
    <File>agl-20250630_cal.xml</File>
    <File>agl-20250630_def.xml</File>
    <File>agl-20250630_lab.xml</File>
    <File>agl-20250630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="710">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "agl-20250630.htm": {
   "nsprefix": "agl",
   "nsuri": "http://agilonhealth.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "agl-20250630.htm"
     ]
    },
    "schema": {
     "local": [
      "agl-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "agl-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "agl-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "agl-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "agl-20250630_pre.xml"
     ]
    }
   },
   "keyStandard": 217,
   "keyCustom": 24,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 15,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://fasb.org/us-gaap/2025": 2
   },
   "contextCount": 171,
   "entityCount": 1,
   "segmentCount": 44,
   "elementCount": 503,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 710,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4,
    "http://fasb.org/srt/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://agilonhealth.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
     "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-56",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-56",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://agilonhealth.com/role/Business",
     "longName": "9952157 - Disclosure - Business",
     "shortName": "Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://agilonhealth.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRisk",
     "longName": "9952159 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk",
     "shortName": "Revenue, Receivables, and Concentration of Credit Risk",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurements",
     "longName": "9952160 - Disclosure - Marketable Securities and Fair Value Measurements",
     "shortName": "Marketable Securities and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://agilonhealth.com/role/OtherAssets",
     "longName": "9952161 - Disclosure - Other Assets",
     "shortName": "Other Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://agilonhealth.com/role/MedicalClaimsandRelatedPayables",
     "longName": "9952162 - Disclosure - Medical Claims and Related Payables",
     "shortName": "Medical Claims and Related Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://agilonhealth.com/role/OtherLiabilities",
     "longName": "9952163 - Disclosure - Other Liabilities",
     "shortName": "Other Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://agilonhealth.com/role/Debt",
     "longName": "9952164 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://agilonhealth.com/role/CommitmentsandContingencies",
     "longName": "9952165 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://agilonhealth.com/role/CommonStock",
     "longName": "9952166 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://agilonhealth.com/role/NetIncomeLossPerCommonShare",
     "longName": "9952167 - Disclosure - Net Income (Loss) Per Common Share",
     "shortName": "Net Income (Loss) Per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssets",
     "longName": "9952168 - Disclosure - Goodwill and Amortizable Intangible Assets",
     "shortName": "Goodwill and Amortizable Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://agilonhealth.com/role/SupplementalCashFlowInformation",
     "longName": "9952169 - Disclosure - Supplemental Cash Flow Information",
     "shortName": "Supplemental Cash Flow Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://agilonhealth.com/role/VariableInterestEntities",
     "longName": "9952170 - Disclosure - Variable Interest Entities",
     "shortName": "Variable Interest Entities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://agilonhealth.com/role/DiscontinuedOperations",
     "longName": "9952171 - Disclosure - Discontinued Operations",
     "shortName": "Discontinued Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskTables",
     "longName": "9955512 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk (Tables)",
     "shortName": "Revenue, Receivables, and Concentration of Credit Risk (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables",
     "longName": "9955513 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)",
     "shortName": "Marketable Securities and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://agilonhealth.com/role/OtherAssetsTables",
     "longName": "9955514 - Disclosure - Other Assets (Tables)",
     "shortName": "Other Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesTables",
     "longName": "9955515 - Disclosure - Medical Claims and Related Payables (Tables)",
     "shortName": "Medical Claims and Related Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://agilonhealth.com/role/OtherLiabilitiesTables",
     "longName": "9955516 - Disclosure - Other Liabilities (Tables)",
     "shortName": "Other Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables",
     "longName": "9955517 - Disclosure - Net Income (Loss) Per Common Share (Tables)",
     "shortName": "Net Income (Loss) Per Common Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://agilonhealth.com/role/SupplementalCashFlowInformationTables",
     "longName": "9955518 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://agilonhealth.com/role/VariableInterestEntitiesTables",
     "longName": "9955519 - Disclosure - Variable Interest Entities (Tables)",
     "shortName": "Variable Interest Entities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://agilonhealth.com/role/DiscontinuedOperationsTables",
     "longName": "9955520 - Disclosure - Discontinued Operations (Tables)",
     "shortName": "Discontinued Operations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://agilonhealth.com/role/BusinessDetails",
     "longName": "9955521 - Disclosure - Business (Details)",
     "shortName": "Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "agl:NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans",
      "unitRef": "member",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "agl:NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans",
      "unitRef": "member",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9955522 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails",
     "longName": "9955523 - Disclosure - Revenue, Receivables, and Concentration of Credit Risk (Details)",
     "shortName": "Revenue, Receivables, and Concentration of Credit Risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-75",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-75",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails",
     "longName": "9955524 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Details)",
     "shortName": "Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails",
     "longName": "9955525 - Disclosure - Marketable Securities and Fair Value Measurements - Narrative (Details)",
     "shortName": "Marketable Securities and Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:InvestmentIncomeNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:InvestmentIncomeNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails",
     "longName": "9955526 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities Maturity (Details)",
     "shortName": "Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails",
     "longName": "9955527 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities, Unrealized Loss Position (Details)",
     "shortName": "Marketable Securities and Fair Value Measurements - Schedule of Marketable Securities, Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails",
     "longName": "9955528 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Fair Value Assets Measured on Recurring Basis (Details)",
     "shortName": "Marketable Securities and Fair Value Measurements - Schedule of Fair Value Assets Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://agilonhealth.com/role/OtherAssetsDetails",
     "longName": "9955529 - Disclosure - Other Assets (Details)",
     "shortName": "Other Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "agl:LoansToPhysiciansPartners",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "agl:LoansToPhysiciansPartners",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://agilonhealth.com/role/OtherAssetsNarrativeDetails",
     "longName": "9955530 - Disclosure - Other Assets - Narrative (Details)",
     "shortName": "Other Assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LoansAndLeasesReceivableRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LoansAndLeasesReceivableRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails",
     "longName": "9955531 - Disclosure - Medical Claims and Related Payables - Schedule Changes in Medical Claims and Related Payables (Details)",
     "shortName": "Medical Claims and Related Payables - Schedule Changes in Medical Claims and Related Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesNarrativeDetails",
     "longName": "9955532 - Disclosure - Medical Claims and Related Payables - Narrative (Details)",
     "shortName": "Medical Claims and Related Payables - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "agl:LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "agl:LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails",
     "longName": "9955533 - Disclosure - Other Liabilities - Schedule of Other Liabilities (Details)",
     "shortName": "Other Liabilities - Schedule of Other Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LossContingencyAccrualCarryingValueNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails",
     "longName": "9955534 - Disclosure - Other Liabilities - Narrative (Details)",
     "shortName": "Other Liabilities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LossContingencyAccrualCarryingValueNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-125",
      "name": "us-gaap:LossContingencyAccrualCarryingValueNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://agilonhealth.com/role/DebtDetails",
     "longName": "9955535 - Disclosure - Debt (Details)",
     "shortName": "Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://agilonhealth.com/role/CommitmentsandContingenciesDetails",
     "longName": "9955536 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-142",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "lawsuit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-142",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "lawsuit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://agilonhealth.com/role/CommonStockDetails",
     "longName": "9955537 - Disclosure - Common Stock (Details)",
     "shortName": "Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-25",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-25",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails",
     "longName": "9955538 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Computation of Basic and Diluted EPS (Details)",
     "shortName": "Net Income (Loss) Per Common Share - Schedule of Computation of Basic and Diluted EPS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails",
     "longName": "9955539 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Antidilutive Securities (Details)",
     "shortName": "Net Income (Loss) Per Common Share - Schedule of Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-144",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-144",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails",
     "longName": "9955540 - Disclosure - Goodwill and Amortizable Intangible Assets (Details)",
     "shortName": "Goodwill and Amortizable Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails",
     "longName": "9955541 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details)",
     "shortName": "Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails",
     "longName": "9955542 - Disclosure - Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations (Details)",
     "shortName": "Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash Equivalents from Continuing Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails",
     "longName": "9955543 - Disclosure - Variable Interest Entities - Schedule of Consolidated Asset and Liabilities Include VIE Assets and Liabilities (Details)",
     "shortName": "Variable Interest Entities - Schedule of Consolidated Asset and Liabilities Include VIE Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails",
     "longName": "9955544 - Disclosure - Variable Interest Entities - Narrative (Details)",
     "shortName": "Variable Interest Entities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "agl:NumberOfGeographicalLocation",
      "unitRef": "geography",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "agl:NumberOfGeographicalLocation",
      "unitRef": "geography",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails",
     "longName": "9955545 - Disclosure - Variable Interest Entities - Schedule of Equity Method Investments (Details)",
     "shortName": "Variable Interest Entities - Schedule of Equity Method Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "agl:EquityMethodLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails",
     "longName": "9955546 - Disclosure - Variable Interest Entities - Schedule of Operating Results (Details)",
     "shortName": "Variable Interest Entities - Schedule of Operating Results (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-164",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails",
     "longName": "9955547 - Disclosure - Variable Interest Entities - Schedule Balance Sheet (Details)",
     "shortName": "Variable Interest Entities - Schedule Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-168",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://agilonhealth.com/role/DiscontinuedOperationsDetails",
     "longName": "9955548 - Disclosure - Discontinued Operations (Details)",
     "shortName": "Discontinued Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-170",
      "name": "agl:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-170",
      "name": "agl:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agl-20250630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "agl_ACOREACHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "ACOREACHMember",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACO REACH",
        "label": "ACO REACH [Member]",
        "documentation": "ACO REACH"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "verboseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r1049"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r166",
      "r643"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r82",
      "r173",
      "r640",
      "r685",
      "r686",
      "r1132"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11",
      "r19",
      "r522",
      "r525",
      "r576",
      "r681",
      "r682",
      "r986",
      "r987",
      "r988",
      "r1041",
      "r1042",
      "r1043",
      "r1044"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1133",
      "r1202"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Shares withheld related to net share settlement",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r895",
      "r905",
      "r937"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r898",
      "r908",
      "r940"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r933",
      "r941",
      "r945",
      "r953"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r193",
      "r350",
      "r352",
      "r773",
      "r775",
      "r776",
      "r778",
      "r780"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r128",
      "r170",
      "r206",
      "r209",
      "r210",
      "r239",
      "r250",
      "r274",
      "r277",
      "r324",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r513",
      "r518",
      "r558",
      "r628",
      "r629",
      "r636",
      "r722",
      "r792",
      "r793",
      "r804",
      "r838",
      "r860",
      "r862",
      "r876",
      "r1094",
      "r1095",
      "r1147"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "terseLabel": "Current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r174",
      "r206",
      "r209",
      "r210",
      "r324",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r513",
      "r518",
      "r558",
      "r838",
      "r1094",
      "r1095",
      "r1147"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r209",
      "r210",
      "r324",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r513",
      "r518",
      "r558",
      "r1094",
      "r1095",
      "r1147"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r796"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r632"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BaseRateMember",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate Loans",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": [
      "r985",
      "r1092"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/Business"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business",
        "label": "Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r164",
      "r774"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities and Fair Value Measurements",
        "label": "Cash, Cash Equivalent, and Marketable Security [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, cash equivalents and restricted cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r98",
      "r203"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash and equivalents, beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash and equivalents, end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r98",
      "r203"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r98"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/SupplementalCashFlowInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Information",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r118",
      "r638",
      "r709"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r365",
      "r366",
      "r766",
      "r1080",
      "r1085"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://agilonhealth.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r868",
      "r870",
      "r871",
      "r872",
      "r873",
      "r1041",
      "r1042",
      "r1044",
      "r1133",
      "r1199",
      "r1202"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r710"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance, (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r76",
      "r710",
      "r728",
      "r1202",
      "r1203"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.01 par value: 2,000,000 shares authorized; 414,283 and 412,194 shares issued and outstanding, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r415",
      "r420",
      "r639",
      "r838"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income (loss) attributable to agilon health, inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r180",
      "r182",
      "r190",
      "r626",
      "r653",
      "r655"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Comprehensive (income) loss attributable to noncontrolling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r36",
      "r45",
      "r180",
      "r182",
      "r189",
      "r625",
      "r653",
      "r654"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r111",
      "r180",
      "r182",
      "r188",
      "r624",
      "r653"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r283",
      "r688",
      "r689",
      "r765",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r283",
      "r688",
      "r689",
      "r765",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r283",
      "r688",
      "r689",
      "r765",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRisk"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Receivables, and Concentration of Credit Risk",
        "label": "Concentration Risk Disclosure [Text Block]",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r245",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r786",
      "r1047"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r765",
      "r785",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r283",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r765",
      "r785",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r283",
      "r688",
      "r689",
      "r765",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities",
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r148",
      "r207",
      "r212",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519",
      "r577",
      "r631",
      "r767",
      "r977",
      "r978",
      "r979",
      "r1093",
      "r1096",
      "r1097"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities",
        "label": "Consolidated Entities [Domain]",
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r148",
      "r207",
      "r212",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519",
      "r577",
      "r631",
      "r767",
      "r977",
      "r978",
      "r979",
      "r1093",
      "r1096",
      "r1097"
     ]
    },
    "agl_ConsolidatedSecuritiesMatterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "ConsolidatedSecuritiesMatterMember",
     "presentation": [
      "http://agilonhealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Securities Matter",
        "label": "Consolidated Securities Matter [Member]",
        "documentation": "Consolidated Securities Matter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r782"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails",
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails",
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r811",
      "r813",
      "r825",
      "r839",
      "r864",
      "r1194"
     ]
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses",
        "negatedLabel": "Expenses",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r967",
      "r968"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r1091"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r1091"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Advantage Payors",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r1049"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r206",
      "r208",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r373",
      "r374",
      "r384",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r400",
      "r407",
      "r408",
      "r410",
      "r520",
      "r567"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r396",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r520",
      "r631",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r836",
      "r1035",
      "r1036",
      "r1037",
      "r1040",
      "r1145",
      "r1146"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r31",
      "r32",
      "r47",
      "r107",
      "r108",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r396",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r520",
      "r631",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r836",
      "r1035",
      "r1036",
      "r1037",
      "r1040",
      "r1145",
      "r1146"
     ]
    },
    "us-gaap_DebtSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities [Abstract]",
        "label": "Debt Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowances for credit losses",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails",
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Four",
        "documentation": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Three",
        "documentation": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Three"
       }
      }
     },
     "auth_ref": []
    },
    "agl_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Two",
        "documentation": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, Year Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 Months or Greater",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r335",
      "r796"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 Months or Greater",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r335"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less Than 12 Months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r335",
      "r796"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less Than 12 Months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r335"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails",
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails",
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "totalLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Four",
        "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Three",
        "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Three"
       }
      }
     },
     "auth_ref": []
    },
    "agl_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Two",
        "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, Year Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails",
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r796"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Marketable Securities, Unrealized Loss Position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r796",
      "r1070"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable debt securities [Line Items]",
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities",
        "label": "Debt Securities [Member]",
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r868",
      "r1204"
     ]
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtWeightedAverageInterestRate",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average effective interest rate",
        "label": "Debt, Weighted Average Interest Rate",
        "documentation": "Weighted average interest rate of debt outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r28",
      "r192",
      "r775",
      "r776",
      "r778",
      "r780"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r28"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r194",
      "r239",
      "r255",
      "r277",
      "r775",
      "r792",
      "r793"
     ]
    },
    "agl_DerivativeMattersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "DerivativeMattersMember",
     "presentation": [
      "http://agilonhealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Matters",
        "label": "Derivative Matters [Member]",
        "documentation": "Derivative Matters"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/DiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments on sale of assets, net",
        "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax",
        "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r54"
     ]
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments on sale of assets, net",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r54",
      "r63"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (loss) before gain (loss) on sales",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r60",
      "r86",
      "r1162"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations, basic (US dollar per share)",
        "verboseLabel": "Net income (loss) per common share from discontinued operations, basic (US dollar per share)",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations, diluted (US dollar per share)",
        "verboseLabel": "Net income (loss) per common share from discontinued operations, diluted (US dollar per share)",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]",
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "presentation": [
      "http://agilonhealth.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations, Disposed of by Sale",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://agilonhealth.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://agilonhealth.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "agl_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/DiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Disposal Group, Including Discontinued Operation, General And Administrative Expense, Net Of Adjustments",
        "documentation": "Disposal Group, Including Discontinued Operation, General And Administrative Expense, Net Of Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/DiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) from operations",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/DiscontinuedOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r101"
     ]
    },
    "agl_DistributionsOfEarningsFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "DistributionsOfEarningsFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Distributions of earnings from equity method investments",
        "label": "Distributions Of Earnings From Equity Method Investments",
        "documentation": "Distributions Of Earnings From Equity Method Investments"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per common share, basic and diluted",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss) Per Common Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r236",
      "r237",
      "r238"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://agilonhealth.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r155",
      "r157",
      "r158",
      "r184",
      "r185",
      "r186",
      "r213",
      "r214",
      "r215",
      "r217",
      "r224",
      "r225",
      "r227",
      "r240",
      "r325",
      "r326",
      "r354",
      "r412",
      "r435",
      "r486",
      "r498",
      "r499",
      "r503",
      "r504",
      "r505",
      "r507",
      "r510",
      "r511",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r533",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r570",
      "r576",
      "r651",
      "r681",
      "r682",
      "r683",
      "r697",
      "r746"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r502",
      "r558",
      "r963",
      "r964",
      "r965",
      "r1126",
      "r1127",
      "r1128",
      "r1129"
     ]
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r206",
      "r210",
      "r324",
      "r558",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r206",
      "r210",
      "r324",
      "r558",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees",
        "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]",
        "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity."
       }
      }
     },
     "auth_ref": [
      "r981",
      "r1035",
      "r1039",
      "r1067",
      "r1144"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/OtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/OtherAssetsDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investments",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r260",
      "r277",
      "r319",
      "r983",
      "r1066"
     ]
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments",
        "label": "Equity Method Investments [Table Text Block]",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "agl_EquityMethodLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "EquityMethodLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity method liabilities",
        "label": "Equity Method Liabilities",
        "documentation": "Equity Method Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "agl_EquityMethodLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "EquityMethodLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method liabilities \u2013 CMS ACO Models",
        "label": "Equity Method Liabilities, Noncurrent",
        "documentation": "Equity Method Liabilities, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r895",
      "r905",
      "r937"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r892",
      "r902",
      "r934"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "agl_ExtendedTermOfLettersOfCredit": {
     "xbrltype": "durationItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "ExtendedTermOfLettersOfCredit",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extended term of letters of credit",
        "label": "Extended Term Of Letters Of Credit",
        "documentation": "Extended term of letters of credit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Assets Measured on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1136"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r548",
      "r771",
      "r827",
      "r835"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r548",
      "r771",
      "r827",
      "r835"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r546",
      "r547",
      "r549",
      "r551",
      "r581",
      "r582",
      "r583",
      "r771",
      "r800",
      "r801",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r825",
      "r828",
      "r835"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r448",
      "r453",
      "r454",
      "r536",
      "r547",
      "r551",
      "r581",
      "r771",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r825",
      "r835"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r448",
      "r453",
      "r454",
      "r456",
      "r536",
      "r537",
      "r547",
      "r551",
      "r582",
      "r771",
      "r800",
      "r801",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r825",
      "r835"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r536",
      "r537",
      "r538",
      "r539",
      "r547",
      "r551",
      "r583",
      "r771",
      "r800",
      "r801",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r825",
      "r828",
      "r835"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r546",
      "r547",
      "r549",
      "r551",
      "r581",
      "r582",
      "r583",
      "r771",
      "r800",
      "r801",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r825",
      "r828",
      "r835"
     ]
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FederalFundsEffectiveSwapRateMember",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overnight Federal Funds Rate",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails",
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails",
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r336",
      "r337",
      "r409",
      "r433",
      "r520",
      "r531",
      "r550",
      "r557",
      "r559",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r595",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r634",
      "r652",
      "r796",
      "r825",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r839",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1134",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r338",
      "r351",
      "r773"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r941"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r941"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r941"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r941"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r941"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Adjustments on sale of assets, net",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r731"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r339",
      "r622",
      "r793",
      "r797",
      "r816",
      "r817",
      "r818",
      "r821",
      "r826",
      "r838",
      "r1072",
      "r1073",
      "r1130"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Amortizable Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1074"
     ]
    },
    "agl_HealthPlanDepositsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "HealthPlanDepositsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/OtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/OtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health plan deposits",
        "label": "Health Plan Deposits, Noncurrent",
        "documentation": "Health Plan Deposits, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) attributable to common stockholders before discontinued operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r85",
      "r100",
      "r158",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r232",
      "r235",
      "r511"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r122",
      "r127",
      "r628",
      "r630",
      "r646",
      "r777",
      "r779",
      "r781",
      "r789",
      "r792",
      "r1046",
      "r1054",
      "r1055",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) from continuing operations",
        "terseLabel": "Income (loss) from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r127",
      "r158",
      "r206",
      "r209",
      "r210",
      "r216",
      "r224",
      "r324",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r413",
      "r486",
      "r506",
      "r511",
      "r534",
      "r558",
      "r646",
      "r789",
      "r1046",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1094"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations, basic (US dollar per share)",
        "verboseLabel": "Net income (loss) per common share from continuing operations, basic (US dollar per share)",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r123",
      "r158",
      "r191",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r231",
      "r233",
      "r234",
      "r413",
      "r506",
      "r511",
      "r534",
      "r627",
      "r1163"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations, diluted (US dollar per share)",
        "verboseLabel": "Net income (loss) per common share from continuing operations, diluted (US dollar per share)",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r158",
      "r191",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r231",
      "r233",
      "r234",
      "r235",
      "r511",
      "r534",
      "r627",
      "r1163"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/DiscontinuedOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) from discontinued operations attributable to common shares",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r63",
      "r161",
      "r501",
      "r647"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations:",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total discontinued operations",
        "terseLabel": "Income (loss) from discontinued operations",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r60",
      "r63",
      "r111"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (loss) from equity method investments",
        "negatedLabel": "Loss (income) from equity method investments",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r84",
      "r121",
      "r239",
      "r257",
      "r277",
      "r319",
      "r645"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://agilonhealth.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://agilonhealth.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r13",
      "r17",
      "r49",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r62",
      "r64",
      "r65",
      "r103",
      "r356",
      "r357"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit (expense)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r134",
      "r206",
      "r226",
      "r227",
      "r239",
      "r258",
      "r277",
      "r490",
      "r491",
      "r500",
      "r656",
      "r777",
      "r779",
      "r781",
      "r815"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r488",
      "r489",
      "r492",
      "r493",
      "r494",
      "r497",
      "r691"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r202",
      "r495",
      "r496"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapital",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes in operating assets and liabilities",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital",
        "documentation": "Amount of increase (decrease) in asset and (increase) decrease in liability, used in operating activity in reconciling net income to reflect cash provided by (used in) operating activity when indirect cash flow method is applied."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r933",
      "r941",
      "r945",
      "r953"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r957"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r957"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r957"
     ]
    },
    "us-gaap_InsuranceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InsuranceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance [Abstract]",
        "label": "Insurance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/GoodwillandAmortizableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross carrying amount of amortizable intangible assets",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r777",
      "r781",
      "r989"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r200",
      "r201"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r93"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total outstanding letters of credit",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r863"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "terseLabel": "Liabilities",
        "verboseLabel": "Current and total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r67",
      "r68",
      "r69",
      "r71",
      "r72",
      "r73",
      "r74",
      "r206",
      "r209",
      "r210",
      "r324",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r514",
      "r518",
      "r519",
      "r558",
      "r708",
      "r788",
      "r804",
      "r876",
      "r1094",
      "r1147",
      "r1148"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r119",
      "r642",
      "r838",
      "r860",
      "r862",
      "r1035",
      "r1039",
      "r1067",
      "r1144"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r163",
      "r206",
      "r209",
      "r210",
      "r324",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r514",
      "r518",
      "r519",
      "r558",
      "r838",
      "r1094",
      "r1147",
      "r1148"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical claims and related payables",
        "verboseLabel": "Medical claims and related payables",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date."
       }
      }
     },
     "auth_ref": [
      "r855",
      "r859",
      "r860",
      "r1158",
      "r1167"
     ]
    },
    "agl_LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related payables associated with retained liability",
        "label": "Liability For Claims And Claims Adjustment Expense, Amounts Recoverable",
        "documentation": "Liability For Claims And Claims Adjustment Expense, Amounts Recoverable under risk sharing arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "agl_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Medical claims and related payables, beginning of the year",
        "periodEndLabel": "Medical claims and related payables, end of the period",
        "label": "Liability For Claims And Claims Adjustment Expense, Including Amounts Recoverable",
        "documentation": "Liability For Claims And Claims Adjustment Expense, Including Amounts Recoverable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical Claims and Related Payables",
        "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]",
        "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r675"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract",
     "presentation": [
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Claims paid related to:",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails": {
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current year",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r855"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails": {
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prior years",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r855"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Incurred cost related to claims",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process."
       }
      }
     },
     "auth_ref": [
      "r855",
      "r1165"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract",
     "presentation": [
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of incurred costs related to:",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "presentation": [
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "agl_LineOfCreditFacilityAccordionFeatureIncreaseLimit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimit",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, accordion feature, increase limit",
        "label": "Line Of Credit Facility, Accordion Feature, Increase Limit",
        "documentation": "Line Of Credit Facility, Accordion Feature, Increase Limit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility remaining borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r70"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility remaining borrowing capacity",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r70",
      "r374"
     ]
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, unused capacity, commitment fee percentage",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://agilonhealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://agilonhealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansAndLeasesReceivableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansAndLeasesReceivableRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/OtherAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans receivable",
        "label": "Loans and Leases Receivable, Related Parties",
        "documentation": "For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r120"
     ]
    },
    "agl_LoansToPhysiciansPartners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "LoansToPhysiciansPartners",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/OtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/OtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans to physician partners",
        "label": "Loans To Physicians Partners",
        "documentation": "Loans To Physicians Partners"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r117",
      "r207",
      "r212",
      "r397",
      "r411",
      "r631",
      "r800",
      "r801",
      "r836",
      "r1159"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current debt",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r1081",
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r30",
      "r1081",
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency Nature",
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r367",
      "r368",
      "r369",
      "r372",
      "r487",
      "r687",
      "r798",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://agilonhealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r367",
      "r368",
      "r369",
      "r372",
      "r487",
      "r798",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://agilonhealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r367",
      "r368",
      "r369",
      "r372",
      "r487",
      "r798",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_LossContingencyAccrualCarryingValueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualCarryingValueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails",
      "http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term contingencies",
        "label": "Loss Contingency, Accrual, Noncurrent",
        "documentation": "Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Nature",
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r367",
      "r368",
      "r369",
      "r372",
      "r487",
      "r687",
      "r798",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyNewClaimsFiledNumber",
     "presentation": [
      "http://agilonhealth.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, new claims filed",
        "label": "Loss Contingency, New Claims Filed, Number",
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period."
       }
      }
     },
     "auth_ref": [
      "r1086",
      "r1087"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r806",
      "r808",
      "r853",
      "r858",
      "r1164",
      "r1168",
      "r1169",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1195",
      "r1196"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Table]",
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Marketable Securities",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r248",
      "r368",
      "r369",
      "r370",
      "r371",
      "r457",
      "r481",
      "r482",
      "r483",
      "r487",
      "r539",
      "r612",
      "r679",
      "r680",
      "r687",
      "r700",
      "r701",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r759",
      "r760",
      "r761",
      "r762",
      "r768",
      "r769",
      "r795",
      "r805",
      "r814",
      "r816",
      "r819",
      "r820",
      "r828",
      "r829",
      "r833",
      "r834",
      "r854",
      "r1098",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "agl_MedicalServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "MedicalServicesMember",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical services revenue",
        "label": "Medical Services [Member]",
        "documentation": "Medical services revenue."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r248",
      "r368",
      "r369",
      "r370",
      "r371",
      "r457",
      "r481",
      "r482",
      "r483",
      "r487",
      "r539",
      "r612",
      "r679",
      "r680",
      "r687",
      "r700",
      "r701",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r759",
      "r760",
      "r761",
      "r762",
      "r768",
      "r769",
      "r795",
      "r805",
      "r814",
      "r816",
      "r819",
      "r820",
      "r828",
      "r829",
      "r833",
      "r854",
      "r1098",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r806",
      "r808",
      "r853",
      "r858",
      "r1164",
      "r1168",
      "r1169",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1195",
      "r1196"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) attributable to common shares",
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r100",
      "r124",
      "r158",
      "r161",
      "r178",
      "r181",
      "r186",
      "r206",
      "r209",
      "r210",
      "r211",
      "r216",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r232",
      "r324",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r413",
      "r416",
      "r418",
      "r421",
      "r486",
      "r506",
      "r511",
      "r534",
      "r558",
      "r650",
      "r729",
      "r744",
      "r745",
      "r777",
      "r779",
      "r781",
      "r874",
      "r1094"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      },
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Noncontrolling interests\u2019 share in (earnings) loss",
        "negatedLabel": "Noncontrolling interests\u2019 share in (earnings) loss from continuing operations",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r112",
      "r178",
      "r181",
      "r224",
      "r226",
      "r227",
      "r649",
      "r988"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per share attributable to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r933",
      "r941"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r435",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1202"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "agl_NumberOfDirectContractingEntities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "NumberOfDirectContractingEntities",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of direct contracting entities",
        "label": "Number Of Direct Contracting Entities",
        "documentation": "Number of Direct Contracting Entities."
       }
      }
     },
     "auth_ref": []
    },
    "agl_NumberOfEquityMethodInvestments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "NumberOfEquityMethodInvestments",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of equity method investments for VIEs",
        "label": "Number Of Equity Method Investments",
        "documentation": "Number of equity method investments."
       }
      }
     },
     "auth_ref": []
    },
    "agl_NumberOfGeographicalLocation": {
     "xbrltype": "integerItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "NumberOfGeographicalLocation",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of geographies",
        "label": "Number of Geographical Location",
        "documentation": "Number of geographical location."
       }
      }
     },
     "auth_ref": []
    },
    "agl_NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans",
     "presentation": [
      "http://agilonhealth.com/role/BusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of medicare advantage members enrolled with private health plans",
        "label": "Number Of Medicare Advantage Members Enrolled With Private Health Plans",
        "documentation": "Number of Medicare Advantage members enrolled with private health plans."
       }
      }
     },
     "auth_ref": []
    },
    "agl_NumberOfPhysicianGroupPartners": {
     "xbrltype": "integerItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "NumberOfPhysicianGroupPartners",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of physician group partners",
        "label": "Number Of Physician Group Partners",
        "documentation": "Number of physician group partners."
       }
      }
     },
     "auth_ref": []
    },
    "agl_NumberOfWhollyOwnedRiskBearingEntities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "NumberOfWhollyOwnedRiskBearingEntities",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of wholly-owned risk-bearing entities",
        "label": "Number Of Wholly Owned Risk Bearing Entities",
        "documentation": "Number of wholly-owned risk-bearing entities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) from operations",
        "terseLabel": "Income (loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r777",
      "r781",
      "r789",
      "r1046",
      "r1054",
      "r1055",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, long-term",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/OtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/OtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use lease assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets, net",
        "label": "Other Assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r169",
      "r635",
      "r793",
      "r860",
      "r862",
      "r876"
     ]
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets [Abstract]",
        "label": "Other Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/OtherAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets",
        "label": "Other Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/OtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/OtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://agilonhealth.com/role/OtherAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/OtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "totalLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized gain (loss) on marketable securities, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r651"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r651"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r15",
      "r179",
      "r182",
      "r187",
      "r224",
      "r560",
      "r561",
      "r566",
      "r623",
      "r651",
      "r986",
      "r987"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "agl_OtherEquityMethodInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "OtherEquityMethodInvestmentsMember",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Equity Methods",
        "label": "Other Equity Method Investments [Member]",
        "documentation": "Other Equity Method Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other liabilities",
        "label": "Other Liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r637",
      "r704",
      "r705",
      "r804",
      "r860",
      "r862",
      "r876",
      "r1160",
      "r1200"
     ]
    },
    "us-gaap_OtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities [Abstract]",
        "label": "Other Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/OtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities",
        "label": "Other Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for other liabilities."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r72",
      "r1079"
     ]
    },
    "agl_OtherLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "OtherLiabilitiesLineItems",
     "presentation": [
      "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities [Line Items]",
        "label": "Other Liabilities [Line Items]",
        "documentation": "Other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "totalLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "agl_OtherLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "OtherLiabilitiesTable",
     "presentation": [
      "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities [Table]",
        "label": "Other Liabilities [Table]",
        "documentation": "Other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesTableTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/OtherLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Liabilities",
        "label": "Other Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other noncash items",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "agl_OtherOperatingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "OtherOperatingMember",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating revenue",
        "label": "Other Operating [Member]",
        "documentation": "Other operating revenue."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/OtherLiabilitiesScheduleofOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Noncurrent",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r116"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r897",
      "r907",
      "r939"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r900",
      "r910",
      "r942"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r900",
      "r910",
      "r942"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Claims paid related",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r855",
      "r1166"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "agl_PaymentsToAcquireLoansReceivableAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "PaymentsToAcquireLoansReceivableAndOther",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in loans receivable and other",
        "label": "Payments To Acquire Loans Receivable And Other",
        "documentation": "Payments To Acquire Loans Receivable And Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investments in marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "agl_PayorAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "PayorAMember",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payor A",
        "label": "Payor A [Member]",
        "documentation": "Payor A."
       }
      }
     },
     "auth_ref": []
    },
    "agl_PayorBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "PayorBMember",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payor B",
        "label": "Payor B [Member]",
        "documentation": "Payor B."
       }
      }
     },
     "auth_ref": []
    },
    "agl_PayorCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "PayorCMember",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payor C",
        "label": "Payor C [Member]",
        "documentation": "Payor C."
       }
      }
     },
     "auth_ref": []
    },
    "agl_PayorDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "PayorDMember",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payor D",
        "label": "Payor D [Member]",
        "documentation": "Payor D."
       }
      }
     },
     "auth_ref": []
    },
    "agl_PayorEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "PayorEMember",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payor E",
        "label": "Payor E [Member]",
        "documentation": "Payor e."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "agl_PhysicianCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "PhysicianCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Physician compensation expense",
        "label": "Physician Compensation Expense",
        "documentation": "Physician compensation expense."
       }
      }
     },
     "auth_ref": []
    },
    "agl_PlatformSupportCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "PlatformSupportCostsMember",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Platform Support Costs",
        "label": "Platform Support Costs [Member]",
        "documentation": "Platform Support Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets, net",
        "verboseLabel": "Prepaid expenses and other current assets, net",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_ProceedsFromRepurchaseOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRepurchaseOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from (payments for) equity issuances, net",
        "label": "Proceeds from (Repurchase of) Equity",
        "documentation": "The net cash inflow or outflow resulting from the entity's share transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of marketable securities and other",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r1060"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r152",
      "r281",
      "r613",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r678",
      "r772",
      "r776",
      "r779",
      "r781",
      "r806",
      "r807",
      "r852",
      "r854",
      "r856",
      "r859",
      "r865",
      "r966",
      "r980",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1088",
      "r1089",
      "r1164",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1195",
      "r1196"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r152",
      "r281",
      "r613",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r678",
      "r772",
      "r776",
      "r779",
      "r781",
      "r806",
      "r807",
      "r852",
      "r854",
      "r856",
      "r859",
      "r865",
      "r966",
      "r980",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1088",
      "r1089",
      "r1164",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1195",
      "r1196"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r161",
      "r178",
      "r181",
      "r198",
      "r206",
      "r209",
      "r210",
      "r211",
      "r216",
      "r224",
      "r226",
      "r227",
      "r324",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r413",
      "r486",
      "r506",
      "r511",
      "r512",
      "r515",
      "r516",
      "r534",
      "r558",
      "r628",
      "r630",
      "r648",
      "r696",
      "r729",
      "r744",
      "r745",
      "r822",
      "r823",
      "r875",
      "r988",
      "r1094"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross carrying amount of property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r165",
      "r644"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r575",
      "r633",
      "r644",
      "r838"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r248",
      "r368",
      "r369",
      "r370",
      "r371",
      "r447",
      "r457",
      "r481",
      "r482",
      "r483",
      "r485",
      "r487",
      "r539",
      "r584",
      "r596",
      "r612",
      "r679",
      "r680",
      "r687",
      "r700",
      "r701",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r759",
      "r760",
      "r761",
      "r762",
      "r768",
      "r769",
      "r795",
      "r805",
      "r814",
      "r816",
      "r819",
      "r820",
      "r828",
      "r829",
      "r833",
      "r834",
      "r854",
      "r868",
      "r1084",
      "r1098",
      "r1138",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r248",
      "r368",
      "r369",
      "r370",
      "r371",
      "r447",
      "r457",
      "r481",
      "r482",
      "r483",
      "r485",
      "r487",
      "r539",
      "r584",
      "r596",
      "r612",
      "r679",
      "r680",
      "r687",
      "r700",
      "r701",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r759",
      "r760",
      "r761",
      "r762",
      "r768",
      "r769",
      "r795",
      "r805",
      "r814",
      "r816",
      "r819",
      "r820",
      "r828",
      "r829",
      "r833",
      "r834",
      "r854",
      "r868",
      "r1084",
      "r1098",
      "r1138",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables, net",
        "verboseLabel": "Receivables, net",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r1058"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r892",
      "r902",
      "r934"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r693"
     ]
    },
    "agl_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r893",
      "r903",
      "r935"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r894",
      "r904",
      "r936"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r891",
      "r901",
      "r911",
      "r943"
     ]
    },
    "us-gaap_RestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash equivalents",
        "label": "Restricted Cash Equivalent",
        "documentation": "Amount of cash equivalent restricted as to withdrawal or usage. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r764",
      "r1032",
      "r1155",
      "r1161"
     ]
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashEquivalentsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofCashCashEquivalentsandRestrictedCashEquivalentsfromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash and equivalents",
        "label": "Restricted Cash Equivalent, Current",
        "documentation": "Amount of cash equivalent restricted as to withdrawal or usage, classified as current. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r764",
      "r982",
      "r1032"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r109",
      "r641",
      "r684",
      "r686",
      "r694",
      "r711",
      "r838"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r157",
      "r158",
      "r213",
      "r214",
      "r215",
      "r217",
      "r224",
      "r225",
      "r227",
      "r325",
      "r326",
      "r354",
      "r412",
      "r486",
      "r498",
      "r499",
      "r503",
      "r504",
      "r505",
      "r507",
      "r510",
      "r511",
      "r521",
      "r523",
      "r524",
      "r526",
      "r533",
      "r568",
      "r570",
      "r681",
      "r683",
      "r697",
      "r1202"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r239",
      "r251",
      "r252",
      "r272",
      "r277",
      "r281",
      "r282",
      "r283",
      "r444",
      "r445",
      "r446",
      "r613",
      "r777",
      "r781"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer Benchmark",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical Services Revenue",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r770"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset obtained in exchange for new operating lease liability",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r837"
     ]
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties [Abstract]",
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsNarrativeDetails",
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/SupplementalCashFlowInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents from Continuing Operations",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/SupplementalCashFlowInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Cash Flow Information",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheet",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r1036",
      "r1040",
      "r1156"
     ]
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/DiscontinuedOperationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Statements Related to Discontinued Operations",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r13",
      "r17",
      "r49",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r62",
      "r64",
      "r65",
      "r103",
      "r1077",
      "r1078"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Computation of Basic and Diluted EPS",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r502",
      "r558",
      "r963",
      "r964",
      "r965",
      "r1126",
      "r1127",
      "r1128",
      "r1129"
     ]
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "presentation": [
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Changes in Medical Claims and Related Payables",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/OtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Assets",
        "label": "Schedule of Other Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Results",
        "label": "Schedule of Other Operating Cost and Expense, by Component [Table Text Block]",
        "documentation": "Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/SupplementalCashFlowInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Cash Equivalents from Continuing Operations",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r113",
      "r1161"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Variable Interest Entities [Table]",
        "label": "Variable Interest Entity [Table]",
        "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r513",
      "r514",
      "r518",
      "r519",
      "r592",
      "r593",
      "r594"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Consolidated Asset and Liabilities Include VIE Assets and Liabilities",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/RevenueReceivablesandConcentrationofCreditRiskTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedules of Concentration of Risk as a Percentage of Revenues and Receivables",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r1048",
      "r1053"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredOvernightFinancingRateSofrMember",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral."
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "agl_SecuredRevolvingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "SecuredRevolvingFacilityMember",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Revolving Facility",
        "label": "Secured Revolving Facility [Member]",
        "documentation": "Secured Revolving Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "agl_SecuredTermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "SecuredTermLoanFacilityMember",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Term Loan Facility",
        "label": "Secured Term Loan Facility [Member]",
        "documentation": "Secured Term Loan Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r239",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r283",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r353",
      "r363",
      "r364",
      "r508",
      "r509",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r791",
      "r792",
      "r793",
      "r797",
      "r857",
      "r1164",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1195",
      "r1196"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r263",
      "r264",
      "r277",
      "r792"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r280",
      "r282",
      "r790",
      "r791",
      "r794"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484"
     ]
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Shares withheld related to net share settlement (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205"
     ]
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StandbyLettersOfCreditMember",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standby Letters of Credit",
        "label": "Standby Letters of Credit [Member]",
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1090",
      "r1197",
      "r1198"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r159",
      "r239",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r283",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r353",
      "r355",
      "r363",
      "r364",
      "r508",
      "r509",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r791",
      "r792",
      "r793",
      "r797",
      "r857",
      "r1164",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1195",
      "r1196"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://agilonhealth.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r76",
      "r79",
      "r80",
      "r155",
      "r157",
      "r158",
      "r184",
      "r185",
      "r186",
      "r213",
      "r214",
      "r215",
      "r217",
      "r224",
      "r225",
      "r227",
      "r240",
      "r325",
      "r326",
      "r354",
      "r412",
      "r435",
      "r486",
      "r498",
      "r499",
      "r503",
      "r504",
      "r505",
      "r507",
      "r510",
      "r511",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r533",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r570",
      "r576",
      "r651",
      "r681",
      "r682",
      "r683",
      "r697",
      "r746"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r240",
      "r414",
      "r415",
      "r417",
      "r419",
      "r570",
      "r613",
      "r690",
      "r698",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r710",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r746",
      "r779",
      "r781",
      "r869",
      "r1201"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r240",
      "r284",
      "r414",
      "r415",
      "r417",
      "r419",
      "r570",
      "r613",
      "r690",
      "r698",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r710",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r746",
      "r779",
      "r781",
      "r869",
      "r1201"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r896",
      "r906",
      "r938"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of liabilities through issuance of stock",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://agilonhealth.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued to settle liabilities (in shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r75",
      "r76",
      "r109",
      "r692",
      "r746",
      "r756"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r75",
      "r76",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://agilonhealth.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued under share-based awards (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r75",
      "r76",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r75",
      "r76",
      "r109",
      "r467"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r75",
      "r76",
      "r109",
      "r697",
      "r746",
      "r756",
      "r875"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r76",
      "r79",
      "r80",
      "r109"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity (deficit)",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r43",
      "r155",
      "r156",
      "r157",
      "r158",
      "r185",
      "r213",
      "r214",
      "r215",
      "r217",
      "r224",
      "r225",
      "r325",
      "r326",
      "r354",
      "r412",
      "r435",
      "r486",
      "r498",
      "r499",
      "r503",
      "r504",
      "r505",
      "r507",
      "r510",
      "r511",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r533",
      "r560",
      "r562",
      "r566",
      "r569",
      "r576",
      "r682",
      "r683",
      "r695",
      "r712",
      "r728",
      "r747",
      "r748",
      "r757",
      "r860",
      "r862",
      "r875",
      "r1035",
      "r1038",
      "r1039",
      "r1067",
      "r1144",
      "r1202"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity (deficit):",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/CommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r520",
      "r532",
      "r749",
      "r750",
      "r758"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://agilonhealth.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://agilonhealth.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary Sale Of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "agl_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "agl_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agilonhealth.com/20250630",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary Of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowElementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]",
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://agilonhealth.com/role/SupplementalCashFlowInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current year",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r855"
     ]
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agilonhealth.com/role/MedicalClaimsandRelatedPayablesScheduleChangesinMedicalClaimsandRelatedPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior years",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r855"
     ]
    },
    "us-gaap_SuretyBondMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SuretyBondMember",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Surety Bond",
        "label": "Surety Bond [Member]",
        "documentation": "An obligation arising from a three-party agreement that legally binds together a principal who needs the bond, an obligee who requires the bond and a surety company that sells the bond."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://agilonhealth.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails",
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails",
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r409",
      "r433",
      "r520",
      "r531",
      "r550",
      "r557",
      "r559",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r595",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r634",
      "r652",
      "r825",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r839",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1134",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofFairValueAssetsMeasuredonRecurringBasisDetails",
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesDetails",
      "http://agilonhealth.com/role/MarketableSecuritiesandFairValueMeasurementsScheduleofMarketableSecuritiesUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury notes",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r784",
      "r809",
      "r811",
      "r813",
      "r825",
      "r1157"
     ]
    },
    "us-gaap_UnassertedClaimMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnassertedClaimMember",
     "presentation": [
      "http://agilonhealth.com/role/OtherLiabilitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unasserted Claim",
        "label": "Unasserted Claim [Member]",
        "documentation": "A claim for damages that is likely to be made and for which it is reasonably possible that there will be an unfavorable outcome, such as a likelihood that lawsuits from parties as yet unidentified will be filed alleging injury from using a product when other parties have successfully sued the entity for such use."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://agilonhealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r242",
      "r246",
      "r247",
      "r248",
      "r628",
      "r630",
      "r787"
     ]
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entities",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableInterestEntityLineItems",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleBalanceSheetDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofEquityMethodInvestmentsDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofOperatingResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity [Line Items]",
        "label": "Variable Interest Entity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r518",
      "r519",
      "r592",
      "r593",
      "r594"
     ]
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "presentation": [
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://agilonhealth.com/role/VariableInterestEntitiesNarrativeDetails",
      "http://agilonhealth.com/role/VariableInterestEntitiesScheduleofConsolidatedAssetandLiabilitiesIncludeVIEAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Primary Beneficiary",
        "verboseLabel": "Variable Interest Entity",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r513",
      "r514",
      "r518",
      "r519"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": [
      "r985",
      "r1092",
      "r1131"
     ]
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://agilonhealth.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": [
      "r985",
      "r1092",
      "r1131"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding \u2013 diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r235"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://agilonhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding \u2013 basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r235"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://agilonhealth.com/role/NetIncomeLossPerCommonShareScheduleofComputationofBasicandDilutedEPSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "12",
   "Subparagraph": "(f)(2)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481410/810-10-15-12"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-6"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-9"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/230/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2AG",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-15"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-33"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-35A"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/944-40/tableOfContent"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-3A"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-12"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-34"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-7"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-7"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-12"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-15"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405/tableOfContent"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480190/470-10-S50-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-15"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-16"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001628280-25-037430-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-037430-xbrl.zip
M4$L#!!0    ( /F!!%N@!OJ:&S@! 'L\$P 0    86=L+3(P,C4P-C,P+FAT
M;>R];7>C2)(&^GU_!5>]NU-U#I9Y%[*K=8_*EKL]4V5[+'?WSOTR)PTIBRD$
M:D!^Z5]_(Q/0BX4LD)"4H-RS4RT+!)D13T1&1$9&?/E_7T>N\(R#T/&]G_\F
M-Z6_"=BS?-OQGG[^6[=_<7W]M_^W\U]?_I^3D__[>O]-N/2MR0A[D7 18!1A
M6WAQHJ$0#;'PAQ_\<)Z1<.>B:. 'HY.3^&<7_O@M<)Z&D:!(BI[>EEX-SF3U
ML65HEG&"E$?I1$-MZZ2M2>:)HFN#EJE)$GJ4Q*<SI)G60#;M$VV@XA--,^R3
MMJT.3@Q5-65S8"K*0!+M,UW':MM43*S8LF8^2LA0+%F1#44S'B6C9=#W#B.8
M,\S;"\_0D_MS8QA%X[/34_3DN+XWQ,B-ADW+'YV2 4N&*C62FR?AR1-"X^D/
M!BA\;/K!TVER@?X@O=EYC4Y";$UO?GEY:<+?S2?_^=3Q7,?#A*"G48"\D- +
M1< !>(*LG\#L53E]3AA$RR^$+Q=>]@K/^['PJA>5WBBWV^U3>C6Y=?5-A"K3
MP8>^ILBMA9M?'P.7WJY(DGJ:W#$= %QT/KK="R/D67A&G54WR^H<>>:(F7W_
M1Y14I!-).9&5]"%+-%H<(KG\B,+I$&T\FQ"],^4>7%@D/ERTW]V;/-4XC2].
M;PV=+ ; G?+I_WW_UK>&>(1.WA,+6W;V2.#";"1G+@*9;6#OY+=^H_,%<&QW
MOHQPA 3RTQ/\Y\1Y_KEQX7L1R._)P]L8GF_%?_W<B/!K=$H1<-KYK__ZKR^1
M$[FX ])QD@K!E]/XNR^G\9,???NM\\5VGH4P>G/QSPW;"<<N>COS? _#^YW7
M,W(C#N*/CFUCCWZ$ZS>@0P+'BE__&MWCP<\-ZP0@[Z$1>1)VSGH>O.[M @87
M(/?:L_'K/_!;0W" $H,3Q6AT)*"9J<I2N_7E=.&I!5YR,0D">,.5$UK(_1=&
M0<^S+T&M-8081S\W 'AG-GQS,H*G#,DO3VST=H*]Z5!:C<XEMO#H$0>"*F\^
MEE2SS@9S!=^$T_>8C0YA15DON(/;?7OQ%>U&YY_*YB_HPM-M^@87/2V2<."\
M8OMD@%PB7O';0*UVZ!>%7JBF+TQ4[MGM& <@\-[3-PRR^\U!CXX+P+GQ/2MF
M;C\"]I%1W0ZN' _$RH')^Z%#E$3O%= ?.H\N_#",TI'I+>#I1RK^IUM8\(+T
M70X.9V\K-!EM+Y,QRYO,Z:(D!WB X3X+AQGZAZC3LY J-)BN0->@LPBTSL^-
MT!F-7:+=Z'?#@%!C7M4T7T,;]!!]W>P=R2M#?Q+0O^B2<S;QG(A.-1PBN-A(
MOQ\!!2<![L1_Q1>_G"Y>2_\FSUAZW@3&\/YAR:)W]EO_LNBS0-[Z9!#39X+F
M=&P\?RLE,XK\8,/7+OV>?'F)/7\$4,EX;%[2+#SB=''T'\UZ1)7B$A&!TV?Q
MI4(T]":93XO_&L/'0D]ST4LX<:+,P277"CT/T^4J\W'QI4)/<[QG'$9$SC.?
M.+M<Z*EC%$3>"H8DUPH][PG[3P$:#[.G/;V:YYF)7J2/):M*^GU,N_0O0!S\
M/7!@I:6*!6<:UQ?7_UBT#M[_>#J"Q:>/Z8J8_@466! 16X"NNB>2#/^?_FYV
M;3I,>^Y6XX182XM7TK_3EYPNS#N;# H#9(A-T2B96>M$G1(AO;+)S%3F9C;/
MLVUFIK$U,PW<GY)XIN]Z9HELX2>BV.(_;7C9Z]AU+"?Z'EO8MC,B1H[OP8(?
M1&?@S82^ZQ +W:8> ]@OW5<'S(#4I/H=!6#:N/@:Y@+K7!3[%7>!,T+!VU?L
MX0$\'3Y^GUN1EEX[I=!T= <#F,'9L#$;2I2&%HMLN M\>V)%MT$?!\^.A6,6
MD,7X.[8=</J2[\/RJ?Q^N=3VOUR:G"6K6:+E9XE6'DO:G"6L&96RQ'GRH9CD
MY4F)8B+OW.$IER<T8C2-5=5R,9%W[GQ5F"6'64SDG7N-%6;)@1:3G;N[%6;)
M@=:2G?OI%5'@.W>4*Z(U=^ZI5D0NF',/T]#(=$^O]^>$;'G[H['OP9_O(BCP
M_<CW^I%O_=AUK$HM*4@B,^?_%:1YU[;IUBIR[Y!C7WL7:.Q$R*T*_17F?+V"
M]+_'$7(\;/=0X,&"O0/O;T>$9\ZA*PI\RYJ,)BZ)YU*;B=P7X"%YVC.^]BQ_
MA"O#"_:VT4J;&G,>$7/RS8 EJC#G)%5!&;# ..:V/%DR&5E@$'.;H:S:ERPP
MB[DM4Y:D:3?) DK5G=X#.6"ET;_J#O"^';"R"*]6W?-EP $KC1=5=X;WI?BU
M\CQ#E;GMRPHH_C+ISSWS Q&>.]OL\*+J_C,Y"04S"GS7!1E(4U<K0WX6=D!W
M-+6J^Y)[#GP>9NM9K;KWN2_Y9X%75?=4#Q^D/@SCM*I[NOL+4A^(055W?P\3
MI#X0LZKN-^\Q5E':D<FJ^\H'BE641O^JN\S[CE641OBJ^\<,Q"I*XT75MY(/
M$ZLHC?PL9"GO:&I5]X+W9U*4=CI;J[PW>Q"3HKQ:$55W2O=L4I1'^,H[FP<W
M*<KC1=5]R?UGYQ[@"*->>>_SX('/ S&NZF[K7K-S#\&@RKNWA\K./02SJN[_
M[LM+44LT$*J^BWT(+Z5,^E?=,]^KEU(FX2OOGA_82RF1%T;57?4#!#[+)#\+
MM6YW-#7N_Q8R_ Y3%\.HNO][J"2M0_"JZB[OX6,5!V)<U5WAO29I'8)!57=_
M#Y:D=0AF,><W?UQU+NV(UI^,QWX07?AAM,Z6* Z/KY,0;)4P[,>##F>OO\?D
MK:3X=G*MEL?+#>:<>0Z*@Z=S&NP'&MAAT6'DML5^_($=%AU&BEK,)15PU7KP
M#:,6<]$=#HJ#6^8M]H-)[+#H0'++?@R)'18=2(J8BQ81U?H=_<</+B9AY(]P
M,,>3._3F!]VR5.F%[UF8]/PEP8Q[)_SQ]8UT*GX7C4I&L73S#D?Q%7O6<(2"
M'^_W")ZQ-\%7@3^Z(%%H9$5_.-$P'6$]37;F@F4<GVSB\T#^"I/Q08Y/]O!Y
M(!.,R5 EQR=[^#R0_<E<U'0M/K]R?!Z/_6DR%S+F^&03GX>Q/TTFX^4<G^SA
M\S#VI\EDZ)[CDSU\'L;^-)G;15B+SPN.SR.R/YG;0N'X9!:?AUC?J[=_=,GQ
M>43ZLWK[1SV.SR/"9_7VCS@^CVE]K][^T='Z[UW+\B=>%-YC"SO/)'.))9=]
MX:SO5I"LWI;1T;I$>X?D8;1DNWJ[1!R2]=:2[>IM#!VM8WXL6K)Z>T$<DC77
MDM7;_CE:]_M8M&3U=GPX)&NN)9G;Y$D9<.5XR+,<Y%Y[811,R*_?%Y,)QCYP
M$E_BQZB/K4G@1 ZN3&_Q-G/;%TQ3OL2*ZFWF O.Y*?];_R' *)P$;Q4$/'/Q
M9G;)7B;:F8NI3LF.G.!WY$[PU[=N&.+HPD7ANWI4NU8P#&P3RA)S$<8"#+I
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MY#E_T;_?Z>.R70NV*/'INGG?[#>%I#1DP#+7%@53N/&;6:RJFIM35$-U;3O
M89C\YQL\3TZU4[O1T31)N/-=!*(HW*'@QPMZ>Z^FQ,(NP/(KE>EVC=3H]"<.
MZ %=E]@TU4HE^P5\O T>_)?I*BK+C<X?)-<K>'9<=VDEW9C:5+O>!G>P;(.Z
MRK^JRTJC<SMTED(EFX[CSH<7N?^?,XYMB^0E*D!-E<R5_A^+^N-3,B-BFH\#
M(*HS1JZ 7[%%*VS"UP-R-'JU/5XIV!*D=@.,%MBF 15T0_F\!3B^^;"BW0U]
M[UU40-8;'44W3E138E01K$#%S!G]WY],16Z=AT*$73PF4TR")M03=2=DL1?
M6D9 '_N#/4D69G4%V@*,,L(WD:H.^ ,E^$>>G7XU<$)@IT"V(V"2 ^*3>D_@
MHH9$YP@N"B/P8DEX-J^7FK5_2+]R/+)\GZFQ)[MG<LRJYR9..0Y@DN-)$$Z(
M=Q[Y0A_'AJNL?'K\3#0$"3UVK>B,5>]\LVT-56^V6EHISKFB-\$-*N51=%2[
MVB+9AS?:SA?F=Z(X=Q C:RA8)!66?4<[Y]0"1+5C^#9Z]-U/<XMHQ2=VD\3R
M*,OP:ZP?!5 4+T,'OIEIDY*\_X/$3K*59GZ;(%&O;[+R2#$^M0F,>!O")\/V
MK1^B\-]24Y*%,0J$9^1.2HX[5<7ISD_81*SZ5*JF5&TU.MU?OGUL9+$K=SM#
M7R^1SGA/X;V[1&3WG:=D@GC#./_E!S\$6CU?2!^Q/K2W,L+  +[VM^'$CH5W
M[9'Z5A$6'M_ B,7 RQ')'7P98AJ<)-;<W';,)_FS,$0AW1BU!>2ZB95+S,,_
M)PXQ#L$F?,3)#?#,J7VHDGAAO F?6(ESQF6*'V(YDLMD$UZPX2HLC>36<8 M
M3!=*61%H1E H?(+G 5B%< +K23CTR9Y0NM,=#5'T?NPO:'&4='.7_CB9PV>1
M6OB?E'B.CP!YN/[X'Y@!N9_>"C\BHTB>0RORTD'001*KORT)-GH+FX7#!A>3
M((#'Q4D=1'=%*)J$4YEK-SK_PN'*U*9=9:UD@^;U4-O5-[<'FK%_1$).P ^X
M'SE1!)("+KT5!;Y'UC7W3<"PQKT)M,0[HEUIA4L4(8%D.[S7 ;-GS#N,]Q.X
M4Y-T(N;W^&GBQE'I_LF#\(DDA[3.%55I)C=$0X?N]X[)?F\>A;"I,HC'.I5Q
M''XN+L%S1"$T201ZFB@K<0DF$NQS"=ZY!(/0(,&%:6$!619(<$ .6U-@!V21
MR_Q6 %2>9%P(1R#X\(X@79E $D8P^S>RH,.S8!4D]'L2G@+_)1JF5YNPOF/!
MQ@/'HTEH-'Q,(H4*S&_%T.AE^3R];>T-*X>6WD?6\^3>%<-,[W2\6#.!*W:B
MI!;*O%G29#6@M6&ZB2HWY9922AA*;\IR.4^26TU3;9<5&U,,M;3Y?1S[VU'6
M L/.XRS),;@  7WR@[?I2B<W.M^HA'?G!)C>N@O?>_^IW&N6U!S3F)[2K4+N
M=?9T,WA[T)SRTLV$N7AD^OKD3N.#4]H%.7S8VPYX?J(L&-Z\,UIJ"\7:*Y1^
M8LQ-(R#"16RBU8.;19=62HZODQ >%(9K#_DHRKI3/ER5L2X [X[&5.5H5DF3
MJ8$&ZZ4NYB^QBWG4^BLE1DR+A!3K]9B:2X]MD*?*4"QG\$'8A*1,989ZG$%6
MG)9&9\'L\7P:7)V$F-X%<XS/8V<< O0#^B[WC;S\Q8%7DUB.!]/R223EV0EI
MN,5#GN4@ET1IR!D)FJ00(<]&@1T*)'W2L5>E JF?T.?,$ H/_>TG]!<.L>M.
MPW2? "<T#A<?H?HXS/59^%>O?V@^'<VV4F&CD# VMR[5/JK-4451Z$;"WR?N
M6U+N08[+/8@$PP$67L@_"4&OZ#X,Z**)Y\3D#(<HP&!'+Y)8:8!D6 Z8VN'/
MC>N;JXQM69J&0[,<^O01MY.(ZD%@_B('O,GHQ/9IK3SR0%C;8<&&9TE3?NB-
MCB9KHJ:HHDQJ;BV.M2/$8TRE,EC.KWV7!40D?)HC)/BS@>6-56>>XZA$]'KC
M"GO:IA7V"*@+%MF;KR8Y]N-E^"S 9,?S&2_5EYR-@KY>FOT$/8:^.XF6?Q(+
M8.?+8W":64NQ:%W,UK0NYC"8F:9/^.0QP.C'"1H 0LZ0^X+>0C)[7CQS\V$<
MI'CFG@]=9)Y*WUPQ[7GTUS>7O?_+5470K,ZNGPP7E'*2SUMFLT42Z4MXE-%L
MJQ\/*C.\8Y26W)K\_H3<3-Y)<IS3[P**B>1+!G"9J;]V\[(E_07F2A'514XY
MWG7O'X3KIG!U?=.]N;CN?A/ SKJ]_]Y]H)52E_18@4A1L9B?0/_;5-O[CAZ]
MKP52;O2O;M/::41WM<@3^AT@67LWLISULJUE684E,<(CP-I&4LOYM#\^74VC
M=_0T]"@U&<^XKN6ZML+<96(C;5/=M ,7,TM=',#3_7@8!507/?9& HQD"^)B
MKD^0\!6YB)RL[@\QCD)2%@R\85+Z54BKOM)<STMLQ?U4DN"@MLNE*O;'5IZ2
MHWX#7ZK6\%M=P:&*:*1=*V:NO[G^KH[^;J_4WS,[E"CN69>JZ>&Y!W@+ICJ\
M[[P*WWUZHJ=']["7U3S7[*QK=E)2J]J:_<!Y3ERU<]7.D&HG^:6Y5#M)3@CP
MD#0S?,8"*;@ZPL*G;WX8?N:ZOI:ZGD!#Y[J>ZWJNZVNBZ_6<NIYF10U]%UX1
M)CE*0MSV6?ATB0>DO2Q7^C55^H 1@RM]KO2YTJ^)TC?S&O@H' I7KO\RB]UP
MA5X#A0[\-ZNMT'DLGNMSKL\3>59E<C8^@N%$/E72*Y3[JE01KJ@95=2$L6VN
MJ)D[,IX%;)Z[5@S;K7:28Z@PG&/(UYX\;/R.//1$EY/IZ;5+)[0F<6--XA)T
M/>2^A0YU*F:K$%FFXO/*Y)Y['$[<]WO&?'EB7(05A:]/?'VJ(;AE*5V@5+Y
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MYA*/ _@Q/:@)GUU,BZ5Y=G=$ZJ;]1;\OO/C0%LB:IHN*QDHQ?%Z?=C]Y1@=
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MA7"(: $\X1-&@0>WA)\%8I_RC->-FGS@:.;B%3]V\7%HK,U3P"H$JU(K;6R
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M8\THI17!>=52\_+:.B@<"@/7?PF%0>"/!'^,B=$*GAEQBI_!%<+A60DY>UM
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M-59JJ];/<:R8$9$-8 !:NC;X \'UO:>3" <C .KC$>7&EN@8S@AZ._@&Y'P
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M,6Y9.X#/B,I>6.IET3/8(AS9Y&;+*!!&22GIF'1/%!0=4756X+YAKZS7T5+
MN@"ACQ[WJILM,FQ%G ($L$D5J)$N>V7! Z0'G2XS3M<MB,Q6>2L>ZM 1CRBF
MX!S<<3P:P74*PP.=(!]+;K?M&7WB)+Q+=<YB>]$Q5M(MG)(&$IFC=T4VX;8W
M8!;TB,>'-+AGW&RD'"4<:7M!ZFNZWI0%.Q\HR&",7=%3PZ*0RMP* ,F96+A,
MFX7KUZ/B<;P;,X_%*0P5/$6/Q=JJU,)E-#PAL@T-S"Y9B_R.(E%J$9F5A(HA
M5@@"))W;9KM^0CYN+B='&,8F'%&$QV=@ 2,UB<OE1=('09EO3*=X;D;H3ZN
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M)MZ8Z!  :[8Q8-H:(!D;COY-_;/<)-$[50PGI)1L-4X+66O_A!)(YFUC*VX
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M^Q>9[AN;DI2H^0V>_@Y,R>\)R,%"YX"(!2;^ NZ*\RJ;5Y]7^6P%,S;%)@+
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M%:+*MV -AK<-49MP7/P4>7L2O<+PDWCT6S*0YNZ8VR"D/?AFG%A"=+/PL'S
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M5LRMF%LR=RVR+-J]JO/X%',KYE;,?>X$EW9U"2[GY^L2<XOR&W<C,+8W4>Z
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M#NDMDA8C [QMDP-N.<?[Z%K"$I67B=?;W,<?@)+T%IL#G&8 Y:^A.9-K!+(
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M,GL8X-VZSIP9+:B7;]N-G$@8S@00(T!2XS!3T=*K+JJI*&%$D,5GHHI48/@
MQL:9MTVMW:VJ668-7!Y%15LZLU9/17A.VM):PZJ,?&7*;PFV*?MZ'_L:(?<5
M .(MJR'[]LU=6VL>WFA8F=?UHJ,RT^:KI*/.S=U :[4/;BUQB=9U+6IZ2@:=
M5/[GL0!S%6*CC/JI1F!T;^ZZ'6W0KZH[[ 5D;Q]^QJ&X5W'O@4J_&N[%WO@]
M36]5W!K_[ G9)T;NOTK_KS 73&[_%KF8<M^VY<?=5IP@5RYC*!4P.^6+WZZ
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M+,M9^8E4'V+E)8J/ B,_TD<^(!9',E'BK.T:3H+95RFP?967?</+?L/+-MM
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ML(Y>/%AGAS+J85Q&K:;Q7.0TGN*B\_RZLE,?.@9\SEH-]MEP@*HP8!D76J)
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MBBAT2P<, ;CE=-X R I]X=2#^V>#)?*$=LW"<Y\L<3"-QPXR R$^PDL<#R6
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MW07G[X4:SNO%&LY:2\_?-ZA-+<[1)FY_X=+L'=XO+[\MZ0RC7RH40<OZW1\
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MI&PA?42"&L105"&6_2$5Z^@48PQK343A"1W8\L6=%_NY\4I/A8A%3&<5X['
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M?,<)E+LALEL5'%;!$[__)IM[/.R6/H>?R%M/Y9E*23ZM%,TMP6$UFT=(<:K
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M'S:=KCVR;*MKM[O#9K?7_5?OU;MOQ!I ]#?P0: 64"R==V7(>U2V'5Z4@1@
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M-\EIP&$0\'B^NLH&B.-PY%&BPH.73);S$V Y)S'@6X3V42*_.12P Z'3!\(
M" 4^$Z?#6/PGQ20(D%& 9R<RY@(#&(@%W!>LX02QW"@L(WX 52$N"Q]$,!G.
MW5TD[F!3IMJE%XS2*%+C+V*!,R:"$?P5:#*('9DT08T=]+E,^F:<A*/O5T-U
MW"G2+>VW)*'D=7\5T87A&0IZF!7BIO)[>&*]D^R$(_R7[SLZC4-G?A1WX@7
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M(G?Y>?341<HM!/0!%RN]PZC>/ZI]K$F[FSSNP<2;-;I3YB#:181U]4M3NNA
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MV@O&3#TQ<V&U35B<2Y6JA)2!:?>MXS#+*7NT/BYUW3^?*B7+[&R= <,U%X?
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M!AQ";@$W+\D<WIT;XL<()_",G'B"$UVF82#F..[UNX"_CT:@-23PE8>)-YK
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M_PZ%QBYIT6A/@J4*0$A\Q+N;PO%SHR)7R:1UBRL0RSD&,EF$$U$=%U@=.0\
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MV,14D\45F'2!I.Q<+B*;863.%1CX7*!@6A(%PWXI5[H[O,A ^UYHRW;-9!F
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M5.+@/\<_&W__\-MO7S_\?\;MS=_^>?W'A__]P(A^?E^;YG)KFRI3P4JM!E-
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M4#%RFL@);C!2^O%H]@INT-6TYM">(0?;BO*ZG?)NM"MC(I&CS+/@'.EX?8,
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M:9B%R-Q;MC.5/]S+<MND8\S1 GYX\W]02P,$%     @ ^8$$6^[5,U*#'0
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M6R;EYD';4R%M$>#U8I0;!8-;W4LX")H7ETH]A?,.5"B"W.O@@,<@=0G98/,
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M'9+V4C^Y?NC_@4[Z^>OU2PPS_,N?_@]02P,$%     @ ^8$$6_Q=V^)1/
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M,B9;B.V:U_$>OU1G9/1I,7+BE%GG=0H,C*#73@ENP'/MP7B2<E#",-%-(-(
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M&V@W M;_<4%;/F]-%FU-1C>YXAK$32]#B24NEIA/@= (RQRH:#T0S'JG#_V
M&VM5;'V:L [+$].+)B+O98OY]I'^Z>(0E!DFG7-@,"=0.2L(F25(4D9+(+W4
M/?BL*SA/VUW=2>@=I&MOKY;^X:IX80-H?3FIE[".QC_=C<('8^+]Y-^'R;@"
M,1C#R,(5D$[0QI9KIQ5F#K)((YRW)36_@KEWU=C>%^U<,[81>Q<:L?1N;D%<
M3=1WQG%!BU7:D_=-UI'V3./ %?J!RC')T#PI>#^D(_ N=J7OIEHTE'U#5[/6
MW/X:_G,\6>%;U%79HITU]5H%4\>E)T?>4_6HBF."!6Z-41N=]CU00W[[R4_
M>V@@TH:'=A7-VW"&)^4:IJ5&;P*J8:?(6B#]=XKLR]"X*_$V[A-9#RYP;K*K
MX&RI P8, Y>1@X@Q>B-*46*CLH[CXOR>/I%>*-]&JJV[1,*W\>3916^#*!IM
M!EX*K<S5.U)$G?OKT#$6I18WQW;?W1=RY3/[[01I).)Q _DTW&\O<#Q?XN F
MI%)3G!:M *6XJ;=<1$"A?!3>9"[#ICP]?T(\[2*?+MZG%ZOR8IX+2F8@Q517
MI!%\K:N0'E7(QH6LU*8\O7A"/.TBGX;YD L<+Y<XR*)K@3R!U:::]:3!VV#
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M*YE:&Z$[8!S@(HC>(M%]I=Z!7=GB!/#N-.3:%&$].'>*XJI8#!E,*^O<(YY
M8_0:>4&+K<_-.EO,4U;*X]" M3;N2'M$KA_,O!M/!XN;%0[?.7(_LJ/J)]E"
MB(VRU.M?ICIW;S Z'Y^O077I8L3I?$#?J=/.1BX\E&JTE>:^5C<$""RY(*((
MO+3.WS:$W^W&\0"(1?K-R2Q95![0DC>MI-,0/'G83A?+: _,RO6[0VR"NJ_\
M^*$T=;OMH3G/1Y-<7U/67!R)4"H-R:JZECJ"AZ&%VF0;BG8^V]:M9D?6$-.W
M0FS8.;,-,<?>A[#)6O[LG%F7"VBA(%TV).S"[K%KK/:6,2T3).\SJ#KIUM69
M _7>1%?(W9?VS\Z9QZ:HVY#:>^=,"JP$+CFHX@P%ET[6/01!B5*K[(4D6?W9
M.=,-UUMUSFQ#5+^=,T&&FM,WP#(R6C,6"$$D8$GRR+C"I%O''T^V<V8?_6E$
M47^=,^4^7_<BZK*\R)BR!*.R)76W=5:8+<!E]DZI*&7'4RFVP]N_ AYYB-N>
MY=[S]P_)\0U.IQ\_AQ$7O])O?IZ>.A9(5/3>BFQ=G9MFP!N.M#BF3;2!9=YZ
M5VV[@D-7;G>I/5ME9CJEOO<FQ8=6LUK%R>3->/2)-@YCR" P)D G1EZ'TO5>
M[:2!.9,YXU;RU)/QW7$%?RIR']1WT!NS^ZYVI?FG?OM"ME'GQ(5-$.?#83%F
M6I"M5:M,6N,*>="MVV::+^+[]2X.JP]'9ZEO[CLW%GDJ9>22802G>1U761"\
M,!0 Q"1=9A1+-I]AUNF"'I/B-U&X3KV4?;3EZ%Z%FSO7S<59G;PN60"/0I'8
M-1(!FH'P)GDN&.:;PX./S(?Y\U4X4FU9Z_8<0;7-FEK.\8U:SKY+;;:$=; Z
MFWW$=Y!6T&RU3D9I0%$SAP8E!(HVP2NA0K2><]$Z4CNZ5E!KO=;(&)10Q]5[
M5.1?DI%)!I4WR*1H/@;LT;:";J,ON[2";L/%L5>KF(RI:(D@LJ.UA$AK057
M)::DRL7[YHT!CZI:90?&-RQ'V4;RQWZXO\E:_BQ'V?*4?RL%Z?*4?Q=VCUUC
M@]%1UNX:3*[>N5S;*SQJ2"%%PXW,R=GO3E-W+$<Y&D7=AM3>RU%DHLC/1@G:
MD"^B%(\0.'H(Q7,3BBGDM/Q9CM(-UUN5HVQ#5+_E*%IYY0@;2*4"*%TB>%9'
M)@H9%<M*!]8Z"'BRY2C[Z$\CBKH<@?#\V\67?Q_@A![R^=L;_(K#N<7F6MF<
M0P K,=99Q0Q<)-N-'",KR&V*S6O4-T+V9(. ]KQT<#!Y9^+H-M[E&[0)V*ZG
MO6P"]. C7)HQODZI.J.K2PNU$6A?)Q>B,( A(RBG%43O$%@H,D01C',;W>O]
MN'1K\W$JQZ%:V[#4I4K-)S9,YQ+@R_U8.)USX82EZ$Q"X/5<AF027 U:(G>Z
MM!XC> ^< \Z]:$_D.I79DX4.7.J[H(F5M^]"<9@R,%.GMC!RW0(%KN3R)Q4,
MO22%M>[1O0?.]Z8@N[#0DP612V@.BTDQ9##*DAEE(M21MARLB]):%A+7K0M>
M[X'SO2G(+BP<SSAKH;CE2FDP!>MX,R\@.EG &=284!>K6[LOCV6<];$<Z37A
MKI_[:T]FGW'R9A#B8#A?2H,AU0]^9(,JA>U@[UEA4.^EOOG 2S4RTJ009"!S
M9,B*1!7!E5A 9G))C D^E/B Q.Y]P#ZWC=_\T-4 6N8*00/A90(EI(8@HP6F
M FJFC#52[("XE]/[=EQ<O75\?SD=RYE\+<I:U'1]PE&BI3S_]K8.]">;>/GM
M;_-8CAD5H\@9M*KWY.2BP=?0#DVD?5$9LHBMO=3-T?6=M&ND!>->V.C 6[V.
M=(ERZ7]M JVCI-P]L Z3@NN*T7L59W\Z>M:8[)PTA4?PAI$=EE9 2-H"]RBU
M#*;.%WSLFO) 0NT(%&4;%CI0D-]&83K%R0SSBV$8G*T:\[G Z+% D:* TEI#
MU)@A(M(N35+(S>=]W@FD_^BD&54W3P[WEG,'Z;$;BYT'0F'X@MST;_2M>43^
M=CRJM<'D])QB=EI8ID 67Z]$4!)<\A3K%\\#*B&\Z]85>0!@?\K2WK_MGI%^
M(M4:<N\>E%[]UPWBS[5@&A6SU\^_K"^XH@ L>EV+H:*NI0"*WN^H/0=O+8K@
M72P8&[\H:Z"TR'Y=?NS"U=99Z<AI.<[4N1NBU!H'QX )6Y0GO8^YBX+T&S#Z
M*D!OP?%=>:E]I'HL8>QBSN_/H4Y)GRV]I,Q*Y+'.IJIVB">$(#))2:@DC$"G
M;>OJRMLH#EE+LA>O-ZO5]I-O%X6.UQ"M0IT-,'44>=Z%YS AY[Y<W4O]'H+N
M2PE$M+PD[4#H9$"EY"%HS<"3E\RU\J*PUA%#?^0_$$7VP?TV\FW(>?5TYT<H
MF#_BY.S-.(Q6P%:7G]CB4Z*-,!M+/JC%>CZG _TU4DSD:NZM/.#V/?B0_L/
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M@"+I#_# ;,/UB,;$ZMQ1 4Q2--U./<9#=]_T(BE--TC[1R%78"/P![75-GR
M:[%)>E8P9[NAQQ1FWO8\*^+Q_N;Y2\W32%Z7G_F2JQ[;'SA6*P"#'/93]TZM
M5VW,"=@0!AUEXQ3TDW(/ZYD+D<V4S%9:H^R0(9&L$D-.#CA;3LB0./UTD,'K
M;&LM/SQ6_"LOZORI"TK\R%=-&KA683/A(19F L,PC7V(:!9 0E@*,Y0&A)$X
MQ$%@UA3M0HZTWNQ+6J3M\:?RM!6'71<T?%#(K#C33LVT9O-ESTAO*IX#=VN+
ML@-\+\I[O[#<[&7D'$'FK%3T9=S,7$7:"73'!:;=#&M1ZNT;KMB7A_L/Q6/^
MNJA99938>OKNB1V3ABCXDC\H[?CP\>Y&10_4N937))?UC.#C?LGE,IO9D2%Q
MG>:N#@MF5YOM])#S%64;%&FO&MOPE<Z]E 4*LLSS10:93S%$L?1%"&88LI@E
MJ8^"%./4))QX@):1/IK'$[?=A>C>=)?OI98=^A?X/E^6!?C*\7+U]4I=_&=G
MKL7E;L,/Z!+<8;=QRAK23S^[_S SM\6L;&D85+WU]WFAS@:;3BCO,%5AT,^J
M(6/%\K)XQYOX*4FLDDLE_EY:_94T%8AP'"&(LSB R.,<DHS%:H\NQ,(G:91I
M13%;49]X,E?\J->>MIUA1,?2%< ;IH!HN6KL1,,76"K&]-LCF",^;$,FQ]%P
M?U!!>+MMKO-N"^&6'_!N ^&&)?!^:@CU&TY,"J5=_XD)(#5J36$-R4"G"O,Q
M9VM<82UNOX^%_2#FJZ9N'^LC?M **#VX96*3JDCHKX/ZHHPO?BRE,#-HFZW7
M04&,EC8GV+9:S_3'F6T1<X+Y_LKEU,]35=U8<"9\AI,$$C^((**Q@&G(J2JU
M$X;"YSSQ [?%,R9>O"BO>WBQ(G][D/:^[H6G;DHQL+SN>G?(I?ATK3N<5;^8
M3F7M6FI,O<S11V2V$A0_6B6)<VL?@SO-ET!OOZ]XP3A39ZNWXCU?J5EN,W<O
ML@SY+$MC2+R40X2X@%E,$$PXCP-,4QZG6FV"1BE-/ ]O:(.5.KN7[_RR);];
M[NC[W\.(C2]7G.%@9A:V$#3A"]*A[BCO?&M7$.@O-YQ!8;>T&'\KSN^%&:TA
MM.0<6"\,WS_;VD!+C/XZ0.\&.P_I^@GG2S5;J7*^>,D_<]J%X*@0D5U SG_E
MJZ]Y<5OPOW)<O<-Y]3M>KOE")%SP,,Y@XL72>\)^#-,@"& H2$IQD&4I,0JB
MO(R=B<V?>J',/*$+T=7SDN;#S,Q4-FGN.V:D<[1A%$I?$RI6KX#B S2,7&W"
MO]2FQ+*Q!-*FJ *)G^4L+=VIS<_@C?SE"B@I@)3&G7/E!DA'CM>%S,SJE+D!
M[M!A<S2J>9&N-]TT^$XNAO"RK7S^3GY7+[)0NG)$KJ'CR/,A\J((9B)!,.,H
M](GT[E(N=,S=()6)K=B&+F@)=V7[04-:OVS7>8R&C98SR0UMD8W01L6\1H6R
MJNEU?M392GN-"M:O\#5^L8N-G#>]78K=\NUT?,DG_JB*N!;W;5+0(HX(R8A'
M81+'5'HL40!)B@+H,U_$S,>I'WCV^ST7<#;+F?8$^SN7/(PTPYAB1B%!5$"4
M"@*)( $,PBR23XG'(39*2'Z9A^&D9>X/]F1L-NAFPOOB?;P^GS_(3IX#Z";9
M\+N$KQ?<%W0 Y_#VH0L"=C/A)TYY_J1&KN_*94Z?=T4&,I0F/"8A].,(010%
M(<0Q9]#W8Q[*53EGV*A:S'E2$YO''F$S^S< CIY!<R.RF87:T01_M$2G*: P
M+ILC$S) :%:;,"[PH9)KW.&F4.U!>1"<9ED69Q$4L6KUD05$+BEQ"*.,!9BE
M)$I"K76E'KF)M;=?-.2H2NEEE5FMJJJX \-,KX]DG[0\BIZ4$Q5K?<EB)WJ"
MCQ5M=5*Z9"_LFJ^^ELR\Q_SIVR=6V?V(_(:T1=[!@<3#VNE(6#.5/"'G%)WA
MA\6Z+._@8,SY$P]."W4R\^#,I69*55>KQ7NIH_>-C_T:U_R+'.!-^8#S8I%@
M'L=-N@$+8SEQ,A_B+,30\W&61JD((J&U@3!$9&+=VY%5%2ND#]A2U2S9,8C.
ML :ZDME,!8W%U58]'7F&YC]Y?V_NDW_M-'!PZ%E44$>XC0YJ73M50-T=KU[A
M.J=-J]B%8*K^<4@@PD@5,.4)3/V PC3C:9!DW/>%43$.0_H3JVXO(*SL;2,1
M11_\]-MGP,KE$E= _M;VD#9L(6V*-DDI3S%!,,8>@BC@'DS33*XE?![C(,T2
MFF&]5C(SX&W5:^8XN%%ANPEH5"RT6WST!WLR-MNI3M&^>-/T3/"C9 @T'+5M
MO^>,=#R)Q6QAC_O4?[ 8R)/0F =$GA[&OIG%[@3_\&R_Z[3(V>NR7KW]3I=K
M)CFYIK1:<[9)"K\6\K\J-.0;ECC).]L(*"6!G&@H8U&"56GL%**491"+S(/2
M.:0BQ)DO$F)RK#<MNQ.?]6W9 XH_\\X:$SXG/4/XXZ!O9C>U0I[VG\X5V$H
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M",5MLQZ1)L)/D >#R$<0)9'J[1;XD".?AH$0RK_5K3%@0'=B=>HX4=GU/5[
MCAFPX<:L%9(INL,*.2%F9NKZH\"E7[M@(MCL*AGHP^>FH(&%\ /E#4Q&FZW8
M@86(_=('-K?;]HHJZ=]OZGK-V9MUI09ODA>;H\^Z^?<5KM6.^,,C+^KVQ0Y3
MGV,LE]19JNJZJ,Z:)/(]Z"5!R(6(D7%[7F,>)K:_']</A%<JDKN)DJA!WG '
MU@7;1$Y HG@"6.URUJH,?W>I842%#?YZZ_R)436TT"V,+3M7;=!$W?T7-GR
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MBX*$PR-.K'S]"GU,<M+T,JM:7L"&&;LJA2-(#2OK=""9*?)>!4.%C^0"?#K
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M,E)6;$P\A^Y:-AE6B++#-")!F/% 0"]4>;,)QBH++H,D#A/ER<1)Y)LLN&;
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M S,V4NMICXTL9EHS*H9Y0,4!SZXB)S;#SALB<2#,42S$X>\VJ=-JOE.+\+:
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M4V_R#/K7=:7RP/4W7#&5CM PJZ(C6G;K)M.ID<EAR7QKT%R5Q3=G8-[2]]8
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M4':<)).!%X!I%34;>=_/L'7COHCZ:2U-_%?131TX^:L0:D)FD]4187GH%VF
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M@P\9WMXU%2PJPW)3EG+1AT)UY*9A@'PL0H1C59I+68B*@,6DH#Z/4E"WSF,
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MBE 0XHOXH5[79 FY8=4##A+Q'0H7.#Y-4QS>OR];[^_+2%V7"[JIFW[F]?K
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M3%&>2)WIAR+)J<AS3D)04H\QFRRD-U_""#W=9TP>3+\IR@XOW(\OS>^(W3F
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M\K>]@)U9=!:Q&B=H*TP33QDV(ZENENM*W*^_K%X6*G>IS2/1-&?/K^ ZO-(
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M0T2Z(RA+(D9I[$=^;'%DQH78.A;](/1:\')_Y+$H)-C2YG2,2_=*S^7Y878
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M]7^1M:;)=KO6FBY0@YC8-O3V>?5M\_Q<OJEV!E6]NJ=+B=OURY(N_UG"HOZ
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MZ%1S?EG2F 8(S*H/S1ETK.TN6.F">P"I8ZN/?['EX^]D^?6E5.FXQW$_P^L
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M>)*98G5Q@ZEYR^4U_]?]6D&!7<^>ONE:YRV7WE&R7_\*$# <[Y3F<45T.;E
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MU"ZN/TE[UEC^NMZLEJ+M J<K0IJX\V#D4%>M+H/?/[SK"X2./F(;[)]^"=
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MK6:%2+G.;J"(,L:0GNI=)(3$190!FGX;D#3ZIE[=X7MWX0X:XFV"F)EV7@N
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M-_4/)($+9FT2V3E#T4?(",H:!!^S!ZV\I"7$$TFS,>".(GB<OBW#H?%TVNL
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M<CHQ1\V1=)38>T30J]7JC-A0N@1//B0(H\ABRXADL4E0,B3-R-64SK4^7W^
ME+%/,(=%S@'B[A$UU\<7>;*5.25.#EQBM,6; -YB!&31<Q^]36%PP[/OQ*@!
M#Q6'Q<^A@N\ 1.?]$J)VM@A?![-7<2@>(&#Q@(C!)\\1U3#=ML<^A6L*C .$
MV0$$KE>2D\,5E!0(=7(B*%8;J#BO("29K'&TD^JA[F+O6FX]6,%J8S <*M;O
M:@;(^P_T[R\O?_WP_LW/;]Z^?/?LPROZ;:L#JP>>/MQAU2[L-#JHVA:07&+N
MJOF-HF"\) 4JU;F#PE@((6J0/D<NBR(\MF\W=R\IC8^CBJX]NU&!*'4-I,+
MA\@@!2&<*,%PV9JQGHZC6NC[B1.H?20\\@'#V^4BGZ4UQ?^X_#I-N$FC,QZR
MK&91*\Y!V2QJ>YY"\K"*<<>8QQ9'"_>]NY,<RP%Z7#04:A^@V!1^;#FXR'P'
M:U0=%T'Q&",F<J1X/N1(W]K(E,@EB9VBF=V0<9> \8X#CM?I78 <*> 144)N
MP^07S+5ZY(*!\P,+[31JFRW$Z&OQ9:[#X&4$88T,Q3F+-CSA@CSX\-&U?ZS"
M%BVE-[+Z-Z6X;[[@,M2+BN?T^UQX9#X MR[3)IHE<6(3($5@L3 G=.8[:/^^
M9X^3,QU&^4?+KH-H]9XH+<@Z;9<A)%TDJ. LB<,YT$)$IZU7SK4O0>[ZJ.\0
M#Z*1@#N R#O\BO,SO&HHRI5)@GD'/J*HT[L]Q&QE'7F +CJ#(;;NFGF;ADX<
MS -U>N<:SQ$"[@<@/Y.<ZH7WRL*_3=>?GI^MUA2C+:\F^JQ62/_+]79'MBB+
M-+2D<JZI(!8AHC+ 39(Y",?-HS-PC\#0/F2."[/C<'$_R 934@<XO-R*SSLM
M7@DN!)<D,0,V>DT.F8[@3:%_0M%83Z)*\[FP#Q+3R<[6QG2U$7D'V'F^6*W?
ME-H;_YJ#>+DH7B#1E:8;+='7,]RH:YZ??:XW>OYS\W/R_!*+R3J0VW[ZM$YC
M#B1'[4T47J;B0V.0'4_UN!:N$7SN'"B>5)<=H/<O."=!SBH7^?-T/JU"7$^_
MXD7+65VX-8X+R"80.Z(ZL$E;8$JG4,]+1&Q=^? $2>-:P6%PUU(+'8#J^D*Y
MO3XHB)4B*(1(3)%G0,&S-\R =05U=@Q%;GT9YA%RQBVG&09,K:3? 9"J/:Z6
M^$(^DU22QBP41*MKKU!6N\H&#EE(M)9<2Q^&V"FOTS!N!<UP^][!<N[@#O&E
M5*ZZ 4Q0>0IVR%+RF!5!77((13D0UB>22U1)M;Y;> \9W=7K-?'9#Q1S!TCY
M=3%?W.3B8D;GQ3HRRI!>BR4V<IWT&LF!L\;7NC$><HED+EM?B7F2J.ZJ]HY!
M45L5=+!+7:V&FB/97H__!=>?%OG5_"MN1SBL)CDF+4RNG2$"JT6M!;REG9AK
M9KV+CKO0.I.P$V'CQG&-P7!GI&%KS70 MP=%-G&\A*"5@EQLO:]1^STX'4!C
MT:88E61HG5Y_D)AQP[1A8=5& QU Z?(2XI;\ZWQ-2 QH%2>QU#-)E1.K(V1-
MC1P\JER<2*T#M4?(&=>/&MI*M='"_H#R6T#-\6.]_/5AH!UQV\OXC-@Y=R 7
M\]5/6!;+\^9='\+ON'KY.PF2]#B=A^6WC9/Q0'LC)YCEM:-_CK4#,LOU/IH5
M((NQFO$L6/,*^0'9Z:[L_AC/KA>U=Q!G7+)XOJBW-[O7$^:D-/2_NI1#[=^M
M(2;A:3W3JBZ8-38?ZO  *=W5^!^/O./$?:SY/)'E/*@GG'#%&Z$9N*A-'<-:
MYZ/X#"5P5+S0)E5:)T.&X63<SFLGMY>#*[L;4WDAA1?35=H* O.5'"YZ>U[U
MB_)U8%1(Q)FCA6T#>5XY13 HI62>-@G=.DMS")T[P=5]EW =0%$=1$3W<K4#
MX[<<FXG#6)3*'$ST'E3A'IQ3 420WA?GO9"M#6XCTGNXG3,DQFZ?EHV@\%YQ
M_I<PG5>FW\SIUU\6JS![4^[]X&6K962E,%,G'-4LAS)U;)\C_XH7+W3,M1BZ
M^6EN$\K'34_U@?)AU=T!R/<2\PW/ZAU^J0[7_..V/=>$6>=U"@R,H"6N!#?@
MN?9@/&DE*&&8&"9L:T#\N*FSDT-]'*5WX$>_72XHY-T<RG)GDF9)0)&6-J,H
M OB<#121HLW2<FE;=P^X>OM.>//?B<][H% [@ -A_&HI[!0W>NLYQ8BE-LX4
M9-TE!V=\ %8GT/A@7&[>Y6AO(G?S3MEW@JYA==3/>< -/B=."^8CSV"YV[C*
M$;SE), 0537X:%QKZW2#@-TP]+W< 3I<MAT8J8OY0Q<M!R\] *9LUM(P8%X0
MV)/RX(,T$ 3%4A&Y\<V[;SQ$RVYP^5[N7321>'>^_7VY4^+PI[":IFTOR\B<
M=RKZ>C*/H!P9SI@<>9A%1*.)2:U:SWO:D\1Q$R]M<+%W@OMP)7TO&'PQG9W1
M9KIE4"JG522.C#%DGJ6I@WQ%INC&>V]2D+GYY<6]B1PW-3(>#@]65 =(/#2+
M>1$(WUR&'K$8+CC%V[6M2> ,O-$:2LJR,*6XQ]9U9$T9&#?C,0B"QU/P'P/=
M-Q8W:LF0>PO"Y S*4DP?9# UL#>1\5 \:^T+-&9AW(+P7A%^L)([P/B_X?3C
M)R+^V5?BZR/^>E9[PKPI=_K:;E;QA.<DLU4%$M..PCRE(-;Q;EXD'T0@_F1K
M"[T7@>.6M0V"S^$4U"_ZKB^H&\V5D>@WPBMP0A)[6@6(V0O@7A!W-@NE6@_U
MV)/$<<O;3HG )DKZ;IO=/G_SR]MW+_]*GWGUKR]?_4K?OGS]YOT@G6\?>M5I
MVN#NQ&C[X8W;'?C9/-\S=?D2U=X540K7)%"_Z9U:@.+U"-Q)[VG3=<4,UE)V
M-Q(;'JX5)J(1UH T/(!RG*+"B!:BU[X8M"GKUL<D>QZNG6*48W-</'+RMH_$
M.]A,=QE23AO#M-Y"2TL,*WR!V_]>"2ZCB3H@%"[)><VV@*=] X0H*CA!'/O6
M^^OQ5'?2G^@$V#RQACO']+.O83JKIY8_+Y;OPPS?8SI;;H<RYO\XV]ZRO"PA
M"BS1^@VJ>B&^]L<A]\29 $:J8HM6RI76A;NM:!^YX]&),;<'Y <#0.? )W;)
M)9\_/R.ZYNG;AV68KTC.V[XKF^]F6WC<E8*-(N88')#\215!<(@R9\B,!8H=
M-0K7.@4U#"<CMV/J=U&<"!P=+)%[!'#!RD'W5[1)DM5C%WI5!.4#N7LI)*"?
MI:ACR-JT3FXU9J&3KB\G\(3&U'T']2N/L+\CNSXIJPTPI6+MRYK(^%@!V46G
M30P>8^M2J"-)[J05S;C0;J[;+NZ>/L+P)&69K1'DJ]4A%[79 802.&C)G$U*
MB)1;9W@>(:>36_/C@G OG32SE:?.[[[_\.;Y__SKF]<O7KY[__)__>W5AW]_
M\?+G5\]??1@BP_OPRTZ3X]V1V?99WLT,S4^+&2V<U;9-TA5Z@_>F'F+1]EMJ
M[]$,47$%VJ+-&(O-?K"A#H\1UG@JFDY68;V_1U%I/2SQ$4)&"=)84T@ +H4\
M%)L=3$5KCX4G9J3M(^\.8IQ+ZK<2J69Y,:_=PS9SH#!IK3"0)992US$? 0)G
MFKZ-24E.UE^V/A)XE*!.L'2 IA\"S=%B[P!#MW@XGR%D"C(I2J0U)6@7#TI"
M,"%0[,.0959X]*T3HO<2T@EFCE?T[8+WHZ7> 72>7TVZ/I\6550QP14)/"$Y
ME4$FB($C%"T"%^@<#P-$CC>)&+EB_7C%/CQ/_  I=P"39SE/J_C#[&V8YE?S
MY^'+E-SW<V92*%P65L HG4!%92&HHF@+=\(SZ^HXY,:0>92@D0O-F\.GG?0[
M@-([7),\,%]4,IUS$9.T,J$%=+7-A6$<@B8AJ:0]]\:8+%J?6]Q/R<@UWLW!
MTT#>':#F64IGG\]F-27UT-G(Q;1#([E)V8*)M)$K9AQX3 90),Z=L4ZZU@FE
MG8D;N;JZO6$:1"L=P.W^S.LY+UEC$J*6X$9F26(Y@XLY@7:)19>]DM@Z<?$8
M/2.71#<'53/9=X"C^^[8%HM%N0S)> /*<C*\1#1]Q0R&PK)D<:B0_G67LTR;
MQ/&'";@#B-RN'W@UOYLG>T=KX>?%\K>PS),H2U*,F.(FB-H)/(+CC@()KD3P
M$7T*K?>W/4GL). _$!%W;W@.IIX.T'<M,KU;YU^,#"%I 488"E)Q<YLO>M"6
M%Q=9Y)JU;L+V&#VC-Q <#@@/YPN.T\K!"/NRJ6VBM;1<-]H(;\OJH"H.9ZWE
MQGF0'I&V?Y]HTR!?4A>=8TDA!.V;;YXM*!^]+>#)L#N"IKM!^;6K!40_46@S
ML! W>XZOO9(%Q&2%E;[0#UH'"7M>YABR,]_)T':@Q#O8>7>I,)VXPKA2R@*C
M0!F44PR"U@PP6!=U--(V3\;O0M>X>8Q3XJNYECI WD9:KU:K,\POSI;5+F_-
MX,;3V/SRS9=-[Y*7O^,R35>8)]85R5)AP)RI8]Z]!6>L EEB,%&@RZ6U)[@_
ME>,F0DZ^QPZGP7XQ^J]A=H;W,YBB-)Z5#+00J_E/"(%1D!=TTDC2C2ZV;HR^
M-Y'CWAWO *&-]-<O0+=+\!UYL,MIJI?GZ\>>57%N=@L2;<'I^HP^,_$D2Z93
M!A12@F+%D*NB-:1,W\?"8LFM]_:CB1YW2DH' !Y(O_T">K-B=^)7%!UIL7(0
MJA2*V'2"J!6"R+6RSZ-EHG45P+$TCSM%I0,X#Z/='M"\6:>U7(*8(!_]WZ;K
M3U6PQ'F]2UI_^Q.)?%->3W[]=HA]EDP(QQ(8VG+JR&E;)YT;*#P$H:SDC#?/
M+AU Y[A]T$^*VJ&UV$\GZZO;FK2[;$[4/RQVY=@H7LO&$)(K"E0RY-L7<O#1
MYQ!"3L&&UDT=CB!WY$[KI\3OJ93:#XP?=9M^Q=\VOUI-I"@&8Q; >'7VE0WD
M&T4&CL)1Q.BT;-XH<3?*1F[AWH%+<(RJ>MCX'W%TKICB,<M@6:&=P?%Z&QAI
M<=49[09IBRAN@%F_.Q$V<DOX#N!WA*(Z0-\U@_]A\4#9[F:!Q=OV_AV2=%?3
M-;['Y==IPJTTWF%:?)QOGK(1S*0.@_'!(01?(JU&%R$J(R#;4HPQ-F76^EAI
M:)YVP_P?XK2J*WATL%P>K7.0UC+%0X:8ZWE>P 0>E0?)<HPJB>*;3[H\OOKD
M#W'HU4PM1Q[,OYRWZ3_0J"0A2Y<S]P6D39KV(B/!*QG($THE&&*OR.^X^(3_
M<4[&3JOJIB _>9?;9^__^O/K-_\V3%_;RX>?J)/M_<RT[VKP/*P^_3Q;_+:Z
M&BR90^':.N A6@*,,Q!8],!M2249+BB<'ZJJ^QYZ&LQ5J\]\NUQ\G9+D?OKV
M-_)'7LW/>^///SY+Z^G7;2.^"PD8Q8Q"J\$X76!3#A%#$;1T98K9162NM77<
MG\I.2I./1= ]H]J&5%<'GN+U<9F)R/8N0,I1U1DC1+1T&F1FELED8VC>$[J7
M-LE#Z_F1&:5["+T#N-P(M&J4-$_3&=Z8:/AAL:\H5?)%RIJ+J/Z \EJ"RSJ
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ME=:NSFNC]<YJ#4'7,34\%()'K<1R601K,%O7NL#U?DJ.[P]^_:E7J!0YF$S
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M4Y]5>14OHU$R$.P1UDD@[@-%EL1\J#-GDA(VAO+/^?0D]B \ZM>$QY?16P,
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MSCO_WV&IF8U%BJ5B=A%7*/6R?"CA?A:23)H32Y''!,ZR%#!R(5 DB(!@F1I
M3>DLZ&,*!O=WW+C9*(SL]/9\^O 1B(^3GW$VC_&K'<?SM!#KF]NG?WC]QY;6
MV9 4X&0/".<!;UP&CUR* <44I&>YZB64ED9)^NL:IP'(>M(E4DNI#9R-=P_?
M+'D!L_"CFRRR7XMF+NFU4U(CNX@7-)-("T:1-M)%*H2-KO2DKIT$U85</9P\
M':I12&D-('"#AU74XZ)-%'8T4B%9Q*-SN4Q&(J4)D8Y@\&)/<U)L$%(9<>44
MW966>@/0>>#$K(-;A8,B>8Z,-A#<<B60%08CGVPT&LC'O/1M_Q,B6C@7!REV
M<V#<("DW )-[4_S 0M_',BI!^**L1S%&G;>10YI[8"EPCBV1@6[.!BOHAFVC
MJ&XJH9U3KIS:6@!AIO[C;'83P[N;*<2^%XM7Z[]^!Z7,%O_,C:<A;]PXF2VT
M?0D,6LY!>@1'GYU:A0SE%L$O>'[RFN+R <+Q9+;BE U'R1,WZ[0J:QV5RY]_
MZ*9?X_3GR,<\"DH;FZP&W.3GT+7*'H>(R*ADDO/,PRGPDH!\0F$KIO-EL3A,
M4:WFSS['^<<)_%O,"4-@=^6'9([OWWG/F^]F^:TNY7I7;R?AW6A\,X_A_<77
M_HFWDE\ODK$[F3A*I?KL-/?19-(61-VE9@C'U!I+46(NY"F/'MG\6(+QD>HH
M30JI])2<YV@9:BX?Z>#L)\@R>SG?N@<N\O=N#$9FMI#]G0@4\*D"T8A(G=/E
M7"*3:$(JRF1B\%@5[VON26KEX*4$AC9-YTLHK8&C_)['#R#7Y07+#0AS]?9U
M-YG!GQC?Y%:DBVZZT.A\/ATY,!<+<>1'1^ O 57PA:MUX>PEI59ZXS2"D"^_
M..M3GC)N$)4<$T5!&,6A>QI.ZB+[14#8-8>(!O;%8\D?PJ 1UAMN.!(JY4XL
M0Y'ADB+.>(K@2UGK#ZI3ZVVM2Z'Y9(YN#32?5H_' ]4L@3J)5[G@ZH5,^*7U
MVF#J'(IYF SW." 7"$;!)I6\S0W*I>L4]E-5=Q!!FZ;U*$T5>V6[%/9RK?N2
MJ1CN>0))GZ=O]H_'N^]+_)%/C\G5>_@+\]M++X)+1&EDF;>($T:0M5:A0+C$
M,?)D0^DD03'BZPX]J(_DE])[:W[!I3&:A\0U>#$05G ; ](.8T2)T$Q&:^#_
M3WGFUYV$4/T\/TK^#5C+C3;#9=7:>5JFXQX,?7@L+J$8YD$Z%!+V(*X@D>-8
M(.R\QE$*2W7I"1R]"*WK7)XD"7!ZA35@THYB\E+$I!B3$BF21_,KV,;:,8V4
MD301RQA5I<.<HPBL&["_ &"&0/0H[;4+S55J^@F/EU3:Q74)XI' >>"M0RXE
M 0>-528J);DO77EV)(EUC60S\"RBP08 >K@+M.+X_E@23EA.@;/ \X3HW)L3
M D.&ND@"44S+TI/<>A-;-U*OG-X?HK@&$+H_YP!R7>SWA7 O/68\PC&!%*<8
M\0 NM94*(Q HESX(+VEI;_-($E]+2GX0<([.'/778F^0@DEWW4O"].&I<6F
MCP0'$\)Y@ */EB,C*/ I@#?EC7+%:WV/)O*UY-M?'*J]-=D$6+?FNPY(B:TS
M8H_WJD@N&*]X'C $?H]U(&=M8WXTUS.LO:.^M,4MRL!KR>.7!'D]!/Q9-L C
M"P":H(12 P( =XX[G9#5<%PE3;A++'@(3=O; D=;^@:N !K;!+U14' ;U"A
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M9R@&$5SW_OI%C.#+*+/8N-#"+NUO=CI:%><M$KB+,;H0"CQ\S64RZ\:CL+C
MSY$CN%CKR!#^X')Z?_SMX_OEC>OCW^WOP;X0844<UAI"+.2?GD^O[&1U?7Y/
M9-[?DW#Q0"#G:14OVO'=>Z#W>S"R@*,2&'DN3)ZZK)!AVD&4F!*U)G!,36&S
M5H3P<DWRST%@V2)@$^%6!XLX'&CPC^20UM@CR94(! =&:.DKJ -)J^OEOCSZ
MGN^!+Z?!BE[*;#J_?&AKUDPLND3!G;+<<XDT\QSQ_!*K8=+FOBEFO-3JP-I-
M^,@#!,*_W:-OU_=;:2,OJ.BNL-0;1,ZJ?<\:9Y,,'"FI<L,F,\@!&XB#Z^Z9
M%-I(>B+LU&S>+J?9/5#I(>8&@J&M6^GV8CJZMM/;-W$2T\CGERA7G9K@D!M+
MB0>!:0:N>N[_M>"O&VRUY!0+*0X"T1''X'$4M@6R/ICH7DQ!34R.V\[?I_L6
M-2FDB4XC;018<\\8,@%DY[#6P*,B!)=VO/:0U$KK:_E3\!0Z:<#&K:K8U\XF
MD\J#T1=(BH@AZ(^P&Q/#R%HJ-)&1*UV\Z_H1!77=J*+*W2SE[B_I)HS182EU
MQ_+6 KE$*\&<)\60\RH@891B8'QET*4[J%[!?<<0W?>ZV3A&#0U8H>>SD,"&
M9RIIY 1-P(B+R!"BD <J4B))6U'ZD8IAZ>+3S2 IAZ$RXFX"-SX"[6"Q\P-J
MZSN78!S/HRD0T4% Y.+!2CM%$1<<O$H&$F*E[URW$E+W>J$H7H:*N8D3[&(:
M?]A1>/_'CSB913"BY_/O<;J4TYHIPHV"P$ @3# 8S@ "T[G(6P2'K; D&%VZ
M7>, LNJVNQ5$4FD5-(*K[D><0N YMI,Y\)0-ZH^<Q,WUWH8Z*S!$F7E<*>)2
MV+Q+X& FTH5(+;'%*TAWT5/W$<2B2"HD]"8@M-G9"4P\[7HW+J24)$;4Y,>6
M R9(*P4RBTY8%KC#IO0]U"%T'00I^0H@55P)34#K@86]Y-:HE,M/./.P+QC-
M_>D<8@.<:&1:>E_\=<P'GS\(*.H5 *6O2!OPF!]<O-\WDR@J-0L!V83!D1-*
M(,=)1(D1+%G2VOC2B>LM9-2-KDZ9^1DJ\X9@<_NAF[X=V]'U+.<@EK\(_[F9
MS?/)N_+J+H%^K)VT*)!<.21"OD.2$4%,P+A4L#UDZ?CK&/KJIH(&@^$9<!77
M3!.'UYGW>13>[,+>YMT)K,%/IC?Q80'17:FE5<X:"!2(4W R.ZF1U<(ADCLU
M"<F!0VGWZ CRZIJWTJ@[E5Z: -WB>'_ R&4P(2XZA(@T.+^UHY +$%-P@R%4
MM9I%<A*WZ0$-=7-)I>$S2,+MOF;TW*WC9SO-S3@_8_F"T2=+G[3D<S<C315M
M\D0-1/L*^?PJ%A>2YVGL!%D/@&).XQ1*)_)>5=$FX\I% 1ZL86(QH RV+PD"
M*4>8=SX)*4N?EG^AHLUCT->W:/,8#398>K<H,@/3GDQ0%J)PQB&LHA@9&A,*
M$KOH";?6'=0;^*<NVCQ*T8<4;1XC]0:1LZH<H])(9CA&4>*8*\<<,I%S%'S4
M,3"=M#FHV^C/5+1YE&8/*]H\1LP-9"J.K DT$3MAA4!1VP2.)TW@Q3J'M&2*
M<BX==:7K"_X$19M'86)8T>8Q"FH6?I^[^;,,.JF"T9$A2VT.>(A%1AJ&",[7
M"<+:I$J7W!U-9)WDQ8N#L)2:&L#AIVYR!:M=OXMN_@W^SN)TP$PYQXQ!#+A!
M/+ \*59S9 C6F!-A;"@]+&8;':^C2+B/UU5,^@TB:+7K?'Z,SPIP+@S3B'.2
M1Z\'@Y(7. DO0J2E7Z793DGE-/Y@#>^!3 ]Q-P":KS?3.+]]TTW"RFQJ(B*1
MW"-,(D4\>8XLT2%7WMM 9=(NE+Y;W*2A+:#TT>N3R;8#A-P 2/;=M0+)N=<U
M(*(BR(:0B*Q)##D903H^&ES\)<L2;2VG&Q3Q B=629U4A)B]&E]^OLF;XCS]
MZWLW'M^>_SZ)X<MH]M\W$5B<7*U%=AE<2IP8@IB7P!'+V3GJ$A**4>5X# FG
M/4GYP[_6=EO+4<KM3BKI1K"3JPGGX/K/OW=A.59PD=^]I 0[QRE'WEJ&.&4!
M+*V-2', A;%18&./ ,TSGVF[%&8H6DK(MA&8O!M-HY_GJ7LYZ_\0\X(2JUAR
MB/B0'P.FP$R$DSY!^&C@A/9&D". \NR'ZIY,IX9*&?DVX/)D+_#;R@N\5%XK
M 9X9,E1:Q!W!$"8XFX>!*Y&H38:DPO[-P^_7;28X!60&2[D1<W+Q_7:6DTZ3
M7Z;=S8\+.YU/8/W+*"" M.#(>2DA8*#:YI+CB+ PX-8%#>(YQI9L_TK=QH!3
M&Y("DFT$([_$[FIJ?WP?>3O^E/]&?FTL!(T-$1A9*1.$E%2"9*Q%*NGD E#B
M+3X"(=N^4;?*_]3X&"S55H<Z[Q_>]HP[=LK9=GL^^4)3ZXYAO*G2)D.,LPX;
M1(/*E[PVCZ^ >$I;8W 447OQUYY'9[30T5@D+0'YB"B0M1CB34&X),H075P^
M?Z'2IF/0UWL>W1$:K%R@<L_2=GOR]*<Q?K;7RPL#ZCFQ' (8)5.>Z>K5\MC"
M.A"%DZ(\'51]L*>$90B-KZ-$ZBC =!6T5QFES_&QNHU(.$C.B4'2>P%^<,QC
MWF1 5 M,,# 68XGY=[NIJ%?I\G(HZ$ZBDLJAR:*:_QEO:GU#15-DTB?$),\]
M(#HBG0)'!$OJM4C)&79 @++_2_5 5%*?W<F$6QDJ9V_/O[P_>_N/]40^G3Q3
M!$(JF@)0CA=WY101S;ABAE$6^ &P>+QJO6*E$T%@@- :2'WN[:Q54GL:-+(I
M+MZPYL@ZZW,-1;"6.,ETZ>=A_AQ##'NX/*?020,0>^Y&R3DJM1$484;!,.;;
M1Y=D0C(HA[U4N8V[,+2&W.C5&VMXC+J[\K*O?"@]9.%A4Z)SDFIG*7AV^>57
MXSWL,'#OC+5!11]!-H=<]CZS?-N7O'T@44J6Q\/!+.$PB5>Y3KAF-O7NC<DO
M<78S/FT:];EOO5#^]"!6FTJ<YM8[J0-%#.=9TTHS9%)PB##E5?#&1O.7[@F-
M@<@4A4$A&(JX-@II%C5BA',N,4E)EZ[M_0LE3H]!7]_$Z3$:K)R2NIAVX<;/
MSZ=?X_3GR"^3*0$(C9H$1**2B#-&D<4VOWZE9.+>BG#8"W9[$E';OOTZ$IU'
M*;@K*.TVT)*'VZPX6+<!<:]=8(HAR1W$08H&I!WC2&MMK?3 1CRHJ>4PR#PE
MH%[&:;A.GP)DH( K>_+_C"'?X*\96"5,.'BN$D-H['/6)$_^1]IP@JA,EL1$
MC8OJ #]^Z^+5M3]485U)Z;60B+YS2]?I,L&#4"0A3&R6AB?(,HN1\Y@I22T1
M=I\K_MS:]3*-Y94_6';-YH'RZ_ /NDC7B=F%M20!"ZMS!A4;\,FDC<AXX9 D
M.D8M*-:BM,=[-)&O(QW9QS%Y&;V]-F"N-K+64E.M#3)6$["[>::H%1+A:(V4
M44C)9$UHMM"%>6+@#(%I#RV^-J">3Q?5M.=I_8.URQ"X-<9BAIC0*D>Z"6P!
MAF-#,D\]'$^^^$#9(H2_(C#W@=<0.!?1=0, WY?W-BDJE<\M%7D"@7J-G*,>
MN:"58]0P7'Q"]I^B]W3(\5]2)PU [$O\&2<W\0/(<MVY]*_1_/O;F]F\NX[3
MNY'R>8 X_#=\LW]<>F]XC' B*1$A:L<4#B@M)5+>JNBD=2J6SDSW(+/M6\RC
M8/+DA9O3ZJR)N;9ON]G\/.67#![$C7>LO8M F1\MU F_'L=5@OOLNIO.5\GO
M2^Z$-"3W4]'\<J(.^5TQAY$/TAL'1Y%0I5O7AE/=]DWK$-B^L$8+7LP.N I<
MYR@^@J-R'3]UL]FE8II+%R.*S#'$N;+()(N1"C(RF;A4Q6=H;2&C[5[<(3@;
M*O,&3N7/<?Z ^&2DE]9*9 4%Z.?*71/ =55*XJ P52:4MF./"&B[!W<(5/K+
MN7+R^*Y%]&UWG5]+6&AC_7 "QT)38AUBEBTF.PGDF [(>I*X8)0(<TBAZJYO
MM-V VP<21:7:@ FYLX(K^F>7%$?OD^.(\OS.&(- W 4+L;"4Q)C\PUC\88!-
M(MINS"URZO22]VOMR'UCQW;BX]?O,<Y/5SVV[2LO4C>VE[VF*L:$M4XHPU%4
MV3OF<'YI3SPR2@4&OR/T9F/]7ZMBC$<'MIMI1!>CG7!N:4@+GY 3"C(BD9<>
MU?87JA@[!GU]*\:.T6 #9_#Q-SX"!(5CHB@*Q7)WE$1."($,CUAQ[0TM/H'R
M-%>\U6O/CH+*X"O>8_3VVH"YNKW)=374!(6<S?O;D@#<J3Q36N6)GE$;5WH>
M\U_@BO<HX!2XXCU&BZ\-J,]>^W&5")6P^2%>R_/7X!^.N-R$2*SE(I'R&;>_
MZ!7O4? ZR17O,;IN .#[0E)I.?<,3C E9/:J(!K5A@BDB-,JB2BY+%WS]:=H
M.!UR_)?420,06[[]O'[@,A@3K:=PPEBN8(?F7RFED60T8AM!-*;T&S*/"&C[
M6O8HU6X^,]I;SLV )!O;]4.HQADKJ4/1P3\XUP[".>R12E@;PP,SMG2PO$E#
MVU>APZ'24]K-H.52Q,0UD(:8)?E= )I3XBG33Q(W23J<2A>"++_<]N7E<&0<
M)=G^>.CF=EQF8O"#YFF.9?3YGL1@[8%@"\X@M0))CBWE7.6NGL*@.+91O=I=
MY1!D])5QNR\0OQO-P+6?CR8W,:RN3\#3[W^-L'N](A<&1Y!<Z&I@^Q?/)@%^
MXT<WL^-%''2?AF644$.L09Q%AK@7#+D0*4H.XJ% / ZQ]#S)(TD<:FR6-_9W
M&>B'=S2Y7BB$4?Z^'6>RQMWL!I3]YO8Q*;#$JNIH*^G+$")@HV@4"M%H6'[<
M.R%K(*J5>7:OL(GBX@-97HBUNC[X*1&]:31;Q$H#_MLC#M^.[6PV2J/E(.E%
M5A)HQC9 ](R9 /=#&H*LHB0/_XHJ:6LCM^6-R"Z2ZD*V21AUI]-IVQ!=YQH-
M58'Q@#"6V3,&]]@8QA"&6$K9Y"EP]7(@;>'ZH2@$#H=7#WVT ;!MKMR"3?A)
M>G/[U8[C*JOL'3 !,1G"4B<$K ED,4B.:8.)B%QB4[J_\1CZFH5='V@\!=YI
M]-0 !D]_KMS'G@9C(TA,B.%%TY,%-XHJBP33&@)&FK#FK\Z=;>16XC7X!ZUB
MK7(E]2,.=S/X2YS K\8+:5V/)J,<G\Q'/^.JXO-SG)^GL_"?F_5429\"YU+E
M5"XCB!.CD1')@!%,G"ANF+<;A\;6.NS34?AG=ZI[ K)K#AT-'%5'2&); PXQ
M7 L:-9+@@<+!S VR&EB.D4)4#[\I<>EKQV$4_]D/E&%[HP(J&KCFV+[OP<'-
MS.1VW+4X\F.06_[HFYBZ:5SRGYMRB:16Y6E5D6!PBTED8 *(1=(DS[V6(;(3
M;(J2+-2]B'M%NZ0:;AHX.NXW_(K7+8)>'(^9-X>Q"D)@Q&B>%&^#0Y8YBCRF
M,49A98JG"5,.HZ_N_>)K ?S)-%[L$.A]E;E8>Q;]_[[J?OZ?Z,-R^;/?[31\
M&UVOY+J4_?XKS$?0?;CH$K4^W(-U^Q>.O-3L3?S RTSXU.7R*]>+3]R'[7W%
M\?R*/8W5PP7_.?DQRHM^ [;?P&_^MPB93U>M$G[MU<5Z,Q\DD8K'RR/Z%E7#
MA?6UL6:5@*"?MK9+HQ%=7<!GY]/K2?@PME=%-/5XQ2HN:2\];95$(UK*._[M
M9!:FY=2TL6053ZJW]7LJBT84]8_N]WOZREK 9Y:N,ONAE^)VRZ:R N_.U-%U
M#!^Z:1XZ\9L=#]YNN]:M,G[A*-4=()46-M[L+;C)\5MW1VZ^GRFX^_:L?X@>
M5?TM>)B4FM7GB=1XD/9TH]IK1&D?)V'T<Q1N['A1'39$41M+U0W*=LN\VR>
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MV.4K5UN+G^Z6[8Z]W?LG4$L#!!0    ( /F!!%MF6K_G;@@  -,K   7
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ML'I9Y>V6#%((P!BNIV22\%MP"+@?T^ ] 80/%CM]@7.002 UZ@DT2[$[>B)
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M$?8.^AN3+R?4@. (%B/K[]+1^7_XN.WM- $\Z<[KV?"#3C<PX<\QZW4%Q*7
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M@?)PS,EM'JK;,[=CA<^[(+.3_>L2EI^7$Q68%GE=R 8DP-:R7P5:V2^N;#F
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M &5=1SV5MY6;=%O7";NG-(*A/>'6>0Y'&-K#\)%%7C:TAREWU6^(VYJ*'/4
M'VYSU4Y[ELTF]E]JZ\>;6:!I1HXP#60O$W9SX] ZKXP/.3;L-\%'F$N.>()/
M8CC/?H+/P<E3NN>TUZ--\P'57FT0Y'1UGC&'63"JH)VE-D$_E8M6CS.!<^9]
MT<A5DB3 7;OSQT X8$1A.N;:'>1)['P]S6U=];F>]WJSN@SBM+J5@<QK:/N'
MDIY)AIQ#HB1O(0=R#HF1?*I^^TSO92LBQ:I3 >N" #:0,SXR[@6A3G(CSJ)#
MK,=,[/"TJ>81]?M=44[GRYG:@K'JV#.>F+DWKSTQ1N"N-S)!K2B-6^'QR1)K
MC9%%\2FTHO$C*5;F<2?3LT)26:%%4A)M(1MZ).VV6VH& KLQ!^VT3^;%;8%7
MP)>KXVOT53:-1]9N&W*2'67TK59V-2>/"FL,Q5E,Z.N/;L&/*I:9"9Y^>$N/
M1NJ!=(#94C.!TIEXO;FY5=<OVN1QEE@1=@^H8=*9U IJ.S%';-+.P(R?YXC+
MAP)TQE,?2KTL3Q5NJ.?X=LM.:S#U^]]PNP'CP0=2CUHH4M(7K3R!$#E^5"5L
M0QN*$]-D5DH:RDB(D^<1I23Q*<\#[!81FO8LXPQ8PH2[9Q=WJ'E:5B 5J][]
M">J1ZLF/N)&!IF9_/[O 6SV'B8.OOPM''148JZ]4@4SL3D>2=SP/V[6RK+%&
M>)2^?EX#/9@H3<PM^+FTEB\?F\9GCZ-A=N.,1/V.?G?U:Q9ULR@,[>R10 3>
MUA<6I80ZG]J1F:  NU8R#SD)G9TNF8A7H:Q1A7B_EIG7(H>]J1WPS:GZ9$6Y
M1%OAUKQ$W]"LSP$B&76_)A!US9J7NB%9LQ"K)RW*DX='NCM5K>5I5[([#T;\
M5K^KKI;7AIQK&YN"G_)6@L=%OQ8VMD@(=SF8$/%I.0[?6+^L6X%;VC5FZ*@!
M*9+CV#17'AW($>Y8- F),\$]8".9=5!A[=I)F9&\\+#YBIW<JK6I ]&J&4P'
MXTC-0FEJYVJ\$#_[]00C!Q%EZASL%D@Q24R A_4P!QH$K-^*ZLP[QRI(Z!_K
M@G<0N.(>L Z=1JG; >NQ5<);B17HF!ZI?:"K)''79Q.:IIWUH'5\ B%=U\BV
MQGK'NI Q;D5[EC#3QN FZEF)ZWW2#;!(C<*AG=G%)C_V()$#P<,I#U2L4]M8
M;2(2XK&SC_0))?P(?7WO<K3(@93&UKX^#YVUH2"G<12.\-H%S>15@7<'$V%L
MUH.'TM<,E9%4/"7"^ER9,8XZOH<>1?L8*AK"0OJ6$F8B2FT3HT^8[</+M_V^
M[FR2=!51K DST!C>KT'=>Z1><P(WHS^<\<9-GL,21I!:)0IWJ?EX^#SJW(C<
MM1VD74=&)Y*&U2S GG"7+4/-)$K$F"7_F+J:V38;Y2GFH.6W'NP! GZ=!B!_
M+GN&42(^RK(W)E@'$O']7=^9< _E79+Z78YU(Z.ABA/W!_M>8LMTU8;_Z>K*
MSJ?[ O,_RM6(9*368C0E+'Y*QWY]Q>4X-&4%9>$5.Q&K21.UIV_/51Y+:CDS
M*6/T4LLL3<PH<C>;5=PEO_^Y0)MLXM0&%!M;3=+'@'(V"D.=DG 7<#E-AF0,
MOE;/%BNAX[7GQVJ9A%KRD4?4,+L),XO"-\'9"0/<^FJ/HV%VBTGFKL5[#*HK
M$+73'EBVMU9Z5&VU842XL\1F%'<3FKKN(""^T>0C5@Z!B*E==!Y6P^P6V=%K
M3F"5D=3L>A+[02]BPG2+>D -M%M*W%&[URU;B[JH:JPVV2';<RP@L6XE8DRR
MQY2-6;9'M^O:H*YZWF5[93MS:YDW51F\N[^1T)FK'IGZS;D=2ORDD]=^I]O-
MWY_KJ<.8^:1^S-1Z.;!HS-WK MJ.Z:,Z:=";GEW.@BD,C()B%"R-$@;4ETTQ
MD^;Z@=1I>YA-GS==T_L,%I+Z6H^O[^5T,-:HXNBMM66_1HUJXFM4:[,(VK7_
MK6M4>?#C35Y>2ZC*_J@^3EW-D5J,"4ZR?IW*O6@)VGXND:A=\&LEO)!P5W%C
M3"*&^@#"(DXB<8P^4Y;%Q-!Y?B[U)B/OK,S*AJ48Z -+L"&^0ZMJ"R0@?@2G
MCSLVBT?-!XH3DK$N_1RTZDC2:FTAI!BFE.VHC3%GI^\T)2*SY1]]EJN6;=.J
M4!:< %+;L9 Z3!7JL8"+5=/C:HQL<%W=23U$5AUI+^NVF,YE\']^_J\NL >E
MMN^_BS*T% @1):Y[)@0C-+)9,L/4PVJ;+"/.6B-C0DV.Y1PK5"!/=&!<O!=L
M0E,R.;NXJ>Y5+(,VO=H).[J-1E#':>XZ0U$'9TGRQMB][O/(PD9G>0NCUF&+
MO)S=%F71M.HJZ@1BLLCY9/X0S*3)A,D&#BK7534+KO*BO3E_?%BIIM-E74N8
MT6XWW=7I!O.2<+:QX%X263CVTHK-(-J#^'F@UT99!9=S!7]( ]^I-7*?U[-&
MO<L$G?T.AUHV"YMBZT?M.DP]?QK,8UT04%S9/G7!%R4WK)PDY&.NPHQ#A08J
M$UN['([(VHA=X?I$9A,.!Z4R9D_V^DR/U"(TC$]#*$..)$I#XDZR/^Q8U#"W
M"ZM%>&C%PCR2AME-$,&.4<A9<?-SM)@2G$3)/IU]'E_;;9@,J=-_ SQ]&C.K
M?O"J2,H2$IDC6]#F];5L@W<T#/^?]^I3W,DY5GBQ.#0!M9N=,,TZCM1SDM.C
M%,VJ /WNOFAOX-QK9UX&:#N1O/S$^A!*XS?&!3O6(!M=[-.E085I^<=4-LV:
MT&?<A/$/RW*N?P8<V?NBZ25S+"GV<3ZTT-P-S"O!CW32*T&%U2,F7B2Q*>*<
M74R+>KJ\A82C6@-HA<DIH^[.A3$Q6Z$K,02#WOY_>TA>(:\'T0\?-MW&))_^
M?EU7RW+V85K-J_J'X+N_Z#_J1U4]D^H;=/%'H%Y>S(+O?E1_/NHA<U)9[:YH
MBDDQ+UKU:_)E6RECSJN\[4S1,W_8NQE!;;KK5GG$HH2TA?H%\/[U5Q\#8%2H
MJ]W_$-P4LYDLU4/(9S/#'.P_D%K.=79\XYKJKVW]1,.M3U,OSSCM -Q_:W=A
M6[;:ZC%4:+[=:<#UJ3H<'F_YAX<$?.H31"\N,IU=L"%PMG8:ANA]GE_XU4?W
MY.*OZ_UY_*9<__$(\:R;7/]NZ@GQ/;-D70?53T4SK26\%4887DZA4:3&K-_!
M.#73-3P#WIA#A5714Q+44:>;)(3C3FTQP39T#;C)0R0D,H#ZI6HAP[ JD.?E
M0WL#7T!(DX.(O#EK]24"E?-&:M)(>9PH?N+A7WDZ...H41F!G*[/MSYA89P4
M4VPU$1MA!D!D9L+GFXD"W7;%THZ="_ZT5L$-5D)J&MMST:M"6Q"&>Q//0I(>
MH3PU6:(M>H:Q44?Q0!I,R>#NDL:B.Y$VR\F_Y!0MFD1$Z.OON/C1I+9=X:P8
MMZ)BH#T84!CTXKW2062#U-W4J:2+_=0Q%*M%TE %2E_+='A4[;:AVIZB8Y#&
M6-3)Q,^+VZ+%2I!F,/C-1^/#[08RW>YX#I1P<_!6WVVF=3%!V[/+XFB'(KX'
MU':[921QEN9/NZPLVAX]F*S MM.D/8ZVCE1@1K+'IU57A7@5#/J3W6"[\9 Y
M%?A8]9/-\Q)K[I*SA(0>2\/MQE6$<YSYPB/P4%Q8_76/JF%VBT)[>'&D;67'
M4CUB"&-U58*F)/0!U'"[,>9PL@+^0%SPT";F/(Z&V2TBU-EL,QJ2S"C(X<TU
M";7-4;_-#;>;VN:XLVTNL:R$LPMU!1G,5GQ)K!M=!$<+#ZN#*&P[6/7#>_,3
M$X??YE@K+IJ U:L6O'X9#S4!*V9:#WFD!"R%#8/OO..48SUN9E8F[G6AS<TT
M1;S^,LM@HN\QFCI&D,*@5-C-Q(-JF-T2E[WL*S*6;?+':I6(D62O2>4>6=MM
M&!/ACC":D<B<&J#) ZM)DHAD?=F2US\UX(=5DJF@ZAB]1&O%02NYB=1"3.WG
M\>O7B- CBRD?PYUI N!GDC*6DNBKLWX\IG;:D#/+ZO:LTJX7%)2C>F#9/M+=
MHVK73*EG<GM>=7?-0<I.4<_&CZN,$^;,6ZGMP^02M8("4I-P1@GWP=0!=HML
M]=_1QD=M@JK ZI2X'HMTTG8*_*@2$4F=U;2CF%B^3:<'@;4$*4)&8A]('6"W
MF+BC2 ANU,] R-D*0Q:WLM$CHY>+JM3?0VHI/[)FK?08D;>E]N6TS C\_2YS
M(>M;@]YI5<[TE1N8:?Y<Q-1,2US-<\(XU5P=28T:S)MYK*\QU7SF1=QZ95#>
M=<']4@7_ /W>M7Z;G'5#DY$:C$61H8)Z&3=CCI1L)"<[56Y+3;,&W@")Q;&M
M);C96W@W(/"+VD,Z(7C881KU&.9&DTWK93=ZLU'?59^N;F\ZZ3:D9M3$KJWQ
M>9@=*3YGG>0MQC"+TA&3N7ALABZ?77R64W@'4F"GE+#T:8SRRC*$EG&"U<6F
MB561<EIU9%A3&5E,6-('RJM[S<BTF^!%%,3&[K0ALHY776'-X5-*[4!N[YF&
M<@,39^DQ_)UHE,4[.*;>'VV?G >5#Q\Z/14<2\GK,VKP.R7H'W,_>I%CC9>H
M.E,GR3YE1>^@MMOP6)S2$01/6;9A[*GW68.R:&'D<+2GB+OTO?P#Y-J:.5HN
M8$1)G.R#+>^[MMLP,9T1CFK8W1C=1J+EOR>,>"=U@-E2V\;N)/5,#5W@[$+G
M[Y':1('%>Z3A1HL<*BGC3QMP/1NP%UV^OB@2>N?$6>B'HS^V"(]V#$?WWFD[
MA90Z%+,9B:ID''L/]5(;)H,(25_#%2,V# =F'5:39,*.#/(N:A@K.70HQ4T5
M+LW2FF#=ZX2ZA^SUZ>WH?1)(<";."B]CB)H$%SNTVKQ+VFZWC*3.>(!"(8G:
M#.9TOFR*.[1X2E4 V.<_O7Y3%WXOE84D>Q9]>CFB'GU4'3,2'T@-MYO3T>5J
M,^6F[I*76*?CZ#8N=RQ6S&U<E"5CGM<;A9&1$=>EG W<^GRQF!?3?#*7RAZZ
MITM+/A@VON[G:I8+63=R)F&6>E#IAIC>!6HYSS5_'ZW"C5X-[G8;U*M!A.,6
M3XVZHOGFKI/S8%G.9=.8OEV#=?WE"O#!JMJND'^E%L9JV<SS,I@\!&5^*_55
ML3>J.*O=,#.)#>F*B/B8^WRI2$AJ#F$K^8-'*)[E+<Y&WB1]@XV\[F*NS,I
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MDS*!.4W+/Z9RT:I78%T(<&1VQD' O1#$V)>!T;7MFK:!SMG7U],">[/S8+D
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MI=QA__,8]/E8UHF&>>A\A:?<20XX\3U)=ZJW [2P6@7.F#Y"VH<0R3>0NIU
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MR=P$U4291U^J 4WT5H_2R&N8& #HJ,K2RB+"F[1>])U4UH-W&D%IW6?13>+
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MS*'VP_;#7=$4DV)>M.K7Y,NV4H:<5WG;6:%G^K!W,X+:RL9M7E\7)0C2JE\
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MBTD<]4SC;%*E@FABW-,E*.HBCB%!"K7/^3T!K3S).F8KE*:*M@GD'S?%!+Y
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MIJSX*,%=D7<7PKHH0 #-76H>]4J(^)A9OQ2ZX<U&<2\5UENYEB65:Z9CEP-
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MW:N5D)#U@>(1-3QA1<W9UQGORD1WQ>UB7L@9UJV7\M=7UL*/)<$=2B8G9JZ
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M\O]I=$3Y&?08@:$ X0$YHZ1C\>;7"B!8;S[E).K3:XX8..-'2AH;.<QOK1&
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M;JC\K;1![=TC$VW?;9_UR/S[)3TRZ=OLD4FVAGP']<CH$:OZ1FW'%]*]DJK
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MS^UL*B1A)-T&V$)M?ZJK&S3&W+WC79STE_.8C3N<V_1-1TY>7$__Q4<]%!S
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M_^W#1^//CY^__/GIPY>/OQB?O_S^X7\9?_V&-N3O?W[\^,^/OWUYT?4GU@6
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MU]___.?[+Y]^_^W]/XR/__SC'[__GX\?C??_]?[/7UYTR<.7)YUM++GK"96
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M2>2<).6@X]@$V[F4E,03IR8\FHY3<H'J9+J)^T]-L)6HY2/8E+@A_O<_E.O
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MC8F+K P$X]);P9$QB,W6-,O<>TF7Q5V3>4?HPCLL646K;2CSJ;Z+AXHEX+;
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M_J/U?(=R0@@;)F?B"&^']WG@L3"E.9VQ#5WVC@[>#<N3;(W[6'DY1L:6K.8
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M]&D5BF/:_@]=KQP-F[==:+ZB0NAXNV:/63WZ>[,HV'W.2JOV0/ <T^ZA93^
M;!@!G\&]^@P=.DI@1N%)!;;($6DD,!#KNJKC/(7U-.B_U_H6V>R G%5#3'>4
MV#C9J\<L<M]T16Q4T61=P@NU'9F#0Q'/.>M-=T0XCAS5-39?P@%07RU#I^+J
MF<=K)S02>K&NE^T3H;Q]A8&LM9(^B7)XE2N%N=;3C"79PVU=QBE--5T&U[4%
M+?4*"UEBM$7(</RD/6$?$C$&\HVV+6V68WK7<&.SPK@MOME3H5C;1C+/]LPS
MUE.TQP1.L1AE,H)7UORK%.U.D2VP37< 1;;!48:(90GU@;.AU-7;=A'+DW'
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MT^_1(PJ[UQ&&T92+0"D\HUBRBE9&O8AK(^5+I>FZ>! )CDWKPB7^(+2B/0O
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M 4=V]UXYRBT3.M,?=\O<:YE^P"W3C1/Y#!9;U,V>@W0W[I2(Z;H/0(D[N2>
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MV^^4LYV<<[;GG.TA!'M,P.K.V3;O2DE9EI._Q6R!3N+2G&:4/L\QN95*G2C
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MO87_KNI%]N;_ U!+ 0(4 Q0    ( /F!!%N@!OJ:&S@! 'L\$P 0
M      "  0    !A9VPM,C R-3 V,S N:'1M4$L! A0#%     @ ^8$$6R$A
M:3@Z#@  B*   !               ( !23@! &%G;"TR,#(U,#8S,"YX<V10
M2P$"% ,4    " #Y@01;[M4S4H,=   W(0$ %               @ &Q1@$
M86=L+3(P,C4P-C,P7V-A;"YX;6Q02P$"% ,4    " #Y@01;_%W;XE$\  #Q
MD ( %               @ %F9 $ 86=L+3(P,C4P-C,P7V1E9BYX;6Q02P$"
M% ,4    " #Y@01;ZHG3&/[6   ==P@ %               @ 'IH $ 86=L
M+3(P,C4P-C,P7VQA8BYX;6Q02P$"% ,4    " #Y@01;B$A)J>Y\  #?S 4
M%               @ $9> ( 86=L+3(P,C4P-C,P7W!R92YX;6Q02P$"% ,4
M    " #Y@01;UE[<-H((  #D*P  %P              @ $Y]0( 86=L+3(P
M,C4P-C,P>&5X>#,Q,2YH=&U02P$"% ,4    " #Y@01;9EJ_YVX(  #3*P
M%P              @ 'P_0( 86=L+3(P,C4P-C,P>&5X>#,Q,BYH=&U02P$"
M% ,4    " #Y@01;1M227=P$  "7%   %P              @ &3!@, 86=L
M+3(P,C4P-C,P>&5X>#,R,2YH=&U02P$"% ,4    " #Y@01;TP 9_<L$  "(
M%   %P              @ &D"P, 86=L+3(P,C4P-C,P>&5X>#,R,BYH=&U0
M2P$"% ,4    " #Y@01;XNM<R1<A 0#W]1( "@              @ &D$ ,
@97@Q,"TQ+FAT;5!+!08     "P + - "  #C,00    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>agl-20250630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:agl="http://agilonhealth.com/20250630"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="agl-20250630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:PlatformSupportCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:PlatformSupportCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:PlatformSupportCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:PlatformSupportCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">agl:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">agl:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnassertedClaimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnassertedClaimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-18</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredRevolvingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-18</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-18</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-18</startDate>
            <endDate>2021-02-18</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredRevolvingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">agl:SecuredRevolvingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">agl:ConsolidatedSecuritiesMatterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">agl:DerivativeMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SuretyBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SuretyBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">agl:OtherEquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">agl:OtherEquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">agl:ACOREACHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">agl:ACOREACHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:MedicalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agl:OtherOperatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="member">
        <measure>agl:member</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="lawsuit">
        <measure>agl:lawsuit</measure>
    </unit>
    <unit id="entity">
        <measure>agl:entity</measure>
    </unit>
    <unit id="investment">
        <measure>agl:investment</measure>
    </unit>
    <unit id="partner">
        <measure>agl:partner</measure>
    </unit>
    <unit id="geography">
        <measure>agl:geography</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-26">0001831097</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-27">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-30">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-577">http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-578">http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40332</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">agilon health, inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">37-1915147</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">440 Polaris Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 550</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Westerville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">43082</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">(562)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">256-3800</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">AGL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">414423149</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">171416000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">188231000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsCurrent contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">0</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">5629000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">155585000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">211737000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">1047164000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">1017040000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">78495000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">35137000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">1452660000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">1457774000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">27410000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">28169000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">65595000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">72771000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">24133000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">24133000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">143097000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">151136000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">1712895000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">1733983000</us-gaap:Assets>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">1042257000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">931664000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">171886000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">220342000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">34945000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">1249088000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">1152006000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">34904000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-63" unitRef="usd">54878000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">76121000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-65" unitRef="usd">1303966000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">1263031000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-67" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-68" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="2"
      id="f-69"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="2"
      id="f-70"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-71" unitRef="shares">2000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-72" unitRef="shares">2000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-73" unitRef="shares">414283000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-74" unitRef="shares">414283000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-75" unitRef="shares">412194000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-76" unitRef="shares">412194000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-77" unitRef="usd">4143000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">4122000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-79" unitRef="usd">2083234000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">2053895000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-81" unitRef="usd">-1679235000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">-1586977000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-83" unitRef="usd">787000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">-88000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-85" unitRef="usd">408929000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">470952000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-87" unitRef="usd">1712895000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">1733983000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets contextRef="c-5" decimals="-7" id="f-89" unitRef="usd">1190000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-6" decimals="-7" id="f-90" unitRef="usd">1170000000</us-gaap:Assets>
    <us-gaap:Liabilities contextRef="c-5" decimals="-7" id="f-91" unitRef="usd">1200000000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-6" decimals="-7" id="f-92" unitRef="usd">1130000000</us-gaap:Liabilities>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-93" unitRef="usd">1392039000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-94" unitRef="usd">1479579000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-95" unitRef="usd">2921918000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-96" unitRef="usd">3080774000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-97" unitRef="usd">2943000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-98" unitRef="usd">3179000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-99" unitRef="usd">5846000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-100" unitRef="usd">6338000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-101" unitRef="usd">1394982000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-3" id="f-102" unitRef="usd">1482758000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-103" unitRef="usd">2927764000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-3" id="f-104" unitRef="usd">3087112000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-105" unitRef="usd">1445245000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-8" decimals="-3" id="f-106" unitRef="usd">1374060000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-9" decimals="-3" id="f-107" unitRef="usd">2847112000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-10" decimals="-3" id="f-108" unitRef="usd">2817902000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-11" decimals="-3" id="f-109" unitRef="usd">2164000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-12" decimals="-3" id="f-110" unitRef="usd">76523000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-13" decimals="-3" id="f-111" unitRef="usd">82357000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-14" decimals="-3" id="f-112" unitRef="usd">161947000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-15" decimals="-3" id="f-113" unitRef="usd">56281000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-16" decimals="-3" id="f-114" unitRef="usd">69612000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">122237000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-17" decimals="-3" id="f-116" unitRef="usd">146034000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization contextRef="c-15" decimals="-3" id="f-117" unitRef="usd">7319000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-16" decimals="-3" id="f-118" unitRef="usd">5907000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">14195000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-17" decimals="-3" id="f-120" unitRef="usd">11751000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses contextRef="c-15" decimals="-3" id="f-121" unitRef="usd">1511009000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-16" decimals="-3" id="f-122" unitRef="usd">1526102000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">3065901000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-17" decimals="-3" id="f-124" unitRef="usd">3137634000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-3" id="f-125" unitRef="usd">-116027000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-16" decimals="-3" id="f-126" unitRef="usd">-43344000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-127" unitRef="usd">-138137000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-17" decimals="-3" id="f-128" unitRef="usd">-50522000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-15" decimals="-3" id="f-129" unitRef="usd">5412000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-16" decimals="-3" id="f-130" unitRef="usd">9955000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-131" unitRef="usd">18084000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-17" decimals="-3" id="f-132" unitRef="usd">15639000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-133" unitRef="usd">7879000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-16" decimals="-3" id="f-134" unitRef="usd">4841000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-135" unitRef="usd">17140000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-136" unitRef="usd">10733000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseNonoperating contextRef="c-15" decimals="-3" id="f-137" unitRef="usd">1572000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-16" decimals="-3" id="f-138" unitRef="usd">1697000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">3087000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-17" decimals="-3" id="f-140" unitRef="usd">2981000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-141" unitRef="usd">-104308000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-142" unitRef="usd">-30245000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-143" unitRef="usd">-106000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-144" unitRef="usd">-27131000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-145" unitRef="usd">62000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-146" unitRef="usd">417000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-147" unitRef="usd">258000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-148" unitRef="usd">284000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-149" unitRef="usd">-104370000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-150" unitRef="usd">-30662000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">-106258000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-152" unitRef="usd">-27415000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c-15" decimals="-3" id="f-153" unitRef="usd">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c-16" decimals="-3" id="f-154" unitRef="usd">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c-1" decimals="-3" id="f-155" unitRef="usd">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c-17" decimals="-3" id="f-156" unitRef="usd">-518000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="c-15" decimals="-3" id="f-157" unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="c-16" decimals="-3" id="f-158" unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="c-1" decimals="-3" id="f-159" unitRef="usd">14000000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="c-17" decimals="-3" id="f-160" unitRef="usd">-8763000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-15" decimals="-3" id="f-161" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-16" decimals="-3" id="f-162" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">14000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-17" decimals="-3" id="f-164" unitRef="usd">-9281000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-165" unitRef="usd">-104370000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-166" unitRef="usd">-30662000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-167" unitRef="usd">-92258000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-168" unitRef="usd">-36696000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-169" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-170" unitRef="usd">20000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-171" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-172" unitRef="usd">50000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-173" unitRef="usd">-104370000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-174" unitRef="usd">-30682000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">-92258000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-176" unitRef="usd">-36746000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-15"
      decimals="2"
      id="f-177"
      unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-15"
      decimals="2"
      id="f-178"
      unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-16"
      decimals="2"
      id="f-179"
      unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-16"
      decimals="2"
      id="f-180"
      unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-181"
      unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-182"
      unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-17"
      decimals="2"
      id="f-183"
      unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-17"
      decimals="2"
      id="f-184"
      unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-15"
      decimals="2"
      id="f-185"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-15"
      decimals="2"
      id="f-186"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-16"
      decimals="2"
      id="f-187"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-16"
      decimals="2"
      id="f-188"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-189"
      unitRef="usdPerShare">0.03</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-190"
      unitRef="usdPerShare">0.03</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-17"
      decimals="2"
      id="f-191"
      unitRef="usdPerShare">-0.02</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-17"
      decimals="2"
      id="f-192"
      unitRef="usdPerShare">-0.02</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="0" id="f-193" unitRef="shares">413836000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="0" id="f-194" unitRef="shares">413836000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-16" decimals="0" id="f-195" unitRef="shares">411271000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-16" decimals="0" id="f-196" unitRef="shares">411271000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-197" unitRef="shares">413388000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-198" unitRef="shares">413388000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-17" decimals="0" id="f-199" unitRef="shares">409152000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-17" decimals="0" id="f-200" unitRef="shares">409152000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-201" unitRef="usd">-104370000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-202" unitRef="usd">-30662000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">-92258000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-204" unitRef="usd">-36696000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-205" unitRef="usd">210000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-16" decimals="-3" id="f-206" unitRef="usd">325000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">822000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-17" decimals="-3" id="f-208" unitRef="usd">-132000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-209" unitRef="usd">34000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-16" decimals="-3" id="f-210" unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">53000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-17" decimals="-3" id="f-212" unitRef="usd">-17000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-213" unitRef="usd">-104126000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-214" unitRef="usd">-30362000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">-91383000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-216" unitRef="usd">-36845000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-217" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-218" unitRef="usd">20000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-220" unitRef="usd">50000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-3" id="f-221" unitRef="usd">-104126000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-16" decimals="-3" id="f-222" unitRef="usd">-30382000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">-91383000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-17" decimals="-3" id="f-224" unitRef="usd">-36895000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-18" decimals="-3" id="f-225" unitRef="shares">413023000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-3" id="f-226" unitRef="usd">4130000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-3" id="f-227" unitRef="usd">2070446000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-20" decimals="-3" id="f-228" unitRef="usd">-1574865000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-229" unitRef="usd">543000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-230" unitRef="usd">500254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-23" decimals="-3" id="f-231" unitRef="usd">-104370000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-232" unitRef="usd">-104370000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-24" decimals="-3" id="f-233" unitRef="usd">244000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-15" decimals="-3" id="f-234" unitRef="usd">244000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-25" decimals="-3" id="f-235" unitRef="shares">24000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-26" decimals="-3" id="f-236" unitRef="usd">110000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-15" decimals="-3" id="f-237" unitRef="usd">110000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-25" decimals="-3" id="f-238" unitRef="shares">1733000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-25" decimals="-3" id="f-239" unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-26" decimals="-3" id="f-240" unitRef="usd">-18000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-15" decimals="-3" id="f-241" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-25" decimals="-3" id="f-242" unitRef="shares">497000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-25" decimals="-3" id="f-243" unitRef="usd">5000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-26" decimals="-3" id="f-244" unitRef="usd">2685000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-15" decimals="-3" id="f-245" unitRef="usd">2690000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-3" id="f-246" unitRef="usd">15381000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-247" unitRef="usd">15381000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="-3" id="f-248" unitRef="shares">414283000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-249" unitRef="usd">4143000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-250" unitRef="usd">2083234000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-251" unitRef="usd">-1679235000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-252" unitRef="usd">787000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-253" unitRef="usd">408929000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-31" decimals="-3" id="f-254" unitRef="shares">410843000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-255" unitRef="usd">4108000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-256" unitRef="usd">2020803000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-257" unitRef="usd">-1332890000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-3" id="f-258" unitRef="usd">-2747000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-259" unitRef="usd">-788000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-3" id="f-260" unitRef="usd">688486000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-37" decimals="-3" id="f-261" unitRef="usd">-30682000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-38" decimals="-3" id="f-262" unitRef="usd">20000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-263" unitRef="usd">-30662000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-39" decimals="-3" id="f-264" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-16" decimals="-3" id="f-265" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-40" decimals="-3" id="f-266" unitRef="shares">42000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-40" decimals="-3" id="f-267" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-41" decimals="-3" id="f-268" unitRef="usd">170000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-16" decimals="-3" id="f-269" unitRef="usd">171000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-40" decimals="-3" id="f-270" unitRef="shares">690000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-40" decimals="-3" id="f-271" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-41" decimals="-3" id="f-272" unitRef="usd">-6000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-16" decimals="-3" id="f-273" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-40" decimals="-3" id="f-274" unitRef="shares">128000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-40" decimals="-3" id="f-275" unitRef="usd">1000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-41" decimals="-3" id="f-276" unitRef="usd">634000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-16" decimals="-3" id="f-277" unitRef="usd">635000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-41" decimals="-3" id="f-278" unitRef="usd">18207000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="-3" id="f-279" unitRef="usd">18207000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-3" id="f-280" unitRef="shares">411447000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-281" unitRef="usd">4114000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-282" unitRef="usd">2038540000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-283" unitRef="usd">-1363572000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-284" unitRef="usd">-2447000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-285" unitRef="usd">-768000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-286" unitRef="usd">675867000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-48" decimals="-3" id="f-287" unitRef="shares">412194000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-288" unitRef="usd">4122000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-289" unitRef="usd">2053895000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-3" id="f-290" unitRef="usd">-1586977000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-3" id="f-291" unitRef="usd">-88000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-292" unitRef="usd">470952000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-52" decimals="-3" id="f-293" unitRef="usd">-92258000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">-92258000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-53" decimals="-3" id="f-295" unitRef="usd">875000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">875000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-54" decimals="-3" id="f-297" unitRef="shares">24000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-55" decimals="-3" id="f-298" unitRef="usd">110000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">110000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-54" decimals="-3" id="f-300" unitRef="shares">2604000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-54" decimals="-3" id="f-301" unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-55" decimals="-3" id="f-302" unitRef="usd">-26000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-54" decimals="-3" id="f-304" unitRef="shares">539000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-54" decimals="-3" id="f-305" unitRef="usd">5000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-55" decimals="-3" id="f-306" unitRef="usd">2846000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">2851000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-55" decimals="-3" id="f-308" unitRef="usd">32101000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">32101000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="-3" id="f-310" unitRef="shares">414283000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-311" unitRef="usd">4143000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-312" unitRef="usd">2083234000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-313" unitRef="usd">-1679235000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-314" unitRef="usd">787000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-315" unitRef="usd">408929000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-56" decimals="-3" id="f-316" unitRef="shares">406387000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-3" id="f-317" unitRef="usd">4064000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-318" unitRef="usd">1986899000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-319" unitRef="usd">-1326826000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-320" unitRef="usd">-2298000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-321" unitRef="usd">-818000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-3" id="f-322" unitRef="usd">661021000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-62" decimals="-3" id="f-323" unitRef="usd">-36746000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-63" decimals="-3" id="f-324" unitRef="usd">50000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-325" unitRef="usd">-36696000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-64" decimals="-3" id="f-326" unitRef="usd">-149000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-17" decimals="-3" id="f-327" unitRef="usd">-149000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-65" decimals="-3" id="f-328" unitRef="shares">1476000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-65" decimals="-3" id="f-329" unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-66" decimals="-3" id="f-330" unitRef="usd">2611000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-17" decimals="-3" id="f-331" unitRef="usd">2626000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-65" decimals="-3" id="f-332" unitRef="shares">1860000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-65" decimals="-3" id="f-333" unitRef="usd">17000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-66" decimals="-3" id="f-334" unitRef="usd">-17000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-17" decimals="-3" id="f-335" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-65" decimals="-3" id="f-336" unitRef="shares">250000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-65" decimals="-3" id="f-337" unitRef="usd">2000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-66" decimals="-3" id="f-338" unitRef="usd">1279000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-17" decimals="-3" id="f-339" unitRef="usd">1281000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-65" decimals="-3" id="f-340" unitRef="shares">1974000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-65" decimals="-3" id="f-341" unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-66" decimals="-3" id="f-342" unitRef="usd">15210000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-17" decimals="-3" id="f-343" unitRef="usd">15230000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-66" decimals="-3" id="f-344" unitRef="usd">35116000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-17" decimals="-3" id="f-345" unitRef="usd">35116000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-3" id="f-346" unitRef="shares">411447000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-347" unitRef="usd">4114000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-348" unitRef="usd">2038540000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-349" unitRef="usd">-1363572000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-350" unitRef="usd">-2447000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-351" unitRef="usd">-768000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-352" unitRef="usd">675867000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">-92258000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-354" unitRef="usd">-36696000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-355" unitRef="usd">14195000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-17" decimals="-3" id="f-356" unitRef="usd">11751000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-357" unitRef="usd">32101000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-17" decimals="-3" id="f-358" unitRef="usd">35116000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-359" unitRef="usd">18084000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-17" decimals="-3" id="f-360" unitRef="usd">15639000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <agl:DistributionsOfEarningsFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-361" unitRef="usd">0</agl:DistributionsOfEarningsFromEquityMethodInvestments>
    <agl:DistributionsOfEarningsFromEquityMethodInvestments contextRef="c-17" decimals="-3" id="f-362" unitRef="usd">-3340000</agl:DistributionsOfEarningsFromEquityMethodInvestments>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">14000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-17" decimals="-3" id="f-364" unitRef="usd">-3784000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">3107000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-17" decimals="-3" id="f-366" unitRef="usd">837000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInOperatingCapital contextRef="c-1" decimals="-3" id="f-367" unitRef="usd">-14081000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital contextRef="c-17" decimals="-3" id="f-368" unitRef="usd">67312000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-369" unitRef="usd">-67072000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-17" decimals="-3" id="f-370" unitRef="usd">-66493000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-371" unitRef="usd">7099000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-17" decimals="-3" id="f-372" unitRef="usd">6451000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-3" id="f-373" unitRef="usd">9717000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-17" decimals="-3" id="f-374" unitRef="usd">17893000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <agl:PaymentsToAcquireLoansReceivableAndOther contextRef="c-1" decimals="-3" id="f-375" unitRef="usd">1000000</agl:PaymentsToAcquireLoansReceivableAndOther>
    <agl:PaymentsToAcquireLoansReceivableAndOther contextRef="c-17" decimals="-3" id="f-376" unitRef="usd">9742000</agl:PaymentsToAcquireLoansReceivableAndOther>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-377" unitRef="usd">60154000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-17" decimals="-3" id="f-378" unitRef="usd">12006000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-379" unitRef="usd">125339000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-17" decimals="-3" id="f-380" unitRef="usd">115747000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-381" unitRef="usd">47369000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-17" decimals="-3" id="f-382" unitRef="usd">69655000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepurchaseOfEquity contextRef="c-1" decimals="INF" id="f-383" unitRef="usd">-2741000</us-gaap:ProceedsFromRepurchaseOfEquity>
    <us-gaap:ProceedsFromRepurchaseOfEquity contextRef="c-17" decimals="-3" id="f-384" unitRef="usd">1345000</us-gaap:ProceedsFromRepurchaseOfEquity>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-385" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-17" decimals="-3" id="f-386" unitRef="usd">2500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-387" unitRef="usd">-2741000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-17" decimals="-3" id="f-388" unitRef="usd">-1155000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-389" unitRef="usd">-22444000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-17" decimals="-3" id="f-390" unitRef="usd">2007000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-4" decimals="-3" id="f-391" unitRef="usd">193860000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-61" decimals="-3" id="f-392" unitRef="usd">114329000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-3" decimals="-3" id="f-393" unitRef="usd">171416000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-47" decimals="-3" id="f-394" unitRef="usd">116336000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c-1" id="f-395">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 1. Business&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agilon health, inc., together with its consolidated subsidiaries and VIEs (the &#x201c;Company&#x201d;), through its partnerships and platform, provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. As of June&#160;30, 2025, the Company, through its contracted physician networks, provided care to approximately 497,500 Medicare Advantage members enrolled with private health plans. Additionally, the Company participates in the Centers for Medicare &amp;amp; Medicaid Services' (&#x201c;CMS&#x201d;) Accountable Care Organization Realizing Equity, Access, and Community Health (&#x201c;ACO REACH&#x201d;) Model and Medicare Shared Savings Program (&#x201c;MSSP,&#x201d; and together with ACO REACH, the &#x201c;CMS ACO Models&#x201d;) through its equity method investments.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 14 for additional discussions related to the Company&#x2019;s involvement with VIEs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s largest shareholder is an investment fund associated with Clayton Dubilier &amp;amp; Rice, LLC (&#x201c;CD&amp;amp;R&#x201d;), a private equity firm. All funds affiliated with CD&amp;amp;R are considered related parties.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <agl:NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans contextRef="c-3" decimals="-2" id="f-396" unitRef="member">497500</agl:NumberOfMedicareAdvantageMembersEnrolledWithPrivateHealthPlans>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-397">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:24pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included. Operating results for the three and six months ended June&#160;30, 2025 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2025. The accompanying condensed consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December&#160;31, 2024 included in the Company&#x2019;s Annual Report on Form 10-K filed with the Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported (&#x201c;IBNR&#x201d;) claims), and the valuation and related recognition of impairments of long-lived assets, including goodwill. Management&#x2019;s estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025 and December&#160;31, 2024, the Company&#x2019;s gross carrying amount of property and equipment was $58.6 million and $52.9 million, with accumulated depreciation of $31.2 million and $24.7 million, respectively.  For the three months ended June 30, 2025 and 2024, the Company recognized $3.9 million and $2.9 million, respectively, in depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recognized $7.7 million and $5.8 million, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, in depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the income tax provision for interim periods using an estimate of the Company&#x2019;s annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, the &#x201c;One Big Beautiful Bill Act&#x201d; was signed into law in the U.S., which contains a broad range of tax reform provisions. The Company is evaluating the provisions of the legislation and the potential effects on its estimated annual effective tax rate, financial position, results of operations, and cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates a Medicare-centric, capitated line of business and is organized as a single operating and reportable segment based on the manner in which the Chief Executive Officer, who is the Chief Operating Decision Maker (&#x201c;CODM&#x201d;), evaluates performance and makes decisions about how to allocate resources. Segment asset information, which is presented on the consolidated balance sheet, is not used by the CODM to assess performance and make decisions about how to allocate resources. The Company's segment measure of profit or loss is consolidated net income (loss). The CODM uses the segment measure of profit or loss to assess performance and make resource allocation decisions, primarily through periodic budgeting and company performance reviews. Significant expense categories included within the segment measure of profit or loss that are regularly provided to the CODM include medical services expense, other medical expense, and platform support costs. Medical services expense and other medical expense amounts are included in the consolidated statements of operations. Platform support costs were $37.4 million and $41.7 million for the three months ended June 30, 2025 and 2024, respectively. For the three months ended June 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $14.5 million and $21.2 million, respectively. Platform support costs were $81.7 million and $87.4 million for the six months ended June 30, 2025 and 2024, respectively. For the six months ended June 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $8.9 million and $56.6 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2023-09&#x201d;), which amends certain disclosure requirements related to income taxes. The amendments in ASU 2023-09 require public business entities on an annual basis to: (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The amendments in ASU 2023-09 can be applied on a prospective basis or retrospective application. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2024-03&#x201d;). In January 2025, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2025-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2025-01&#x201d;). The amendments in ASU 2024-03 require public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement expense line items by breaking down certain expense line items into specified natural expense categories, including purchases of inventory, employee compensation, deprecation, intangible asset amortization, and depletion. The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The amendments in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2024-03 can be applied on a prospective basis or retrospective basis and early adoption is permitted. The amendments in ASU 2025-01 clarify the effective date of ASU 2024-03 stating that all public business entities are required to adopt the update in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. ASU 2025-01 does not change the effective date of ASU 2024-03 but was issued to provide clarity on the effective date for public business entities that do not have a calendar year-end. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 and ASU 2025-01 on its disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-398">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-399">The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-400">&lt;div style="margin-bottom:12pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported (&#x201c;IBNR&#x201d;) claims), and the valuation and related recognition of impairments of long-lived assets, including goodwill. Management&#x2019;s estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-5" id="f-401" unitRef="usd">58600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-5" id="f-402" unitRef="usd">52900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-5" id="f-403" unitRef="usd">31200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-5" id="f-404" unitRef="usd">24700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="c-15" decimals="-5" id="f-405" unitRef="usd">3900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-16" decimals="-5" id="f-406" unitRef="usd">2900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-407" unitRef="usd">7700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-17" decimals="-5" id="f-408" unitRef="usd">5800000</us-gaap:Depreciation>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-409">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the income tax provision for interim periods using an estimate of the Company&#x2019;s annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.&lt;/span&gt;&lt;/div&gt;On July 4, 2025, the &#x201c;One Big Beautiful Bill Act&#x201d; was signed into law in the U.S., which contains a broad range of tax reform provisions. The Company is evaluating the provisions of the legislation and the potential effects on its estimated annual effective tax rate, financial position, results of operations, and cash flows.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-410">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;The Company operates a Medicare-centric, capitated line of business and is organized as a single operating and reportable segment based on the manner in which the Chief Executive Officer, who is the Chief Operating Decision Maker (&#x201c;CODM&#x201d;), evaluates performance and makes decisions about how to allocate resources. Segment asset information, which is presented on the consolidated balance sheet, is not used by the CODM to assess performance and make decisions about how to allocate resources. The Company's segment measure of profit or loss is consolidated net income (loss). The CODM uses the segment measure of profit or loss to assess performance and make resource allocation decisions, primarily through periodic budgeting and company performance reviews. Significant expense categories included within the segment measure of profit or loss that are regularly provided to the CODM include medical services expense, other medical expense, and platform support costs. Medical services expense and other medical expense amounts are included in the consolidated statements of operations. Platform support costs were $37.4 million and $41.7 million for the three months ended June 30, 2025 and 2024, respectively. For the three months ended June 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $14.5 million and $21.2 million, respectively. Platform support costs were $81.7 million and $87.4 million for the six months ended June 30, 2025 and 2024, respectively. For the six months ended June 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $8.9 million and $56.6 million, respectively.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-67" decimals="-5" id="f-411" unitRef="usd">37400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-68" decimals="-5" id="f-412" unitRef="usd">41700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-69" decimals="-5" id="f-413" unitRef="usd">14500000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-70" decimals="-5" id="f-414" unitRef="usd">21200000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-71" decimals="-5" id="f-415" unitRef="usd">81700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-72" decimals="-5" id="f-416" unitRef="usd">87400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-73" decimals="-5" id="f-417" unitRef="usd">8900000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-74" decimals="-5" id="f-418" unitRef="usd">56600000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-419">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2023-09&#x201d;), which amends certain disclosure requirements related to income taxes. The amendments in ASU 2023-09 require public business entities on an annual basis to: (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The amendments in ASU 2023-09 can be applied on a prospective basis or retrospective application. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2024-03&#x201d;). In January 2025, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2025-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2025-01&#x201d;). The amendments in ASU 2024-03 require public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement expense line items by breaking down certain expense line items into specified natural expense categories, including purchases of inventory, employee compensation, deprecation, intangible asset amortization, and depletion. The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The amendments in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2024-03 can be applied on a prospective basis or retrospective basis and early adoption is permitted. The amendments in ASU 2025-01 clarify the effective date of ASU 2024-03 stating that all public business entities are required to adopt the update in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. ASU 2025-01 does not change the effective date of ASU 2024-03 but was issued to provide clarity on the effective date for public business entities that do not have a calendar year-end. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 and ASU 2025-01 on its disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c-1" id="f-420">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:24pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 3. Revenue, Receivables, and Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medical Services Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors (&#x201c;payors&#x201d;). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month (&#x201c;PMPM&#x201d;) fees to provide a defined range of healthcare services for Medicare Advantage health plan members (&#x201c;members&#x201d;) attributed to the Company&#x2019;s contracted primary care physicians. In certain of the Company&#x2019;s payor arrangements, it is also financially responsible for Medicare Part D pharmaceutical costs for prescriptions rendered to members. PMPM fees are determined as a percent of the premium payors receive from CMS for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are generally recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue From Contracts With Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price for the Company&#x2019;s capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS&#x2019;s risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member&#x2019;s health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company&#x2019;s contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of incentive revenue will not occur once any uncertainty is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management&#x2019;s estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company contracts with various payors whereby the Company is entitled to monthly PMPM fees to provide a defined range of healthcare services for members attributed to its contracted primary care physicians. The Company generally accepts full financial risk for such members and therefore is responsible for the cost of all healthcare services required by them. Substantially all of the Company&#x2019;s receivable balances are from a small number of payors. Revenue from Medicare Advantage payors constitutes substantially all of the Company&#x2019;s total revenue for the three and six months ended June&#160;30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the Company&#x2019;s revenue concentration with respect to major payors as a percentage of the Company&#x2019;s total revenues: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt"&gt;Less than 10% of total revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the Company&#x2019;s concentration of credit risk with respect to major payors as a percentage of receivables, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt"&gt;Less than 10% of total receivables.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-421">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medical Services Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors (&#x201c;payors&#x201d;). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month (&#x201c;PMPM&#x201d;) fees to provide a defined range of healthcare services for Medicare Advantage health plan members (&#x201c;members&#x201d;) attributed to the Company&#x2019;s contracted primary care physicians. In certain of the Company&#x2019;s payor arrangements, it is also financially responsible for Medicare Part D pharmaceutical costs for prescriptions rendered to members. PMPM fees are determined as a percent of the premium payors receive from CMS for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are generally recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue From Contracts With Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price for the Company&#x2019;s capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS&#x2019;s risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member&#x2019;s health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company&#x2019;s contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of incentive revenue will not occur once any uncertainty is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c-1" id="f-422">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management&#x2019;s estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized.</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-423">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the Company&#x2019;s revenue concentration with respect to major payors as a percentage of the Company&#x2019;s total revenues: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt"&gt;Less than 10% of total revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the Company&#x2019;s concentration of credit risk with respect to major payors as a percentage of receivables, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31pt"&gt;Less than 10% of total receivables.&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-75" decimals="2" id="f-424" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-76" decimals="2" id="f-425" unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-77" decimals="2" id="f-426" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-78" decimals="2" id="f-427" unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-79" decimals="2" id="f-428" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-80" decimals="2" id="f-429" unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-81" decimals="2" id="f-430" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-82" decimals="2" id="f-431" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-83" decimals="2" id="f-432" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-84" decimals="2" id="f-433" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-85" decimals="2" id="f-434" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-86" decimals="2" id="f-435" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-87" decimals="2" id="f-436" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-88" decimals="2" id="f-437" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-89" decimals="2" id="f-438" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-90" decimals="2" id="f-439" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-91" decimals="2" id="f-440" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-92" decimals="2" id="f-441" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-93" decimals="2" id="f-442" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-94" decimals="2" id="f-443" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-444">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 4. Marketable Securities and Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s marketable securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;128,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;211,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;211,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended June 30, 2025, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $3.6 million, of which $2.6 million was related to its marketable securities investments and $1.0 million was related to interest on cash and cash equivalent balances. For the three months ended June 30, 2024, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $4.8&#160;million, of which $3.3&#160;million was related to its marketable securities investments and $1.5&#160;million was related to interest on cash and cash equivalent balances. For the six months ended June 30, 2025, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $7.9&#160;million, of which $5.7&#160;million was related to its marketable securities investments and $2.2&#160;million was related to interest on cash and cash equivalent balances. For the six months ended June 30, 2024, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $10.2&#160;million, of which $7.2&#160;million was related to its marketable securities investments and $3.0&#160;million was related to interest on cash and cash equivalent balances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s marketable securities maturity as of June&#160;30, 2025 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of June&#160;30, 2025 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of December&#160;31, 2024 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;111,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unrealized losses from marketable securities as of June&#160;30, 2025 and December&#160;31, 2024 were caused primarily by interest rate increases. As of June&#160;30, 2025, all of the Company&#x2019;s marketable securities carry an investment grade rating by nationally recognized statistical rating organizations. The Company does not intend to sell marketable securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. There was no allowance for credit losses on available-for-sale marketable securities at June&#160;30, 2025 or December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash and equivalents, marketable securities, receivables, other liabilities, accounts payable, certain accrued expenses, and borrowings which consist of a term loan and a revolving credit facility. The carrying values of the financial instruments classified as current in the consolidated balance sheets approximate their fair values due to their short-term maturities. The Company's cash and cash equivalents are classified within Level 1 of the fair value hierarchy. The carrying values of the term loan and revolving credit facility are a reasonable estimate of fair value because the interest rates on such borrowings approximate market rates as of the reporting date. Such borrowings are classified within Level 2 of the fair value hierarchy. During the three and six months ended June&#160;30, 2025 and 2024, there were no material transfers of financial assets or liabilities within the fair value hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;unobservable inputs reflect the Company&#x2019;s market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1&#x2014;quoted prices for identical instruments in active markets; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2&#x2014;quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3&#x2014;fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s financial instruments measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-445">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s marketable securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;128,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;211,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;211,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s marketable securities maturity as of June&#160;30, 2025 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-95" decimals="-3" id="f-446" unitRef="usd">26330000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-95" decimals="-3" id="f-447" unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-95" decimals="-3" id="f-448" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-95" decimals="-3" id="f-449" unitRef="usd">26357000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-96" decimals="-3" id="f-450" unitRef="usd">110820000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-96" decimals="-3" id="f-451" unitRef="usd">91000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-96" decimals="-3" id="f-452" unitRef="usd">204000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-96" decimals="-3" id="f-453" unitRef="usd">110707000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-97" decimals="-3" id="f-454" unitRef="usd">128575000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-97" decimals="-3" id="f-455" unitRef="usd">712000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-97" decimals="-3" id="f-456" unitRef="usd">59000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-97" decimals="-3" id="f-457" unitRef="usd">129228000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-98" decimals="-3" id="f-458" unitRef="usd">101059000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-98" decimals="-3" id="f-459" unitRef="usd">184000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-98" decimals="-3" id="f-460" unitRef="usd">213000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-98" decimals="-3" id="f-461" unitRef="usd">101030000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-3" decimals="-3" id="f-462" unitRef="usd">154905000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-463" unitRef="usd">741000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-464" unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-3" decimals="-3" id="f-465" unitRef="usd">155585000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-466" unitRef="usd">211879000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-467" unitRef="usd">275000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-468" unitRef="usd">417000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-3" id="f-469" unitRef="usd">211737000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:InvestmentIncomeNet contextRef="c-15" decimals="-5" id="f-470" unitRef="usd">3600000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-99" decimals="-5" id="f-471" unitRef="usd">2600000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-100" decimals="-5" id="f-472" unitRef="usd">1000000.0</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-16" decimals="-5" id="f-473" unitRef="usd">4800000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-101" decimals="-5" id="f-474" unitRef="usd">3300000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-102" decimals="-5" id="f-475" unitRef="usd">1500000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-5" id="f-476" unitRef="usd">7900000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-103" decimals="-5" id="f-477" unitRef="usd">5700000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-104" decimals="-5" id="f-478" unitRef="usd">2200000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-17" decimals="-5" id="f-479" unitRef="usd">10200000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-105" decimals="-5" id="f-480" unitRef="usd">7200000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-106" decimals="-5" id="f-481" unitRef="usd">3000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-3" decimals="-3" id="f-482" unitRef="usd">40260000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-3" decimals="-3" id="f-483" unitRef="usd">40248000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <agl:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo contextRef="c-3" decimals="-3" id="f-484" unitRef="usd">62145000</agl:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearTwo>
    <agl:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo contextRef="c-3" decimals="-3" id="f-485" unitRef="usd">62389000</agl:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo>
    <agl:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree contextRef="c-3" decimals="-3" id="f-486" unitRef="usd">27966000</agl:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearThree>
    <agl:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree contextRef="c-3" decimals="-3" id="f-487" unitRef="usd">28194000</agl:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree>
    <agl:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour contextRef="c-3" decimals="-3" id="f-488" unitRef="usd">24534000</agl:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearFour>
    <agl:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour contextRef="c-3" decimals="-3" id="f-489" unitRef="usd">24754000</agl:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearFour>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-3" decimals="-3" id="f-490" unitRef="usd">154905000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-3" decimals="-3" id="f-491" unitRef="usd">155585000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-492">&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of June&#160;30, 2025 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of December&#160;31, 2024 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;111,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-95" decimals="-3" id="f-493" unitRef="usd">747000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-95" decimals="-3" id="f-494" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-95" decimals="-3" id="f-495" unitRef="usd">3999000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-95" decimals="-3" id="f-496" unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-97" decimals="-3" id="f-497" unitRef="usd">25613000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-97" decimals="-3" id="f-498" unitRef="usd">55000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-97" decimals="-3" id="f-499" unitRef="usd">12985000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-97" decimals="-3" id="f-500" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-3" decimals="-3" id="f-501" unitRef="usd">26360000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-3" decimals="-3" id="f-502" unitRef="usd">55000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-3" decimals="-3" id="f-503" unitRef="usd">16984000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-3" decimals="-3" id="f-504" unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-96" decimals="-3" id="f-505" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-96" decimals="-3" id="f-506" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-96" decimals="-3" id="f-507" unitRef="usd">73128000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-96" decimals="-3" id="f-508" unitRef="usd">204000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-98" decimals="-3" id="f-509" unitRef="usd">25295000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-98" decimals="-3" id="f-510" unitRef="usd">104000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-98" decimals="-3" id="f-511" unitRef="usd">38787000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-98" decimals="-3" id="f-512" unitRef="usd">109000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-4" decimals="-3" id="f-513" unitRef="usd">25295000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-4" decimals="-3" id="f-514" unitRef="usd">104000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-4" decimals="-3" id="f-515" unitRef="usd">111915000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-4" decimals="-3" id="f-516" unitRef="usd">313000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-3" decimals="INF" id="f-517" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-4" decimals="INF" id="f-518" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-519">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s financial instruments measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-107" decimals="-3" id="f-520" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-108" decimals="-3" id="f-521" unitRef="usd">26357000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-109" decimals="-3" id="f-522" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-110" decimals="-3" id="f-523" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-111" decimals="-3" id="f-524" unitRef="usd">110707000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-112" decimals="-3" id="f-525" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-113" decimals="-3" id="f-526" unitRef="usd">129228000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-114" decimals="-3" id="f-527" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-115" decimals="-3" id="f-528" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-116" decimals="-3" id="f-529" unitRef="usd">101030000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-117" decimals="-3" id="f-530" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-118" decimals="-3" id="f-531" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-119" decimals="-3" id="f-532" unitRef="usd">129228000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-120" decimals="-3" id="f-533" unitRef="usd">26357000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-121" decimals="-3" id="f-534" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-122" decimals="-3" id="f-535" unitRef="usd">101030000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-123" decimals="-3" id="f-536" unitRef="usd">110707000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-124" decimals="-3" id="f-537" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="c-1" id="f-538">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-right:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 5. Other Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s other assets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loans to physician partners&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health plan deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;151,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;See Note 14 for additional discussion related to the Company's equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loans to Physician Partners&lt;/span&gt;&lt;/div&gt;Loans to physician partners primarily represent loans in connection with taxes payable on shares distributed to them in connection with the IPO. These loans mature between 2026 and 2031 with nominal interest compounding annually and no prepayment penalties. At June&#160;30, 2025, $21.4 million of these loans were reclassed to Prepaid expenses and other current assets, net on the condensed consolidated balance sheet as the maturities were less than 12 months. Such loans are stated at the amount expected to be collected.</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock contextRef="c-1" id="f-539">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s other assets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loans to physician partners&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health plan deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;151,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;See Note 14 for additional discussion related to the Company's equity method investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <agl:LoansToPhysiciansPartners contextRef="c-3" decimals="-3" id="f-540" unitRef="usd">39381000</agl:LoansToPhysiciansPartners>
    <agl:LoansToPhysiciansPartners contextRef="c-4" decimals="-3" id="f-541" unitRef="usd">63155000</agl:LoansToPhysiciansPartners>
    <agl:HealthPlanDepositsNoncurrent contextRef="c-3" decimals="-3" id="f-542" unitRef="usd">2051000</agl:HealthPlanDepositsNoncurrent>
    <agl:HealthPlanDepositsNoncurrent contextRef="c-4" decimals="-3" id="f-543" unitRef="usd">2051000</agl:HealthPlanDepositsNoncurrent>
    <us-gaap:EquityMethodInvestments contextRef="c-3" decimals="-3" id="f-544" unitRef="usd">77906000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-4" decimals="-3" id="f-545" unitRef="usd">61756000</us-gaap:EquityMethodInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-546" unitRef="usd">8838000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-547" unitRef="usd">8783000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="c-3" decimals="-3" id="f-548" unitRef="usd">14921000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="c-4" decimals="-3" id="f-549" unitRef="usd">15391000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-550" unitRef="usd">143097000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-551" unitRef="usd">151136000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:LoansAndLeasesReceivableRelatedParties contextRef="c-3" decimals="-5" id="f-552" unitRef="usd">21400000</us-gaap:LoansAndLeasesReceivableRelatedParties>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock contextRef="c-1" id="f-553">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 6. Medical Claims and Related Payables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical services expense represents costs incurred for medical services provided to members by physicians, hospitals and other ancillary providers for which the Company is financially responsible and are paid by payors with whom the Company has contracted. Medical services expenses are recognized in the period in which services are provided and include estimates of claims that have been incurred but have either not yet been received, processed, or paid and as such, not reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Such estimates are developed using actuarial methods commonly used by health insurance actuaries that include a number of factors and assumptions including medical service utilization trends, changes in membership, observed medical &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cost trends, historical claim payment patterns and other factors. Generally, for the most recent months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average PMPM medical costs incurred in prior months for which more complete claims data are available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each period, the Company re-examines previously established medical claims payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claims information becomes available, the Company adjusts its estimates and recognizes those changes in estimates in the period in which the change is identified. The difference between the estimated liability and the actual settlements of claims is recognized in the period the claims are settled. The Company&#x2019;s medical claims payable balance represents management&#x2019;s best estimate of its liability for unpaid medical costs as of June&#160;30, 2025 and 2024. The Company uses judgment to determine the appropriate assumptions for developing the required estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of changes in medical claims and related payables (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Medical claims and related payables, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;918,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;723,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of incurred costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,810,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,802,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,847,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,817,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims paid related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,821,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,806,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(930,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(650,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,751,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,456,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Medical claims and related payables, end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,013,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,084,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical claims and related payables also include $28.5 million and $13.3 million, as of June&#160;30, 2025 and December&#160;31, 2024, respectively, that is recoverable from other parties under risk sharing arrangements and is presented as prepaid expenses and other current assets, net in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense contextRef="c-1" id="f-554">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of changes in medical claims and related payables (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Medical claims and related payables, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;918,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;723,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of incurred costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,810,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,802,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,847,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,817,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims paid related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,821,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,806,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(930,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(650,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,751,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,456,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Medical claims and related payables, end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,013,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,084,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable contextRef="c-4" decimals="-3" id="f-555" unitRef="usd">918395000</agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable>
    <agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable contextRef="c-61" decimals="-3" id="f-556" unitRef="usd">723071000</agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense contextRef="c-1" decimals="-3" id="f-557" unitRef="usd">2810528000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense contextRef="c-17" decimals="-3" id="f-558" unitRef="usd">2802803000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-1" decimals="-3" id="f-559" unitRef="usd">36584000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-17" decimals="-3" id="f-560" unitRef="usd">15099000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 contextRef="c-1" decimals="-3" id="f-561" unitRef="usd">2847112000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 contextRef="c-17" decimals="-3" id="f-562" unitRef="usd">2817902000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1 contextRef="c-1" decimals="-3" id="f-563" unitRef="usd">1821175000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1 contextRef="c-17" decimals="-3" id="f-564" unitRef="usd">1806692000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1 contextRef="c-1" decimals="-3" id="f-565" unitRef="usd">930606000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1 contextRef="c-17" decimals="-3" id="f-566" unitRef="usd">650106000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense contextRef="c-1" decimals="-3" id="f-567" unitRef="usd">2751781000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense contextRef="c-17" decimals="-3" id="f-568" unitRef="usd">2456798000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable contextRef="c-3" decimals="-3" id="f-569" unitRef="usd">1013726000</agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable>
    <agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable contextRef="c-47" decimals="-3" id="f-570" unitRef="usd">1084175000</agl:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingAmountsRecoverable>
    <agl:LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable contextRef="c-3" decimals="-5" id="f-571" unitRef="usd">28500000</agl:LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable>
    <agl:LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable contextRef="c-4" decimals="-5" id="f-572" unitRef="usd">13300000</agl:LiabilityForClaimsAndClaimsAdjustmentExpenseAmountsRecoverable>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-573">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 7. Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s other liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term contingencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;L&lt;span style="-sec-ix-hidden:f-577"&gt;&lt;span style="-sec-ix-hidden:f-578"&gt;ease liabilities, long-term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method liabilities &#x2013; CMS ACO Models&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;__________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;See Note 14 for additional discussion related to the Company's equity method liabilities related to its CMS ACO Models investments.&lt;/span&gt;&lt;/div&gt;As of June&#160;30, 2025 and December&#160;31, 2024, the Company&#x2019;s accruals for contingent liabilities related to unasserted claims were $35.0 million and $49.0 million, respectively.</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesTableTextBlock contextRef="c-1" id="f-574">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s other liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term contingencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;L&lt;span style="-sec-ix-hidden:f-577"&gt;&lt;span style="-sec-ix-hidden:f-578"&gt;ease liabilities, long-term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method liabilities &#x2013; CMS ACO Models&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;__________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;See Note 14 for additional discussion related to the Company's equity method liabilities related to its CMS ACO Models investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesTableTextBlock>
    <us-gaap:LossContingencyAccrualCarryingValueNoncurrent contextRef="c-3" decimals="-3" id="f-575" unitRef="usd">35000000</us-gaap:LossContingencyAccrualCarryingValueNoncurrent>
    <us-gaap:LossContingencyAccrualCarryingValueNoncurrent contextRef="c-4" decimals="-3" id="f-576" unitRef="usd">49000000</us-gaap:LossContingencyAccrualCarryingValueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-579" unitRef="usd">6428000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-580" unitRef="usd">6599000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <agl:EquityMethodLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-581" unitRef="usd">10355000</agl:EquityMethodLiabilitiesNoncurrent>
    <agl:EquityMethodLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-582" unitRef="usd">12290000</agl:EquityMethodLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-583" unitRef="usd">3095000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-584" unitRef="usd">8232000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-585" unitRef="usd">54878000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-586" unitRef="usd">76121000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LossContingencyAccrualCarryingValueNoncurrent contextRef="c-125" decimals="-5" id="f-587" unitRef="usd">35000000.0</us-gaap:LossContingencyAccrualCarryingValueNoncurrent>
    <us-gaap:LossContingencyAccrualCarryingValueNoncurrent contextRef="c-126" decimals="-5" id="f-588" unitRef="usd">49000000.0</us-gaap:LossContingencyAccrualCarryingValueNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-589">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 8. Debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;18, 2021, the Company executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021 and the Second Amendment to Credit Agreement, dated as of May 25, 2023, the &#x201c;Credit Facility&#x201d;). The Credit Facility includes: (i) a $100.0&#160;million secured term loan facility (the &#x201c;Secured Term Loan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Facility&#x201d;) and (ii) a $100.0&#160;million senior secured revolving credit facility (the &#x201c;Secured Revolving Facility&#x201d;) with a capacity to issue standby letters of credit in certain circumstances up to a maximum of $100.0&#160;million. Subject to specified conditions and receipt of commitments, the Secured Term Loan Facility may be expanded (or a new term loan facility, revolving credit facility or letter of credit facility added) by up to (i) $50.0&#160;million plus (ii) an additional amount determined in accordance with a formula tied to repayment of certain of the Company&#x2019;s indebtedness. The maturity date of the Credit Facility is February&#160;18, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company had $35.0 million outstanding under the Secured Term Loan Facility and availability under the Secured Revolving Facility was $19.4 million, as the Company had outstanding letters of credit totaling $80.6 million. The standby letters of credit are automatically extended without amendment for one-year periods, unless the Company notifies the institution in advance of the expiration date that the letter will be terminated. No amounts have been drawn on the outstanding letters of credit as of June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective with the Second Amendment to Credit Agreement on May 25, 2023, the Company transitioned to the Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) as a benchmark interest rate used in the Credit Agreement. At the Company&#x2019;s option, borrowings under the Credit Facility can be either: (i) SOFR Rate Loans, (ii) Daily Simple SOFR Rate Loans, or (iii) Base Rate Loans. Daily Simple SOFR Rate Loans and SOFR Rate Loans bear interest at a rate equal to the sum of 3.50% and the higher of (a) SOFR, as defined in the Credit Agreement, and (b) 0%. Base Rate Loans bear interest at a rate equal to the sum of 2.50% and the highest of: (a) 0.50% in excess of the overnight federal funds rate, (b) the prime rate established by the administrative agent from time to time, (c) the one-month SOFR rate (adjusted for maximum reserves) plus 1.00% and (d) 0%. Additionally, the Company pays a commitment fee on the unfunded Secured Revolving Facility amount of 0.375%. The Company must also pay customary letter of credit fees. As of June&#160;30, 2025, the effective interest rate on the Secured Term Loan Facility was 8.279%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Facility is guaranteed by certain of the Company&#x2019;s subsidiaries, including those identified as VIEs, and contain customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios. Failure to meet any of these covenants could result in an event of default under the Credit Agreement. If an event of default occurs, the lenders could elect to declare all amounts outstanding under the Credit Agreement to be immediately due and payable. The Company was in compliance with all covenants under the Credit Facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-127" decimals="INF" id="f-590" unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-128" decimals="INF" id="f-591" unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-129" decimals="INF" id="f-592" unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <agl:LineOfCreditFacilityAccordionFeatureIncreaseLimit contextRef="c-130" decimals="INF" id="f-593" unitRef="usd">50000000</agl:LineOfCreditFacilityAccordionFeatureIncreaseLimit>
    <us-gaap:LongTermDebt contextRef="c-131" decimals="-5" id="f-594" unitRef="usd">35000000.0</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-132" decimals="-5" id="f-595" unitRef="usd">19400000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-133" decimals="-5" id="f-596" unitRef="usd">80600000</us-gaap:LettersOfCreditOutstandingAmount>
    <agl:ExtendedTermOfLettersOfCredit contextRef="c-134" id="f-597">P1Y</agl:ExtendedTermOfLettersOfCredit>
    <us-gaap:LongTermDebt contextRef="c-133" decimals="INF" id="f-598" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-135" decimals="4" id="f-599" unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-136" decimals="2" id="f-600" unitRef="number">0</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-137" decimals="4" id="f-601" unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-138" decimals="4" id="f-602" unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-139" decimals="4" id="f-603" unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-140" decimals="2" id="f-604" unitRef="number">0</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage contextRef="c-141" decimals="5" id="f-605" unitRef="number">0.00375</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtWeightedAverageInterestRate contextRef="c-131" decimals="5" id="f-606" unitRef="number">0.08279</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-607">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:14pt;padding-right:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 9. Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is a party to, or has a significant relationship to, legal proceedings, lawsuits, and other claims that arise in the ordinary course of the Company's business. Except as described in this Note 9, the Company is not aware of any other legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company's business, prospects, financial condition, results of operations or cash flows. The Company&#x2019;s policy is to expense legal costs as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February and March 2024, three class action lawsuits were filed and later consolidated as one matter captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re agilon health, inc. Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 1:24-cv-00297 (W.D. Tex.) (the &#x201c;Consolidated Securities Matter&#x201d;). The Consolidated Securities Matter names the Company and certain current and former members of the Company&#x2019;s executive team and Board of Directors as defendants, among others. The Consolidated Securities Matter generally asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;) and under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), in connection with statements made between April 2021 and February 2024 in the Company&#x2019;s annual and quarterly reports, investor presentations, and earnings releases related to, among other things, the Company&#x2019;s financial guidance, medical margin and Adjusted EBITDA results, growth strategy, and data management. The Consolidated Securities Matter seeks compensatory damages, judgment interest, attorney&#x2019;s fees and costs, and other unspecified equitable and/or injunctive relief.&#x202f;The Company and other defendants filed motions to dismiss the complaint on November 8, 2024, and the motion is now fully submitted and pending before the Court. The Company intends to vigorously oppose the complaint, but is unable to predict the outcome or estimate any ultimate individual or aggregate amount of monetary liability or financial impact due to the early stages of the litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May and October 2024, two putative stockholder derivative class action lawsuits were filed: (1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Douglas v. Steven J. Sell et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 1:24-cv-00531 (W.D. Tex.) and (2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bingham v. Steven J. Sell et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 1:24-cv-01181 (W.D. Tex.) (the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Derivative Matters&#x201d;). The Derivative Matters name the Company and certain current and former members of the Company&#x2019;s executive team and Board of Directors as defendants. The Derivative Matters generally assert claims under Sections 14(a) and 10(b) of the Exchange Act, as well as common law claims including breach of fiduciary duty, among others, in connection with statements made between April 2021 and February 2024 in the Company&#x2019;s annual and quarterly reports, investor presentations, and earnings releases related to, among other things, the Company&#x2019;s financial guidance, medical margin and Adjusted EBITDA results, growth strategy, and data management. The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Douglas&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lawsuit also asserts claims under Section 20(a) of the Exchange Act in connection with the same allegations and seeks contribution under Section 11(f) of the Securities Act and Section 21D of the Exchange Act. The Derivative Matters seek compensatory damages, restitution, punitive damages, attorney&#x2019;s fees and costs, and other relief.&#x202f;The plaintiff in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Douglas&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; action also seeks corporate governance reforms. The Derivative Matters were consolidated in November 2024 into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In Re agilon health, inc. Shareholder Derivative Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 1:24-cv-00531-DII. The consolidated derivative matter is currently stayed, pending resolution of the motion to dismiss in the Consolidated Securities Matter. The Company intends to vigorously oppose the complaint, but is unable to predict the outcome or estimate any ultimate individual or aggregate amount of monetary liability or financial impact due to the early stage of the litigation.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-142"
      decimals="INF"
      id="f-608"
      unitRef="lawsuit">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-143"
      decimals="INF"
      id="f-609"
      unitRef="lawsuit">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-610">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 10. Common Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During the three months ended June 30, 2025, the Company issued approximately 1.3&#160;million shares of common stock primarily in connection with vesting of stock-based awards. During the six months ended June 30, 2025, the Company issued approximately 2.1&#160;million shares of common stock primarily in connection with vesting of stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During the three months ended June 30, 2024, the Company issued approximately 0.6&#160;million shares of common stock primarily in connection with exercises and vesting of stock-based awards. During the six months ended June 30, 2024, the Company issued approximately 3.1&#160;million shares of common stock primarily in connection with exercises and vesting of stock-based awards. Additionally, during the six months ended June 30, 2024, the Company issued approximately 2.0&#160;million shares of common stock to settle liabilities related to the exchange of common stock for reduced physician partner compensation percentage in certain ACO REACH entities.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-25" decimals="-5" id="f-611" unitRef="shares">1300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-54" decimals="-5" id="f-612" unitRef="shares">2100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-40" decimals="-5" id="f-613" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-65" decimals="-5" id="f-614" unitRef="shares">3100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c-65" decimals="-5" id="f-615" unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-616">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 11. Net Income (Loss) Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per common share (&#x201c;EPS&#x201d;) is computed based upon the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed based upon the weighted average number of common shares outstanding plus the impact of common shares issuable from the assumed conversion of stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on basic net income (loss) per share are included in diluted net income (loss) per share during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(104,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(106,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncontrolling interests&#x2019; share in (earnings) loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) attributable to common stockholders before discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(104,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(106,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(104,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(92,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(36,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;413,836&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;411,271&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;413,388&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;409,152&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net income (loss) per share attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) per common share from continuing operations, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) per common share from discontinued operations, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,980&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,421&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,177&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-617">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(104,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(106,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncontrolling interests&#x2019; share in (earnings) loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) attributable to common stockholders before discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(104,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(106,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(104,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(92,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(36,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;413,836&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;411,271&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;413,388&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;409,152&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net income (loss) per share attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) per common share from continuing operations, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) per common share from discontinued operations, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-618" unitRef="usd">-104370000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-619" unitRef="usd">-30662000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-620" unitRef="usd">-106258000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-621" unitRef="usd">-27415000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-622" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-623" unitRef="usd">20000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-624" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-625" unitRef="usd">50000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-15" decimals="-3" id="f-626" unitRef="usd">-104370000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-16" decimals="-3" id="f-627" unitRef="usd">-30682000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-1" decimals="-3" id="f-628" unitRef="usd">-106258000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-17" decimals="-3" id="f-629" unitRef="usd">-27465000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-15" decimals="-3" id="f-630" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-16" decimals="-3" id="f-631" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-1" decimals="-3" id="f-632" unitRef="usd">14000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-17" decimals="-3" id="f-633" unitRef="usd">-9281000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-634" unitRef="usd">-104370000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-635" unitRef="usd">-30682000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-636" unitRef="usd">-92258000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-637" unitRef="usd">-36746000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-3" id="f-638" unitRef="shares">413836000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-3" id="f-639" unitRef="shares">413836000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-16" decimals="-3" id="f-640" unitRef="shares">411271000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-16" decimals="-3" id="f-641" unitRef="shares">411271000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-642" unitRef="shares">413388000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-643" unitRef="shares">413388000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-17" decimals="-3" id="f-644" unitRef="shares">409152000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-17" decimals="-3" id="f-645" unitRef="shares">409152000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-15"
      decimals="2"
      id="f-646"
      unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-15"
      decimals="2"
      id="f-647"
      unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-16"
      decimals="2"
      id="f-648"
      unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-16"
      decimals="2"
      id="f-649"
      unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-650"
      unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-651"
      unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-17"
      decimals="2"
      id="f-652"
      unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-17"
      decimals="2"
      id="f-653"
      unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-15"
      decimals="2"
      id="f-654"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-15"
      decimals="2"
      id="f-655"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-16"
      decimals="2"
      id="f-656"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-16"
      decimals="2"
      id="f-657"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-658"
      unitRef="usdPerShare">0.03</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-659"
      unitRef="usdPerShare">0.03</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-17"
      decimals="2"
      id="f-660"
      unitRef="usdPerShare">-0.02</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-17"
      decimals="2"
      id="f-661"
      unitRef="usdPerShare">-0.02</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-662">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,980&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,421&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,177&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-144"
      decimals="-3"
      id="f-663"
      unitRef="shares">20980000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-145"
      decimals="-3"
      id="f-664"
      unitRef="shares">17421000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-146"
      decimals="-3"
      id="f-665"
      unitRef="shares">25623000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-147"
      decimals="-3"
      id="f-666"
      unitRef="shares">20177000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-667">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 12. Goodwill and Amortizable Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of both June&#160;30, 2025 and December&#160;31, 2024, the Company&#x2019;s goodwill balance was $24.1 million. There were no events or circumstances that warranted an interim impairment test for goodwill during the six months ended June&#160;30, 2025. &lt;/span&gt;&lt;/div&gt;As of June&#160;30, 2025 and December&#160;31, 2024, the Company&#x2019;s gross carrying amount of amortizable intangible assets was $122.8 million and $123.8 million, respectively, with accumulated amortization of $57.2 million and $51.0 million, respectively. For the three months ended June 30, 2025 and 2024, the Company recognized $3.4 million and $3.0 million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recognized $6.5 million and $6.0 million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill contextRef="c-3" decimals="-5" id="f-668" unitRef="usd">24100000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-5" id="f-669" unitRef="usd">24100000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-3" decimals="-5" id="f-670" unitRef="usd">122800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-4" decimals="-5" id="f-671" unitRef="usd">123800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-3" decimals="-5" id="f-672" unitRef="usd">57200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-5" id="f-673" unitRef="usd">51000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-15" decimals="-5" id="f-674" unitRef="usd">3400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-16" decimals="-5" id="f-675" unitRef="usd">3000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-676" unitRef="usd">6500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-17" decimals="-5" id="f-677" unitRef="usd">6000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="c-1" id="f-678">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 13. Supplemental Cash Flow Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides supplemental cash flow information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplemental cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplemental disclosure of non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use asset obtained in exchange for new operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlement of liabilities through issuance of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;188,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;193,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________________________&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c-1" id="f-679">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides supplemental cash flow information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplemental cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplemental disclosure of non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use asset obtained in exchange for new operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlement of liabilities through issuance of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-680" unitRef="usd">2659000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-17" decimals="-3" id="f-681" unitRef="usd">1981000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-682" unitRef="usd">480000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-17" decimals="-3" id="f-683" unitRef="usd">355000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-684" unitRef="usd">1602000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-17" decimals="-3" id="f-685" unitRef="usd">326000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1 contextRef="c-1" decimals="-3" id="f-686" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-17" decimals="-3" id="f-687" unitRef="usd">15230000</us-gaap:StockIssued1>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-689">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;188,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;193,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________________________&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-688">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;188,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;193,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________________________&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-690" unitRef="usd">171416000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-691" unitRef="usd">188231000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsCurrent contextRef="c-3" decimals="-3" id="f-692" unitRef="usd">0</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsCurrent contextRef="c-4" decimals="-3" id="f-693" unitRef="usd">5629000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-694" unitRef="usd">171416000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-695" unitRef="usd">193860000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="c-1" id="f-696">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 14. Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agilon health, inc.&#x2019;s consolidated assets and liabilities as of June&#160;30, 2025 and December&#160;31, 2024 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to agilon health, inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agilon health, inc.&#x2019;s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,046,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,015,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical claims and related payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,042,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;931,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;199,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-bearing Entities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At June&#160;30, 2025, the Company operates 33 wholly-owned risk-bearing entities (&#x201c;RBEs&#x201d;) for the purpose of entering into risk-bearing contracts with payors. Each RBE&#x2019;s equity at risk is considered insufficient to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;finance its activities without additional support, and, therefore, each RBE is considered a VIE. The Company consolidates the RBEs as it has determined that it is the primary beneficiary because it has: (i) the ability to control the activities that most significantly impact the RBEs&#x2019; economic performance; and (ii) the obligation to absorb losses or right to receive benefits that could potentially be significant to the RBEs. Specifically, the Company has the unilateral ability and authority, through the RBE governance and management agreements, to make significant decisions about strategic and operating activities of the RBEs, including negotiating and entering into risk-bearing contracts with payors, and approving the RBEs&#x2019; annual operating budgets. The Company also has the obligation to fund losses of the RBEs and the right to receive a significant percentage of any financial surplus generated by the RBEs. The assets of the RBEs primarily consist of cash and cash equivalents, receivables, net, intangible assets, net, and other assets. Its obligations primarily consist of medical claims and related payables as well as operating expenses of the RBEs (accounts payable and accrued expenses), including incentive compensation obligations to the Company&#x2019;s physician partners. On February 18, 2021, the Company executed the Credit Facility, which is guaranteed by certain of the Company&#x2019;s VIEs. Assets generated by the RBEs (primarily from medical services revenues) may be used, in certain limited circumstances, to settle the Company&#x2019;s contractual debt obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company had 12 equity method investments (liabilities), including 10 wholly-owned CMS ACO Models entities discussed below, that were deemed to be VIEs. The Company has determined that the activities that most significantly impact the performance of these VIEs consist of the allocation of resources to and other decisions related to clinical activities and provider contracting decisions. Because the Company does not have the ability to control these activities due to another party&#x2019;s control of the VIEs&#x2019; board of directors, the Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs. The Company provided support to assist its CMS ACO Models investments in obtaining surety bonds related to risk-bearing capital contributions to CMS. As of June&#160;30, 2025 and December&#160;31, 2024, the CMS ACO Models investments had $131.6 million and $65.2 million, respectively, of outstanding surety bonds. The Company's maximum loss exposure as a result of the Company&#x2019;s involvement with the unconsolidated VIEs cannot be quantified as the Company has the obligation to provide ongoing operational support to the unconsolidated VIEs, as needed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s equity method investees (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments - Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments - CMS ACO Models&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method liabilities - CMS ACO Models&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;Included in Other assets, net in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;Included in Other liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a partner in 10 wholly-owned CMS ACO Models investments in collaboration with 13 of its physician group partners operating in 12 geographies. The combined summarized operating results of the Company&#x2019;s CMS ACO Models investments are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;434,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;446,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;848,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;887,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical services expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(401,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(406,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(753,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(805,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other medical expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) from operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:26.68pt"&gt;The three months ended June 30, 2025 and 2024, includes physician incentive expenses of $8.8 million and $13.7 million, respectively. The six months ended June 30, 2025 and 2024, includes physician incentive expenses of $36.6 million and $30.4 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;The three months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $4.3 million and $1.3 million, respectively. The six months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $8.5 million and $2.6 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;Included in Income (loss) from equity method investments in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The combined summarized balance sheet of the Company&#x2019;s CMS ACO Models investments are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;524,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;444,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;526,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;446,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current and total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;467,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;406,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock contextRef="c-1" id="f-697">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agilon health, inc.&#x2019;s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,046,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,015,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical claims and related payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,042,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;931,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;199,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-698" unitRef="usd">57361000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-699" unitRef="usd">78650000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-700" unitRef="usd">0</us-gaap:RestrictedCashEquivalents>
    <us-gaap:RestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-701" unitRef="usd">5627000</us-gaap:RestrictedCashEquivalents>
    <us-gaap:ReceivablesNetCurrent contextRef="c-5" decimals="-3" id="f-702" unitRef="usd">1046335000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-6" decimals="-3" id="f-703" unitRef="usd">1015753000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-704" unitRef="usd">31599000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-705" unitRef="usd">17725000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-706" unitRef="usd">1114000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-707" unitRef="usd">1255000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-708" unitRef="usd">43651000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-6" decimals="-3" id="f-709" unitRef="usd">49406000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssets contextRef="c-5" decimals="-3" id="f-710" unitRef="usd">5584000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="c-6" decimals="-3" id="f-711" unitRef="usd">4790000</us-gaap:OtherAssets>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-5" decimals="-3" id="f-712" unitRef="usd">1042257000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-6" decimals="-3" id="f-713" unitRef="usd">931664000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-714" unitRef="usd">154932000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-715" unitRef="usd">199432000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilities contextRef="c-5" decimals="-3" id="f-716" unitRef="usd">1381000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities contextRef="c-6" decimals="-3" id="f-717" unitRef="usd">2270000</us-gaap:OtherLiabilities>
    <agl:NumberOfWhollyOwnedRiskBearingEntities contextRef="c-5" decimals="INF" id="f-718" unitRef="entity">33</agl:NumberOfWhollyOwnedRiskBearingEntities>
    <agl:NumberOfEquityMethodInvestments
      contextRef="c-148"
      decimals="INF"
      id="f-719"
      unitRef="investment">12</agl:NumberOfEquityMethodInvestments>
    <agl:NumberOfDirectContractingEntities
      contextRef="c-149"
      decimals="INF"
      id="f-720"
      unitRef="entity">10</agl:NumberOfDirectContractingEntities>
    <us-gaap:LongTermDebt contextRef="c-150" decimals="-5" id="f-721" unitRef="usd">131600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-151" decimals="-5" id="f-722" unitRef="usd">65200000</us-gaap:LongTermDebt>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c-1" id="f-723">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s equity method investees (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments - Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments - CMS ACO Models&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method liabilities - CMS ACO Models&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;Included in Other assets, net in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;Included in Other liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments contextRef="c-152" decimals="-3" id="f-724" unitRef="usd">9378000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-153" decimals="-3" id="f-725" unitRef="usd">9365000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-154" decimals="-3" id="f-726" unitRef="usd">68528000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-155" decimals="-3" id="f-727" unitRef="usd">52391000</us-gaap:EquityMethodInvestments>
    <agl:EquityMethodLiabilities contextRef="c-3" decimals="-3" id="f-728" unitRef="usd">10355000</agl:EquityMethodLiabilities>
    <agl:EquityMethodLiabilities contextRef="c-4" decimals="-3" id="f-729" unitRef="usd">12290000</agl:EquityMethodLiabilities>
    <agl:NumberOfDirectContractingEntities
      contextRef="c-149"
      decimals="INF"
      id="f-730"
      unitRef="entity">10</agl:NumberOfDirectContractingEntities>
    <agl:NumberOfPhysicianGroupPartners
      contextRef="c-149"
      decimals="INF"
      id="f-731"
      unitRef="partner">13</agl:NumberOfPhysicianGroupPartners>
    <agl:NumberOfGeographicalLocation
      contextRef="c-3"
      decimals="INF"
      id="f-732"
      unitRef="geography">12</agl:NumberOfGeographicalLocation>
    <us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock contextRef="c-1" id="f-733">The combined summarized operating results of the Company&#x2019;s CMS ACO Models investments are as follows (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical services revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;434,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;446,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;848,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;887,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical services expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(401,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(406,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(753,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(805,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other medical expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) from operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:26.68pt"&gt;The three months ended June 30, 2025 and 2024, includes physician incentive expenses of $8.8 million and $13.7 million, respectively. The six months ended June 30, 2025 and 2024, includes physician incentive expenses of $36.6 million and $30.4 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;The three months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $4.3 million and $1.3 million, respectively. The six months ended June 30, 2025 and 2024, includes operating expenses for services provided by the Company of $8.5 million and $2.6 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;Included in Income (loss) from equity method investments in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-156" decimals="-3" id="f-734" unitRef="usd">434806000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-157" decimals="-3" id="f-735" unitRef="usd">446914000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-158" decimals="-3" id="f-736" unitRef="usd">848271000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-159" decimals="-3" id="f-737" unitRef="usd">887074000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-156" decimals="-3" id="f-738" unitRef="usd">401902000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-157" decimals="-3" id="f-739" unitRef="usd">406921000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-158" decimals="-3" id="f-740" unitRef="usd">753755000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-159" decimals="-3" id="f-741" unitRef="usd">805713000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-160" decimals="-3" id="f-742" unitRef="usd">17848000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-161" decimals="-3" id="f-743" unitRef="usd">22268000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-162" decimals="-3" id="f-744" unitRef="usd">54090000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-163" decimals="-3" id="f-745" unitRef="usd">47673000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:OperatingIncomeLoss contextRef="c-164" decimals="-3" id="f-746" unitRef="usd">6396000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-165" decimals="-3" id="f-747" unitRef="usd">11325000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-166" decimals="-3" id="f-748" unitRef="usd">22609000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-167" decimals="-3" id="f-749" unitRef="usd">20857000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-164" decimals="-3" id="f-750" unitRef="usd">5395000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-165" decimals="-3" id="f-751" unitRef="usd">9921000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-166" decimals="-3" id="f-752" unitRef="usd">18072000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-167" decimals="-3" id="f-753" unitRef="usd">15552000</us-gaap:NetIncomeLoss>
    <agl:PhysicianCompensationExpense contextRef="c-164" decimals="-5" id="f-754" unitRef="usd">8800000</agl:PhysicianCompensationExpense>
    <agl:PhysicianCompensationExpense contextRef="c-165" decimals="-5" id="f-755" unitRef="usd">13700000</agl:PhysicianCompensationExpense>
    <agl:PhysicianCompensationExpense contextRef="c-166" decimals="-5" id="f-756" unitRef="usd">36600000</agl:PhysicianCompensationExpense>
    <agl:PhysicianCompensationExpense contextRef="c-167" decimals="-5" id="f-757" unitRef="usd">30400000</agl:PhysicianCompensationExpense>
    <us-gaap:OperatingExpenses contextRef="c-164" decimals="-5" id="f-758" unitRef="usd">4300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-165" decimals="-5" id="f-759" unitRef="usd">1300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-166" decimals="-5" id="f-760" unitRef="usd">8500000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-167" decimals="-5" id="f-761" unitRef="usd">2600000</us-gaap:OperatingExpenses>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c-1" id="f-762">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The combined summarized balance sheet of the Company&#x2019;s CMS ACO Models investments are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;524,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;444,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;526,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;446,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current and total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;467,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;406,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:AssetsCurrent contextRef="c-168" decimals="-3" id="f-763" unitRef="usd">524238000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-169" decimals="-3" id="f-764" unitRef="usd">444963000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-168" decimals="-3" id="f-765" unitRef="usd">1894000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-169" decimals="-3" id="f-766" unitRef="usd">1894000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c-168" decimals="-3" id="f-767" unitRef="usd">526132000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-169" decimals="-3" id="f-768" unitRef="usd">446857000</us-gaap:Assets>
    <us-gaap:Liabilities contextRef="c-168" decimals="-3" id="f-769" unitRef="usd">467959000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-169" decimals="-3" id="f-770" unitRef="usd">406756000</us-gaap:Liabilities>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-771">&lt;div style="margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 15. Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discontinued operations is a component of an entity that has either been disposed of or is deemed held-for-sale and, (i) the operations and cash flows of the component have been or will be eliminated from ongoing operations as a result of the disposal transaction, and (ii) the entity will not have any significant continuing involvement in the operations of the component after the disposal transaction. On October 31, 2023, the Company completed the disposition of MDX Hawaii, Inc. and its related operations. The Company&#x2019;s decision to exit Hawaii and the Independent Practice Association line of business represents a strategic shift that will have a major effect on its operations and financial results. As such, the Company&#x2019;s Hawaii operations are reflected in the condensed consolidated financial statements as discontinued operations for all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of discontinued operations are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments on sale of assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net income (loss) from discontinued operations attributable to common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="c-1" id="f-772">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of discontinued operations are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments on sale of assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net income (loss) from discontinued operations attributable to common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <agl:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments contextRef="c-170" decimals="-3" id="f-773" unitRef="usd">0</agl:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments>
    <agl:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments contextRef="c-171" decimals="-3" id="f-774" unitRef="usd">518000</agl:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpenseNetOfAdjustments>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="c-170" decimals="-3" id="f-775" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="c-171" decimals="-3" id="f-776" unitRef="usd">-518000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="c-170" decimals="-3" id="f-777" unitRef="usd">14000000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="c-171" decimals="-3" id="f-778" unitRef="usd">-8763000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-170" decimals="-3" id="f-779" unitRef="usd">14000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-171" decimals="-3" id="f-780" unitRef="usd">-9281000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-15" id="f-781">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-15" id="f-782">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-15" id="f-783">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-15" id="f-784">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
